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This thesis is expected to contribute to the practice of treatment of rare diseases by 
integrating the three perspectives Evidence Based Medicine (EBM), Quality of Life (QoL) 
and Health Economics (HE) considerations into a comprehensive framework. Rare diseases 
have low prevalence but combined affect approximately up to 10% of the overall population, 
posing unique challenges across all three perspectives. Multiple stakeholders exert influence 
and drive decisions based on different and sometimes conflicting criteria and objectives, 
resulting in controversies and real or perceived suboptimal outcomes and deployment of 
resources which affect the well-being of patients. EBM, QoL and HE are not directly linked 
with one another and most often not considered together in all relevant decisions. Agency 
theory is utilized as an underlying theoretical framework. Both previous research and current 
empirical evidence have identified some gaps which are consistents with the double agency 
theory framework and, in addition, with the missed opportunity to fully integrate the three 
perspectives. This thesis aims to confirm and possibly close some of these gaps, broaden the 
scope and applicability of the theory, attempting to offer an integrated approach that 
mitigates the current empirical observation that each approach is taken independently forces 
on the other stakeholders’ suboptimal results. A deductive research method was selected and 
both qualitative and quantitave research was pursued. This thesis reports on research that 
focuses on Hereditary Angioedema (HAE) as an example for rare diseases, using a 
combination of a broad survey with treating physicians, a search on social media and a meta-
analysis of scientific articles and research on the condition and its relevant aspects. The 
chosen methodology allowed for a broad scope of sources and perspectives, consistent 
findings and strong conclusions, and the identification of potential gaps and misalignments. 
The research confirmed patients, the physicians and the payers as the most important 
stakeholders. It also provided insights on the variables leading to diagnosis and treatment 
decisions, which included specific aspects of the condition, behaviors by patients, caregivers 
and physicians, alternative treatment options and objectives, with their corresponding 
implications on clinical outcomes, QoL and costs. The different components of the research 
mapped into the themes identified in the literature search, reinforcing the application of the 
theoretical framework and extending its application into the area of rare diseases. While 
answering the RQs and substantiating the application of the double agency theory as an 
underlying theoretical framework, the thesis was able to prove the interrelation of the 
different variables, possibly setting the groundwork to develop an algorithm or a formula 
which would allow to optimize the outcome of the treatment and the funding decisions. 
However, current constraints such as high variability and lack of sufficient data would 
probably cause such an algorithm to be cumbersome and of limited use in real life. On the 
other hand, the prioritization and quantification of the variables, may be instrumental and 
could contribute to building bridges across the stakeholders patients, physicians and payers, 
enabling the sharing of knowledge and augmenting its impact through the integrated 
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Angioedema Swelling of the area beneath the skin, similar to 
urticaria, or hives, but different as urticaria affects only 
the top layer of skin. Angioedema affects the deeper 
layers, including the dermis, subcutaneous tissue, the 
mucosa, and submucosal tissues 
Appendicitis  Inflammation of the appendix, that causes pain in your 
lower right abdomen 
C1-inhibitor C1 esterase inhibitor 
DALY Disability-Adjusted Life Year, a time-based measure 
that combines years of life lost due to premature 
mortality and years of life lost due to time lived in 
states of less than full health 
EBM Evidence based medicine 
Epidemiology Study of distribution, determinants and control of 
health-related states and events in populations 
ER Emergency room 
Erythema marginatum  Redness of the skin or mucous membranes involving 
pink rings on the torso and inner surfaces of the limbs 
which can manifest over several months.  
FDA Food and Drug Administration 
HAE Hereditary angioedema 
HCP Healthcare professional 
HE Health economics 
HRQoL Health-related quality of life 
ICER Incremental cost-effectiveness ratio, to compare two 
treatments, divides difference in cost by the difference 
in effect 
ICU Intensive care unit 
Incidence Epidemiological measure that takes into account the 
time when a new disease or a new case of a known 
disease occurs among members of a population. 
Captures the dynamic of the disease in a particular 
population. 
Intussusception  Serious condition in which part of the intestine slides 
into an adjacent part of the intestine. This "telescoping" 
often blocks food or fluid from passing through 
IV Intravenous 
LTP Long term prophylaxis 
Mesenteric lymphadenitis  Inflammation of the lymph nodes which are in a 





NRCT Non-randomized clinical trial 
RCT Randomized clinical trial 
RWE Real world evidence 
QoL Quality of life 
QALY Quality-adjusted life year, the number of quality years 
of life that would be added by an intervention. One 
QALY is equal to one year of life in perfect health. 
Often measured in terms of the person’s ability to carry 
out the activities of daily life, and freedom from pain 
and mental disturbance. 
SC Subcutaneous 
Strangulation ileus  Loop of the small intestine caused by abnormal 
adhesion 
Thyroiditis urticaria Chronic skin condition characterized by recurrent 
attacks of itchy hives that may vary in size, number 
and distribution, that patients experience daily for 
more than 6 weeks 
YPLL Years of potential life lost, by reference to the number 
of years between a subject’s age of death and his/her 







1 CHAPTER 1 - INTRODUCTION 
1.1 Overview 
Healthcare systems profess to have the patient at the center, yet it is healthcare professionals 
and payors that do most of the therapeutic decision making on behalf of the patient (Szasz, 
1997) and few are involving the patients or even adjust care to the patient’s preferences 
(Couet, 2013). Applying agency theory, patients are the principals, while physicians and 
payors are agents (Tofan, 2012). Using healthcare systems over time, physicians have 
developed and are using Evidence Based Medicine (EBM) as a decision-making tool to 
optimize the clinical outcome for the patients (Greenhalgh, 2014, Sackett, 1997). They are 
looking for efficacy. Payors (healthcare authorities, insurers) on the other hand pursue 
Health Economics (HE) and need to allocate limited resources across an ever-increasing 
number of patients with costs of drugs and healthcare services surging at the same time. 
They are looking for effectiveness (Eis, 2012) and use Real World Evidence (RWE) to 
determine it. Patients, on the other hand, are living with the condition, the symptoms, the 
co-morbidities (other coexisting conditions), and the burden of the disease which impacts 
their Quality of Life (QoL). The different stakeholders have different skills, priorities, 
incentives and most often are not communicating with each other on each case. This causes 
a disconnect between stakeholders as the three perspectives are not considered in a holistic 
way when making treatment and funding decisions. Each approach taken independently 
forces suboptimal results on the other stakeholders. This disconnect between the approaches 
is a source of controversy and misalignment between patients, physicians and payors (Fuchs, 
2011) although there have been attempts to involve patients towards EBM in order to lead 
to more efficient decision-making (Greenhalgh, 2014). This thesis first analyzes the different 
perspectives and then their dependency, differences and gaps, aiming to provide a more 
comprehensive evidence-based decision-making framework which improve the alignment 
of all stakeholder needs and priorities and which may support the achievement of improved 
and more cost-effective healthcare solutions. The rare disease Hereditary Angioedema 
(HAE) was chosen as a sub-segment of medicine, as it allows focus while meeting a strong 






1.2.1 Healthcare systems and drivers 
In physics a mechanical system of three bodies subject only to the force of gravity is already 
known to be “unstable”: there is no combination of position and movement that ensures 
equilibrium. In a similar way, healthcare systems have more than three independent forces 
(or stakeholders) which interact and which affect the clinical outcome, the QoL and the 
economic aspects of a treatment. Similarly as in physics, no healthcare system appears to be 
in equilibrium, or even recognized by all stakeholders for offering the best possible solution.  
Different processes and incentive systems for the different stakeholders generate different 
forces with varying degrees of negotiating power. Even a regulator backed by government 
and law is not omnipotent and will be forced to change when the political power shifts. 
Supremacy through information asymmetry, for example, healthcare professionals 
recommending over-sophisticated expensive treatments to naïve, unaware and intimidated 
patients, can only go so far. Patients do not get necessary treatment when they cannot afford 
to pay or when payers (insurance companies and reimbursement agencies) put in place 
budgetary blocks based on real-life health outcomes combined with a measure in monetary 
terms. Willingness to pay is influenced and sometimes limited by the ability to pay. If a 
disease can be treated by a low-cost generic, payers may not see the need and pay extra for 
the drug with a new mechanism of action with apparently no superior efficacy. If the disease 
can be treated effectively with an injection, why should the payer pay much more for an oral 
formulation and its increased convenience (Insight, 2016)? Should a part of the budget be 
used for a severe need of a few or rather for a medium or moderate need of many more? 
How much of the budget size and allocation is influenced by advertising and lobbying? 
1.2.2 Current challenges and opportunities 
The “freedom of therapy” (or ”clinical autonomy” (Britten N. , 2001)) enjoyed by doctors 
until recently, may be coming to an end. Scientific progress translated into consensus on 
therapy standards, improved transparency, increased exposure to malpractice suits, 
augmented pressure from insurers and payers to reduce spending, the introduction of AI for 
diagnostics and therapeutic decision making and more, might be limiting the available 
choices, while at the same time enable more efficient decisions which should produce better 
outcomes. New technologies such as Watson, AI and machine learning have been developed 
or are being developed for use in healthcare mainly to support the management of large 
quantities of data. During the writing of the thesis, the use seems still not to be firmly or 
consistently established. While the situation is evolving, it can be observed that even 
healthcare systems which are very advanced and which have some of the largest healthcare 
spending per inhabitant as a percentage of GDP and in absolute terms (Reinhardt, 2004), 
can be facing a reduction in life expectancy (NCHS, 2017). Despite better education, better 
drugs, better diagnostics, more available funds and better data, suffering and morbidity are 
increasing (Anderson, 2003). Morbidity increases with lifestyle choices on diet and physical 
activity. Yet, in addition, such outcomes can be explained by a combination of suboptimal 




making driven by specific processes and incentive systems which do not drive the right 
therapeutic behaviors as required (Davis, 2007; Starfield, 2000).  
1.2.3 Implication for rare diseases and rationale for this thesis 
While above holds true for practically all areas of medicine across therapeutic areas and 
healthcare systems, it is especially true for patients afflicted by rare diseases who suffer the 
most. Rare diseases are mostly debilitating and life-altering, wrong therapeutic decisions 
have a significant impact in terms of health outcomes and quality of life (Schieppati, 2008). 
The gaps between what is theoretically and practically possible today and what truly happens 
in real life, can in many cases not be explained by lack of solutions, lack of funding or even 
lack of policy or goodwill. The main goal of this thesis relates to how fully integrated 
evidence-based decision making would provide important benefits to patients, healthcare 
providers and payers. Comprehensive real-world data can provide the evidence in a way that 
clinical trials cannot, for example, that increased patient convenience leads to improved 
long-term outcomes (through better compliance) and thus justifies the higher cost. 
1.2.4 Decision-making challenges in healthcare 
The healthcare industry is a complex system of stakeholders with widely differing 
objectives, incentive systems, depths of knowledge, experience, criteria for decision making 
and personal exposure to the consequences of the decisions made. The road to the ultimate 
goal of universal, optimal and affordable health coverage for all is paved with challenges 
and inefficiencies (Evans, 2013), and still a long way off into the future (Shaikh, 2017). At 
the center of healthcare is the patient who has a medical need. The prescribing doctor 
performs a diagnosis, prescribes treatment and assesses the outcome (Couet, 2013, Szasz, 
1997). While this basic process is followed around the globe, it is also burdened by 
complexity and conflicting forces.  
In the recent past, the term EBM was coined to describe and promote the process of 
systematically finding, appraising and using contemporaneous research findings as the basis 
for clinical decisions (Rosenberg, 1995; Straus, 2019). This approach factors in the clinical 
outcome of the therapy (also expressed as efficacy). After two decades of enthusiasm and 
significant improvements, a set of challenges surfaced, such as distortion of the evidence 
brand, an unmanageable plethora of evidence, increasingly marginal gains, overemphasis 
on following algorithmic rules, and a poor fit for multimorbidity (Greenhalgh, 2014). More 
research is needed to incorporate all available evidence, address the newly identified 
challenges and improve the treatment approaches for the well-being of the individual patient 
(Hoffmann, 2014), while maximizing the effectiveness within the larger socio-economic 
context. A society governed by the laws of economics, i.e. with limited resources and 
funding, needs to make choices and set priorities on which treatment to offer one or more 
individuals and at what cost, in order to maximize the health outcome of the whole 
population. Payers already have to make these decisions with the support of bodies dedicated 
to evaluating healthcare excellence (NICE, 2018). Some drugs and treatments are not 




especially for the affected individual patient (Donnelly, 2015) and are or should be the result 
of clinical, ethical and economic considerations.   
This thesis set out to analyze the current decision-making process, drivers, incentives and 
impact of the key stakeholders on the treatment of rare diseases.  
1.3 Motivation for the thesis 
1.3.1 Challenges specific to rare diseases 
Rare diseases pose a number of additional and unique challenges that have a direct impact 
on the well-being of the affected individuals, their families, their workplace, social 
environment and, by aggregation, to society. Awareness concerning rare diseases is low due 
to the extremely low prevalence of these conditions. Relative lack of experience and 
education frequently are reasons for no diagnosis or misdiagnosis (Shen, 2017). For several 
rare diseases, patients are diagnosed only after years, decades, and sometimes never (Knight, 
2006, Zanichelli, 2015). The identification of patients through classical screening programs 
is economically and logistically not viable given the low probability of finding patients when 
the prevalence is less than 1:10,000. Innovative approaches using big data, social media and 
medical record data mining, bio markers and more, are required to provide the diagnoses for 
rare disease. These approaches are also required in some cases to discover the patients, and 
for evidence-based decision making in the course of action. Rare diseases are mainly 
genetic, frequently hereditary, but they can also result through genetic mutations. In almost 
all cases they are debilitating and cannot be cured, except with gene therapy which is in its 
infancy (Schieppati, 2008). The only options for people living with a genetic disease are 
drug therapies which aim to mitigate the symptoms and allow for a better quality of life. 
Rare diseases often increase their devastating impact on patients through co-morbidities 
(other coexisting conditions) which impede normal life. Education, professional 
development and career opportunities are significantly affected causing stigma, as the 
patients tend to fall behind in their professional development, refrain from participating in 
social activities, and are perceived or perceive themselves as not being “normal”. 
1.3.2 Expected contribution of this thesis 
This thesis was expected to contribute to the decision-making process in regards to optimize 
the use of resources to help affected patients. Drugs that treat rare conditions are called 
orphan drugs. Their discovery and development costs are approximately the same as for 
mass-market conditions, but the small number of diagnosed and treated patients allow for 
only a fraction of the drug consumption. Thus, there is a significantly reduced volume base 
to recoup the investments made in orphan drug discoveries. For this reason, treatment costs 
are significantly higher and, in most cases, not affordable by the individual. Regulatory 
bodies and payers cannot apply the same criteria for approvals and reimbursement as for the 
more classical treatment methods. From a utilitarian perspective, it would be considered 
unethical to invest substantial amounts of resources to develop treatments for rare 




opportunity costs (Gericke, 2005). On the other hand, society has the moral obligation not 
to abandon individuals that are affected by severe conditions, as rare as they might be.  
While in many cases scientific knowledge, drugs and even funding do exist to mitigate the 
condition, in real life only a minority of patients benefit. A comprehensive and fully 
integrated evidence-based decision-making protocol for healthcare systems could provide 
economically viable and acceptable relief to people affected by these conditions and with a 
significant unmet medical need.  
The focus of this thesis relates to the effectiveness - the extent to which an intervention does 
more good than harm when provided under the usual circumstances of healthcare practice - 
vs. efficacy - the extent to which an intervention does more good than harm under ideal 
circumstances such as within a trial. To evaluate the efficiency and the cost efficiency of 
therapies, clinical trials need to be supplemented with RWE, and this thesis builds heavily 
on performing meta-analyses by consolidating a body of knowledge built over the recent 
years for HAE. 
1.4 Thesis aims  
The thesis aimed to first understand and describe in a structured way existing decision-
making processes, variables and criteria used by the different stakeholders involved in 
therapeutic decision making and funding. Agency theory was used as an underlying 
theoretical framework and as a basis for understanding better the connectedness of a 
healthcare system. The thesis aimed to validate its mechanisms and some of its gaps, like 
the complication that within healthcare systems there are multiple agents for the same 
principle, that they influence one another, that there are different information asymmetries 
which can be in either direction. This was expected to be achieved with an analysis of new 
data that has become only recently available thanks to the soaring digitalization, the 
diffusion of databases, and the advent of complex analytics. The objective was to integrate 
the increasingly granular and longitudinal RWE and relevant socio-economic data into one 
framework which could subsequently be used to drive decisions which maximize both health 
and quality of life outcomes at the individual level and within healthcare systems as a whole. 
The full integration of all known considerations is key to achieving a more comprehensive 
evidence-based decision-making framework. By applying agency theory, it was envisaged 
that such a framework would be explained in such a way that a network of relationships 
could be better articulated between health providers, payors and end-users within the 
healthcare space.  
This thesis focuses on rare health conditions, specifically a potentially fatal condition, or 
HAE, where the burden of the disease, impact of drugs and economic implications are 
stronger than for comparable mass market and specialty ailments (Angelis, 2015). Further, 
this segment of the healthcare space has been going through a rapid transformation which is 
raising new challenges to all stakeholders (Schieppati, 2008). This is the case for health care 
providers and payors who face unmet medical needs combined with economic constraints, 





In this thesis, a theoretical framework and some of its gaps are validated. With the newly 
accessible data, possible extensions in scope have been explored, aiming to develop a more 
comprehensive framework. This framework is expected to describe and guide through an 
improved and optimized collection, interpretation and leverage of evidence which can then 
be utilized by the various stakeholders to produce better health outcomes. Beyond the 
principles, possible solutions and improvements have been developed for systems, 
processes, decision-making criteria, incentive systems, behaviors and communication by 
and between the different stakeholders. While the point of “perfect equilibrium” can 
probably not be reached, there is room for significant improvement, which was translated 
into more cost-effective, rapid and impactful healthcare. Optimized healthcare finds a 
balance between five closely interrelated dimensions (Groves, 2013) including (1) healthy 
living with individual lifestyle choices that maximize health and prevent disease, (2) 
appropriate care providing timely and appropriate treatment, (3) qualified healthcare 
provider performing the adequate activity to achieve the outcome, (4) appropriate resourcing 
ensuring cost-effectiveness while eliminating fraud, waste and abuse, and (5) appropriate 





2 CHAPTER TWO - RESEARCH QUESTIONS 
AND THEORETICAL FRAMEWORK 
2.1 Problem Statement 1 
EBM alone does not explain all therapeutic decisions made by physicians. Multiple 
stakeholders around the patient influence and drive therapeutic decisions based on different 
and sometimes conflicting criteria and objectives, resulting in controversies and real or 
perceived suboptimal outcomes and deployment of resources. The issue is further 
accentuated for rare diseases with far fewer patients, facing significantly higher treatment 
costs, and less information and experience available to drive decisions. The vast majority of 
rare diseases are genetic and cannot be cured. A few high-cost treatments exist, but they can 
only mitigate the impact on the quality of life of patients exposed to life-altering and 
debilitating symptoms.  
RQ 1.1: How do different stakeholders and decision-makers have an impact on patients 
with rare diseases? 
RQ 1.2  Are diagnosis and treatment decisions made with EBM, QoL, HE and RWE 
considerations in mind? 
2.2 Problem Statement 2 
The three perspectives EBM, QoL and HE/RWE are not linked and most often not 
considered together in all relevant decisions. The three key groups of stakeholders HCPs, 
patients and payers do not share objectives, decision-making criteria and not systematically 
communicate with each other neither on policy nor on the treatment of individual patients. 
This results in suboptimal clinical results, conflicts and missed opportunities of cost-
effectiveness.  
RQ 2: How can the decision-making process and the available and potentially available 
data be combined to allow the stakeholders to make economically more efficient therapeutic 





2.3 Theoretical framework 
2.3.1 Agency theory 
The thesis builds on the agency theory, which describes systems with principals and agents. 
“Agents” are persons or entities who are able and expected to make decisions on behalf of 
other persons or entities (“principals”) and where the outcomes are the consequence of the 
agents’ actions (Bandura, 2001). Dilemmas arise in circumstances where the agent is 
motivated to act following other interests that are different or even contrary to the ones of 
the principal. These dilemmas are called moral hazard. In its original form, agency theory 
argues that in the modern corporation, managers decide and act in their own interest, which 
leads to different activities and lower shareholder returns, compared to if the owners 
exercised control. (Pratt, 1985, Jensen, 1976). Another problem highlighted by agency 
theory is the problem of risk sharing, when principal and agent have different attitudes 
towards risk. These problems generate so-called agency loss which results from the 
asymmetry of information (Tofan, 2012) and misaligned incentive schemes. Agency theory 
has also developed mechanisms to reduce agency loss. (Eisenhardt, 1989, Dwyer, 2012). 
The basic idea of agency theory is illustrated in Figure 2.3.1. 
 
 





2.3.2 Agency theory adaptation to healthcare systems 
The agency theory has been adapted from the business world to the healthcare space, with 
the aim to describe the mechanism, challenges and potential dilemmas (Langer, 2008, Gafni, 
1998).  Previous scholars have already identified the doctors as double agents, accountable 
to both the patients and the payors (Tofan, 2012, Angell, 1993), as illustrated in Figure 2.3.2. 
 
 
Figure 2.3.2 - Possible adaptation of agency theory to healthcare systems 
Reality seems to require a more comprehensive and complex adaptation of agency theory: 
there are multiple interdependencies between all three parties and further complications 
producing information asymmetry, which can run in opposite ways across all stakeholders. 
Despite the complexity, the theory is expected to describe the mechanisms that lead to 
suboptimal outcomes and possible solution paths (Shortell, 1998, Scott, 2003, Stavropoulou, 
2012). 
This thesis is expected to observe and potentially confirm the real-life implementation of 
governance approaches in the area of modern treatment of rare diseases, which has been 
partially discussed in more generic settings by previous research (Vick, 1998). It will attempt 
to observe and confirm the governance devices in place to alleviate the agency problems 
between patients and physicians and then possibly contribute to the expansion of the theory 
with an integrated framework which can offer real-life results through better clinical 





3 CHAPTER THREE - LITERATURE REVIEW 
The literature search was conducted through a systematic search by relevance (variables, 
rare disease, HAE, less than seven years) but also extended its scope beyond HAE and rare 
diseases to ascertain transferability of concepts. The literature search analyzed and extracted 
data from a selection of articles in Medline and Embase filtered for duplication and relevance 
based on the presence of relevant keywords. Articles were searched based on selected 
keywords such as EBM, QoL, health economics, diagnosis, treatment, clinical outcome, on 
demand treatment and other technical terms relevant to the treatment of medical conditions. 
These were subsequently combined with each other and with the terms “rare disease”, 
“genetic disease” and “hereditary angioedema” to ensure all literature pertinent specifically 
to the slected condition are also included. All references cited in the literature were also 
followed to include the original sources and the the sampling of articles was performed 
based on publication date (priority on articles after 2010) and availability of numerical data 
and quantitative analysis. 
3.1 Evidence Based Medicine (EBM)  
3.1.1 History of EBM 
Florence Nightingale wrote in her book (Nightingale, 1863) about 150 years ago that “In 
attempting to arrive at the truth, I have applied everywhere for information, but in scarcely 
an instance have I been able to obtain hospital records fit for any purpose of comparison. If 
they could be obtained, they would enable us to decide many other questions. They would 
show subscribers how their money was being spent and what good was really being done 
with it.” In contemporary society, we still face the challenge of deciding how to use limited 
funds to decide on treatments relative to each other in terms of efficacy and cost-
effectiveness. 
In the 1980s the concept of Evidence Based Medicine (EBM) was coined at McMaster 
Medical School in Canada as a process to turn clinical problems into questions and then 
systematically locating, appraising, and using contemporaneous research findings as the 
basis for clinical decisions. The approach was triggered by the limitation of most doctors 
having a narrow perspective, limiting themselves to their own experience and that of a 
relatively few colleagues with whom they exchange views. This sometimes led them to 
make erroneous conclusions while also failing to search for evidence which might cause 
them to reach a different conclusion or allow them to come to a more balanced decision 
(Grahame-Smith, 1995). The physician’s personal experience can in most cases be 
characterized as anecdotal, ungeneralizable and not the best basis to make scientific 
decisions with the patient’s health as an objective (Green, 1998), yet still today it appears to 
be a most powerful persuader and driver, more so than scientific publications. All too often 
physicians, in their daily work, are unaware of the available clinical and scientific evidence 
and/or fail to apply it (Guyatt, 2004). Their values differ from the patients, who sometimes 




3.1.2 Role of Randomized Controlled Trials in EBM 
Randomized Controlled Trials (RCT) are the ‘gold standard’ for establishing efficacy and 
required to seek regulatory approval to market a drug, but they draw their data in an idealized 
environment and can only measure efficacy in limited populations. As such, compared to 
real-life data, they cannot provide a true indication of a drug or a treatment’s effectiveness. 
(Annemans, 2007). Results are obtained in a highly controlled environment, over a small set 
of subjects, over a short period of time, across a handful of highly dispersed clinical trial 
centers. Regulatory bodies ask questions about the sole dependence on randomized clinical 
trials and the lack of real-life supporting evidence by pharmaceutical companies on the 
efficacy and effectiveness of new drug treatments (Saha, 2015). Subjects and patients are 
often highly selected (e.g. younger, stronger) raising questions on the representation of “all 
patients in the world”. Further not every clinically important question can be addressed 
through clinical trials be it for recruitment challenges, ethical constraints, or other limiting 
factors. Real-life data needs to be sourced outside of the scope of a clinical trial and includes, 
for example, epidemiology, compliance, adherence and cost insights (Dangi-Garimella, 
2017). An interesting side effect and reality check would be that real-world adherence is 
lower than in a clinical trial setting.  
3.1.3 Use of evidence in EBM 
EBM is the conscientious, explicit, and judicious use of current best evidence in making 
decisions about the care of individual patients. The approach integrates individual clinical 
expertise with the best available external clinical evidence from systematic research 
(Sackett, 1996). Computer power (hardware and software) theoretically permits to rapidly 
locate any relevant evidence that would make it easier for busy clinicians to make best use 
of the published literature. (Rosenberg, 1995). With the invaluable skill to appraise critically 
publications of all types, it is possible to close the gulf between good clinical research and 
clinical practice (Rosenberg, 1995), especially to overcome the human trait of over-
interpreting experiences with individual patients. EBM claims that experts are more fallible 
in their treatment recommendations than evidence from sound systematic observation, 
presuming further that in most cases basic science alone does not provide valid and practical 
guidance (Brian Haynes, 2002).  
Hence the EBM approach is used across all steps from diagnosis, prognosis, treatment, 
quality of care, and health economics, with this latter still demanding most of the work and 
research. 
3.1.4 Introduction of EBM into clinical practice 
Historically medicine was based on the physician’s authority, his personal experience, and 
a component of tradition. Few people understood the work of a medical doctor (Hoffmann, 
2014). The basic assumption that led to EBM was that evidence from sound systematic 
observation enables better healthcare and better care for patients. The objective of EBM is 
to augment the individual clinical experience of healthcare practitioners, not to just replace 
their experience (Brian Haynes, 2002). On this pursuit, physicians, practitioners, health care 




that are both scientifically valid and applicable for treatment. In order to reach this improved 
state, practitioners in general had and still have to accept that the bases for therapeutic 
decision-making can change, they have to accept that some decisions made in the past are 
not valid anymore, and they have to embrace these evidence-based changes, sometimes 
admitting to them and explaining them to their patients. 
In the more of two decades since its inception, the concept of EBM has delivered numerous 
successes, yet there is still a wide variation in its implementation, which is cause for 
challenges (Greenhalgh, 2014). Pharmaceutical and medical device companies have an 
economic interest which sets their strategic agenda. They decide on the drugs that will be 
pursued, the tests and treatments that will be compared, and frequently also the measures 
and the values which define both what is the condition and what is considered to be success 
in its treatment.  
3.1.5 Current state of affairs of EBM 
For some conditions with a high prevalence affecting a large share of the population and 
where significant clinical progress has been achieved, the volume of evidence available has 
increased exponentially. The volume of relevant data has become such that making it 
available and keeping the clinicians up to speed has posed a new hurdle (Greenhalgh, 2014). 
Conditions that have been at the center of attention for a longer period of time have been 
thoroughly researched and EBM is providing only marginal gains. Rare diseases that have 
been identified relatively recently appear to be subject to comparatively large investments, 
strong progress, and therefore surge in the available evidence.  
Widespread use of EBM has made it a tool also for institutional control and healthcare 
policy, hence it has assumed a political component. As a consequence, changes and funding 
of medical practice have political, legal and medical implications which requite the attention 
and endorsement by the respective institutions (Greenhalgh, 2014).  
Rare conditions have a dominantly genetic cause and often multimorbidity. Clinical trials 
aim to have a narrow scope to enable isolation of cause and impact, using or defining 
algorithmic rules. Subsequently, both the evidence and the algorithmic rules have a 
constrained spectrum of applications, which limits their usefulness in complex multimorbid 
patient situations.  
3.1.6 EBM applied 
Following the diagnosis of the patient, the clinician evaluates all available evidence in the 
form of articles, with a set of questions the reflects common sense, but is not always obvious 
(Rosenberg, 1995), for example 
• Are the results valid? 
• Was the assignment of patients to treatments randomized?  
• Were all patients who entered the trial properly accounted for and attributed at its 
conclusion?  
• Was follow up complete?  
• Were patients analyzed in the groups to which they were randomized?  




• Were the groups similar at the start of the trial? 
• Aside from the experimental intervention, were the groups treated equally? 
• What are the results? 
• How large was the treatment effect? 
• How precise was the treatment effect? 
• Will the results help me care for my patients? 
• Can the results be applied to my patient care?  
• Were all clinically important outcomes considered?  
• Are the likely benefits worth the potential harms and costs? 
While the evidence would not automatically dictate patient care, it does provide a broader 
and more robust factual basis on which decisions can be made, compared to previous 
personal and more limited experience of the health practitioner. EBM takes all aspects of 
patient care into consideration and can subsequently be utilized directly in a patient's care 
or further, to develop team protocols or even hospital guidelines (Rosenberg, 1995). 
3.1.7 EBM requirements  
EBM demands a willingness to admit uncertainty, to encourage skepticism, and to be 
flexible, but with the advantage to accommodate new evidence which may contradict 
previous assumptions and practice (Rosenberg, 1995). This indicates that its potential for 
improving continuity and uniformity of care across health systems through the common 
approaches and guidelines developed by its practitioners is the basis of the ultimate objective 
of this thesis: broadening the scope to include healthcare effectiveness including wider and 
deeper socio-economic considerations. 
3.1.8 EBM advantages 
EBM offers a range of advantages: external clinical evidence invalidates previously 
accepted diagnostic tests and treatment and replaces them with new ones that are more 
powerful, more accurate, more efficacious, and safer (Sackett, 1997). It allows clinicians to 
routinely upgrade their knowledge base, improve their understanding of research methods 
and makes them more critical in using data, improves their confidence in treatment and 
management decisions. Clinical teams benefit from a framework for group problem solving, 
for teaching and for juniors to contribute usefully to the team. Most important is that patients 
benefit from more effective use of resources and a better understanding and communication 
about the rationale behind treatment decisions (Rosenberg, 1995). 
3.1.9 EBM challenges 
To complete the picture, EBM also poses a number of challenges: it takes time both to learn 
and to practice. Inevitably, it exposes gaps in the evidence, but this additional rigor and 
transparency forces research and development to higher standards of quality. While 
technology has become a strong enabler, electronic databases used for finding relevant 
evidence could still be not comprehensive, nor always well indexed, nor contain the 
information needed to avoid litigation (Sackett, 1996; Straus, 2019). Authoritarian clinicians 




practice as obsolete or occasionally even dangerous (Rosenberg, 1995). Despite the use of 
much broader, validated and stronger evidence, the inherent bias of journals and authors 
towards positive results stays: they are not so interested in negative conclusions; things are 
much more interesting if they turn out positive (Grahame-Smith, 1995). Some critics argue 
that at best, EBM is a heuristic method for a lower level of partial abstraction (Sackett, 1996) 
not giving justice to its strengths when fully applied. Another potential risk could be that 
taken in isolation, better data can lead to additional activity without improving overall 
patient outcomes (e.g. unnecessary screening to amortize expensive equipment or 
resources). Additional evidence would need to come together with more transparency, 
improved scrutiny and realigned incentive systems to prevent such abuse. The primary 
challenge with real-world data and true evidence is to ensure quality and the right incentives 
at the point of care to extract relevant information (Dangi-Garimella, 2017). The use of real-
world evidence could introduce new sources of bias which can completely distort the results: 
different degrees of severity of a condition are often treated with different drugs which 
makes some treatments look more or less effective than what they really are or than what 
would be visible in an observational study. Ultimately, a practical limitation may need to be 
considered: most busy prescribing doctors simply lack the time or the skills to track down, 
absorb and integrate the evidence into their daily routine (Davidoff, 1995). To help the 
physicians with their treatment and to ensure a consistent approach across patients and 
healthcare systems, clinical guidelines are being used. 
3.1.10 Purpose of clinical guidelines as an execution instrument for EBM 
Clinical guidelines have been introduced and are a widespread and essential tool to ensure 
high-quality medical practice. They deal with clinical conditions or symptoms, health care 
providers and clinic managers use them in their daily patient management (Woolf, 1999) 
through health care policy, planning, delivery, evaluation, and quality improvement. They 
consolidate and bridge the gap between EBM, policy, local contexts and patient choice 
(Kredo, 2016). Clinical guidelines are transparently constructed, and continuously updated 
evidence-informed approaches integrated with expert opinion and patient values (Grilli, 
2000). 
Guidelines can be developed by representative groups of specialists, or also by official 
institutes like the National Institute for Health and Clinical Excellence (NICE) in the UK. 
NICE produces clinical guidelines, quality standards, public health and health technology 
appraisal guidance for the National Health Services. In its function, the institute 
commissioned the National Clinical Guideline Centre (NCGC) to produce clinical guidance 
and quality standards on patient experience in adult NHS services. Such a process showcases 
the important role that guidelines have in ensuring high-quality, effective and appropriate 





3.1.11 Application of clinical guidelines in medical practice 
Clinical guidelines assist physicians and patients when making therapeutic decisions about 
appropriate health care for specific clinical circumstances (Graham, 2011). In practice, 
clinical guidelines are recommendations intended to optimize patient care, built on a 
systematic review of the evidence and an assessment of the benefits and harms of alternative 
care options. In addition to recommendations on specific drugs to be prescribed, they may 
offer concise instructions on which diagnostic or screening tests to perform, how to provide 
medical or surgical services, how long patients should stay in the hospital, or other details 
of clinical practice (Woolf, 1999). Other frequently used descriptions are protocol and care 
pathways. Protocols are sets of rules or instructions about how to do a particular process 
explicitly, and without error (Campbell, 2003). Care pathways describe series of evidence-
informed steps, which lead the journey of care of patients following a particular diagnosis 
(Rotter, 2010). 
The adherence by physicians and patients to guidelines improves effectiveness and quality 
of care, decreases variations in clinical practice and decreases costly and preventable 
mistakes and adverse events (Kredo, 2016). 
3.1.12 Clinical guidelines as a means to reduce complexity and costs 
A few decades ago, for most conditions, there was a single class of drugs built on a single 
mechanism of action, with a few primary drugs with similar profiles that could all be 
prescribed. Science and medical knowledge have increased exponentially and today, for the 
same condition, several biochemical processes are addressed by multiple classes (for some 
oncologic conditions there can be at least seven or eight primary drugs that in addition can 
freely be combined between them (Frank, 2007)). Healthcare costs are rising rapidly, driven 
by an ageing population with increased demand for care which includes more and more 
expensive technologies. 
The concomitant cognitive burden faced by many physicians can cause wrong or delayed 
decisions, additional costs, and suboptimal health outcomes for the affected patient. In 
addition to the complexities driven by scientific progress, physicians are exposed to other 
sources of complexity as well. Globalization has caused many countries to become more 
diverse in terms of cultures, races, ethnicities, with consequently different attitudes and 
levels of experience towards illness and responses to treatment. Healthcare systems appear 
to have stratified with more fragmented insurance arrangements. Physicians are serving 
patients covered by different insurance plans with each plan possibly having different prices, 
coverage and constraints on utilization of care and prescribing.  
Such complexities and diversity can cause variations in service delivery among providers, 
hospitals, and geographical regions. A likely result would be that at least some of this 
variation stems from inappropriate care and the overuse or underuse of services. Healthcare 
professionals desire and are bound by agency to offer the best care possible and therefore 
clinicians, policy makers, and payers see guidelines as the instrument to make care more 
consistent and efficient (Woolf, 1999). Guidelines, protocols, pathways on what physicians 
and health care professionals should do in particular situations are instruments in the effort 




therapeutic execution based on updated guidelines would reduce complexity, close the gap 
between what clinicians do and what scientific evidence supports, providing solutions that 
timely and effectively benefit the majority of all stakeholders in a consistent manner. In 
short, clinical guidelines improve efficiency through standardized care and optimized value 
for money. 
3.1.13 Clinical guidelines vs. customization 
Customization of medical care drives four types of costs (Frank, 2007): (1) Communication 
costs: Communicating with patients to determine their symptoms, histories, and preferences 
take time and effort. More and more patients seek information on the Internet or have already 
been influenced by friends or family members, by direct to consumer advertising or by the 
popular press. Frequently the treating physicians need to correct or complete wrong or 
misleading perceptions developed by nonprofessionals and persuade or negotiate the 
following of the correct treatment (Groopman, 2007). (2) Cognition costs: Effort and time 
required by a physician to absorb, comprehend and factor in all information from different 
sources (including patients and clinical evidence) necessary to decide on treatment and to 
follow up based on outcomes. (3) Coordination costs: Moving away from consensus 
treatment paradigms and guidelines, physicians possibly need to involve other stakeholders 
either for advice or for approval for decision and execution of treatment. (4) Capability costs: 
To provide customized medical care, physicians need to have the right capabilities to 
understand and be able to prescribe different therapies or combinations thereof. Such 
specialization requires upfront one-time investments and normally also continuous medical 
education to stay up to date with scientific progress.  
3.1.14 Limitations of guidelines 
Despite their known benefits, studies have shown that guideline implementation is complex 
and challenging. The different stakeholders (patients, physicians, health institutions, 
healthcare systems, and more) are often subject to misaligned or even competing drivers and 
incentives (Liang, 2017). In areas undergoing rapid scientific advancements and progress, 
guideline developers and implementers may find it harder to stay updated or even aware of 
the latest and most relevant theories and results among the multitude available, when 
choosing or tailoring medical interventions. 
Guidelines are by definition designed for an effective health impact on broad classes of 
patients. Individual patients might be exposed to unique circumstances and the optimal 
treatment might not be aligned with the guidelines and in addition entail costs of 
coordination and cognition, which takes the treatment approach back to how it was done 
historically (Frank, 2007). Rigorously following the guidelines may lead to wrong 
recommendations for individual patients or groups of patients. 
More fundamentally, concerns have increased on the quality, reliability, and independence 
of practice guidelines. It has to be remembered that scientific evidence about what to 
recommend can still be lacking, misleading or misinterpreted. The guideline development 
groups additionally influence the content of the guidelines through opinions, different 




not require unanimous endorsement to become effective. Studies have been conducted on 
the quality of guidelines measured in terms of whether they reported the type of 
professionals and stakeholders involved in the development process, the strategy to identify 
primary evidence and how recommendations were graded according to the quality of 
supporting evidence. The majority did not meet the criteria indicating that basic 
improvements need to still be made, including the setting up of explicit methodological 
criteria for the production of guidelines (Grilli, 2000; Kung, 2012; Shaneyfelt, 2012; Ruan, 
2015). 
3.1.15 Evaluation of healthcare 
The evaluation of health care depends on the criteria used by every stakeholder. Overall it 
has been advocated at a relatively early stage that in aggregate three criteria should be used: 
clinical effectiveness, economic efficiency and social acceptability (Doll, 1974). This thesis 
aims precisely to measure the impact of the different stakeholders and the roles of the 
different perspectives in the decision making and execution of alternative therapies, with the 
objective in the second phase to explore the combination of all in order to attain superior 
outcomes in a more cost-effective way. Social acceptability plays a key role, as Doll (1974) 
already noted, “there is no point providing a health service that is clinically effective and 
economically efficient, but no-one wants”. 
3.1.16 EBM and shared decision making 
EBM is defined as the explicit, judicious, and conscientious use of current best evidence 
from health care research in decisions about the care of individuals and populations (Brian 
Haynes, 2002). Once a diagnosis of the condition is confirmed, ideally patients and 
healthcare provider decide together on the course of action based on the available and known 
evidence. The treatment decision by the physician should not only build on research and 
clinical evidence, but also reflect the patient’s values, preferences, circumstances and local 
context. (Hoffmann, 2014). Patients and clinicians would-be partners and such a partnership 
would presume that the treating physician facilitates patient involvement and is open to 
adjusting the treatment to the preference of the patient. Studies have shown that patients are 
unable to fully partner during the clinical encounters, and at the same time, physicians do 
not like their patients to engage (or interfere) in the decision-making process (Couet, 2013). 
Lack of time, skills, knowledge, mutual respect and effective communication processes pose 
barriers to effective shared decision-making (Staniszewska, 2014). It appears that a large 
portion of doctors believe they know how much the patient wants to be involved and even 
what therapy the patient would prefer, if he or she had full access to and ability to fully 
interpret the clinical data. With this approach, EBM could turn into forcing evidence and 
measures onto a not fully engaged patient resulting in suboptimal adherence and clinical 
outcomes.  
The ideal working solution is best described as shared decision-making, where both clinician 
and patient jointly assess options with their benefits and harms, and together decide, 
incorporating the patient’s values, preferences, and circumstances (Hoffmann, 2014). High-




physician: the patient is an active participant, the physician is responsive with his or her 
services, he or she offers an individualized approach, provides a lived experience that 
includes continuous care and relationship, and lastly offers timely communication, 
information and support (Staniszewska, 2014). 
3.2 Randomized Clinical Trials (RCT) 
3.2.1 RCTs 
EBM had been mainly defined by scientifically validated evidence generated through RCT 
(randomized clinical trials). Increasingly there is awareness and belief that the patient’s 
experience of the condition, as well as the real-life implications,  should be included in all 
EBM considerations (Greenhalgh, 2014). RCTs are designed to demonstrate under ideal and 
controlled conditions the causality between the use of a specific drug or treatment and the 
intended and unintended effects on the health of the study subjects. RCT generate results 
from a small set of patients in a highly controlled environment, across a handful of highly 
dispersed clinical trial centers over a short period of time (Saha, 2015). 
RCTs follow a few key concepts (Gerss, 2010). They need to be externally valid, which is 
achieved through the recruitment of representative samples and the use of inductive 
statistical analyses, where the results can be generalized from the sample to the total 
population. To assess the effect of the studied treatment, internal control groups are assigned 
to receive a control intervention which can be a placebo, a reference treatment (if a head to 
head comparison is the goal), or the same treatment with different dosing administration 
quantities, or scheduled, or no treatment at all. Internal validity across patient groups is 
obtained through randomization and both subjects and trial personnel are kept blinded, 
which coined the name “double blinded”, to remove bias. Primary and secondary outcomes 
are pre-specified before the trial starts, and carefully defined to satisfy criteria of validity, to 
measure what is intended, to eliminate or minimize bias, to be reliable, sensitive to change 
and realistic. The analysis has to be pre-specified to ensure validity is obtained, and that 
basic null- and alternative hypotheses are specified. Scientific evidence is achieved by 
statistical significance, which defines the sample size based on the upper bound of false 
positives that is considered acceptable, which usually is set at 5%. When publishing results, 
it is expected that the researchers reveal the level of scientific evidence and the limitations 
of the trial and its conclusions. 
3.2.2 Limitations of RCTs 
RCT narrow down the scope to highly selective populations which as a result cannot be 
compared with or are not representative of the more heterogeneous populations in real life 
where patients show varying genetic make-ups, present different comorbidities and/or are 
already under treatment with other medications. The majority of RCTs fail to achieve their 
initial enrollment projections and delays in patient recruitment can disable the trial and 
potentially halt the whole R&D program (Davis, 2017). RCTs are not the only source of 




trials can help address the challenge of individual low powered clinical trials (Day, 2010). 
Another approach is Real World Evidence (RWE).  
3.3 Real World Evidence (RWE) 
3.3.1 RCTs vs. RWE 
RCTs are required by regulatory bodies as a mechanism to evaluate the efficacy of new 
drugs. RCTs cannot be replaced as controlled environments are needed to separate the 
impact of medical interventions. RCTs presume data being generated by a given probability 
distribution curve whereas different causes and effects are being tested. To evaluate the cost-
efficiency in absolute terms and in relation to other treatments, RCTs need to be 
supplemented by RWE (Saha, 2015). Increasingly regulatory bodies such as the FDA expect 
from pharmaceutical companies additional real-life supporting evidence on efficacy and 
effectiveness of new drug treatments. The differences are, that in RCTs patients are 
randomized to the treatments; physicians, and patients’ choices are not considered for 
selection of the treatment, non-adherent patients are taken out of the analysis and the 
experiment is based on an artificially created homogeneous treatment group. The purpose 
of RCTs is to establish the efficacy of the medication/therapy. With RWE on the other side, 
therapy or medications to patients are determined by doctors’ choices as per standard 
practice, non-adherent patients can switch the treatment and in such a case are likely to 
remain included. RWE contains heterogeneous patient populations reflecting realistic 
scenarios which are likely to indicate the effectiveness of the drug/therapy under various 
conditions. Real world data for RWE enables to better understand the full impact of a 
condition at a much larger scale than is possible with RCTs: it can enable researchers to 
observe and understand the patient’s experience across millions of patients versus the few 
thousand that are part of a typical RCTs. (Davis, 2017). RWE is the intersection between 
the structured rigor of RCTs, and the clinical exposure a treatment receives in real-life 
practice (Looney, 2016). RWE covers the whole patient journey through the treatment cycle 
and enables the learning of how the treatment performs in a wider variety of populations and 
practice settings. Observing how drugs are dosed and applied in clinical practice and how 
patients adhere to the prescribed therapies, would allow for a definition of more realistic 
clinical practice standards and guidelines. Under every scenario, RWE should substantiate 
the findings and the conclusions generated in more controlled settings, while also 
contributing to the generation of hypotheses to identify new drug targets, drug labels or new 
patient populations that may benefit. RWE is expected to generate insights that can be 
leveraged to affect decisions from R&D through commercialization, through the entire 
product life cycle. For rare diseases, it is often not possible to recruit an adequate sample 
size to attain statistical significance and test treatments following accepted and robust study 
designs for hypothesis testing (Hughes, 2005). This reality would further support the use of 
RWE for such conditions.  
In connection with RWE, the expresssion real-world data is also frequently used. The two 
terms real-world data ad RWE are used interchangeably but are in fact different (Elton, 




appropriate treatment decisions. RWE is the next step: the data is used to generate insights 
utilizing a rigor of analysis comparable to randomized and controlled clinical studies. As 
such it becomes representative and timely, complements traditional sources, validates 
clinical trials and becomes the foundation for pricing linked to therapeutic value and health 
outcomes as a whole for health systems. Real-world data is observational data which can be 
categorized into four types: (1) Patient claims data (available typically with payer, 
prescriptions, procedures, demographics, diagnoses, etc.); (2) Patient registries (available 
with provider and payer, demographics, diagnosis, prescriptions, laboratory tests results, 
outcomes, etc.); (3) Electronic health records (EHR/electronic medical records (EMR)), 
demographics, family histories, hospitalization details, etc.); (4) Web/social data 
(sentiments, dialogues). Real-world data can have a broad range of applications and is of 
immense value, yet it may not be a replacement for RCTs which, for the foreseeable future, 
appear to continue being the “gold standard” for demonstrating safety and efficacy. 
3.3.2 Big Data, AI and machine learning 
In the recent years technological progress in the information technology sector has brought 
substantial innovation opening possibilities to work with large amounts of data. The rapid 
surge of information thanks to the digitization has coined the term Big Data: not only for its 
sheer volume, but also for its granularity, complexity, diversity and timeliness. Researchers 
and practitioners can now mine the data to see what treatments are most effective for 
particular conditions, assess side effects, and increasingly important, assess and compare the 
socio-economic impact, from the costs to the quantification of QoL parameters (Lumry, 
2018). This has been a hot topic for some years and there is a wave of research and attempts 
at applications, but reality suggests challenges in execution and conversion of the concept 
into execution (McAfee, 2012; Mayer-Schönberger, 2013). Focusing on healthcare, Big 
Data paves the way for huge potential, applications like Watson by IBM, which are built on 
solid research and state of the art visionary technology (Groves, 2013) however the 
outcomes so far have been below expectations. The tipping point seems imminent, and yet 
elusive. Not only new tools and applications are necessary to take advantage of the new 
insights, but also new mindsets, system changes, and safeguard policies to protect the 
privacy of the patients. The full value will also come by changing the paradigm from data 
analytics and interpretation to predictive modeling and simulation of outcomes, which have 
never been used in a scale of this magnitude. Combinations of data systems and pools 
multiply the quantity and quality of insights compared to individual sets (for example 
combining treatments, clinical outcomes, behavioral data and costs) (Groves, 2013). 
Complexity and amount of data appear to require game-changing technologies and the use 
of AI (Artificial Intelligence) and ML (Machine Learning) appears to be the enabler. 
3.3.3 The influence from and on daily reality 
This broader approach on EBM needs to be effectively executed and therefore take into 
consideration the daily reality of the users, their routines, belief system, behaviors, 
expectations, time, and ability to absorb and act on information (Bates, 2003). Key 




when addressing behaviors and beliefs in real-life settings. Today’s technology and leverage 
of networks enable “on the spot” accessibility of information/evidence, which can be real-
time and possibly predictive and normative: EBM can even anticipate the needs of the 
treating physicians and the affected patient. On the downside, such an enabled and possibly 
wide-ranging approach can lead to information overflow, which needs to be managed as 
well as how accountability is to be managed. Discussions and decisions have to take place 
in regard to how difficult it should be made for physicians to overrule EBM based on 
possibly outdated information, limited experience or erroneous beliefs. 
The healthcare industry is lagging behind and reluctant to change, as healthcare 
professionals are used to making decisions independently and leveraging their own personal 
experience and clinical judgement. Due to privacy and ethical concerns, it is still not easy to 
share data, and the link or measure of a universal good, health, to economic values, appears 
to still be a taboo to many. Better clinical outcomes combined with cost pressures (e.g. 
already in 2009 healthcare costs in the US represented 17.6% of GDP) will be the main 
drivers to fully leverage what is technically possible in terms of both data and tools. 
Optimizing both may allow health care to take a leap, and with this thesis, we aim to 
contribute by describing a broader and deeper evidence-based approach. 
This thesis builds on the broadly accepted EBM concepts and extends it by pooling currently 
fragmented and dispersed data pools and insights, which combined are expected to be 
strengthened in content and depth. 
3.3.4 RCTs/RWE and meta-analysis 
RCT remains the ideal and most credible instrument for scientifically funded conclusions 
on treatment effectiveness, but they have logistic and ethical challenges (Richesson, 2010), 
which are even more dominant for rare diseases. As it becomes difficult to recruit sufficient 
patients for large RCTs, the question to ask is if a “large” study or a meta-analysis of two 
(or more) smaller studies leads to stronger results. Previous research suggests that every trial 
probably has some degree of bias inherent in it. While the investigators aim for an unbiased 
RCT, bias cannot be fully excluded, as small and inconsequential as it might be (Day, 2010). 
Further, it cannot be said how significant it, or even in which direction it skews the results. 
Avoidance of bias is one of the most critical features of any study and the original primary 
reason for randomizing. Two or more trials might reduce any possible bias, especially if 
these RCTs are executed by different organizations in different regions and possibly 
different patient populations. The results of such meta-analysis would be statistically 
stronger compared to those of a single study, even if the number of subjects was the same. 
This thesis builds on meta-analysis combining RCTs and RWE. 
3.3.5 From efficacy and effectiveness to RWE 
Efficacy is the extent to which an intervention does more good than harm under ideal 
circumstances, while effectiveness is the extent to which an intervention does more good 
than harm when provided under the usual real-life circumstances of healthcare practice. 
When improving and funding healthcare, payers focus on the cost-effectiveness of 




RWE. The disparity between the therapeutic efficacy of treatment observed in a tightly 
managed RCT and the effectiveness in a real-world setting is called the “efficacy-
effectiveness gap.” (Makady, 2017). RWE provides insights, foresight and predictive 
findings on diseases, products and patient populations based on observational data in real-
life settings. While RCTs focus on the lenses of the clinician and the patient, RWE patient 
outcomes incorporate also the perspectives of the payer, the drug or device manufacturer, 
and more (Looney, 2016).  
3.3.6 Sources for RWE 
RWE is typically generated from secondary analysis of observational non-interventional 
data provided by the health care system and the patients themselves, for example through 
digital health applications. These data sources reflect or measure the consumption of drugs 
or the use of medical devices by a mix of individuals in real-world settings, as opposed to 
controlled clinical trials. Sources include claims data from insurers and government health 
programs, clinical data from medical records, patient registries, laboratory results data, 
survey, social media, mobile technologies (health apps). Electronic health records are 
introduced into healthcare organizations worldwide to improve patient safety, healthcare 
quality and efficiency (Yu, 2018). RWE data such as for example the consumption of drugs 
and the impact of the treatment on daily life, can be collected in non-RCT settings, in non-
interventional/non-controlled settings or in non-experimental settings. There is the 
possibility of above-mentioned existing data-sources, but also to purposefully design studies 
that generate real-world data such as observational studies or pragmatic trials. Patient-
reported outcomes are commonly used in many areas of clinical research and have been 
proven useful when studying effectiveness when comparing alternative interventions, when 
monitoring changes in health status over time, or when predicting relevant clinical events 
through analysis of prodrome (Rajmil, 2010). 
Effective utilization of the multiple data sources would require increased transparency, 
standardization of data formats and definitions, advanced analytics, and linkages between 
disparate data types. Strong support in the form of collaborations across health systems, 
patient advocacy groups and digital health providers are key enablers and accelerators. As 
RWE does not involve random assignment of subjects to treatments, the researcher may 
need to additionally deploy advanced matching and statistical techniques to control for 
potential bias (Malone, 2017). The effort is warranted as stakeholders recognize the value 
of RWE in providing or reinforcing the evidence on the effectiveness of medications 
(Makady, 2017). 
3.3.7 Patient registries 
Patient registries are programs that collect, store, retrieve, and disseminate clearly defined 
set of data on identifiable individuals. The definition goes beyond a simple database to 
include also the systematic collection and use of the data stored in the registries. Besides 
patient details, registries also collect information about the condition, patient characteristics 
(family history, genetics), the treatment provided, and health measured taken over the course 




registries is to count and describe health and disease characteristics within a sampled 
population and consequently draw conclusions that can be extrapolated for a larger 
population or a population in a different healthcare system. 
Patient registries are being used for public health surveillance and for research inquiry. They 
are particularly important for tracking trends and understanding rare diseases, as they 
provide consistent streams of data for defined populations that can be shared for research 
and health policy purposes. The data can cover prevalence, incidence, treatments, outcomes 
and spending over time (Richesson, 2010). The value of the registry to a user is directly 
linked to its quality which depends on how completely each patient case is recorded and 
how valid each data point is.  
3.3.8 Challenges of patient registries 
Each registry can be subject to bias if it is linked to a specific center, a region or organization, 
whereas bias manifests in a mistaken estimate of a measure due to any systematic error in 
the design, conduct or analysis of a study. Registries may be affected by selection and 
information biases, with selection bias due to distortions the selection of subjects in the 
registry or from factors that influence participation or inclusion (Rothmann, 2008) and 
information bias due to systematic errors in the measurements (Richesson, 2010). Another 
type of bias could be lead-time bias, which results from advances in testing that enable 
earlier identification of the disease. The number of detected cases can be inflated when 
innovative technologies that can identify diseases non-invasively or earlier in the course of 
the disease are applied. This creates the false impression that the incidence of the disease is 
increasing. (Richesson, 2010). Combining different registries allows the validation of each 
while at the same product more rigorous statistical data. The longer and broader a registry 
has been in existence, the more consistent data collection, documentation and quality control 
have been, the more reliable it becomes, and the stronger the epidemiological findings and 
conclusions become. 
Another challenge arises when too much data is being collected or measured. Important 
funding, effort and time can be consumed for data of secondary importance instead of 
broadening the scope, which would enable stronger findings. Each variable included for 
measurement should have an operational definition and be standardized and simplified in a 
way allowing consolidation and comparison across registries (Richesson, 2010). 
To manage and own a patient registry requires resources, expertise and tight governance 
structures. A current trend suggests patients perform this through patient advocacy 
organizations, yet given the confidentiality of the data recorded, the need for solid data 
infrastructure, and the value of using a standard medical language, leveraging physicians 
and large institutions seems to be more conducive. 
3.3.9 Uses of RWE 
Compared to RCTs which demonstrate efficacy, RWE enables the learning about treatment 
effectiveness in terms of both clinical and non-clinical impacts. The use of electronic health 
records and the other data sets mentioned above to evaluate different treatments has 




experiences is key to decide on how and where best to use new treatments (Malone, 2017). 
RWE measures patient-reported outcomes including health care-related quality of life and 
symptoms, which are normally not collected in RCTs. RWE allows for the comparisons of 
multiple and combined alternative interventions and can include also the economic impact 
on the patient (and his family) resulting from different coverage and payment policies or 
other health management programs. It helps to quantify the risk/benefit profile of a new 
treatment, both on long-term benefits and harms, signal detection and monitoring for 
prevention or proactive action. With the large numbers of patients producing RWE data, it 
is possible to segment patient populations for optimal therapeutic response and safety, which 
enables to assess category dynamics to support different pricing, market access and 
promotion approaches. RWE may provide insights that allow for better target and patient 
cohort identification which enhances RCT productivity. HCPs, institutions and payers can 
analyze and compare the effectiveness of different healthcare solutions to determine optimal 
treatment algorithms, which need to also incorporate patient adherence (the lack of which 
indicates both lower costs but also lower efficacy). The pharmaceutical manufacturers of 
drugs may be interested in learning about RWE as it would help them to better understand 
how their medicines work in the real world, how they work in patients with co-morbid 
conditions and concomitant medications, which are normally excluded from the pivotal 
RCTs used for regulatory registration. 
All combined, RWE may enable the optimization of the therapeutic value, the evaluation 
and strategy development for pricing and market access, the overall assessment of a 
therapeutic area, the comparison of treatment effectiveness, the segmentation of the 
population by for safety and pharmacovigilance purposes, the design and optimization of 
RCTs, the generation/validation of biomarker hypotheses and in summary to optimize the 
resources dedicated to health care services. To gain market access for new drugs, it is now 





3.3.10 Barriers to RWE 
Generating RWE goes well beyond observing and interpreting reality. Non-traditional 
sources are used to collect data which is normally not collected for research purposes. This 
real-world data needs to be scrubbed to be widely accepted for statistical validity. Cost and 
process of sourcing data from these sources such as health care providers, patient groups, 
and societies seem not to be fully established and certain. Privacy and security of patient 
data is a sensitive topic in a world of data breaches also in the health industry. Some 
institutions appear to be less willing to invest in RWE applications or even to share data, 
and patients may be less willing to consent to the use of their data. The true value of RWE 
could come also from offering a complete picture of the patient by linking various sources 
such as medical records, claims and patient-reported data. However, health care systems are 
fragmented organizationally, and, in the way, they collect, store, manage and share their 
data, which in many cases is not even in an electronic format. Overcoming these barriers 
would require not only investments, but also improved IT security, standardization, updated 





3.4 Quality of Life (QoL) 
3.4.1 History of QoL 
QoL has changed the medical paradigm from a disease-centered approach to a patient-
centered approach (Osoba, 1999). In their treatments of patients, physicians should focus on 
QoL because it helps them understand the patient’s point of view about diseases and the 
prescribed treatments, differentiating what is “normal” and what is “abnormal requiring an 
intervention”. A key goal of health care professionals is to improve patients’ QoL, which 
may be as important as alleviating symptoms and pain, preventing disease, effecting a cure, 
averting complications, providing humane care or prolonging life. Lastly, for both 
therapeutic decision-makers and payers, QoL could be an important factor when comparing 
and choosing from the different treatment methods available (Sajid, 2008). While doctors 
may hold more information about the patients’ health status and the available treatments, 
patients on the other side can have a better understanding, beliefs and expectations about 
their lifestyle, the disease and how the treatment should work. Ideally, patients should 
communicate these preferences to their doctors, who then would act as agents for the 
patients, maximizing their utility as if it were their own.  
3.4.2 QoL terminology 
Treatment-induced health outcomes can be divided into five levels: biological and 
physiological factors, symptoms, functioning, general health perceptions, and overall QoL. 
The concept of QoL is related to the strict concept of health, albeit distinct. In some 
literature, the term HRQoL (Health-Related Quality of Life) is used to differentiate to 
indicate that non-health related aspects of life, such as income, housing, employment, 
freedom and quality of the environment, are excluded (Guyatt, 1993). In this thesis we chose 
to use the broader QoL terminology as patients affected by genetic rare disease find other 
not-directly health-related aspects such as income and employment impacted by the 
condition, and therefore they should be considered due to their correlation and causality. 
When a disease is experienced by a patient, almost all aspects of life can become health-
related, especially for rare and genetic conditions, as the data illustrates. 
3.4.3 Factors influencing QoL 
QoL can significantly be affected by cultural, spiritual, economic or political factors, which 
generally do not fall under the purview of treating physicians and the health care systems 
(Wilson, 1995). Soon after the introduction of the concept and with increasing experience, 
it became clear that QoL is influenced more by emotional well-being than by physical 
functioning (Fitzpatrick, 1998). The concept of QoL goes beyond a general health 
perception and includes physical functioning, role functioning, social functioning and 
mental health which affects psychological functioning. When a physician diagnoses and 
treats patients, not only visible and measurable symptoms are analyzed. Emotional and 
psychological symptoms, such as the patient’s perception, feeling or even belief about the 
state of the body, such as an abnormal physical, cognitive or emotional state, would also 




his caregiver, that cause the patients to enter the journey into the healthcare system, 
empirical analyses have shown that between 30% and 80% of patients who see a physician 
may have conditions for which no physiological or organic cause is found after routine 
investigation (Wilson, 1995).  
3.4.4 QoL aspects of rare diseases 
There are thousands of rare diseases that have no treatment and cannot be diagnosed by the 
vast majority of physicians, which may help explain why there are many undiagnosed or 
misdiagnosed conditions. Such healthcare gaps may have a profound QoL impact as many 
rare conditions are debilitating and life-shortening if untreated. Additional complications 
could be added: while functioning is correlated with symptoms and biological and 
physiological variables, variations in functioning cannot be fully explained by the latter. 
Functioning and health variables are conceptually distinct aspects of health status (Wilson, 
1995). As an example, it is often anticipated that happiness or satisfaction with life is 
determined by objective life circumstances, including the level of functioning. Reality 
suggests that measures of life satisfaction tend to be unstable, as people change their 
perspectives and their expectations, adapting to their (deteriorated) condition caused by 
disease or age. As such, QoL is a dynamic concept that bridges between past experience, 
present circumstances, and expectations for the future (Bowling, 2001). 
3.4.5 Measures of QoL 
There are numerous measures of QoL and little standardization, the reason being that the 
measures are disease- or population-specific, dimension-specific, and can be both generic 
or individualized (Garratt, 2002). While RCTs and other evaluative studies of health 
outcome should incorporate the patient’s perspective of outcome, in reality, they neglect 
them. The attention is on conventional clinical, laboratory, and radiological measures and 
possibly some limited and inappropriate surrogate indicators of the patient’s own 
experiences, which often cannot be well validated. Different stakeholder also may have 
different perceptions of QoL and its importance. QoL can have different meanings 
depending on the severity of the condition: for eye conditions, treatment would provide a 
health benefit more likely expressed as improved quality of life, whereas for oncologic 
conditions, treatment aims to extend the patients’ life. Comparisons between such and more 
different benefits are intrinsically difficult and for this reason, NICE and other institutions 
calculate a figure called a Quality of Adjusted Life Year (QALY) (Goodall). 
There are five different types of measures to describe and quantify QoL. The first is specific 
to particular aspects of health and produce a single score (for example the “Beck depression 
inventory” measures psychological wellbeing (Garratt, 2002), the EORTC QLQ-C30 is 
cancer patients participating in international clinical trials, the St George’s respiratory 
disease questionnaire for patients with diseases of airways obstruction). The second type of 
measure is broader in scope and covers several health domains (for example when the 
condition has a range of impacts, like for specific genetic diseases like Gaucher). A third 
type contains generic measures that can be used across different patient cohorts and 




coherent, and easily administered quality-of-life measures, as is the Nottingham Health 
Profile, also intended as a standardized tool for the survey of health problems in a population 
(Hunt, 1985)). Generic tools are valid and useful to be used in addition to clinical interviews 
to evaluate the outcome of medical and/or social interventions. They cover such concepts as 
health induced limitations in physical activities, social activities and role activities, pain, 
mental health (psychological distress and well-being), emotional problems, vitality (energy 
and fatigue), and general perception of health. Individualized measures are the fourth type 
and they allow respondents to change the weight depending on the importance of certain 
aspects of their own life. Lastly, to allow for economic evaluation and comparison, there are 
utility measures which incorporate preferences for health states (for example EuroQol EQ-
5D13). Utility measures are derived from economic and decision theory and help represent 
the preferences of patients for treatment processes and outcomes. The resulting cost-utilities 
are expressed (e.g. in QUALYs) which can then be compared and help policymakers chose 
the optimal (or viable) allocation of scarce resources.  
3.4.6 Challenges of QoL instruments 
The measures defined to determine QoL need to be assessed for reliability (stability and 
equivalence of repeated measures of the same concept), validity (extent to which a test 
measures the construct it purports to measure), precision (can they distinguish between 
health and illness), responsiveness (can they detect clinically important changes), 
acceptability (are patients willing to complete questionnaires), and feasibility (is the timing 
and cost to measure commensurate). Methodologically there are different issues when 
measuring QoL: how to balance or combine objectivity (e.g. mobility) versus subjectivity 
(e.g. feeling), generic versus specific (to the disease (e.g., cancer or heart disease), to a 
population of patients (e.g., children or elderly), to a certain function (e.g., sleeping or 
eating), or to a problem (e.g., pain)), unidimensional versus multidimensional, self-report 
versus proxy report, reliability, validity, and the selection of measures (Li, 2013). 
Questionnaires and interview guides designed to measure QoL may often be perceived to be 
long, complicated, and containing ambiguous statements that leave ample room for 
subjective interpretation. Especially the scoring and weighting of seriousness can be 
subjective and influenced by external factors. Some questionnaires focus on a narrow scope 
or too few dimensions, failing to capture other relevant aspects of QoL. Lastly, to allow for 
comparability, the answers are consolidated into one score, and index, but there can be many 
different ways to reach that number, including combining areas that are not logically 
connected at all. 
3.4.7 QoL intersection between clinicians and social scientists 
Clinicians and social scientists appear to use two different paradigms or models of health. 
Clinicians utilize the biomedical model which focuses on etiological agents, pathological 
processes, and biological, physiological and clinical outcomes. The objective of clinical 
practice is to diagnose the conditions based on symptoms, determine their causation 
symptoms and subsequently treat. Discovery and development of drugs are done following 




genetic, and cellular mechanisms of disease. Biology, biochemistry and physiology are the 
underlying scientific disciplines (Wilson, 1995). On the other side, QoL is built on a social 
science paradigm which focuses on overall well-being and functioning, and where research 
also includes and attempts to measure complex behaviors and feelings. Sociology, 
psychology and economics are the scientific foundations of these models. A holistic 
conceptualization of QoL requires the integration of the two paradigms to understand how 
the QoL outcomes interrelate between them. The difficulty may be compounded by the fact 
that the concepts and methodologies are different and may be unfamiliar between the 
researches operating within the two paradigms. At the intersection of the two paradigms, 
and within the constraints of health economics, physicians can influence the quality of care 
and QoL by persuading patients to demand reimbursement or funding for more or different 





3.5 Health Economics (HE) 
3.5.1 The need to contain healthcare costs 
Already at the beginnings of the diffusion of the EBM concept, some feared that it would be 
misappropriated by purchasers and managers to cut the costs of health care. Promoters of 
the concept counter-argued that doctors practicing EBM would identify and apply the most 
efficacious interventions to maximize the quality and quantity of life for individual patients, 
with the result of increasing rather than lowering the cost of their care (Sackett, 1996). 
Experience has shown that costs have increased significantly with the results of inequality, 
two-class healthcare systems, and virtually every stakeholder in the healthcare space finding 
itself in an economically not sustainable situation. Healthcare systems around the world have 
taken three types of pricing policies with the aim to contain costs (Eis, 2012): price controls 
(price freezes and price cuts), reference pricing and profit controls. These are often 
combined with other interventions to reduce demand by denying or limiting reimbursement 
or introducing co-payments. Taken alone, e.g. without including clinical outcomes, these 
measures cannot optimize the longevity and health of their stakeholders. A comprehensive 
approach is necessary, and EBM needs to be part of the equation.  
3.5.2 History and introduction of HE 
Some healthcare systems (e.g. Australian Pharmaceutical Benefits Scheme (PBS) or the 
National Institute for Health and Clinical Excellence (NICE) in the UK), have been set up 
to assess the efficacy and comparative cost-effectiveness of medical interventions. They are 
independent of the government and have a clear mandate to ensure cost-effective access to 
medicines for the population. This is executed by publishing clinical guidelines, negotiating 
and publishing prices for reimbursement which can be used as a reference and ultimately 
can affect prices and sales in other countries as well (Henry, 2005). In most cases of clinical 
diagnosis and treatment of patients, patient outcomes on an individual basis are the focus of 
the healthcare professional. EBM seems to have greatly contributed to the alleviation of pain 
and prolonged life expectancy. On the other hand, cost-effectiveness is still largely ignored: 
While the individual patient might welcome treatment regardless of cost, any health care 
system is unlikely to be able to afford or condone such behavior. Society expects doctors, 
hospitals and payers to allocate resources on the basis of cost-effectiveness. Consequently, 
in some cases, patients should be denied access to efficacious treatments if such 
interventions are not cost-effective. The necessity to ration or allocate care on the basis of 
cost-effectiveness was recognized by Cochrane already in the 1970s (Maynard, 1997).  
3.5.3 Changes in the compensation models for healthcare services 
Historically physicians have been compensated under a fee for service system that measures 
the volume of work, but not outcomes. Over the last decade, new models were introduced 
in an effort to contain expenses and to encourage better use of resource to benefit patient 
populations. New models have been increasingly introduced to compensate physicians 
based on patient outcomes and total cost control (Groves, 2013). Payers request access to 




outcomes, shrinking reimbursement and volume would be the result. This dilemma is 
especially visible with the treatment of rare diseases, whereas addressing the challenge with 
a revisit and broadening of the concept of EBM to include costs and socioeconomic factors 
will help build a stronger basis for decision making while optimizing treatment effectiveness 
measured in economic terms and ultimately patient outcomes in aggregate (Greenhalgh, 
2014).  
3.5.4 Two perspectives of health economics 
Two perspectives, one being the affected individuals, and the other one being society as a 
whole, often conflict. At an individual level, the efficacy of treatment being the key factor 
measured in clinical outcomes (e.g. life expectancy, blood pressure, frequency of attacks, 
etc.) and quality of life at an affordable price. Key decision-makers are health care 
professionals, patients, payers, regulatory bodies. At the macro-level instead, the 
effectiveness of treatment is the key factor, measured in overall clinical outcomes and costs 
to society benchmarked across therapeutic options, conditions and healthcare systems. Key 
decision-makers are healthcare authorities, payers, market access and pricing departments 
in pharmaceutical companies). This thesis incorporates both perspectives, aiming to 
contribute with a balanced framework which is expected to facilitate the dialogue between 
the decision-makers and the influencers. 
3.5.5 Funding of healthcare – the payers 
Initially and still today in the vast majority of the emerging markets, healthcare appears to 
be funded out of pocket, often in cash by the patients or their direct caregivers. In the more 
advanced markets, there are private or public health care systems where it might seem the 
government is paying. However, behind the government is the taxpayer, and that means 
society as a whole. Even in a private health care system rarely does the patient or his family 
pay in full for diagnosis and treatment. Some or all of it is covered by the private insurance, 
which de facto is a distributor of health care across many premium payers who in solidarity 
cover. For practical purposes, in case of public health plans the government, in case of 
private health systems the insurers, are called payers. Payers can be public or private 
insurances and they ultimately fund medical treatment and testing in whole or in part. Payers 
increasingly encourage physicians to follow treatment guidelines, as customization in 
general increases costs and on average leads to less effective outcomes (Frank, 2007; 
McCauley, 2015).   
3.5.6 Funding constraints and tradeoffs between therapies 
In medical care, there have always been funding constraints where decisions and trade-offs 
have to be made. To maximize efficiency, payers have to consider if the benefit from 
reimbursing an orphan drug for a rare disease patient is greater than the foregone benefit 
from not spending the same resources on other treatments or other conditions. Currently, 
even well-advanced countries such as the UK need to reconsider the reimbursement of 
currently funded standard treatments for cancer, well aware that the lives of thousands of 




what type of treatment at whose expense, who will pay the bill. The assessments, decisions 
and resulting tradeoff are reached by looking at a combination of clinical benefit, survival 
and quality of life, toxicity and safety of the treatment, level of unmet medical need and the 
median cost per patient. Independent institutes who decide on new treatments need to 
evaluate them in a consistent manner that allows for a direct comparison. They review the 
clinical and economic evidence, compare all treatments in isolation and combination. The 
thorough evaluation involves gaining information and insights from anyone affected by the 
decisions: patients, physicians, other healthcare professionals, and the pharmaceutical 
companies (both of the new treatment and the ones that might be displaced by the proposed 
new one). An independent academic group reviews the evidence and the public are consulted 
as well. To compare two treatments, institutes such as NICE calculate the differences in cost 
(the extra spend), and then divide them by the difference in effect (the extra benefit). The 
result is known as an incremental cost-effectiveness ratio (ICER). Clinicians, statisticians 
and health economists integrate all aspects and ultimately the institutes recommend the most 
cost-effective one (Goodall, N/A). Example of such tradeoffs can be the novel CAR-T 
treatment for B-cell acute lymphoblastic leukemia which is expected to add decades of life 
for one child at a cost of fewer than ten years of productive life, or at a cost for a full 
childhood immunization schedule for hundreds of children. 
3.5.7 HE and agency theory 
Agency theory has modelled how different patient segments, based on their know-how, 
confidence and communication skills can influence their relationship with the physician, the 
chosen treatment and ultimately the clinical outcomes. Even before the application of agency 
theory, price-discriminating behavior by physicians has been long-observed, representing 
another form of customized treatment (Kessel, 1958). To address the inefficiencies caused 
by the three-way double agent relationship described above, reducing and withholding care 
may not be an answer and would be ethically questionable. This thesis set out to explore the 
opportunity to increase the quantity and quality of care at existing or reduced costs.  
3.5.8 Role of HE in therapeutic decision-making 
EBM has been showing how to best apply the proceeds in the form of new diagnostic and 
therapeutic interventions. The past few decades have seen dramatically rising health care 
costs driven by ageing populations, increase in lifestyle-driven and chronic diseases coupled 
with the required care given to terminally ill patients (Lopez-Bastida, 2010). As a result, 
concerns among governments and health authorities have escalated in raising new questions 
on both the overall amount that can be funded, and on how resources can optimally and 
fairly be allocated within the health care sector and across all sectors of public expenditure. 
The economic evaluation of drugs and health care services, called health economics (HE), 
is examined from two angles. The first one is the cost of the illness to society, and the second 
one is the cost-effectiveness which compares both costs and results of treatments in 
economic terms (Lopez-Bastida, 2010). Payers have in their scope of their analysis and 
decision making only economic factors, they do not have to conduct clinical trials. Their 




Enforcement of these decisions, which are expressed in policies, takes place through 
extensive administrative requirements and contracts which include incentives and sanctions 
for both patients and physicians to select and follow the approved therapies. Prescription 
budgets for physicians are capped and they cannot give to the patient and bill the treatment 
they would following the traditional physicians’ ethics. Diagnostic and therapeutic activities 
may be restricted, the best or most comprehensive medical treatment is no longer universally 
possible. The other instrument available to payers to influence prescribing physicians is 
through incentives which induce reducing the use of health care resources, improving 
compliance with guidelines and achieving health targets. Such incentives may negatively 
impact the doctor-patient relationship, as financial rewards increase the conflict of interests 
between the two stakeholders, putting their relationship in danger (Chaix-Couturier, 2000). 
Despite this perspective, the patients still have to be regarded as customers of the payers: 
high deductibles and co-pays influence how patients, caregivers and physicians decide on 
treatments to be pursued, and therefore on the clinical outcomes themselves. Patients may 
hold the power to select the treating physicians for diagnosis and treatment, which has 
consequences on competition, health assets utilization and costs (Kaba, 2007). To optimize 
the outcome, payers may have to factor in all consequences, and as such act in different 
ways as the agent for the patients. 
3.5.9 Definition and role of market access 
Market access is the key step between a developed, authorized drug or service and it’s 
prescription by doctors and use by patients. Since the early 2000s, reimbursement for new 
medicines has been secured by submitting formal dossiers to national insurance agencies 
and managed care organizations for reimbursement approval using cost-benefit models that 
utilized health economics analysis. This partially shifted the primary driving of treatment 
decision from physicians to payers. The key importance of market access is also determined 
by the active role it plays throughout the product life cycle, from clinical development all 
the way through after the patent on the drug is expired. The value created goes beyond the 
primary objective of reimbursement at an acceptable price within guidelines. The market 
access function within companies contributes to the success by developing solutions that 
shorten the time to approval (allowing to generate revenues earlier), by ensuring formulary 
listings in cooperation with account management, by developing price defense strategies, by 
influencing and expanding guidelines, by contributing to patient awareness of disease and 
treatment, and by driving patient support programs and other initiatives.  
3.5.10 Dimensions of market access and impact on decision-making 
Market access has three dimensions (Evans, 2013): The drug or service needs to be 
physically accessible, within reasonable reach of those who need it. Such accessibility 
requires a distribution system with either opening hours or appointments to allow the patient 
to obtain what needed when needed. Second, the drug or service needs to be acceptable, 
patients need to be willing to seek it, which presumes it is effective and not discouraged by 
social or cultural factors (such as age, sex, ethnicity or religion). Lastly, the healthcare 




incurring financial hardship, payers need to be willing to pay for it without incurring ethical 
tradeoffs. In addition to raw affordability, indirect and opportunity costs need also to be 
factored in. The National Institute for Health and Care Excellence (NICE), for example, is 
the independent body in the UK which decides and recommends treatments. When NICE 
recommends a new expensive treatment for one group of patients, because of limited 
funding, something else has to give. The criteria to navigate through these difficult decisions 
is the improvement of the health of the whole population (Goodall).  
3.5.11 Information requirements for market access considerations 
One can see that the market access parameters cannot be captured by RCTs, but with RWE. 
To ensure market access, pharmaceutical companies integrate clinical data and RWE and 
health economic considerations into a “value dossier”, which is submitted to payors to 
negotiate the price and obtain reimbursement. Clinical and real-world data accumulated over 
the years can be redeployed into disease management solutions, which become relevant 
post-patent expiry to differentiate established originator products from generic competitors 
and thus protect the revenue stream built up. From a company stakeholder perspective, a 
successful market access approach is comprehensive and requires inputs and seamless 
cooperation from different functions such as government affairs, regulatory affairs, health 
economics and outcomes research (HEOR), pricing, tender management, medical affairs 
and marketing and sales. 
3.5.12 Shift from volume- to value-based payment models 
As part of innovative outcome-based contracts between pharma companies and payers, the 
former need to provide supporting evidence based on real-life data to document drug 
treatment efficiency and cost-effectiveness (Saha, 2015). This is part of the industry-wide 
shift from volume- to value-based payment models which utilize RWE to understand and 
demonstrate the value diagnostic and healthcare treatment innovations. These payment 
schemes are health-outcomes-based and are also referred to as “performance-based 
reimbursement”, “pay for performance”, “risk-sharing”, or “coverage with evidence 
development” (Carlson, 2010). For example, in 2016, 21st Century Cures Act, charged the 
Food and Drug Administration (FDA) with evaluating the expanded use of RWE, to include 
this perspective to support the approval of new indications for previously approved drugs 
(Davis, 2017). The focus on value-based models is further accentuated by the uncertainties 
surrounding novel treatments, of which there are two kinds. The first mentioned above is 
the uncertainty on how the novel treatment will deliver health outcomes within an adequate 
resource utilization in a real-world setting. The second uncertainty is around if and which 
cohort of patients should effectively be treated, vs. the population as a whole.  
Payers and pharmaceutical companies agree on reimbursement schemes which are based on 
the performance measured as health outcomes: price, level, or nature of reimbursement are 
calculated based on future measures of clinical or intermediate endpoints which are clinical 
and relate to patient quality or quantity of life. These reimbursement schemes enable 
providing to the patients’ access to innovative and potentially beneficial drugs and services 




different approaches than the standard reimbursement schemes which contemplate 
discounts, rebates, price/volume agreements, market share agreements, or utilization caps, 
all of which not linking the ultimate price and payment of the drug or service to measurable 
health outcomes. 
3.5.13 Types of value-based schemes 
Value-based schemes need to be analyzed further as they contribute to better understand the 
different stakeholders and their role in the treatment decision-making process. There are 
mainly two types: the first are schemes where the coverage of the treatment is provided 
under the condition that data on the treatment will be collected. These schemes create a 
compromise solution when treatments look promising but the clinical and real-world 
evidence is not sufficient to warrant full coverage. A side-effect is that the use of the 
treatment will be limited in cohorts where benefits and cost-effectiveness are most uncertain. 
A variant can be that only the patients participating in a clinical study are covered, or that a 
study is conducted exclusively in the population covered by the payer and the payer would 
receive the details of the outcomes. The second group are schemes where the reimbursement 
is dependent and calculated based on real-world outcomes. When pharmaceutical companies 
have more confidence in their drugs than the payers, they might be willing to take the risk 
of a lower reimbursement level in case the treatment underperforms. To initiate the 
discussion with the payers, pharmaceutical companies prepare a value dossier for their 
products where they include a comprehensive overview of clinical benefits, safety, 
convenience, adherence and implications on quality of life. In this second group either the 
pharmaceutical companies adjust prices, provide rebates, refunds or substitute therapies if 
their product does not meet the outcome targets, or reimbursement will be provided at a 
level calculated based on the clinical outcome of the therapy using the drug in question. 
Overall both payers and indirectly patients benefit from these schemes as novel therapies 
are provided at an acceptable value, while the pharmaceutical company bears the risk of 
overutilization, a key driver of cost-effectiveness (Carlson, 2010; Carlson, 2014; Damberg, 
2015). 
3.5.14 Price/reimbursement discussions  
Drugs are global like electronics or other movable goods. In theory arbitrage in the form of 
parallel imports and exports should be possible, but in reality, there are still significant 
pricing differences, which are driven by the differing systems. These can be explained by 
the varying degrees of monopoly power on the sell-side and by the and varying degrees of 
monopsony power on the buy side (Anderson, 2003). The US health system operates through 
a vast network of health care providers which are relatively uncoordinated and funded by 
households through money flows of different sizes. Different players which need to make a 
profit which is based on volume, drive prices up. Other geographies such as Europe, Japan 
and Canada have government-controlled health systems with considerably more market 
power on the buy side, thus able to command lower prices for the same drugs. Monopsony 
would reduce total welfare, as it reduces the quantity or quality of the offering. However, in 




by controlling providers’ incomes and redistribute the income (Anderson, 2003). When the 
payers are national, they have a mandate to ultimately decide on coverage for medical 
treatments for the whole country, they hold strong negotiating power with the 
pharmaceutical companies. Holding marketing approval to sell the drug or service is not 
sufficient to generate the bulk of the revenues, as a product that is not reimbursed, i.e. “self-
pay”, is not competitive in a market where every other one is. QoL plays a key role when 
assessing the value of a drug and NICE issued guidance indicating to measure a drug’s 
clinical effectiveness, not all additional months of life are equal. Higher value is given to 
improvements experienced by patients who have worse lifetime health prospects, especially 
if pediatric patients are affected (Simoens, 2011). When the data needed to justify a high 
price or reimbursement is incomplete or inconclusive, innovative reimbursement 
mechanisms have been explored and implemented for orphan drugs. Risk-sharing 
arrangements enable or force the manufacturer to share with the payer the risk that the 
product may not be effective. Under such a scheme it is the pharmaceutical company that 
may lose revenues and profits if the drug does not deliver the expected health benefit. 
Increasingly when deciding on the coverage of a new drug, payers make reference to the list 
price in other healthcare systems in other countries. Performance-linked reimbursements or 
confidential discounts and rebates can be attractive solutions for both pharmaceutical 
companies and payers, as they do not change the reported list price. 
3.5.15 Additional hurdles 
Even when healthcare treatments are available, reimbursed or affordable, patients might still 
not make use of them. The major hurdle, especially in emerging markets, is the lack of 
awareness. Patients are not aware of having a condition that requires treatment (e.g. 
hypertension) and therefore they do not seek a doctor. With rare diseases additionally comes 
the lack of awareness of the doctor. With over 7,000 rare conditions and the high likelihood 
that the particular physician will never see a patient with that particular condition in his or 
whole professional life. The physician will not be able to diagnose the patient, or even worse, 
make a misdiagnosis, followed by a prescription of a wrong therapy or even surgery (Kole, 
2010). 
3.5.16 Managed care combining of EBM and HE 
Managed care described the group of activities, controlled by a Health Maintenance 
Organization (HMO), aimed to improve the health of the covered patients while at ostensibly 
reducing costs. This is achieved by so-called "managed care techniques" which include 
being an essentially exclusive system of delivering and receiving health care, reducing 
unnecessary health care costs through a variety of mechanisms, including economic 
incentives for physicians and patients to select less costly forms of care, programs for 
reviewing the medical necessity of specific services and the inpatient admissions and lengths 
of stay. Cost-control mechanisms may include guidelines, formularies, financial incentives 
and gag clauses, which would force physicians to consider other aspects but the individual 
well-being of the patients, including the managed care organization and their own self-




the increased use of home care could contribute to further reduce costs, thus improving 
healthcare effectiveness. This approach to healthcare has shifted some decision-making 
power away from physicians and reinforced the concept of the double-agent model to be 
applied.  
3.5.17 Managed care impact on patient relationships and trust 
When treating physicians are a priori incentivized to look at cost, the previous patient trust 
and assumption on the doctor being exclusively focused on the well-being of the patient, can 
be further eroded. Trust affects the physician-patient relationship and impacts patients’ 
perceptions about the quality of the care received, followed by an impact on adherence to 
the treatment prescribed, ultimately leading to an impact on health and QoL outcomes. 
Studies have shown that patients that are part of a managed care organization have 
significantly lower trust in their primary care physicians than those with more traditional 
coverage (Dwyer, 2012). The difference in trust may be further accentuated as patients in 
non-HMO settings are freer to make choices, therefore incentivized to seek information, and 
influence therapeutic decision making, which can lead to different health outcomes and 
costs. All factors aggregated need to be considered when deciding on health policy within 
the health system. Health economists and policymakers have explored the importance of the 
relationship between patients and physicians on health systems and continuously review the 
underlying mechanisms to optimize the systems as a whole (Stavropoulou, 2012). 
3.5.18 Price differences across healthcare systems, reference pricing 
Significant price differences for same or similar treatments exist between healthcare systems 
around the world. Healthcare spending in the United States is much higher than in other 
countries. As the use of health services is below the OECD median, the difference in 
spending is caused mostly by higher prices for treatments, services and drugs. For example, 
the average U.S. expenditure per hospital day is threefold the OECD median and health care 
workers’ salaries are higher than in other countries (Anderson, 2003). The factors driving 
the high U.S. health spending can be grouped as follows (Reinhardt, 2004): First the ability 
to pay, expressed as GDP per capita. Second, as health care is labor-intensive, comparatively 
costly labor drives the prices up. Third, the highly complex and fragmented payment system 
weakens the demand side, allocating greater market power to the supply side also driving 
prices up. Fourth, the approach to financing health care is extremely complex and entails 
high administrative overhead costs. Fifth, the unwillingness to ration health care and to 
address two moral dilemmas: How much QALYs should the health system maximally 
procure and fund, and should the maximum price to be paid for added QALYs be uniformly 
applied to all members of society or be allowed to vary based on the individual patient’s 
ability to pay, social status or other factors? In the UK on the other side, the National Institute 
for Clinical Effectiveness (NICE) has been using an apparent cutoff of around USD 53,000 
per QALY beyond which treatments should not be publicly funded (Reinhardt, 2004). The 





3.5.19 Universal health coverage, donations 
The World Health Organization (WHO) defines universal health coverage as a state where 
everybody has access to any health service or product needed in sufficient quality and 
quantity to be effective, while not being drawn into financial hardship because of it (Brady, 
2017). Such a system would generate economic benefits from a healthier and more 
productive population and political benefits through social harmony and solidarity. In the 
meanwhile, the WHO has analyzed in depth the situation in different countries, 
understanding the root cause of the differences. The advice by the organization is to first 
improve efficiency, before looking for places to cut spending on health care. A recent report 
estimated that from 20% to 40% of all health spending was being wasted through 
inefficiency (WHO, 2010). 
Pharmaceutical companies have been enabling the access of life-saving medicines with 
donations or free of charge programs for decades. Different approaches are possible such as 
direct donations in kind, or donations to independent charities that cover drug co-pays or 
health insurance premiums. These programs ensure that financially needy patients get access 





3.6 Agency theory 
3.6.1 Application of agency theory to healthcare 
Exercising control over one’s life and well-being is the essence of being human. Medicine 
has soon become a deeper field of knowledge requiring research and study work, forcing 
health preservation and improvement activities into an agency model of thinking and 
operating. Whenever one individual depends on the action of another, an agency relationship 
arises (Pratt, 1985). Agency theory builds on the principle of separation of ownership and 
control, which generates the need for governance mechanisms that address the conflicts of 
interest between principals and agents. For both parties, the question becomes how the agent 
stays faithful, loyal, honest and diligent while fulfilling his fiduciary duty to the principal. 
The conflict of interest is described as agency loss, which is the reduced return to the 
principals, compared to what it would be if they exercised direct control. The more divergent 
the interests of agents and principals are, the more difficult and costlier it becomes for the 
principal to monitor the agent, the more significant the agency loss affecting the principal 
becomes. Principal-agent relationships can be observed in all interaction processes where 
there is a division of work, hierarchies and relationships of dependence, a delegation of tasks 
or by the allocation of competencies (Langer, 2008). All three criteria are visible in the 
physician-patient relationship, which has been modelled within the agency theory frame as 
patients are principals who depend on physicians for medical advice, while the physicians 
are agents who are responsible for making optimal health-related decisions on behalf of the 
patients (Tofan, 2012).  
3.6.2 Inefficiencies described by the agency theory 
The main aspect and potential source of inefficiency is the information asymmetry which 
favors the healthcare provider (Dwyer, 2012). Another source of misalignment arises when 
the principal and agent have different attitudes toward risk (Eisenhardt, 1989), which can be 
eminent in the healthcare sector (for example when decisions have to be made that directly 
impact the life expectancy of the principal). The principal-agent model has been extensively 
used in health economics both because of its conceptual simplicity and the lack of any agreed 
alternative (Stavropoulou, 2012). Using agency theory, it is possible to explain, address and 
mitigate potential inefficiencies in health-care provision such as when physicians act in their 
self-interest at the expense of the patients, further exacerbated by the information 
asymmetries between the two parties, enabling them to behave opportunistically in front of 
ill-informed patients. Physicians have considerable incentives to manipulate their billing or 
to ‘cream off’ their patients (Kretschmer, 2005). Additionally, physicians face other 
constraints that need to be taken into consideration, such as administrative constraints, time 
issues and personal costs (Britten, 2000). Key opinion leaders, doctors who participate in 
research, who partner with the industry, who are investors or leading own companies, or 
who simply want to improve their income, status or lifestyle, are not driven only by altruistic 




3.6.3 Disconnects between patients and physicians 
The first disconnect may arise when patients expect their treating physicians to be 
transparent and share information on current health status and potential treatment, allowing 
to decide together, while the doctors have no incentive to do so. Agency theory thus bridges 
between medical ethics and economic theory, offering a model to address the ethical 
challenges in the physician-patient relationship (Langer, 2008). Agency theory specifies 
mechanisms to reduce agency loss, which include incentive schemes that reward the right 
behavior and actions. It recommends pay-for-performance models, service contracts and 
monitoring to prevent or solve such inefficiencies, yet it appears the healthcare space limits 
the applicability thereof. A second disconnect may arise because the outcome of therapy is 
not entirely under the physician’s control: poor service delivery by other health care 
professionals or the lack of adherence by the patient to the prescribed therapy, could 
undermine the clinical outcomes significantly. In the case of the patient-physician agency-
relationship, the patient is the principal, the subject of the activity (medical treatment) and 
the observer who attempts to solve the agency problems using certain measures. Such 
inefficiency may cause further agency costs. Monitoring itself is challenging, as the ability 
to do so by the patients may be limited because of their lack of knowledge and experience 
in the field. Unlike other settings, medical practice by tradition lives (or should live) by 
moral constraint and professional ethics as guidelines for behavior in the interest of the 
patient. The physician’s dedication to serving the needs of the patients is the “immutable 
bedrock of medical ethics” (Shortell, 1998). 
3.6.4 Double agency theory 
A view encompassing all stakeholders identifies the treating physicians as double agents: in 
the exercise of their profession, they are accountable not only to the patients, but also to the 
payers and to other organizations such as health insurances. The unsustainable health 
economic situation is the result of inflationary, open-ended funding of increasingly costly 
innovative therapies required by larger patient populations diagnosed thanks to more 
advanced knowledge, techniques, and equipment (Angell, 1993). Physicians are facing 
increasing pressure from having to compromise between increasing demands, resource 
scarcity, and continuous search for efficiency. The physicians being exposed to such 
pressures, while at the same time striving to provide the best possible treatment to the 
patients, sometimes face dual and conflicting obligations (Tofan, 2012). Health insurance 
regulations on reimbursement or employer restrictions do increasingly not allow physicians 
to engage all diagnostic and therapeutic methods available (Shortell, 1998). 
3.6.5 Historic therapeutic decision-making, patients and doctors 
The objective of the doctor-patient relationship is to maximize the utility of the patient. A 
number of factors contribute to this utility among which communication, the patients’ 
understanding of the doctor’s explanations, how much and how well information is 
transferred to the patient, or how long the patient has to wait before seeing the doctor. Studies 
have shown that being able to talk to the doctor is the most important attribute and that the 




is consistent with the fact that EBM, RWE, HE, QoL are complex concepts with significant 
information asymmetry. Utilizing the double-agent agency model, decisions on treatment to 
pursue have to be taken and during the evolutionary course of healthcare practice, three 
types of decision-making can be observed. Traditionally doctors were undisputed experts 
who diagnose and alone decide on the treatment to pursue. The paternalistic model describes 
the patient seeking help, the doctor using his skills to diagnose and choose a treatment, for 
the patient to silently comply with. If there is information to be shared, it is selected to 
encourage the patient to consent to the doctor’s decisions (Kaba, 2007). Patients are reduced 
to a passive role during the decision-making process and to simple executioners of the 
treatment, taking the medication prescribed as indicated. Increasingly this model is seen as 
outdated.  
3.6.6 Modern therapeutic decision-making 
Subsequently, a shared decision-making model (Charles, 1997) became prevalent where 
both physician and patient are involved in the treatment decision-making process, they share 
information, they express their preferences and agreement is attained on the decision on how 
to pursue. At the next level the physician supplies or complements the information already 
known by the patient, and the latter may decide. On the other side, the sharing of information 
between physicians and patients may be paved with hurdles. Research has identified 
fourteen categories of misunderstandings including patient information unknown to the 
doctor, doctor information unknown to the patient, conflicting information, disagreement 
about the cause of side effects, or failure of communication about the physician’s decision 
(Britten, 2000). Two main causes are triggering these misunderstandings: patients not 
participating during the consultation, not voicing their expectations and preferences, or not 
responding, questioning the doctors’ decisions and actions. Such disconnects between 
patients and physicians lead to adverse clinical outcomes when patients do not obtain, or do 
not follow the schedule of their prescribed medication. While economic theory has shown 
utility gains for consumers when they are informed and are free to make their own decisions 
about the goods and services they purchase, some research seems to suggest that consumers 
may experience disutility from being involved in decision making about the treatment of 
their health problems (Shackley, 1994). This can happen when the information or the 
explanations are too difficult, inconsistent with other sources (such as second opinions or 
online sources, or simply describing negative long-term outlooks or risks. 
3.6.7 Misunderstandings between physicians and patients 
It established that to achieve maximum benefit from the patient-physician interaction a 
simple, clear, transparent and seamless exchange of information and expectations needs to 
take place. In reality, different reasons for misunderstandings have been observed and they 
can be categorized (Britten, 2000). Patient information that is relevant to treating physicians, 
but not always communicated, received or understood in full or in part, includes relevant 
facts about the medical history, the patients’ views or anxieties on treatments, the patients’ 
other comorbidities, or their use of other drugs, over-the-counter or on prescription. 




be relevant, and sometimes it is actively concealed. On the other side there is information 
known by doctors that is not properly received, understood or accepted by the patients, such 
as the diagnosis itself, the treatment decision, what the drug does, how it has to be dosed or 
administered (especially if injectable), what potential downsides or side effects could be. 
This information can be simply not understood, but also not conveyed in the first place, as 
some physicians believe the patients do not want to know, do not need to know, or will not 
understand. Other reasons explaining the disconnects or the lack of shared understanding 
arise when patients are facing conflicting information from different doctors, from their 
online search, from family members or their network. Data suggests that doctors make many 
assumptions that are not correct in particular situations and with specific patients (Britten, 
2000). Effort needs to be made in every single consultation, by both physicians and patients, 
to validate or confute the perceptions, be open, transparent and active, with the objective to 
close the information gap.  
3.6.8 Patients’ adherence to decided treatment 
Once patients are diagnosed and treatments have been prescribed utilizing EBM, RWE and 
QoL, and once they have been funded using RWE and HE considerations, there is still one 
step that needs to be taken to attain a clinical outcome and an improved QoL: follow the 
treatment. Adherence has been defined as following the recommendation (Stavropoulou, 
2012) and studies have shown that confidence in the physicians and the health care system 
as a whole led to better adherence and thus better outcomes (Kjellgren, 1998). Empirically 
observed, a follow-up communication style by physicians or clinics, client satisfaction, and 
mutual understanding between physicians and patients are predictors of better adherence 
(Berman, 2009). 
3.6.9 Guidelines vs. agency theory  
Agency theory is well recognized to describe physicians as agents for patients (Arrow, 1963) 
and implies that physicians attend to each patient’s situation acting in their best interests. 
When this is the case physicians sometimes come into conflict with guidelines or with health 
economic driven decision-making criteria (Frank, 2007). Vice versa physicians face 
additional decision complexity when abstaining from prescribing treatments not 
contemplated by the guidelines, but which would still be covered by the generous insurance 
coverage of certain patients. The dilemma may exacerbate when the physicians themselves 
are financially incentivized by a treatment or a test that is not recommended by the guideline, 
especially when they are disagreeing with administrators, practice policies, or even exposing 
themselves to potential legal liabilities.  
3.6.10 Role of compensation of physicians 
Agency theory suggests that agents are more likely to behave in the interests of the principals 
when they share their goals or when the contract between them is outcome-based 
(Eisenhardt, 1989). Agency theory was mainly built on economic principles where 
compensation is performance-based to address the impossibility of factoring in 




multiple interrelated tasks, unexpected events, or team production efficiencies. Clinical 
practice, the relationship between physicians and patients displays some key features that 
characterize economic incentives  (Robinson, 2003). The main component of the 
relationship is the physicians spending one-on-one time with the patients, therefore the 
incentive should be designed towards promoting working long hours, performing many 
procedures, and being attentive, listening and incorporating the needs and preferences of 
each patient into the therapeutic decision and the treatment. Physicians should treat also, or 
especially the sickest patients, the ones with the highest risk. The incentive should, therefore, 
reward taking risks, respectively disincentivize focusing on the healthy and avoiding the ill. 
Care should be adequate in quality and quantity, hence the incentive should steer physicians 
to stay well between over- and undertreating. EBM and guidelines provide a strong validated 
basis on which to treat the majority of patients, the incentive should lead physicians to follow 
them. 
3.6.11 Forms of compensation for physicians 
Whenever decision and behaviors are to be researched, it is key to understand how 
compensations and incentives drive the different stakeholders. Physicians as agents for 
patients merit particular attention as these stakeholders ultimately decide and attempt to 
follow through the therapies prescribed to the patients. The question becomes which form 
of compensation is most suitable to induce physicians to perform in the interest of the 
principals, the patients. Intrinsic rewards are what agents receive from the job, like the 
motivation of contributing to the well-being of patients, alleviating their pain, or even 
keeping them alive. Extrinsic rewards, such as money, have been shown to lower motivation 
as they reduce the impact of intrinsic rewards. Financial incentives lead to a degradation in 
the quality of the output, as the agents then tend to give a narrow focus to the task, try to 
complete it as rapidly as possible, and take few or no risks. Ultimately agents can feel 
controlled by the reward system, which would undermine the tenet of healthcare which is 
precisely to “care” for the person with a medical need (Baker, 1988). A principle of 
compensation system is that the result of the work or the indicator being measured can 
clearly be attributed and is under control of the agent. Especially in medical care, objective 
measures of activity and success of therapy cannot be readily measured, given the 
complexity and interplay of the different activities and treatment aspects, as well as the large 
variability across patients. Complex systems and not well-designed compensation schemes 
can facilitate the achievement of suboptimal results by gaming the system. For example, 
agents measured and compensated based on linear deliverables (such as the number of 
patients treated, capitation), are induced to game the system by sacrificing quality for 
quantity. The next level of fixed-budgets for interventions, and therefore capped 
compensation, do encourage physicians to behave and treat more efficiently, but they also 
compromise the nature of the relationship between physicians and patients, exemplifying 
the effect on of the health-care professional being a “double-agent” for the patients and for 




3.6.12 Incentive options 
Most compensation systems are designed to be simple, easy to understand, easy to 
implement and aimed to leave little room for different interpretations or dispute. Simplicity 
also reduces costs of designing, negotiating, and managing the compensation systems, while 
facilitating transparency in an otherwise complex environment such as the healthcare system 
with multiple physicians, procedures, hospitals, labs, and more. Traditionally in health care, 
one could find fee-for-service, expressed as a linear function of relative value units. 
Capitation is based on patient enrollment and salary on time worked (Baker, 1988). These 
cause fee-for-service, salary or capitation, to be suboptimal compensation methods to 
motivate, physicians as they are not controllable or could be gamed. 
3.6.13 Advantages and disadvantages of different compensation types 
Fee-for-service could drive physicians towards unneeded or inappropriate services, testing 
of equipment owned by the practices, fraudulent upcoding of visits and procedures, more 
frequent calls for visits, referral to radiology centers and clinical laboratories in which the 
physicians have an ownership stake, and the churning of back and forth referrals among 
specialists, all serving the objective to maximize reimbursement. From agency theory 
application in business, it is known that piece-rate, cost-plus-markup, and other retrospective 
forms of payment drive the agent to provide unnecessary, input-intensive, gold-plated 
services which do not add incremental value (Rodwin, 1993). This can be mitigated by 
prospective forms of payment such as pre-assigned or pre-negotiated rates for services (e.g. 
for surgical procedures, called episode-of-illness payment methodology, where the surgeon 
is paid a set fee for the whole episode from preoperative workup, through the procedure to 
postoperative monitoring until dismissal of the patient) including capitation for services or 
treatments. Capitation can also be misguided if it drives physicians to deny appropriate 
services, to refuse to treat the chronically ill, and to discriminate or refer out time- 
consuming patients. Studies have shown that the introduction of capitation reduced the total 
volume of prescriptions by up to 24% and hospital days by up to 80% compared with fee-
for-service. Annual caps on doctors’ incomes resulted in referrals to colleagues when target 
income is reached (Chaix-Couturier, 2000). While fee-for-service encourages, and 
capitation discourages resource consumption, a result-based pay encourages, and salary 
reduces productivity and fosters a bureaucratic mentality where “time passed” is more 
important than “results achieved”. Non-monetary compensation follows similar 
mechanisms, such as promotions, practice ownership, invitations to speak and similar.  
3.6.14 Conclusion on compensation types for physicians 
Overall financial incentives are effective instruments to increase or reduce the use and the 
quality of health care resources, improve compliance with guidelines and subsequently 
achieve health targets. The downside is that these incentives can easily be not aligned with 
the original motivation of health-care professionals and therefore create a conflict of interest, 
possibly an ethical dilemma, between the income of the physician and the quantity and 
quality of care given to the patients. It becomes a task for the payer and society, in general, 




population, adjusting for adequate quality and quantity of healthcare, stratified for different 
levels of severity. Transparency and disclosure of incentives may be key to ensure trust in 
the healthcare system, all the way to the individual physicians.  
3.6.15 Risk considerations 
Risk may need to be factored in, as prospective compensation exposes agents to new 
financial risks for which they might demand extra compensation, which contributes to 
agency loss. Risk that is linked to an overall probability of success that is independent of the 
physicians, for example by strictly following guidelines and drug labels, should be spread 
widely across the population, that is ideally held by a public or private insurance company. 
The technical risk that is linked to the individual decision or execution by the physician or 
the institution, should be carried by the provider who has accepted the clinical responsibility 
(Robinson, 2003). Physicians compensated with a fee-for-service are insulated from both 
types of risk. The capitation compensation exposes physicians to both types, while case 
rates, allocate probability risk to the insurers (physician are sufficiently paid to provide the 
adequate care the patients need) and allocate technical risk to the physicians (i.e. when the 
cause requires more than the capitation foresaw).  
3.6.16 Governance mechanisms in the physician-patient relationship 
Other governance mechanisms have to be used. A factor driving positive outcomes is for 
principals to have access and being able to interpret information to verify the agents’ 
behavior. The interaction between patients and physicians have one objective: diagnosing 
and treating the medical condition that the patient has. This objective requires a decision on 
which therapy to follow and there are fundamentally two decision-making models (Gafni, 
1998): In the first, patients delegate authority to the physicians to make medical decisions, 
who then act as the perfect agents for the patients. Physicians are expected to uncover the 
patients’ needs and preferences so they can decide in their best interest, i.e. to produce the 
best possible outcomes. In the second model, the role of the physicians is limited to provide 
patients with the necessary information, so that patients can make the right medical 
decisions. The physicians are expected to transfer their knowledge in a clear and nonbiased 
way. However, within the patient-physician relationship both models can be difficult, and 
trust plays a dominant role. 
3.6.17 Trust-based governance 
Patients seek the physicians’ advice and implicitly relinquish direct control on how to treat 
their condition, assume their physicians will follow best practice and act in the best interest 
of the patients. Doing so, patients take a risk. The relationship between patients and treating 
physicians is personal, close and bound by confidentiality. Patients are vulnerable, subject 
to information asymmetry, uncertain about the outcome measures in life expectancy, 
symptoms, QoL. Trust is vital for building an effective relationship, for enhancing 
cooperative behavior and thus a prerequisite for successful healing. There are different 
reasons for patients to trust their physicians and high moral standards and ethical credo of 




of information, the asymmetrical distribution of the latter can be reduced. Patients nowadays 
can be empowered which contributes to distrust, or, if the physician is in line with the 
information found by the patient, strengthening of trust. Increased healthcare costs with 
resulting tradeoffs that are not always in the best clinical interest of the individual patients, 
combined with the spreading of managed care systems and the evolution of physicians 
towards tighter work schedules and efficiency orientation, have eroded the trust relationship. 
Fewer and fewer physicians exposed to these regulatory, health economics and political 
pressure may be able and willing to suppress their self-interest. The resulting level of distrust 
depends on patients’ education, confidence, communication style, age, gender, culture and 
more. More qualified and younger patients ask more questions, tend to receive better 
information, can exert more influence on their treatment, and likely achieve better outcomes, 
illustrating distrust-based governance (Tofan, 2012). Such governance itself does not come 
without side-effects: Medical acting may be affected, as physicians will be driven into 
investing more time in discussions on treatments and negotiations with patients, which 





3.7 Rare diseases 
3.7.1 Overview 
Rare diseases are defined as life-threatening or chronically debilitating diseases which affect 
five out of 10,000 individuals or less (Hughes, 2005). In the US rare diseases have originally 
been defined as the ones that afflict fewer than 200,000 individuals (LaMattina, 2018). 
Although these diseases are individually rare, there are about 7,000 rare diseases and, in 
aggregation, they affect approximately between 6% and 10% of the population, which is 
similar to the prevalence of diabetes. In the US estimates indicate more than 25 million 
people, in the EU about 30 million people, and in Australia, about 1.2 million people suffer 
from a rare disease (Knight, 2006). Rare diseases are a major cause of morbidity and 
mortality in western countries. They have major repercussions on individuals, their families 
and health care systems (Lopez-Bastida, 2010). Some are quite well known such as muscular 
dystrophy, cystic fibrosis or multiple sclerosis, but the majority are exceedingly rare, and 
rare are also the physicians that ever see a patient with the specific disease. Approximately 
50% of the people affected by rare diseases are children, of which 30% will not live to see 
their 5th birthday. Rare diseases are responsible for 35% of deaths in the first year of life. 
80% of rare diseases are genetic in origin, and thus are present throughout a person’s life, 
even if symptoms do not immediately appear.  
3.7.2 Challenges of rare diseases 
Rare diseases are also complex since often the causes, the link to the genes and their 
mechanisms are not well understood. Reliable epidemiological data on prevalence and 
incidence is often missing, and while the majority is genetic and inherited, a significant 
number is initiated through mutations and/or acquired through processes triggered by 
environmental factors. Such variability causes complexity and requires approaches, 
viewpoint, and collaborations across different specialized areas (Posada de la Paz, 2010).  
Only about 5% of the known rare diseases have corresponding treatment plans. There is a 
huge unmet medical need which requires important scientific discoveries, the exploration of 
the underlying science and the development of therapies (Shen, 2017). The first step towards 
rare disease research and diagnosis is to identify and document patients with similar 
phenotypes, the clinical observable sign or symptoms. The Human Phenotype Ontology 
(HPO) has been created with the objective to catalog human phenotype information and 
currently covers most of the 7,000 rare diseases (Shen, 2017). To ensure global use, such 
ontology and instruments ideally use standardized medical language to described 
phenotypes, and the natural language processing to assist physicians with the diagnosis. The 
second step is then to provide ready access to such catalogs, registries and treatment results 
to all stakeholders. A standard diagnostic coding for a complete and appropriate 
classification or rare diseases is still a gap that needs to be closed. The presence and the 
burden of most rare diseases are invisible to the health systems due to misclassification and 
lack of appropriate coding (Commission of the European Communities, 2008). The 
generally accepted coding by the International Classification of Diseases (ICD) uses a six-




the ICD (ICD-9 and ICD-10) are being simultaneously used in several countries around the 
world, and within some countries, different versions are used in parallel as well. To further 
exacerbate the gap, according to the Orphanet database, fewer than 300 specific rare diseases 
are identified by a single ICD-10 code (Posada de la Paz, 2010). Such coding is also 
necessary to set up patient registries and to monitor global health trends by the use of reliable 
statistical data (World Health Organization, 2018). In day-to-day life for patients, physicians 
and payers, without the code it becomes virtually impossible to trace and recognize the rare 
disease patient in national healthcare and reimbursement systems, harmonize disease 
surveillance and promote well-conducted epidemiological studies which ultimately will 
benefit the whole population. Beyond the coding, information that needs to be collected in 
a standard way, should cover a number of categories such as general information about the 
disease, its presumed cause, its prognosis, its inheritance capability, and which approved 
treatments are available and then outcomes they generate. Also included should be the 
compounds being researched and developed, the known ongoing and planned studies, and a 
list of patient associations and advocacy groups which also document real-life experiences 
with the condition. With above in place, physicians will improve diagnostics and treatments, 
patient advocacy groups can offer support and contribute to the discourse, research groups 
gain insights on which assets to pursue, development teams write and follow more impactful 
and optimized protocols, payers can better assess the economic value and therefore 
determine the right level of reimbursement of the drugs.  
3.7.3 Orphan drugs 
Drugs for rare diseases are called orphan drugs in allusion to the lack of support that, in 
general, would ordinarily take care of their development. Orphan drugs are defined as either 
a medicinal product intended for a life-threatening or chronically debilitating rare disease or 
a medicinal product that would not be developed without incentives because its sales are 
unlikely to generate sufficient return on investment (Gericke, 2005). Additionally, to qualify 
as an orphan drug, it is required that either there is no satisfactory method to diagnose, 
prevent or treat the disease or, if such a method exists, that the medicinal product will be of 
significant benefit to those affected by that disease. Rare diseases not only make up small 
drug markets that do not justify the investment, but appropriately powered trials are also 
often impossible with the insufficient patients available, compounded by lack of knowledge, 
low awareness and lack of critical mass. Due to the few products developed and prescribed, 
as well as the low number of patients, high-quality evidence about clinical added value 
outcomes of orphan drugs is rarely available (Simoens, 2011). Such is even more the case 
at the time the companies are seeking marketing authorization. To overcome such challenges 
and incentivize innovation, regulators combine push, with development and regulatory 
incentives, and pull incentives, with market exclusivity and tax incentives (Llinares, 2010). 
Increasingly pharmaceutical companies are entering this space, possibly as they are tempted 
to diversify away from the mass market, which is exposed to increased competition, 




3.7.4 Regulatory aspects of orphan drugs 
Orphan drugs appear to offer lower development hurdles, as regulatory bodies such as the 
FDA can more easily monitor the performance of a rare disease drug once it is approved, 
while at the same time the risk and benefits are seen differently for a drug that is prescribed 
to a few patients after launch vs. one that would be prescribed to tens of thousands of patients 
(LaMattina, 2018). An orphan drug can be qualified as such only if provide a significant 
benefit (Simoens, 2011) and pharmaceutical companies need to apply for orphan drug 
designation which, when awarded, provides a few key benefits. The US adopted the first 
orphan regulation in the world in 1983, using as criteria for ODD (Orphan Drug 
Designation) a low prevalence and the fact that some drugs would not generate sufficient 
sales to recoup the necessary investment for their development. Drugs with the ODD 
designation are incentivized with a 7-year market exclusivity, tax incentives, access to a 
dedicated development grant programs, access to protocol assistance for the development 
and fee waivers for regulatory activities. During the first 25 years of the Orphan Drug Act, 
only 326 new drugs were approved by the FDA and approximately 50% of rare diseases still 
do not have a disease-specific foundation supporting or researching the condition. In 2010 
in the US almost 2,000 products have been designated as orphan medicines and about 340 
have received marketing authorization (Llinares, 2010). Regulators globally give more 
attention to rare diseases and orphan drugs. Since the year 2000, the EU implemented 
specific policies to stimulate innovation in the field of orphan drugs (Hughes, 2005). 
Pharmaceutical companies can have their medicinal product awarded orphan status and 
benefit from protocol assistance (scientific advice during the product development phase), 
direct access to the European Drugs Agency (EMA) Centralized Procedure with respect to 
registration, ten-year marketing exclusivity starting from the date of marketing 
authorization. In some case financial incentives in the form of fee reductions or exemptions, 
or assistance with research and development, are also possible. 
3.7.5 Data paucity on orphan drugs and its consequence 
Despite the incentives and support for orphan drugs, there can be situations where the data 
generated at the time of marketing authorization is still not sufficient. As public interest 
driven by the unmet medical need is very high which drove regulatory bodies to introduce 
mechanisms to authorize products under exceptional circumstances and approval 
conditional to conducting post-marketing studies. For the grant of such conditional 
marketing authorization, a few conditions need to be met: there has to be a benefit to public 
health from the immediate availability of the orphan drug, the benefit outweighs the risk 
from having insufficient data, and there is a clear unmet medical need that would be fulfilled. 
Until 2010 the EU authorized 40% of the marketed orphan under exceptional circumstances 
(Llinares, 2010). The combination of the above factors defines a highly dynamic sub-market 
in the healthcare space where therapeutic, pricing and reimbursement decisions have a high 
impact, starting with the affected patients. A more rigorous and broader EBM approach is 
required, which is part of the meta-analysis of this thesis. It is established that using 
information systems built on electronic medical record platforms are key for decision 




practice, improving safety and efficacy (Bates, 2003). Until a few years ago treatment 
modalities for rare diseases such as HAE had been mostly empiric, and consensus guidelines 
were primarily based on limited case series, observational studies, and expert opinions, all 
due to the paucity of controlled studies (Cicardi, 2012). Today in some countries additional 
criteria are used to decide on reimbursement such as the seriousness of the disease, the 
availability of other therapies to treat the disease and the cost to the patient if the medicine 
is not reimbursed (Simoens, 2011). Specifically, the latter drives the need for a broader 
approach to evidence-based medicine which is the focus of this thesis. 
3.7.6 Biopharmaceutical drugs for rare diseases 
Some rare diseases can be treated with both chemically-derived drugs and biologics (for 
example HAE can be treated on-demand with the small molecule icatibant or 
prophylactically with a plasma-fractionated C1-inhibitor. Prices of biologic drugs tend to 
additionally be less regulated and higher, due to a few reasons. There are no generics for 
biologics, but only biosimilars, and demonstrating bio-similarity is more difficult and 
costlier, hence there is limited competition and less opportunity for price comparison. 
Biologics are more expensive to develop and manufacture, generating higher cost-
effectiveness thresholds, especially if they are intended to treat rare conditions. Lastly, some 
countries have policies supporting the development or excluding biologic drugs from 
hospital price regulation.  
3.7.7 Awareness and information on rare diseases 
Agency theory applied to healthcare has already addressed since its beginnings the 
information asymmetry between the agent (physician) and the principal (patient), with the 
resulting inefficiency (Arrow, 1963). With rare diseases, few physicians are aware of the 
conditions and most physicians never see a patient with a specific rare condition in their 
whole professional life. Consequences are that a large share of patients has to wait decades 
from onset of symptoms to a confirmed diagnosis, up to 40% are initially and repeatedly 
wrongly diagnosed, leading to inappropriate surgery, medication, or psychological care 
(Knight, 2006). On the other side, thanks to modern and free access to any type of 
mainstream and scientific media available in the internet, thanks to patient’s health literacy 
skills, and thanks to social media which further accelerate the spread of information between 
populations and patient segments, it is now easily possible that patients have an information 
advantage over their doctor. Such new dynamic has to be taken into consideration as it 
affects the application of the agency model, the decision-making process on which treatment 
to pursue, and as a consequence the overall costs.  
3.7.8 New clinical approaches for rare diseases 
Rare diseases force onto most of the physicians a new approach in how to deal with the 
patients. Both GPs and specialists in every day’s life encounter patients sharing in large 
numbers the same conditions such as hypertension, diabetes, allergy, influenza. For these 
conditions they have available well-established guidelines, recommending “gold standard” 




patients. While there might be guidelines for rare conditions, the variability of symptoms 
and QoL implications are large, requiring a tailored approach to optimize treatment on a 
patient-by-patient basis, which in itself forces a mindset shift. To foster awareness and the 
sharing of information and experience, the European Union-funded Orphanet through a 
consortium of now 40 countries, a web-based database of rare diseases, centers of 
excellence, patient-support groups and major innovation. It is a unique resource with the 
objective of gathering, improving and sharing knowledge on rare diseases in order to offer 
support on diagnosis, care, and treatment of patients affected by rare conditions (Orphanet, 
2018). In the US the National Organization of Rare Diseases (NORD) is similarly focused 
on making information more accessible and on coordinating research efforts into rare 
conditions. Looking beyond, it can be argued that every country should catalog and detail 
the epidemiology of rare diseases and then support the setup and coordination of centers of 
excellence and patient-support groups at a national level. The establishment of umbrella 
organizations such as NORD with connections and sharing of information and best practices 
with databases and experts across the world would both improve access to information and 
strengthen the quality of the content. However, when a rare disease awareness is just at its 
beginning, when very little is known, when virtually no treatment with strong efficacy exists, 
there is not yet sufficient information to build databases, patient registries, or organizations. 
The first step, which treating physicians have been encouraging through the history of 
medicine and genetic diseases, would be to establish and maintain family histories of the 
health and illnesses of family members through multiple generations, documenting the 
occurrence of different inherited conditions. 
3.7.9 Diagnoses and misdiagnoses of patients with rare conditions 
Unless a newly born of a parent with a genetic disease is tested at birth through a blood 
sample from the umbilical cord or in the first months through standard tests, normally people 
seek medical help once symptoms manifest. Some of the rare conditions begin with a genetic 
mutation and symptoms manifest only much later in life. The journey of a patient with a rare 
condition is much different compared to the one of a patient with a more common condition 
like hypertension or diabetes. The first dramatic hurdle for a person living with a rare 
condition appears to be the difficulty in obtaining the correct diagnosis which may take years 
or even decades to overcome Most care providers have likely never seen a patient with a 
specific rare condition before, they are not aware of the condition and lack the necessary 
knowledge and experience, which frequently results in a misdiagnosis (Shen, 2017). A 
recent survey has shown 41% of the rare disease suffering participants having initially 
received at least one misdiagnosis before obtaining the correct one (Kole, 2010). 
Misdiagnosis may result in erroneous treatments by medication but can also lead to surgery, 
psychological and psychiatric treatments including psychological therapy, psychiatric 
hospitalizations, and psychiatric medications, under the assumption that the symptoms are 
due to mental causes. Other deleterious consequences may include psychological and 
cognitive consequences, death, the birth of another affected child, strains to the cohesion of 
the family and loss of confidence in medicine. Misdiagnosis may have a double negative 




of the search for another, the right diagnosis, thus an additional barrier to correct diagnosis 
and treatment comes into the way. Therefore, for many people living with a rare condition, 
it can take years or decades to obtain a diagnosis. Every year close to eight million infants 
are born severe congenital defects, of which more than three million do not survive beyond 
five years (Zarocostas, 2006). For a quarter of the sufferers of a rare disease, between five 
and 30 years elapsed between the appearances of the first symptom and the correct diagnosis 
(Posada de la Paz, 2010). A late diagnosis delays the beginning of the correct treatments and 
can have severe, irreversible, debilitating and life-threatening consequences (Kole, 2010). 
Misdiagnosis can result in the worsening of the clinical status (Bennett, 1991), psychological 
damage (Merelle, 2003) and in some cases death (Kharrazi, 2005).  
3.7.10 Decisions and challenges post diagnoses of rare diseases 
Even if correctly diagnosed, for the vast majority of rare conditions there is no guideline, no 
treatment, and no drug. When they do exist, practice, availability and price can vary 
enormously across healthcare systems, countries and location (e.g. urban vs. rural). Despite 
all hurdles, having a diagnosis is an accomplishment that provides relief as it gives a name 
to the combination of symptoms. A diagnosis would allow patients and physicians to look 
forward and to focus on identifying and following the right therapies, which not only have 
the advantage of bringing forward the benefits of the correct treatment, but also prevent 
undesired consequences of inadequate treatments resulting from a misdiagnosis. Correct 
diagnoses may also enable possible predictions of prognoses and allow patients and their 
families to continue to search for specific information about the conditions, their causes, 
expected outcomes, hereditability, possible future manifestations, the availability of 
treatments, approved ones or under study. With the correct diagnoses of genetic conditions, 
patients and their physicians may test within their families for possibly other relatives being 
carriers of the genes causing the diseases. Assisted conceptions with gamete donation could 
thereby offer an alternative, preventing the disease from being passed on to successive 
generations (Bermejo, 2010). 
Patients reach out to other patients and associations to exchange experiences and to learn 
how to cope and manage their conditions. This sharing provides comfort, reduces anxiety 
and depression, which can be triggers themselves for attacks, such as in the case of HAE. 
More in general, having a diagnosis is pre-condition for the foreseeing of possible 
complications and for taking the best possible preventive measures which lead to better 
clinical outcomes and improved QoL. The ideal approach for physicians who consult 
patients with a rare condition would follow and include a number of adjusted or additional 
steps (Knight, 2006). Diagnosis poses the first challenge as it requires physicians to 
frequently ask themselves if the symptoms observed could be the result of a rare condition. 
In most cases, definitive answers require the service of a specialist (for example a patient 
might seek the help of gastroenterologist for abdominal pain, but the diagnosis needs help 
from an immunologist). Genetic diseases come with a number of co-morbidities and burdens 
that extend beyond the primary symptoms. The patients need to be attended as a whole with 
high-quality care that needs to include other issues (e.g. beyond the HAE swellings, patients 




diagnosed and treated, the physicians should become knowledgeable about their natural 
history, the evidence-based treatment options, the systematic long-term care, the associated 
problems, and genetics. For some rare conditions, there is rapid progress on diagnostics and 
therapies, to stay abreast it is of great support to seek out and link with the centers of 
excellence, appropriate specialist services, and local organizations. When available, 
electronic medical records (EMR) are a good source that can be leveraged to accelerate 
disease diagnosis. They require providers to document and make available associated 
phenotypic information to support diagnosis decisions.  
3.7.11 Role of genetic testing 
Most of the rare diseases are genetic in nature, i.e. they are caused by mutations in a few 
genes. Globally more than eight million children are affected by congenital and inherited 
disorders which can cause long-term disability and have a lifelong debilitating impact on 
health (Jackson, 2010). Birth defects are the leading cause of infant mortality. About 3% of 
birth in the US are affected by structural defects and chromosomal abnormalities (Mathews, 
2008). The number of diseases for which genetic tests are available is growing rapidly and 
can be divided as chromosomal, molecular, or biochemical. In theory, genetic testing could 
be the key approach to determine if there are abnormalities or mutations with the genetic 
code and thus confirm not only the conditions, but also their most likely impact on health. 
Genetic tests have to be validated: their analytical validity confirms the test is able to 
accurately and reliably measure the genotype of interest. Clinical validity confirms the test’s 
ability to detect or predict the clinical disorder or phenotype associated with the genotype. 
Lastly, clinical utility measures how useful it is in the clinic (Grosse, 2010). Genetic testing 
has also its challenges. The patient with inexplicable yet life-altering symptoms is expected 
to achieve great personal utility from having a diagnosis. Such personal utility manifests 
through multiple dimensions, such as reduced anxiety, reassurance, help with family 
planning, career planning, housing, and lifestyle modification. People with a family history 
of the disease, yet test negative, that is confirming they are not carrying and not at risk for 
the condition, feel strong reassurance. On the other side, an asymptomatic person who has 
been tested positive, might be subject to potentially unnecessary treatments, discrimination 
(job market, insurance) and thus to a negative personal utility impact (Grosse, 2010). Along 
the same line, professional organizations do not endorse testing asymptomatic children for 
mutations associated with untreatable diseases (Trott, 2009). Testing even earlier such as 
newborn screening, prenatal or pre-implantation diagnosis or screening raises another set of 
ethical questions depending on what is then done with the acquired information (Barrera, 
2010). 
3.7.12 Role of the family 
Families of patients are also an integral part of the journey, as they are affected in many 
domains of their lives. Either or both patient and caregivers often have to stop working or 
take lower paying part-time or flexible jobs, creating further financial burdens (Kole, 2010). 
Families should be encouraged to ask questions, to join (or even build) patient organization 




reimbursement, or just help navigate through the humanistic burden of the condition. Patient 
advocacy groups play also a role in educating health care providers about optimal care or in 
identifying for their members the most skillful and knowledgeable clinicians who are able 
to provide the best services (Posada de la Paz, 2010). Treating physicians should also 
support the families of patients, contributing to the physical, emotional, psychological, 
spiritual, and social needs of the patient’s support network. At the minimum for some 
conditions, support would be in the form of training on how to administer the drugs when 
they intravenous or subcutaneous. Treating physicians may also be advocates assisting the 
patient’s journey through the medical bureaucracies or social service. 
3.7.13 Data and evidence challenges with rare diseases 
Clinical evidence from orphan drug trials may be limited on purpose when the trials are 
halted early on ethical grounds when an interim analysis demonstrates clinical superiority 
of the orphan drug in terms of an intermediate outcome measure. To overcome the lack of 
data, this approach requires the commitment to continue collecting long term data to assess 
uncertainties and effectiveness (including cost-effectiveness) of the studied compound. 
Ongoing data collection can happen through patient registries, even though they may be 
biased if the patient etiology and disease severity change over time. The above 
considerations can pose a new and unique challenge to the regulator, the payer and 
ultimately the treating physicians: how can weak clinical data, small health benefit, high 
cost and absence of an alternative therapy for orphan drugs be aggregated and taken into 
account for evidence-based decision making? In 2009 NICE issued methodological 
guidance stating the use of the value that patients place on additional months of life to 
counterweigh the uncertainty around the evidence of the drug's clinical effectiveness. Such 
an approach is based on the fact that society attaches a higher value to health improvements 
experienced by patients who have worse lifetime health prospects.  
3.7.14 Innovative mechanisms to decide on reimbursement despite lack of data 
Another approach to address the lack of data and uncertainty on effectiveness builds on 
innovative reimbursement mechanisms for orphan drugs. Orphan drug companies and health 
care payers close risk-sharing agreements in which companies share the risk that the 
products may not be effective for particular patients. The arrangements provide that the 
companies may lose some or all product revenues (or needs to provide replacement 
products) if the drugs do not have the expected effects. Such solutions are fairly recent, rare 
and need to be analyzed and negotiated on a case by case basis, which also requires resources 
and time (which could have been used to treat patients with the often severe, unmet medical 
need). Orphan drugs have to be assessed on an individual basis to determine whether their 
specific features warrant the high prices demanded by the manufacturers. Current and 
planned indications, the existence of alternative health technologies, the total number of 
patients across registered and off-label indications, and R&D costs should all be 
incorporated (Simoens, 2011). Such assessments require and then build the fundament of a 
broader EBM approach to be used in the clinical practice, once the drug is approved, the 




some European countries appear to tend to demand data on the effectiveness of orphan drugs 
in a real-world setting rather than on their efficacy in a structured setting to gain 
reimbursement. The formal economic evaluation requires the calculation of the cost-
effectiveness of an orphan drug relative to a relevant comparator, reinforcing the need for 
comparative data and for a transparent and evidence-based approach towards pricing and 
reimbursement of orphan drugs (Simoens, 2011). 
3.7.15 Importance of RCTs (Randomized Clinical Trials) 
Clinical trials are the bedrock for a number of decisions, from the approval to make new 
compounds available for treatment for medical conditions, to the price at which they are 
sold, to additional information that has to be shared such as safety, side-effects, eligibility 
criteria, and more. Normally RCTs need to satisfy three basic requirements. They should 
examine and validate valuable and important biomedical research questions, they must 
utilize a rigorous methodology, and they must follow ethical considerations, minimizing the 
risks to participating subjects (Evans, 2001). Standard methodological approaches for 
design, execution, and analysis should be applied, and are required by regulatory bodies to 
ensure the quality and applicability of the results. These determine for example the number 
of subjects necessary to achieve statistical significance when producing therapeutic claims 
from the results.  
3.7.16 Challenges for RCTs for rare diseases 
With rare diseases comes the challenge that the number of experimental subjects who can 
be recruited into a trial can be very small. In such circumstances, alternative approaches to 
standard statistical methodology should be considered as the way out from the dilemma of 
having no RCT at all, or one that can still provide some evidence for potential use. Different 
several specific methodological approaches have been explored, that either improve the 
efficiency of standard statistical procedures, or that innovate design and analysis away from 
the classic paradigms (Gerss, 2010). Caution is exercised to ensure that the limits of 
scientific quality are not under-run, in which case alternatives to an RCT can be pursued as 
for example the set-up of an observational registry for the rare disease under study. These 
should include as many patients as possible and can be either complementary to RCT, or 
contribute to providing the bases for setting up a future RCT. Within the scope of RCTs, 
several methodological approaches can be pursued. Some enhance existing statistical 
methods, providing better leverage of the limited sample sizes available, others abandon the 
classical paradigms. None are universally applicable, they need to be reviewed case by case 
for usefulness and viability. As rare diseases pose additional hurdles and challenges 
compounded by smaller patient populations that ultimately help the Pharma companies to 
generate a return on investment, different healthcare systems create more favorable 
conditions. Some regulatory bodies and health authorities offer incentives for development 
(through scientific advice and research grants) and marketing (through market exclusivity, 
regulatory fee reductions) (Llinares, 2010).   Rare disease by definition have fewer patients, 
yet this is compounded by the fact that due to low awareness and diagnostic capabilities and 




subsequently treated. The unmet medical need can be enormous, and compassion could 
dictate exploring potential drug candidates and small clinical trials can be the only option. 
On the other side, small clinical trials may pose a few issues: the validity of results may be 
questionable or might miss some effects (positive or negative) due to low statistical power 
and bias, and they are more prone to variability, resulting in lower precision when 
quantifying the intervention impact (Gerss, 2010). Very small clinical trials might also raise 
new questions on privacy and data protection. Clinical trials on patients with rare diseases 
also raise additional ethical questions. For example, with HAE, patients can suffer life-
threatening laryngeal attacks, and when this is the case, eligible subjects with these attacks 
were not randomized, but treated with open-label icatibant, as it was expected to be the most 
effective treatment (Lumry, 2011). It would be unethical to give a placebo to a patient 
suffering potentially fatal events. However, on the positive side, working with smaller 
sample populations might have them more likely to share specific characteristics which 
subsequently yield more homogeneous results with less variability, which then reduces the 
generalizability, though. Small clinical trials tend to bring investigators and patients closer 
together. Combined with the fact that for many rare diseases the studied new drug is the first 
or last hope of therapy, participants are more involved, willing to participate and comply 
with the protocol.  
3.7.17 Other RCT approaches for rare diseases 
When recruitment of sufficient study subjects is difficult, or when ethical considerations, for 
example, because of a significant unmet clinical need that asks for minimizing the size of 
the placebo control group, alternative randomization approaches can be used. Response-
adaptive randomization, also called “play by the winner”, is such an approach, where the 
probabilities of allocation change through the course of the study based on the cumulative 
and accrued efficacy response data (Gerss, 2010). If one of the one intervention is beginning 
to emerge as superior, new patients will more likely be allocated to that arm, with the benefit 
more patients can benefit from a possibly superior treatment. Another approach that is even 
more flexible, does not predetermine the sample sizes a priori. The RCT is divided into 
stages with initially fixed sample sizes. At every stage, interim analyses would be 
performed, and the sizes for the next stage re-determined. As soon as the trial results are 
strong enough to prove the hypothesis, the trial would be stopped.  When several existing 
trials measure the same outcome, a meta-analysis may become possible, an approach also 
used as part of this thesis. Meta-analysis describes a set of statistical procedures which 
enable the combination of two or more independent studies to produce an overall answer to 
the research question (Schulze, 2004). Combining different studies provides results with 
more power compared to each study on its own, and the studies don’t necessarily need to 
follow the same design, protocol (Gerss, 2010). The effects and the differences in precision 
are weighted by sample size, before being pooled into an overall effect estimate, where the 
power is automatically increased. The effect estimate is, therefore, more precise than when 




3.7.18 From RCT to RWE for rare diseases 
Some orphan drugs are fast-tracked into approval for ethical reasons: the condition is life-
threatening, there is no alternative treatment, and due to the difficulty in recruiting patients 
for an RCT, market authorization is given faster. For many rare conditions there is yet no 
other treatment option which poses a compelling and compassionate argument to provide 
patients, that is study subjects, a hope that there is or there will be a cure, which will extend 
or improve their life, relieve them of symptoms, or possibly even enables a normal life (Day, 
2010). In some other cases, RCTs are initiated but may be halted early for ethical reasons, 
once the first results demonstrate clinical superiority. Either path still requires a commitment 
to ongoing evaluations which can be in form of post-marketing surveillance studies to 
produce efficacy and safety data, or in form of patient registries which collect the necessary 
data to evaluate uncertainties surrounding the longer-term effectiveness and cost-
effectiveness of the orphan drug. Patient registries represent the first step in systematically 
cataloging available information that can be used to estimating prevalence or incidence of 
rare diseases. Combined with the data around patient profiles and treatment outcomes, the 
registries build the base for research, for recruiting patients into trials, and for the exchange 
of information between physicians, including the building of consensus for the writing of 
treatment guidelines. Patient advocacy groups demand and fund registries as it is established 
that they are a strong contributor to improve health and QoL of the affected patients. All 
combined, RWE can enable an expedited assessment of the treatment, for when there is no 
time or opportunity to conduct an RCT. 
3.7.19 QoL with rare diseases 
Not all rare diseases affect life expectancy, but they lead to physical, emotional and 
psychosocial limitations with a wide range of disabilities (Rajmil, 2010). QoL is one of the 
patient-reported outcomes and evolved from simple measures such as pain intensity, to more 
complex constructs such as patient satisfaction, further refined and broadened to 
multidimensional concepts covering the physical, psychological, and social domains. Many 
rare diseases can combine multi-morbidities and may be substantially debilitating, causing 
significant burden not only for the patients, but also for the families, the caregivers, and the 
system. At prima facie “rare disease” and “serious disease” seem not to have a reason to 
correlate, but in reality, and in many cases, they go hand in hand. Particularly when infants 
are born with a hereditary and congenital disease, the severity of it often results in a limited 
life span (Day, 2010). Also, in case of survival into adolescence and adulthood, genetic rare 
diseases often have a debilitating impact that affects virtually all aspects of life. These need 
also to be included in all aspects of therapy, costs and funding. People living with a rare 
condition face a number of obstacles that each have a strong impact on QoL. For most rare 
conditions there is a lack of scientific knowledge and lack of awareness of the disease, which 
undermines any effort for a positive outlook. Most patients don’t have access to the right 
physicians which results in incorrect or delayed diagnosis. When diagnosed, there is still 
limited or low-quality information or support. Rare diseases often come with multi-
morbidities which require multidisciplinary healthcare that is not available or not 




consequences that include isolation, stigma (in some cultures patient seen as cursed), 
impaired education, career and income progression. Patients can be exposed to inequities 
and difficulties in accessing treatment, rehabilitation and care, especially in multi-tier 
healthcare systems. Overall patient studies documented dissatisfaction and loss of 
confidence in medical and social services (Kole, 2010). 
3.7.20 Rare disease costs 
Rare diseases generate a range of negative effects on the QoL of the patients, their caregivers 
and on society. The effects also include the use of health care and other resources. The 
primary disease impact is often further exacerbated by co-morbidities such as anxiety, pain, 
depression, or premature death, which all have an effect on productivity (Lopez-Bastida, 
2010). When looking at costs, different types have to be distinguished. The first type of costs 
are the direct treatment costs that result from the use of resources, outpatient (such as 
physicians, specialists) and inpatient (such as hospital care, emergency rooms), the use of 
diagnostic and other equipment, and the drugs themselves. The second type of costs are the 
non-healthcare costs resulting from the need for additional help at home, special housing 
and transportation requirements. The third type of costs results from the loss of productivity 
caused by sick leave, disability, or early demise. 
3.7.21 The link between QoL and costs of the conditions 
A link is made between QoL and costs by assigning a value to the QALYs, the quality-
adjusted life years, which are calculated by multiplying life years with their quality weight. 
Cost of illness estimated and expressed this way allows to define each condition in monetary 
terms and be compared and allows a direct assessment and justification of an intervention 
or a therapy, therefore an optimized allocation of limited resources through objective 
tradeoffs. The QALY approach can provide an economic framework for evaluation of 
healthcare services which would enable the determination of the most efficient service, 
technology or therapy (Lopez-Bastida, 2010). Combining units that measure both quantity 
and quality of life gained through medical intervention, the QALY, allows more advanced 
analysis of effects compared to mere cost-effectiveness studies. QALY as an index takes 
into account also patient-subjective aspects, which can vary significantly between 
treatments even for the same precise indication (for example a hospital administered 
infusion every two days vs. an oral capsule that can be taken at home once a week). The 
QALY approach may also have disadvantages that need to be weighted in: It can be difficult 
to measure health in monetary terms (how much are ten hours of pain worth?) and how to 
deal with ethical dilemmas (how much more is the life of a child worth compared to a 





3.7.22 Pricing of orphan drugs 
Same as with all pharmaceuticals, the price of an orphan drug is set by a manufacturer in an 
effort to recoup all its costs, especially in research and development, and to return a healthy 
profit in line with market expectations and the investment risk is taken. However, the market 
for orphan drugs has inherent market failures resulting in high prices due to a number of 
reasons (Simoens, 2011). Orphan drugs command a high price for a number of reasons. Even 
at a high price these drugs can save the healthcare system significant amounts of money, as 
these conditions, when left untreated, cost the healthcare system much more mainly through 
their significantly debilitating impact and their comorbidities. Drug pricing, in general, 
follows the same economic logic as for most goods and services, yet orphan drugs also show 
higher prices than drugs in general for a few reasons that can be explained as monopolistic 
power, or market inherent market failure. High-quality evidence about the clinical added 
value of orphan drugs is rarely available because to the challenge in recruiting a large 
number of patients for the studies but orphan drugs serve a small number of patients from 
which they need to recoup the significant R&D costs. They benefit from a period of 
marketing exclusivity in a narrow market where few alternative health technologies are 
available.  
3.7.23 Orphan drugs price finding dynamics 
For the reason explained in section 3.7.22, payers and patients have few, if any, alternative 
options and thus limited negotiating power, compounded by lack of information on the real 
cost structure of orphan drugs. Payers also need to take into account not only the current, 
but also any future planned or possible indications, including possible off-label indications. 
Patient advocacy groups and media may exert additional social pressure, and, in such 
settings, pharmaceutical companies have more leverage when attempting to maximize 
orphan drug prices (Simoens, 2011). Each state governs its own pricing and reimbursement 
of orphan drugs, the stakes and the incentives can further induce the companies to artificially 
create monopolistic market conditions. This can be achieved by splitting up a disease into 
several sub-diseases, which would qualify as a separate rare disease each, in order to attain 
the benefits above. Health care payers on the other side may have limited negotiating power 
and often lack information about the cost structure of orphan drugs. In addition, both 
regulatory bodies and payers can be exposed to pressure from patient advocacy groups and 
media to accommodate new orphan drugs. Under these border conditions, the laws of 
competition don’t necessarily work. Interestingly countries with free-market pharmaceutical 
pricing (e.g. Germany) generally seem to have higher orphan drug prices than countries that 
regulate prices (e.g. Portugal, Spain). Not for all orphan drugs, the need to recoup substantial 
R&D costs from a small number of patients applies: some orphan drugs were approved for 
other indications or on the basis of historical use, when there was no requirement to produce 





3.7.24 Specific aspects of biological and biopharmaceutical drugs 
Many orphan drugs are biologic and biopharmaceutical prices may be less regulated and 
higher than those of chemically-derived drugs, as in some countries they are excluded from 
price regulation when used in hospitals. Price comparisons with other products are often not 
possible, as there are only very few and highly differentiated products. Competition from 
biosimilars can also be hindered by the difficulties to develop, to demonstrate bio-similarity 
and the additional studies (e.g. immunogenicity) that need to be performed. When an unmet 
clinical need or the first treatment for a rare disease is being offered, the cost-effectiveness 
thresholds are also lower. For all these reasons over the recent years, an increasing number 
of Pharmaceutical and Biotech companies seem to have increasingly focused on rare 
diseases, attracted by the opportunities of better differentiation and higher profitability 
compared to mass market Pharma which has come under intense political scrutiny. In all 
markets, manufacturers have an incentive to game the system by artificially creating 
monopolistic market conditions, hence it is no surprise that the same dynamic is observable 
in rare diseases. This and the growth have now made pricing and reimbursement of orphan 
drugs an issue of high priority for policymakers, legislators, health care professionals, 
industry leaders, academics and patients as well.  
3.7.25 Reimbursement of treatments for rare diseases 
Price is the single greatest barrier to patient access to orphan drugs, forcing health care 
systems to developed special systems to ensure patient access whilst managing overall 
budgets (McCabe, 2010). The costs of treating rare diseases have averaged USD 140,000 
per year in 2016 in the US, according to analyst firm Evaluate Pharma (Johnson, 2018). 
There are about 6,500 US citizens suffering from HAE and the annual average cost of 
medications per patient was more than USD 2 million in 2017, according to report by 
Express Scripts Holding (Johnson, 2018). Public health systems and private insurers have 
been set up and are designed for the mass market health challenges that affect large segments 
of the population. Such systems are structured for overall performance and not for unusual 
and unfavorable circumstances (Pratt, 1985), like rare conditions. Policy makers, legislators, 
health care professionals, industry leaders, and patients are driving and witnessing a surge 
in the diagnosis and treatment of rare diseases with orphan drugs. Pricing and reimbursement 
are an issue of high priority. While in some healthcare systems reimbursement of treatment 
is virtually unlimited, in many there are limitations based on such criteria as the seriousness 
of the disease, the availability of alternative therapies, the financial impact to the patient if 
the treatment is not reimbursed (Simoens, 2011). On the other side, while disease severity 
justifies a premium price for drugs, disease rarity does not. For this reason, authorities and 
payers tend to review the effectiveness of orphan drugs in a real-world setting, rather than 
assessing their clinical efficacy in structured and controlled RCT settings. Prices and 
reimbursement are calculated compared to relevant comparators; therefore, comparative 
data should ideally be developed and provided. Many of the new orphan drugs are biologic 
and are priced highly. The US FDA has initially set up a separate category for biologicals 
for the first five cell and gene therapies, which has contributed to a dramatic shift in drug 




sevenfold from USD 1,258 to USD 9,396. The number of the top 100 drugs costing more 
than USD 10,000 per year increased from 26 in 2010 to 47 in 2014 (Campaign for 
sustainable drug pricing, 2016). 
3.7.26 Efficacy and efficiency of healthcare treatments 
With classical medicine and EBM, the focus on the evaluation of treatments is measured in 
efficacy. Drugs are not only a medical good but also an economic good that needs to be paid 
for, and as such standard economic theory applies. When having to choose between goods 
or services or how much to pay for them, efficiency is the variable to be considered. Positive 
efficiency is obtained when the surplus, the excess value to the consumer over the price paid 
is positive (consumer surplus) and/or the excess in price received is above the costs for the 
seller (producer surplus). The sum has to be positive for a product or service to be viable, 
and free markets evolve to maximize this variable. The challenge with rare diseases is that 
under normal conditions the surplus of orphan drugs would be negative, they would be 
inefficient and pharmaceutical companies should not develop them and patients would not 
receive them. To achieve efficiency – and enable treatments to be developed for patients 
with rare conditions - pharmaceutical companies need to receive sufficient return to invest 
and supply, and payers can justify covering such treatments, as with overall budgetary 
constraints, tradeoffs have to be made (McCabe, 2010). Hence, the health economy of rare 
diseases has to be viewed from two perspectives. First, the condition itself causes an 
economic impact from impaired education, professional success, reduced income, additional 
expensed for housing and more. Second, diagnosis and treatment result in additional costs 
that need to be evaluated and weighted against to assess their cost-effectiveness (Lopez-
Bastida, 2010).  
3.7.27 HE challenges of rare diseases 
Each rare disease has by definition few cases and within the large scheme, initially orphan 
drugs were and often still are exempted from the same rigorous value for money 
consideration. This paradigm might have to be revisited as the number of authorized and 
reimbursed orphan drugs is growing rapidly and having a significant impact on healthcare 
budgets (McCabe, 2010). Major regulatory bodies and healthcare systems have introduced 
highly effective measures to incentivize the development of rare diseases, like the Orphan 
Drugs Regulation in Europe. In the meanwhile, the premium prices requested and paid for 
these products added up to such measure as to challenge the notion that the treatments can 
be made available to all patients who may benefit from them (Miles, 2007). Some payers 
still offer unrestricted access, others have introduced regulation ranging from requiring 
individual patient approvals to blanket bans for certain treatments. It can happen that, despite 
regulatory action such as resulting from the orphan drug designation, the development and 
reimbursement of an orphan drug remains inefficient. In such cases, it has been suggested 
to place higher on treating rare diseases than on treating other diseases (McCabe, 2010). 
This claim for rarity rests on the assumption that treating patients with rare diseases is more 
important than treating individuals with common diseases, as the severity, life impairment, 




conditions which would have an equal claim on resources. In Australia, for example, the 
reimbursement scheme acknowledges that not all health gains are valued the same. The 
health gains for patients with severe and rare conditions for which there is no other treatment 
and who face a significant mortality burden, are valued more than others (Australian 
Government, 2016). 
3.7.28 Use of QoL for rare disease HE considerations 
The classic methods to appraise treatments for reimbursement show to be inadequate for 
rare conditions: RCTs are often not viable and alternative approaches have to be pursued to 
obtain regulatory approval to market a new orphan drug. Sometimes is it not possible to 
measure the effectiveness of orphan drugs vs. conventional therapies, the measures 
themselves are not adequate for rare conditions (McCabe, 2010). The QoL perspective offers 
an equity-based approach for HE-driven decisions.  
When having to decide if to fund or which treatment to fund, institutions such a NICE attach 
a monetary value to QALY. Empirical evidence suggests that treatments costing between 
USD 25,000 and USD 35,000 raise questions and the institute reviews carefully at the 
certainty of the outcomes, if the new treatments deliver substantial benefits and whether the 
QoL impact has been measured and reflected adequately. Treatments costing over USD 
35,000 per QALY need increasingly strong evidence for them to be recommended and 
ultimately reimbursed (Goodall). Despite the intent and the models aimed to fully quantify 
QoL, there remains a social value judgement that needs to be considered. For example, 
people strongly fear losing their eyesight and efforts to save children’s lives have strong 
public support. Appraisers and decision-makers on policy, recommendations and funding 




3.8 Hereditary Angioedema (HAE) 
3.8.1 Description of HAE 
The rare condition Hereditary Angioedema (HAE) with a prevalence of 1:40,000 has been 
selected to study the research questions. It is a rare disease characterized by recurrent 
swelling of subcutaneous or mucosal tissue primarily caused by a deficient or dysfunctional 
C1-inhibitor.  
Figure 3.8.1 - Attack sites of HAE 
Hereditary Angioedema was first described by JL Milton in 1876 and Sir William Osler in 
1888 was the first to note the hereditary component of the condition providing a detailed 
description of HAE over five generations. It took several decades before Donaldson and 
Evans discovered the absence of C1-inhibitor as the biochemical basis of the disease in 1963 
(Ghazi, 2013). HAE is a condition characterized by transient swelling of cutaneous, 
subcutaneous, and submucosal tissues resulting from leakage of fluid. Divided into 
histamine-mediated and bradykinin-mediated, HAE is the latter form and hereditary. A child 
of a sufferer has a 50% chance of inheriting HAE. 75% of cases are inherited, 25% 
spontaneous mutation. The condition manifests through swelling attacks which can be 
isolated or recurrent, unpredictable in frequency, severity and site as illustrated in Figure 
3.8.1.1. The attacks can be disfiguring as illustrated in Figure 3.8.1.2, life-threatening if the 




HAE causes a significant burden of disease with absenteeism from work or school increasing 
with attack severity and frequency. Between attacks, the burden of disease is reported 
through reduced productivity, emotional impairment and reduced Quality of Life (QoL).  
3.8.2 Treatment of HAE 
Figure 3.8.2 - HAE during attack and between attacks 
(Source: (https://nuwaupianism.com/360-questions/malachi-york/397-ask-the-nuwaupians-
what-about-malachi-york-s-acute-case-of-angioedema 
Studies have shown QoL to be the single most meaningful way to measure how well 
treatment works (Lumry, 2018). The treatment goal is to prevent or attenuate angioedema 
attack recurrence, and to reduce the symptoms of angioedema attacks as soon as possible. 
Treating physicians are specialists, often Immunologists or Allergists, but in some countries 
Dermatologists, ENT clinicians, Internal Medicine Specialists or others. There are two 
treatment approaches: (1) Treatment of attacks - Acute or on-demand treatment, and (2) 
Prevention of attacks - Both long term and pre-procedure. The WAO (World Allergy 
Organization) guideline says that every patient on prophylaxis should also hold on-demand 
treatment at hand in case of breakthrough attacks. Based on published data it is estimated 
that of the global around 190,000 people living with HAE, about one quarter is diagnosed, 
of which about half is treated, of which about one fifth has access and is treated with modern 
therapies. There is a strong unmet medical need. Most patients are not diagnosed, not treated 
and have limited or no treatment options which leave them completely exposed to the attacks 





3.9 The three perspectives EBM, QoL and HE in the literature search 
A literature review spanning the healthcare industry from a general to a specific rare disease 
focus has been performed and a number of challenges faced by the different stakeholders 
have been identified. Generally speaking, the review has identified many issues centered 
around decision-making processes, incentives and the subsequent impact on patients. EBM, 
the first perspective, was reviewed as described in section 3.1. It is an approach which is 
generally accepted and used across all steps from diagnosis, prognosis, treatment, quality of 
care, and health economics. This review raised the challenge that data pools and insights 
currently remain still fragmented and dispersed, opening the opportunity for this thesis to 
attempt to combine some with the expectation to strengthen content and depth. QoL, the 
second perspective was reviewed in section 3.4, which describes all aspects of life 
experienced by a patient that is impacted when he or she suffers under a disease. The third 
perspective on HE was researched in section 3.5, highlighting the increased need to balance 
between universal access to modern therapies and the limited funds available. The three 
perspectives, affecting the individual, his immediate surroundings and society as a whole, 
are often in conflict. This thesis aimed to incorporate all perspectives, in order to contribute 
with a balanced framework which was expected to facilitate the dialogue necessary between 
the decision-makers and the influencers. Rare diseases and HAE with their specific attributes 
and challenges have been researched in the literature in sections  3.7 and 3.8. Rare diseases 
pose additional challenges such as low awareness of the conditions, how to diagnose them 
and treat them.  
3.10 Emerging themes from the literature search 
The literature search identified recurring themes which could be connected to the problem 
statements and RQs proposed in section 2 and which are illustrated in Table 3.10.1 
RQ 1.1: How do different stakeholders and decision-makers have an impact on patients 
with rare diseases? 
RQ 1.2  Are diagnosis and treatment decisions made with EBM, QoL, HE and RWE 
considerations in mind? 
RQ 2: How can the decision-making process and the available and potentially available 
data be combined to allow the stakeholders to make economically more efficient 
therapeutic decisions with better health and QoL outcomes?  
A thematic analysis was conducted while performing the literature search where the 
different themes, key words and concepts were extracted from the sources and clustered. 
Their importance in the literature was established by the frequency of occurrence, the 
quantity of their citations, and the importance of the role they played in reaching conclusions 
or interpreting observations. Table 3.10.1 crystallizes the themes by cluster indicating the 






Theme Sections Related 
RQ 
Physicians treat patients based on a combination of 
scientific evidence and personal experience. 
3.1.1 RQ 1.1 
Healthcare is mostly funded by payers who face tradeoffs 
and constraints. 
3.5.5, 3.5.6 RQ 1.1 
Pharmaceutical companies pursue market access 
activities to enable and influence the prescription of drugs 




Agency theory describes the dynamics between the 
stakeholders, the resulting potential challenges and 





Established instruments to support Evidence-Based 
Medicine (EBM) such as Randomized Clinical Trials 







RCTs have limitations especially for rare conditions. 





Clinical guidelines support the execution of EBM by 





Treatment guidelines have limitations due to information 
gaps, their strict focus on medical parameters (vs. 
incorporating also QoL and HE considerations) and the 





QoL is a key factor which describes the patient’s point of 
view. For rare conditions the families of the patients also 
play a prominent role and QoL acquires more importance 








Health Economics (HE) and the need to contain 






The significant QoL implications of rare conditions 
generate additional costs. 
3.7.20, 3.7.21 RQ 1.2 
Rare diseases face additional challenges on clinical 
evidence, QoL and HE, which pose additional hurdles 
and complexities for all stakeholders, caused by data 
paucity, low awareness, high treatment costs, and in most 
cases no definitive cure.  







Orphan drugs treating rare conditions are subject to 
similar costs compared to other drugs, but command 
significantly higher prices for different reasons, adding 










Theme Sections Related 
RQ 
Theme Physicians could face dilemmas between the 
clinical guidelines and the need to meet the expectations 
as described by the agency theory. The compensation and 
the incentives for the physicians effectively drive the 
decision-making process and are essential to successfully 






Additional considerations (such as risk management) and 
governance mechanisms (such as trust-based governance) 
need to be factored into the decision-making process and 




Real World Evidence (RWE) complements RCTs to 








HE discussions between payers and pharmaceutical 
companies are shifting from volume- to value-based 




When deciding on the reimbursement of orphan drugs, 
payers need to look at innovative approaches  
3.7.14 RQ 1.2 
RWE is required to understand and include QoL and HE 
into therapeutic decision making and funding. For rare 
diseases the importance of RWE is higher to compensate 





Therapeutic decision making has evolved over time 
paving the way for a more holistic approach that 





Price differences for same treatments across healthcare 
systems and different levels of payment coverage suggest 
different levels of development and possible inequalities 
and inefficiencies. 
3.5.18 RQ 2 
Combining EBM, QoL and HE requires the intersection 
of different paradigms and managed care models aim to 










3.11 Research gaps 
The literature search on EBM, rare diseases, HAE, QoL, HE, RWE showed that each 
discipline or perspective of healthcare management has been subject to detailed inquiry and 
research. Scientific findings have led to theories, consensus for treatment, but also 
challenges. From an examination of the literature review, three gaps became clear. First, 
existing studies and papers are scattered across geographies and specific aspects. A meta-
analysis combining them would allow for stronger conclusions to be drawn; second, the 
three perspectives EBM, QoL and HE inherent to the three groups of stakeholders HCPs, 
patients and payers are taken individually, sometimes mentioned together in context, but not 
fully integrated for consideration and decision making. Third, agency theory has been 
utilized to describe the patient-doctor relationship and partially also the role of the payer. 
Some real-life complications still need to be researched and agency theory can be used to 
explore these complications. This thesis aimed to inform these three gaps by leveraging 





4 CHAPTER FOUR - RESEARCH DESIGN AND 
METHODOLOGY 
4.1 Research design 
 
Figure 4.1.1 - Stakeholder mapping with variables 
To answer RQ 1.1. and RQ 1.2 a literature review and three studies were conducted with a 
specific focus on HAE as an example of a rare disease.  
4.1.1 Selection of research method 
For this thesis, a deductive research method was selected. Within the chosen area of rare 
diseases and medical treatment, a body of research and concepts were available within the 
three dimensions EBM (Evidence Based Medicine), HE (Health Economics) and QoL 
(Quality of Life). With the selected research method and the data collection from different 
perspectives, this thesis aimed to combine them into one framework. The type of research 
is explanatory as it aimed to connect different perspectives and data sources, while 
explaining the interrelations and how these could be used for better clinical, QoL and 
economical outcomes for the stakeholders involved. Figure 4.1 illustrates the framework of 
combining the variables to allow for a more comprehensive therapeutic decision-making to 
allow for improved clinical, HE and QoL outcomes. For the research design, both a 
qualitative and a quantitative research method were pursued. The qualitative method aimed 
to obtain answers to RQ 1.1 and RQ 1.2, while the qualitative method aimed to quantify the 
variables identified and discover how they relate to each other. When devising the sampling 
strategy, two of the three stakeholders were selected: the patients and the physicians. 




privacy of the patients by way of anonymizing the survey. To ensure additional privacy 
protection for the patients, the participation by the physicians themselves was also 
anonymized. Data from the patients were collected through a non-interventional search on 
social media, with special attention not to put at risk the patients’ privacy, which is 
particularly sensitive given the focus of the thesis is on an incurable genetic and rare disease 
with significant impact on health, QoL and costs. 
The RQs formulated in section 2 based on the identified knowledge gaps, determined the 
variables which were researched in the literature review in section 3. The agency theory 
selected as the theoretical framework in section 2.3 and explained in section 3.6 provided 
the backbone of the thesis, establishing the logic, helping to synthesize the findings and 
providing guidance on when gaps could be clarified or closed.  
The survey with physicians was designed to be retrospective, therefore not experimental and 
ensuring that variables could not be controlled or manipulated. The same can be said of the 
research on social media, where the data points (postings) were in existence already before 
the thesis was executed. 
The answer to RQ 2 was to be built on a model which incorporates all variables and their 
values, as verified and measured by the research, into one algorithm that could be used to 
perform simulations which help ascertain the optimal treatment approach which maximizes 
clinical outcomes, QoL and economic efficiency. Such a model could be in the form of a 
formula that utilizes the variables illustrated in Figure 4.1.1. The treating physician, the 
payer and the patient would enter the values relevant for the specific situation of the patiend 
and his or her condition, and the algorithm would suggest the optimal therapeutic decision. 
4.1.2 The three selected study areas 
Consistent with the literature review and personal experience in the field suggested three 
possible study areas with prospects of generating new data which could be cross-checked 
for consistency while enabling to answer the RQs. 
Study 1: Survey with treating physicians  
Study 2: Search on social media  
Study 3: Meta-analysis of existing studies  
Each of the studies analyzed the stakeholders - patients, physicians and payers, as well as 
the three perspectives of EBM for diagnosis and treatment, and QoL and HE/RWE for 
funding. The objective was to understand the gaps of not using all variables for treatment 
decisions and consequently how this impacted patients and society. The approach of a meta-
analysis was selected to achieve more rigorous conclusions due to higher statistical 
significance and which were subsequently combined into a research framework. It is 
expected that following the illustrative framework and testing of the data, that the various 
quantitative conclusions will be derived from the three studies. 
Given the rarity of the medical condition and the relatively limited number of both patients 
suffering and physicians treating the chosen condition, the thesis did not constrain the reach 
of the sources of data. All available literature, the available treating physicians and the full 




expectation was that in this specific scope of the thesis the selected convenience sampling 
might prove to be sufficiently representative, generalizable and consistent across the studies.  
4.2 Variables studied 
4.2.1 Stakeholders 
Stakeholders are persons and institutions relevant to the treatment of the condition of the 
patient. These are either decision-makers, payers or influencers. The objective was to 
provide a qualitative description of stakeholder roles, qualifications, activities and their 
impact on the patients. This part of the thesis was exploratory/descriptive to scope out and 
describe all stakeholders involved or influencing, directly and indirectly, awareness, 
diagnosis, treatment and funding. Data were collected cross-sectionally with primary 
(survey, interviews, and social media) and secondary analysis (secondary published 
literature). The literature search suggested that relevant stakeholders are patients, healthcare 
professionals (physicians, nurses, and pharmacists), payers (for reimbursement), patient 
advocacy groups, caregivers, regulatory bodies, and pharmaceutical companies, with the 
first three being the most relevant ones. The thesis focused on patients, physicians, and 
payers following the double-agency framework described in section 3.6.4. 
4.2.2 Criteria for diagnosis, treatment and to assess success 
The objective of this section was to provide a qualitative and quantitative description of 
criteria utilized by treating physicians for diagnosis, treatment decisions and for assessment 
of outcomes. The literature research appeared to indicate that epidemiology (prevalence in 
population), frequency of HAE attacks (# per year), location of attacks (extremities, 
abdomen, face, laryngeal, etc.), severity of attacks (pain index), fatalities (%), co-
morbidities (e.g. depression, anxiety, hypertension, obesity, etc.), QoL impact (e.g. 
absenteeism, lost income) and treatment costs are the relevant variables. 
4.2.3 QoL aspects  
The objective of this section was to analyze and structure the QoL aspects affecting the 
patients and their caregivers due to the relevant condition including its main symptoms with 
the co-morbidities, the burden of disease and treatment, and the costs of having and 
managing the disease (income and expense).  
The literature search suggested that variables that provide definitions, meanings and 
quantification of QoL (QALY and other parameters) and which cover both qualitative 
(social impact) and quantitative (income and costs) aspects could be used for therapeutic 
decision-making. The key was to utilize the variables that provided values for the HAE 
condition before diagnosis, compared across different treatments and with the healthy 
population. 
4.2.4 HE and RWE considerations  
The objective was to analyze the economics of the condition, undiagnosed vs. treated, and 




use in therapeutic and funding decision making, and their dependency on different types of 
treatment and QoL considerations.  
The variables utilized were expressed as cost to the individual and to society of the 
undiagnosed patient vs. the diagnosed and treated patient. These variables were supposed to 
include all financial implications such as the economic burden driven by symptoms, co-





4.3 Study 1 – Survey with physicians treating HAE 
4.3.1 Participants and objective 
The community of physicians working on or exposed to HAE is relatively limited as it is a 
rare condition about which there is only recent awareness, diagnosis, and treatment. 
Convenience sampling was expected to allow for a sufficiently strong overview and 
representation of the community of treating clinicians. The survey was designed to collect 
data related to HAE. Authors of articles, participants at HAE and Immunology conferences 
and physicians treating HAE were invited to participate in the voluntary survey. The latter 
were identified through online searches of allergology and immunology clinics or 
departments at hospitals. These treating physicians are highly trained and educated 
specialists who on a daily basis see patients with severe genetic conditions that often result 
in fatalities and a shorter life due to their conditions. The survey was designed to better 
understand the diagnostic and therapeutic decision-making process.  
4.3.2 Survey process 
Potential participants were sent an email with an invitation to follow a link if they would 
like to proceed with the survey. Clicking on the link, the participants were led to the survey 
participation sheet, following which they could provide their consent implicitly, by 
continuing to the survey itself and submitting the answers to the questionnaire. In order to 
obtain more and better-quality data, the survey was conducted anonymously, with no 
collection of personal or personally identifying data of either physicians or patients. Answers 
to the questions were entered into an anonymized online questionnaire and analyzed 
statistically. 
4.3.3 Privacy considerations 
This study was chosen to be anonymous for two reasons: first, physicians might be more 
inclined to answer honestly in how they make treatment decisions on their patients, and 
second, due to privacy laws, no patient data of any kind can be shared with anyone outside 
the physician’s office. As the survey and its responses were anonymous, coercion was 
practically impossible. Participants were informed that there was no obligation of any kind 
to complete the survey, and that the data would be utilized purely for research purposes, 
with no commercial objective, and that results would only be published or shared in an 
aggregated way, in form of collective statements not referring to any individual. Since the 
thesis was related to patients with rare conditions, some physicians may have only referred 
to very few patients. With the double protection of anonymized data from both patients and 
the treating physicians, the patients were better protected. To preserve the privacy of the 
participants, all data were checked for any information that might help identify individuals. 





4.3.4 Other aspects of the survey 
While the survey was conducted across multiple countries with as many different languages, 
the language of the survey and all communications were in English. The presumption was 
that potential participants were fluent in English, as all relevant studies, literature and 
scientific/medical discussions identified for the condition are in English. This thesis and the 
survey did not aim to address issues of physician competency and sought to avoid the issue. 
It would have been difficult to ascertain with 100% confidence if an answer to a question is 
based on incompetence. Also, it might have been difficult for the researcher to challenge the 
answers. The participants are trained medical specialists in their field (selection criteria) and 
known to provide treatments in the therapeutic area studied. As the research is anonymous 
and there is no direct benefit, the thesis was built on the good faith and ethical standards of 
the participants including the researcher. Thanks to the high commitment of stakeholders, a 
participation rate of physicians treating close to 3,000 patients. Taking the prevalence of 
HAE of 1:40,000 (see section 3.8) from the scientific literature, this represents an overall 
hypothetical population of 108 million people. Lastly, the data were analyzed to help 
confirm (or confute) the findings from the other studies.  







4.4 Study 2 – Social media research 
4.4.1 Sources and process 
Due to stringent privacy rules and the confidentiality of the doctor-patient relationship, it is 
difficult to contact patients directly for surveys or interviews. Stakeholders who have direct 
access to patients, such as medical insurance groups and patient organizations, do not enable 
or facilitate direct contacts. This thesis aimed to incorporate the voice of the patients in its 
data pool to answer the RQs. The instrument of a social media search was deployed to 
confirm or disprove different perceptions, ranking, and relevance of the variables within the 
patient community. 
Two platforms, Facebook and Twitter, were selected as they have a broad diffusion in the 
population, are used to share all kind of information, and are easily accessible and searchable 
through their own or widely available data mining tools. The search for posts and tweets 
mentioning the combination of keywords was repeated multiple times to obtain sufficient 
data volume and enable statistical analysis.  
4.4.2 Privacy considerations 
The collection of social media postings contemplated no intervention and no interaction with 
the posters. Only existing publicly posted information was collected. Implicit consent of the 
posters on Facebook and Twitter was presumed, as they agreed to the terms of conditions of 
the platforms: The Facebook privacy policy stated that “Public information can be seen by 
anyone, on or off our products, including if they don't have an account. The first statement 
of the Twitter privacy policy was that "Twitter is public and Tweets are immediately 
viewable and searchable by anyone around the world.” However, the thesis acknowledges 
that “just because the data is in the public domain, it does not mean it is automatically open 
to be used for research purposes”. For this reason, two layers of protection were introduced: 
(1) identifiers and posts were separated. Only the posts themselves were saved and used for 
the thesis (Identifiers such as names, nicknames, addresses, locations, were ignored). (2) 
Only aggregated data, no single posts, was presented in the thesis.  
With these steps, the researcher sought to significantly reduce and possibly eliminate any 
risk to the posters, as only data already accessible to the general public was collected. No 
participant was engaged in any activity or was influenced in any direct way by the study or 
the data provided. To be sure, participants were not even actively participating as the data 
already existed in the public domain. 
This part of the thesis on social media could be categorized as a non-interventional 
observational study, but it differs from other data collection methods used in this thesis in 
that participants were not selected by any criteria related to a potential vulnerability such as 
age, religion, or ethnicity. “Participants” on social media are not and cannot be selected, and 
the presumption is that postings were made only by people exposed to the condition, their 




4.5 Study 3 – Meta-analysis 
For the meta-analysis, a structured and systematic review of available sources was 
performed. Relevant databases for studies and reports such as Medline, Embase, Cochrane 
Central Register of Controlled Trials, EconLit were searched for keywords relevant to the 
thesis. Other sources such as articles, study reports and publications in general, which were 
gathered by the research and assessed to be relevant, were included as well. To strengthen 
the pool of sources, relevant citations and references were additionally followed to the 
original sources themselves. Preference for inclusion was given to the most recent sources. 
Few sources had to be filtered out as the vast majority was less than ten years old, and the 
topic of the thesis was relatively new. Sources included reports on CTs, observational 
studies, publications on specific cohorts (e.g. pediatric populations), specific settings (e.g. 





4.6 Ethical Considerations 
Ethical considerations came into play in a few areas of this thesis.  
4.6.1 Survey with physicians treating HAE 
The survey with the physicians was a simple online multiple-choice questionnaire (see 
section 4.3) which was completely voluntary. The objective was to better understand their 
interactions with patients including the diagnostic and therapeutic decision-making process. 
The survey was not expected to generate any form of distress to the participants. If an invited 
physician at any point decided to stop participation, he/she could simply close the browser 
with no consequence of any kind. Participants were also invited to contact the researcher 
and/or his supervisors should they have any question or concern or experience any distress 
arising from the thesis. 
4.6.2 Study 2 – Social media research 
To incorporate the voice of the patients in its data pool, this thesis searched for posts on 
Facebook and tweets on Twitter by HAE stakeholders to analyze the real-life application 
and the quantification of the variables and concepts inherent to HAE (see sections 4.1 and 
4.2). The thesis uses data in the public domain but acknowledges that there could still be 
risks for the posters, which are mitigated as described above: anything that could potentially 
identify individuals or compromise their privacy was not collected or deleted, and only 
aggregated data was reported.  
This thesis follows the guidance and recommendations by the Social Media Research Group 
which was established to ensure ethical social media research (Social Media Research 
Group, 2016), the British Psychological Society Ethics Guidelines for Internet-Mediated 
Research (British Psychological Society, 2017), the Australian National Statement on 
Ethical Conduct in Human Research (Australian Government, National Health and Medical 
Research Council, Australian Research Council, 2018) and the Swiss Ethics Code on 
research with human subjects (Swiss Academy of Sciences, 2015). The study on social 
media was non-interventional, retrospective and all data had been posted for the general 
public to see. Under this condition, the thesis followed the qualifying or waiving conditions 
when explicit consent is not appropriate or impracticable to be obtained, as described by the 
Australian National Statement. 
4.6.3 Study 3 – Meta-analysis 
For the literature search and especially the meta-analysis this thesis collected and analyzed 
the practice of EBM, by building on scientific research and clinical practice. Scientific 
research traditionally was mainly in-vitro and/or already subjected to the ethical guidelines 
and scrutiny of the institute or organization performing the research. As the focus is on rare 
diseases and orphan drugs, only fewer institutions conduct such studies given the high 
degree of specialization and a large amount of funding required (e.g. bio-therapeutics, 
monoclonal antibodies). Clinical practice, on the other side, is built on clinical trials which 
are performed for regulatory submission. The first priority for patient applications is to build 




diagnostics, specialized physicians and cost in the hundreds of thousands of US dollars per 
year per patient. These trials conform to US FDA and EMA guidelines, which require the 
most stringent ethical standards and reviews by independent ethical committees. 
No additional independent clinical studies were performed as part of this thesis. The research 
on real-world evidence and socio-economic considerations is by definition a retrospective 
study and analysis of patterns and behaviors in real life. As such, this key part of the thesis 
was not subject to ethical considerations as it studied phenomena that had already taken 
place independently and without influence by the researcher. Authors of articles, studies, 
and reports were contacted when clarification was required or when additional information 
or insight was solicited. The participants were exclusively academic physicians, department 
heads at hospitals performing research and treating patients or patients undergoing 
treatment. These contacts were in the form of discussions that were purely voluntary and 
based on goodwill. 
4.6.4 Answering the RQs 
The last phase of the thesis was concerned with addressing the RQs and combining the 
findings into a framework for analysis. The latter was built on information that was either 
describing real situations or developed as part of ethically conducted experiments (i.e. 
clinical studies) related to studies 1, 2 and 3 mentioned earlier.  
However, it was expected that some of the derived conclusions reflected in the framework 
could be perceived as “unethical” by some stakeholders. For example, a framework built on 
current clinical data related to therapeutic decisions while common to socio-economic 
practices and ethical standards, might be perceived by a patient’s caregiver as unfair. It was 
acknowledged by the researcher that if such perception gaps existed, they could be closed 
by education and communication. The funding of orphan drug research raises new ethical 
issues and dilemmas, for example, when questions on justice and the moral obligation of 
advancing medical science are considered (Gericke, 2005). These are intrinsic to the overall 





5 CHAPTER FIVE - RESULTS 
5.1 Study 1 – Results from a survey of physicians 
5.1.1 Importance of different stakeholders for HAE treatment decision 
 
Figure 5.1.1- Percentage of HAE physicians rating the importance of stakeholders for treatment decision 
The question highlights from the physicians’ perspective that the patients are the most 
important stakeholders for 84% of doctors when deciding which treatment to pursue for 
treating the rare HAE condition, as illustrated in Figure 5.1.1. Combining “high importance” 
and “critical”, the second most important stakeholders (64%) are family members according 
to participating physicians. While not critical, they are very important as family members 
are also affected as caregivers or indirectly by the condition of the patient. The second most 
mentioned critical stakeholders are the payers and the insurance companies (54%). About a 
third (32%) of physicians also estimate patient associations playing an important role, which 
could be an indicator of the success achieved with their advocacy efforts. Regulatory bodies 
are perceived as critical or very important by about half the physicians (51%), as they 
maintain that only drugs which provide value from an efficacy viewpoint - while offering 
an acceptable safety profile - are approved for commercialization. Pharma companies (29%) 
are seen as very important and critical for therapeutic decision making for mainly two 
reasons. At the forefront, they develop and make new drugs available, and provide and 
sponsor medical education through publications, events (such as congresses, symposia, 

































































5.1.2 Clinical aspects 
5.1.2.1 HAE Patients in treatment 
The 87 physicians who have completed the survey are treating in aggregate 2,952 patients 
which, utilizing a prevalence of 1:40’000 (see section 3.8), would correspond to an overall 
population of about 108 million people. This is a relatively significant figure when factoring 
in that diagnosis and treatment with modern therapies are mostly performed in advanced 
healthcare systems in North America, Europe and parts of Latin America and in countries 
with an advanced reimbursement system in place. The average number of patients per 
treating physician is 33 with a variance that spans from one patient to 150 in Germany, 
probably as that physician is associated with one of the few centers of excellence. 
5.1.2.2 Diagnosed and misdiagnosed HAE patients 
 
Figure 5.1.2- Percentage of physicians estimating the percentage of patients in their country has been diagnosed with 
HAE 
Figure 5.1.2 illustrates that about a third of physicians estimate that less than 10% of patients 
have been diagnosed with HAE in their respective countries. A secondary concentration of 
another third of physicians estimates that between 60% and 80% of patients have been 














Figure 5.1.3 - Percentage of estimated patients diagnosed by region 
Separating the answers to the question by the country of origin of the participating 
physicians, and grouping them by regions, Figure 5.1.3 illustrates the disparity across the 
world. More advanced healthcare systems in Europe and North America suggest a higher 
likelihood for patients born there to be diagnosed. It should be a source of concern that in 
the highly populous regions of the Asia Pacific and Eurasia, the Middle East and Africa, that 




Figure 5.1.4 - Percentage of physicians estimating the percentage of patients in their country who have been 
misdiagnosed before 
Participating physicians treating HAE distribute widely in their estimate of how many 
patients living with HAE have been misdiagnosed before receiving the correct diagnosis, as 
illustrated in Figure 5.1.4. The weighted average of 53% suggests about half the number of 
















5.1.2.3 HAE attacks per year for untreated patients 
 
Figure 5.1.5 - Percentage of physicians estimating the percentage of untreated HAE patients who have so many attacks 
per year 
A first observation indicates that about a quarter of physicians are unable to estimate how 
many HAE attacks for untreated patients occur each year. Figure 5.1.5 illustrates, however, 
an increasing trend with higher frequency numbers. The number is surprisingly high given 
that all participants are treating HAE patients.  
 
Figure 5.1.6 - Normalized percentage of untreated HAE patients who have so many attacks per year 
Some participants provided estimates of patient percentages which do not add up to 100%. 
The percentages have been normalized and then weighted with the number of patients that 
each physician is self-reportedly treating, as illustrated in Figure 5.1.6. The increase of the 
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5.1.2.4 HAE attacks per year for treated patients 
 
Figure 5.1.7 - Percentage of physicians estimating the percentage of treated HAE patients who have so many attacks per 
year 
Figure 5.1.7. illustrates that for treated patients about a quarter of physicians was not able 
or willing to provide the number of attacks per year. Quite possibly, although participants 
agreed to the ethical strategies for this thesis, patient confidentiality may be the key reason 
for patient non-disclosure. These results, at first sight, appear to show a similar dispersion 
as in the previous section 5.1.2.3. 
 
Figure 5.1.8 - Comparison of normalized percentage of HAE patients who have so many attacks per year between 
untreated and treated patients 
Normalizing the data as shown in Figure 5.1.8 seems to suggest that the distribution of 
attacks among treated patients changes significantly. The share of patients with higher attack 
rates per year (more than 7) falls significantly, apparently generating a new peak at about 4-
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5.1.2.5 Criteria for selection of HAE treatment 
 
Figure 5.1.9 - Percentage of HAE physicians rating the importance of criteria for selection of the treatment 
The most important criteria for physicians selecting a treatment for their HAE patients is the 
previous history of laryngeal attacks (56%), assessed as critical or highly important by 86% 
of physicians, as presented in Figure 5.1.9, The following two most important criteria are 
the efficacy of the drug (41%) and the safety profile of the drug (33%), assessed as critical 
or highly important by 92% and 84% of physicians respectively. Treatment costs are 
mentioned to be critical or highly important for the treatment decision by 62% of the 
physicians, consistent with the level of insurance coverage which is considered critical or 
highly important by 67% of the physicians. Combined, the treating physicians have to justify 
the necessity for a patient to be prescribed more expensive modern prophylaxis treatment, 
confirming the insurance will reimburse it, when possibly on-demand therapy might lead to 



















































































































Figure 5.1.10 - Distribution of weighted averages of importance of selection criteria (“irrelevant” = 0, “low 
importance” = 1, “high importance” = 2, “critical” = 4 
The mode of administration and dosing frequency are assessed to be critical or highly 
important by 73% and 65% of the physicians respectively. The survey shows that one-third 
of the physicians assess the economic status of the patient to be irrelevant when deciding 
the treatment, indicating the degree of pervasiveness of universal health coverage (see 
Section 0) and the functioning of reimbursement systems for patients in need. However, 
another third of physicians see the economic status of the patients as critical or highly 
important when selecting the therapy, suggesting that work still needs to be done in those 
healthcare systems where not everybody qualifies for some form of reimbursement. Figure 
5.1.10 illustrates ranking and relative importance of the different selection criteria based on 
the weighted averages of the variable. In the comment section, some physicians mentioned 
that in some healthcare systems not having access to some medications forces the patients 
to follow the treatments that are available, and not the ones they would choose if they had 
the opportunity to do so. One participant mentioned the approach in his center is to first 
achieve control with androgens, and then to reduce the dosing of the drug down to a few 











































































































5.1.2.6 Medications prescribed for HAE on-demand treatment 
 
Figure 5.1.11 - Percentage of physicians prescribing HAE drug for on-demand treatment 
Figure 5.1.11 suggests that overall there is a wide distribution of percentages in relation to 
demand treatments, indicating a diversity of physicians’ attitudes towards prescribing these 
types of drugs. 
 
Figure 5.1.12 - Weighted percentage of HAE patients being prescribed different on-demand treatments  
Figure 5.1.12 illustrates that Icatibant and C1-inhibitors are the most prescribed on-demand 































5.1.2.7 Medications prescribed for HAE prophylaxis treatment 
 
Figure 5.1.13 - Percentage of physicians prescribing HAE drugs for prophylaxis treatment 
C1-inhibitors appear to be the most prescribed prophylaxis treatment (36% of patients) 
followed directly by androgens (35%). Lanadelumab (Takhzyro®) was prescribed to 6% of 
patients, as illustrated in Figure 5.1.13.  
 
Figure 5.1.14 - Weighted percentage of patients being prescribed different prophylaxis treatments for HAE 
The distribution of prescribed treatments illustrated in Figure 5.1.14 is expected to change 












C1-Inhibitor Lanadelumab Androgen N/A









5.1.2.8 HAE Patients switching medication over a lifetime 
 
Figure 5.1.15 - Percentage of physicians estimating the number of times HAE patients  
switch treatment over a lifetime 
Two key results become visible from Figure 5.1.15: treating physicians see the vast majority 
of patients not changing medication more than once during their life, and about half of the 
patients never changing the treatment (weighted average 54%) with the other half only once. 
5.1.2.9 Reasons for HAE patients switching medication  
 
Figure 5.1.16 - Percentage of physicians estimating the percentage of HAE patients  
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Figure 5.1.16 illustrates a wide dispersion of shares of physicians estimating the shares of 
patients who switch HAE medication for different reasons. When calculating the weighted 
percentage of patients switching medications as illustrated in Figure 5.1.17, the most 
frequent reasons relate to the side effects, for about 17% of patients. The second most 
frequently mentioned reason for a switch is the lack of efficacy (15%) which could also be 
the rationale for moving from older therapies to modern ones, for both on-demand and 
prophylaxis treatment. Using costs as a reason to switch medications relates to about 12% 
of patients according to physicians.  
 
Figure 5.1.17 - Weighted percentage of HAE patients switching treatment for a specific reason  
5.1.2.10 Number of HAE attacks considered “acceptable stable condition”  
 
Figure 5.1.18 - Percentage of HAE physicians how many attacks per year is still an “acceptable condition” 
Figure 5.1.18 illustrates that the vast majority of physicians (69%) believe an HAE patient 
needs to have less than three attacks per year to be considered in control, and virtually all 



























































5.1.2.11 Observed, treated and referred co-morbidities to HAE 
 
Figure 5.1.19 - Percentage of physicians observing, treating or referring co-morbidities to HAE 
The co-morbidity most observed by the participating physicians is anxiety which occurs 
about 22% of the time, illustrated in Figure 5.1.19. Depression seems to be observed by only 
8% of treating physicians, the participating physicians refer the patients to other specialists 
in 75% of the cases with depression and 46% of the cases with anxiety, indicating that 
additional specialized medical help is warranted. 40% per cent of physicians treat observed 
additional autoimmune disorders themselves, in line with the fact that the vast majority of 
physicians treating HAE are immunologists and allergists. For the pain indication, the share 















































5.1.2.12 Patients requiring help during HAE attacks or for treatment 
 
Figure 5.1.20 - Percentage of physicians estimating the percentage of HAE patients requiring help during attacks or for 
treatment 
Figure 5.1.20 illustrates that a weighted average of 38% of patients is observed to require 
help from family members when having an attack or when administering treatment. Friends 
or nurses are reportedly providing help for patients in 11% and 20% of the time. The survey 
also illustrates that on average 41% of treating physicians don’t know if their patients are 
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5.1.2.13 Most important desired outcome of HAE treatment 
 
Figure 5.1.21 - Percentage of HAE physicians rating the importance of desired treatment outcomes 
Two-thirds of physicians deem a reduction in frequency and severity of HAE attacks as 
critical, and virtually all of the physicians (94%) see this as a critical or highly important 
and most desired outcome. The data presented in figure 5.1. 21 also illustrates that achieving 
control over the condition, improving QoL and enabling patients to conduct a normal life 
are assessed to be critical for about a third of the physicians in about equal proportion. These 
are factors that are critical or highly important for over 90% of participants suggesting that 
modern medicine has moved beyond the narrow scope of clinical outcomes to encompass 
the holistic view of patients’ QoL and roles in society. The low number of “other” desired 
outcomes indicates that the four main factors provide the key criteria for the importance of 
desired treatment outcomes. In the comment section a few participating physicians noted the 
challenge in answering some of the questions due to the high variability and unpredictability 





































5.1.3 QoL aspects 
5.1.3.1 Days of work, school, commitments missed per year by HAE patients before 
diagnosis 
 
Figure 5.1.22 - Percentage of physicians estimating percentage of HAE patients missing number of days of work, school, 
commitments per year before diagnosis 
The first observation to be made is that for all possible answers illustrated in Figure 5.1.22, 
half or more of the participating physicians responded that they didn’t know how many days 
their patients were missing from work or school. This would indicate that less than half of 
the physicians know or can estimate roughly how many times people with HAE were 
untreated, were missing professionally, educationally and socially. This suggests that the 
contextual aspect related to patients’ economic, social, emotional and other professional 
needs are simply not known. The strongest statement is that 38% of physicians estimated 
that only 10% of patients without treatment can survive a whole year without missing 
treatment days. Figure 5.1.23 illustrates that the estimates for all other number of days 
missed were spread relatively equally at around 12% of patients. In summary it could be 
confirmed that the repercussions of HAE are highly variable, while significant QoL aspects 























Figure 5.1.23 - Weighted distribution of percentage of HAE patients missing number of days of work, school, 
commitments per year before diagnosis 
5.1.3.2 Days of work, school, commitments missed per year by HAE patients when 
treated  
 
Figure 5.1.24 - Percentage of physicians estimating percentage of HAE patients missing number of days of work, school, 
commitments per year when treated 
Participating physicians have been asked to estimate what percentage of treated HAE 
patients is missing how many days of work, school or other commitments per year. The 
purpose was to be able to compare if treated patients are able to conduct a more normal life, 
missing out less than the ones without treatment studied in section 5.1.3.1). Comparing with 
Figure 5.1.22, Figure 5.1.24 illustrates that the number of “don’t know” (grey bar “N/A”) is 
lower for numbers of days passed less than 21. However, when asked how many patients 






























Figure 5.1.25 - Comparison of weighted distribution of percentage of HAE patients missing number of days of work, 
school, commitments per year before treatment vs. when treated 
Comparing directly the numbers before and with treatment, as illustrated in Figure 5.1.25, 
the share of patients who do not miss any days any more thanks to HAE doubles from about 
8% to 20%. Proportionally less but still strong positive impact is observed also for the ranges 
1-5 days and 6-10 days.  
5.1.3.3 Long term consequences from HAE 
 
Figure 5.1.26 - Percentage of physicians estimating the percentage of patients suffering from specific long-term 
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The long-term consequences of HAE in Figure 5.1.26 are spread among answers displaying 
the high variability of the condition, its consequences and possibly the physician’s 
knowledge of the full long-term implications to the patients.  
 
Figure 5.1.27 - Weighted percentage of patients facing long term consequences due to HAE  
The impact on family planning is the one with the highest weighted average as illustrated in 
Figure 5.1.27, impacting 50% of the patients. This could be explained by the hereditary 
nature of the condition. The next four most frequently estimated long-term impacts are on 
social relations (44% of patients), stigma (42% weighted average), career repercussion 
(37%) and education hindrance (33%). Reduced income and reduced life expectancy are 























































5.1.3.4 Working status of HAE patients 
 
Figure 5.1.28 - Percentage of physicians estimating the percentage of HAE patients in different states of working status 
In average across the questions, 40% of physicians answered that they do not know the 
working status of their patients, as illustrated in Figure 5.1.28. Particularly in the sub-
questions on unemployment status or disability, almost half the physicians indicated they 
didn’t know the status of their patients.  
 
Figure 5.1.29 - Weighted percentage of HAE patients in different states of working status 
The most frequent working status of patients is full time working with a weighted average 
of 27% of patients, illustrated in Figure 5.1.29. They are followed with part-time working 
patients and students comprising about 15% and 11%. Homemakers are 9% and retired 
patients about 7%. The share of unemployed and disabled patients is about 6% each of the 



























































































5.2 Economic aspects 
5.2.1.1 Financial impact of HAE on patients 
 
Figure 5.2.1 - Percentage of physicians estimating the percentage of HAE patients exposed to a financial impact due to 
their condition 
Figure 5.1.30 illustrates that one-quarter of physicians treating HAE patients answered that 
they don’t know if their patients carry part of their treatment costs, if they suffer from missed 
income or if they incur indirect costs. 38% of physicians believe that less than 10% of the 
patients are paying any part of the treatment costs.  
 
Figure 5.2.2 - Weighted percentage of HAE patients exposed to a financial impact due to their condition 
An analysis on weighted averages (see Figure 5.1.31) suggests that only 35% of HAE 
patients incur indirect costs, that 33% incur no financial impact at all, and that less than 30% 
of the patients with HAE participate in the funding of their treatments. Lastly, physicians 
estimate that 26% of patients suffer from an income impact and 21% of some other form of 











































5.2.1.2 Funding for HAE treatment 
 
Figure 5.2.3 - Percentage of physicians estimating the percentage of HAE patients subject to full or partial 
reimbursement vs. fully self-pay 
More than 50% of physicians estimate that 100% of their patients are fully reimbursed and 
do not need to spend or contribute anything to their treatment of each, as illustrated in Figure 
5.1.32. 
 
Figure 5.2.4 - Weighted percentage of HAE patients subject to full or partial reimbursement vs. fully self-pay 
Figure 5.1.33 illustrates that a weighted average of 54% of patients are fully reimbursed. At 
first sight, this would represent a maximum scenario where the physician and the patient 
could completely focus on clinical outcomes and QoL without any economic considerations. 
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5.2.1.3 Yearly costs to HAE patients due to condition 
 
Figure 5.2.5 - Percentage of physicians estimating the percentage of HAE patients bearing different costs per year due to 
condition 
Figure 5.1.34 illustrates that for every question between 43% and 77% of the physicians 
were not able to estimate the costs that HAE patients have to bear due to their condition. 
The physicians who answered, estimated in average about 39% of the patients incurred 
between zero and USD 500 of expenses per year due to HAE - the question specifically 
asked to consider all costs including treatment, medical help, support, transportation, etc. 
The remaining patients estimated to incur higher costs with 21% between USD 500 and 









































5.2.1.4 Yearly costs to payer per HAE patient due to condition 
 
Figure 5.2.6 - Percentage of physicians estimating the percentage of HAE patients’ insurances bearing different costs 
per year due to condition 
Estimating the cost that the payers are incurring per HAE patient per year appeared to be 
even more difficult for treating physicians with between 60% and 70% answering that they 
didn’t know, as shown in Figure 5.1.35. The answers by the physicians who were able to 
provide an estimate distributed almost equally across all ranges. Due to privacy and system-
challenges (see section 3.5.5) it is very difficult to obtain the real data. A significant share 
























































































































Figure 5.2.7 - Comparison of weighted distribution yearly costs to HAE patients vs to payers 
Comparing the two questions on costs in Figure 5.1.36, it appears patients bear a higher 
share of costs in the lower ranges and the situation becomes inverse for higher ranges. Based 
on the survey payers are funding more than USD 100,000 per year to about 20% of the HAE 



















































































































5.3 Study 2 – Results from search on social media 
Social media are pervasive and part of people’s everyday life. Beyond the distribution of 
mundane updates, social media can be an excellent instrument to build communities, share 
content and experiences, invite to events or activities. This thesis has analyzed two social 
media channels, Facebook and Twitter, with the objective to qualify the published HAE 
content and to quantify the distribution by topics. The privacy policies of the two channels 
are intrinsically accepted by the users when they post content, and state that the postings 
have to be presumed accessible and visible by anybody anytime anywhere. Such setup poses 
limitations which will be discussed later in section 8.10. Postings have been searched over 
the past two calendar years to ensure a sufficient number of data points and to include events 
that occur during longer time intervals such as launches of new treatments, publications of 
new clinical results, or recurring events such as “HAE day” which have been created to 
generate awareness.  
5.3.1 Facebook 
The thesis analyzed over a couple of thousand postings relevant to HAE across different 
geographies and time intervals. Once information and data appeared to be repeated, the 
analysis reached data saturation. This led to all postings being grouped into nine segments. 
5.3.1.1 Invitations to HAE events and activities 
People living with HAE and suffering from a rare condition are often misunderstood and 
sometimes don’t share with their social and professional environment their condition. As a 
result, they often feel isolated and misunderstood, thus seeking a community of people with 
the same condition to engage in social activities, to share experience, to generate awareness, 
or to advocate for access to treatment or better reimbursement of drugs. About a quarter 
(26%) of all identified postings were invitations to attend meetings, social events, webinars, 
symposia or other gatherings of HAE patients. These were organized by the international 
patient association (HAEi), respectively by its subchapters in the different countries or states 
(such as for example the one for Australasia https://www.facebook.com/HAEAustralasia). 
HAEi specifically established the “HAE Day” every year on May 16th, with the participation 
and sponsoring by the scientific community and the pharmaceutical industry. This day is 
promoted through http://www.haeday.org and includes social gatherings, scientific and 
educational sessions, a walk (e.g. “Camino Walk”) where steps are measured and other 
activities. Local chapters further foster the sense of community through other events such as 
dinners spread around the year, publishing pictures and shared experiences which appear to 
have a positive QoL (section 3.7.19) effect on the patients. Such events are an example of 
patients taking their destiny and well-being in their own hands, possibly as a response to the 
fact that physicians and payers cannot fulfil all their needs as part of the agency framework 
described in section 2.3.  
5.3.1.2 HAE experience sharing 
The second most frequent type of posting representing 20% of posts was about seeking and 




treatments, their efficacy and side effects, or also more personal ones sharing specific day-
to-day challenges and how the patient coped with them. Patients shared how they are dealing 
with anxiety and depression, sometimes receiving words of encouragement and appreciation 
from other members. Various posts were from patients sharing about their experiences with 
specific treatments, which could be both positive (e.g. good clinical results from novel 
treatments such as Takhzyro® or negative (e.g. side effects), including asking fellow 
patients for advice. Patients shared online their experience with treating physicians, for 
example when there are communication barriers or disagreements on the treatment to pursue 
Posts could also be found where patients and caregivers shared their frustrations or inability 
to obtain the needed medication reimbursed by the insurance companies, despite the 
physician writing a prescription in line with clinical needs and guidelines. A recurring theme 
was the patient’s attempts to lead a normal life, with normal interactions, without missing 
out on opportunities professionally, educationally or socially. 
5.3.1.3 Raising funds for HAE activities 
To improve awareness on the condition and its treatments, patients organized activities (see 
section 5.3.1.2) or issued publications and distributed materials which required funding. 
About 15% of the identified posts had as objective to raise funds in the form of donations 
for the cause.  
5.3.1.4 HAE education 
About 9% of posts were about disease education in the form of webinars, links to websites, 
articles, study outcomes, or dinners. HAE education concerns newly diagnosed patients and 
their caregivers by making them aware of current trends and knowledge. HAE education 
was in layman’s language and covered all topics from the selection of the right treatment 
based on the patient profile, how to recognize attack triggers and potentially avoid them, 
and how to treat comorbidities. Physicians and key opinion leaders made themselves 
available and, in some cases, these offerings were sponsored by academic institutions, by 
the pharmaceutical industry, or by donations. 
5.3.1.5 Information about HAE treatments 
Posts containing information about treatments represented 7% of the total. They could be 
both links to official publications such as promotional statements or clinical results (see 
section 3.2.1) and real-life observations (see section Error! Reference source not found.). T
hey covered specific drugs, treatment regimens and diagnostic tools. Patients posting 
information related to their own experience or sharing links contributed to improving the 
efficiency of the healthcare systems closing the gaps inherent to the agency theory 
(described in sections 3.6.1 and 3.6.4) and the therapeutic decision-making (described in 
sections 3.6.5 and 3.6.6). In some cases, patients advised each other on which medications 
to switch to in case of a specific disease profile. Some doctors have shown to be open to 
listening to treatment proposals coming from the patients and willing to experiment with 




5.3.1.6 HAE life advice and support 
About 5% of the posts were from participants who offered life advice and support, either by 
sharing grief, sharing advice on how to cope with specific situations such as stressful events 
and triggers, or simply through some words of inspiration and motivation. These posts were 
frequently met with ‘likes’ similar to those found on a social media platform. Similarly, 
signs of appreciation and even a small sign of caring and positive comments between 
strangers with the same rare condition possibly mitigate the pain of these diseases and help 
to offer a more positive outlook. 
5.3.1.7 Invitations to clinical trials, surveys, registries 
About 2% of the posts were calls to patients, and sometimes caregivers, to participate in 
clinical trials, survey or registries, that have as an objective to gain new knowledge on the 
condition, possible treatments and other ways to improve the situation. These posts are made 
by pharmaceutical companies, contract research organizations, academic institutions, 
consultants and other entities which engage social media to recruit patients. 
5.3.1.8 Selling/offering of goods and services related to HAE 
Another group of postings with free offers, such as digital publications, participations to 
webinars, discussion, and commercial offers, represented 2% of all posts on HAE. 
Commercial offers were more suited to patients with HAE and often consisted of 
comprehensive toolkits that include educational material, posters and gimmicks to be used 
during the HAE day in order to educate and generate awareness. Other more standard items 
included T-shirts or other wearables with logos and simple messages for awareness 
generation. 
5.3.1.9 Sharing of other information 
Lastly, there was a share of about 14% of the postings that included a wide range of messages 
where other information or simple content was shared. These could be links to magazines, 
wishes for the HAE day, organizational announcements within HAEi, special holiday wishes 
(e.g. Mother’s Day), announcements that specific websites had been translated into other 
languages, progress made or milestones achieved in improving access to drugs in some 
healthcare systems, welcoming of new members, and more. This kind of postings appeared 
to address the need of having a form of bulletin board for HAE patients widely dispersed 
globally or within geographies. Some postings were anonymous, and some indicated names 






Twitter can be researched in a similar way as Facebook, as it provides easy access to posts 
through a search capability. The major differences are that posts are limited in their number 
of characters and that there are no closed interest groups of users where the posts are not 
made accessible to the general public. The limitation on the size of the posts that can be 
shared forces users to be succinct and prevents them from sharing directly more details (such 
as experience sharing, educational content, etc.). Latter can still be achieved by way of 
hyperlinks leading to other websites. The impossibility to constrain postings to limited and 
selected users (for example fellow patients carrying the disease) might be a reason why 
Twitter postings on HAE appear in general less personal and detailed. These characteristics 
of Twitter seem to lead to a slightly different type and distribution of posts by category. 
Similar to the study on Facebook, the thesis identified and catalogued a couple of thousands 
of postings over several years and across different geographies until data saturation became 
prominent and beyond which new content seemed to add only marginal, if any, additional 
insights that could be used to answer the RQs or change the findings of the thesis. The same 
nine posting segments were identified as with the search on Facebook, yet with a different 
rank and weight.  
5.3.2.1 Invitations to HAE events and activities 
The share of postings in this segment was 51%, which was about twice as high as in 
Facebook. The vast majority of posts in this category took place around HAE Day on May 
16th of every year and was about invitations to awareness events (such as the HAE walk) 
and other social events for HAE patients and their families and friends to gather. These 
invitations were dominantly posted by patient organizations such has “HAE International”, 
HAE UK”, or “HAE Australasia”, and, as they were for specific on-site events, focused on 
the country where the condition was more known, diagnosed and treated. Virtually all 
content in this category was sourced in the US, Europe, Australia and from a couple of Latin 
American countries. No content could yet be found coming from Asia, Middle East or Africa 
(which represent the majority of the world population), supporting other observations 
suggesting a significant disparity between advanced Western Healthcare systems and the 
rest of the world.  
5.3.2.2 Other information 
About 13% of Twitter posts on HAE were about sharing other types of information such as 
awards being given, wishes for public holidays, recommendations, or updates on the 
patients’ organizations meetings, congress participation or similar activities and links to 
articles. These postings were per se not specific to the condition, to treatments or any 
particular person.  
5.3.2.3 HAE Experience sharing 
The third most frequent type of post could be categorized as experience sharing with patients 
telling about their personal experience with diagnosis, a new treatment, or a particular life 




they could overcome. All postings were biased towards the positive, showing enthusiasm 
and a promising outlook that could inspire other patients. Used in this way, social media 
fulfilled their mission of bringing people together that have things in common. The 
participants were HAE patients and their commonality was their rare disease combined with 
their strive to lead a normal life professionally and socially. Patients sharing their positive 
experience may lead and inspire others to do the same.  
5.3.2.4 HAE education 
Similarly to what was found in the study on Facebook posts related to HAE, also on the 
Twitter platform about 9% of posts were about disease education. Users posted short 
messages suggesting details about symptoms that could indicate a diagnosis might be 
warranted, prodromes that could indicate an impending attack, how to deal with co-
morbidities. As Twitter is significantly limited in the length of the posts that can be 
published, the majority of the ones with the objective of providing educational links to 
webpages, presentations, or speeches that could be followed on Youtube.  
5.3.2.5 Information about HAE treatments 
Immediately after HAE education followed the category of the posts providing information 
about treatments. Some posts were promoted by pharmaceutical companies, most by the 
HAE patients’ organizations and individuals who aimed to spread the news and provide new 
hope to patients who still had unmet medical needs that could not be fulfilled by current 
treatments. One part of the posts shared new clinical data of novel compounds (such as 
Lanadelumab) through links to official study communications. Some posts aimed to raise 
awareness about the new WAO (World Allergy Organization) guidelines (see 3.1.10, 0), 
which was relevant as they moved C1-inhibitors to first-line treatment replacing androgens. 
Another type of posts which fell into this category was when a product achieved 
reimbursement status in a specific country. A concrete example took place when Firazyr® 
obtained reimbursement status in South Korea, which was announced officially in Q3 2018, 
and the word spread via Twitter and other channels fast.  
5.3.2.6 Selling/offering of goods and services related to HAE 
About 4% of posts on Twitter were offering goods and services for patients with HAE, which 
could be divided into three sub-categories. From a number of perspectives, the most frequent 
offering was for “HAE kits to generate awareness”. During the year these were concentrated 
mainly in the weeks and months before the HAE Day on May 16th. The HAE kits were 
assembled and offered by the patient organizations, and contained different material (T-
Shirts, brochures, posters) and content, which patients and caregivers could utilize to 
generate awareness and create the commitment to identify the condition, diagnose the 
disease and offer/reimburse the existing treatments. Some of the awareness material was 
scientific and educational in nature, sometimes also utilized by patients to update their 
treating physicians on the latest treatment guidelines, drugs or scientific data. Other 
offerings were low cost, generic and informative (such as access to newsletters) or tailored 




5.3.2.7 Raising funds for HAE activities 
It appears that when searching under the HAE keyword on Twitter, only around 3% of posts 
were made with the intent to raise funds. All of the invitations were for donations to HAE 
patients’ organizations in order to fund activities such as awareness events, educational 
events, social events, material for disease education or participation at congresses or other 
events.  
5.3.2.8 HAE life advice and support 
Only a small share of around 2% of posts on Twitter fell into the category of HAE patients 
or other stakeholders offering life advice or support. These posts, which sometimes were 
made of quotes and links to other inspirational websites or writings, could be seen as generic 
in nature, in that they could be applied to a large variety of life situations. Possibly posters 
use other channels or user groups to post life advice and support in order to have a wider 
reach. It was observed that retweets do rarely targeted HAE-specific groups or users.  
5.3.2.9 Invitations to clinical trials, surveys, registries 
The smallest group of posts, with about 1% of posts on Twitter, was composed of invitations 
to HAE patients to enroll in clinical trials, to participate in surveys, or to share their medical 
profiles with registries. Overall in Twitter few mentions of clinical trials could be found, 
however for sharing results and not for recruitment purposes. The few posts found in this 
category were mainly for surveys or asking patients to participate in registries, which are 





5.4 Study 3 – Meta-analysis results 
5.4.1 HAE Patient population, epidemiology 
The HAE condition selected for the thesis has a prevalence between1:10,000 and 1:50,000. 
HAE rare diseases, therefore, affect fewer than 8,000 individuals in the United States, less 
than 15,000 in Europe, and less than 200,000 worldwide (Lumry, 2018). 
5.4.1.1 Onset of HAE 
A search through the databases identified 30 studies which mentioned and measured the 
onset of HAE, that is the first time that the condition manifests itself by an attack. 
 
# of sources 30 
Sources (Aabom, 2017), (Agostoni, 2004), (Andrejevic, 2017), 
(Bork, 2003), (Bork, 2006), (Bork, 2010), (Bork 2015), 
(Bouillet, 2013), (Bygum, 2009), (Bygum, 2015), 
(Caballero, 2014), (Christiansen, 2016), (Deroux, 2016), 
(Devercelli, 2018), (Farkas, 2002), (Farkas, 2010), 
(Huang, 2014), (Karkasharif, 2015), (Lei, 2011), (Nanda, 
2015), (Nygren, 2016), (Psarros, 2014), (Riedl, 2015), 
(Riedl, 2017), (Roche 2005), (Steiner 2016), (Tourangeau, 
2012), (Xu, 2013), (Zanichelli, 2013),  
Total # of patients 2,934 
Weighted average Age of first HAE attack 13.3 years 
Range 4-27 years 
Table 5.4.1 - Median age at onset of HAE 
Table 5.3.1 summarizes that all studies combined reported data for 2,934 patients with a 
resulting weighted average of the age when patients reported their first attacks at about 13 
years.  
5.4.1.2 Diagnosis of HAE 
Using the same approach, 33 studies were identified as illustrated in Table 5.3.2, which 
amongst others, the median age of diagnosis was reported. Altogether, these studies 
aggregated data of almost 4,300 patients. As illustrated, the weighted median age of 
diagnosis of HAE resulted to be about 23 years. This figure is about ten years older than the 






# of sources 33 
Sources (Aabom, 2017), (Banerji, 2017), (Bernstein, 2013), 
(Bernstein, 2014), (Bonner, 2015), (Bouillet, 2013),  
(Bygum, 2009), (Caballero, 2014), (Caminoa, 2013), 
(Christiansen, 2016), (Deroux, 2016), (Devercelli, 2018), 
(Farkas, 2002), (Farkas, 2010), (Huang, 2014), 
(Karkasharif, 2015), (Lei, 2011), (Lumry, 2010), (Nanda, 
2015), (Nygren, 2016), (Psarros, 2014), (Riedl, 2016), 
(Riedl, 2017), (Roche 2005), (Steiner 2016), (Tourangeau, 
2012), (Zanichelli, 2013), (Zanichelli, 2015), (Zuraw, 
2010), (Zuraw, 2015) 
Total # of patients 4,298 
Weighted average Age of HAE diagnosis 23.4 years 
Range 3-42 years 
Table 5.4.2 - Median age at diagnosis of HAE 
5.4.1.3 Misdiagnosis and unnecessary procedures 
Several articles and studies mentioned the issue of HAE patients being misdiagnosed. The 
thesis was able to identify one study by Banerji (2015) which attempted to quantify the 
percentage of patients who had been misdiagnosed before obtaining the right diagnosis. 
 
# of sources 1 
Sources (Banerji, 2015) 
Total # of patients 186 
Weighted average 65% of HAE patients have been misdiagnosed 
Range - 
Table 5.4.3 - Percentage of HAE patients that have been misdiagnosed 
As illustrated in Table 5.3.3, about two-thirds of patients had been misdiagnosed before. 
Once misdiagnosed, the patients were likely exposed to unnecessary medical procedures, as 
their treating physicians were attempting to improve the clinical situation. Two studies were 
identified that reported the percentage of patients who underwent medical procedures that 






# of sources 2 
Sources (Banerji, 2015), (Bouillet, 2013) 
Total # of patients 379 
Weighted average 22% of HAE patients underwent unnecessary procedures 
Range 19% - 24% 
Table 5.4.4 - Percentage of HAE patients that went through unnecessary procedures 
Combined the two studies reported data on 379 patients of which more than a fifth (22%) 
underwent unnecessary procedures as illustrated in Table 5.3.4. 
5.4.2 Distribution of HAE attacks 
5.4.2.1 Abdominal HAE attacks  
Abdominal HAE attacks have been found to be most mentioned in articles for mainly two 
reasons: they are the most painful (see section 3.8), and they are also prone to lead to 
misdiagnosis (for example acute abdominal pain) with likely unnecessary procedure and 
treatments that do not lead to improved medical outcomes. The thesis identified 28 articles 
which combined used data from more than 2,500 patients. 
 
# of sources 28 
Sources (Aabom, 2017), (Agostoni, 1992), (Agostoni, 2004), 
(Andrejevic, 2017), (Bernstein, 2013), (Bernstein, 2014), 
(Bonner, 2015), (Bork, 2006), (Bork, 2009), (Bork, 2010), 
(Bygum, 2009), (Bygum, 2015), (Deroux, 2016), (Farkas, 
2002), (Farkas, 2010), (Huang, 2014), (Karkasharif, 2015), 
(Lei, 2011), (Nanda, 2015), (Narissara, 2018), (Nygren, 
2016), (Nzeako, 2001), (Psarros, 2014), (Riedl, 2015), 
(Steiner 2016), (Wilson, 2010), (Xu, 2013), (Zuraw, 2015) 
Total # of patients 2,522 
Weighted average 66% of HAE patients suffered from abdominal attacks 
Range 18%-100%  
Table 5.4.5 - Percentage of HAE patients suffering from abdominal attacks 
As illustrated in Table 5.3.5 on average about two-thirds of HAE patients suffered from 






# of sources 15 
Sources (Banerji, 2017), (Bork, 2009), (Bouillet, 2013), (Caballero, 
2014), (Caminoa, 2013), (Federici, 2018), (Jolles, 2014), 
(Levi, 2006), (Lumry, 2010), (Perego, 2017), (Steiner 
2016), (Tourangeou, 2012), (Zanichelli, 2010), 
(Zanichelli, 2015) 
Total # of patients 2,670 
Weighted average 47% of HAE attacks are abdominal attacks 
Range 32%-58%  
Table 5.4.6 - Abdominal attacks as a percentage of all HAE attacks 
The thesis also searched for how frequent abdominal attacks affect patients, and 15 studies 
reported this variable with an overall average of almost half the HAE attacks being 
abdominal (see Table 5.3.6).  
5.4.2.2 Peripheral cutaneous HAE attacks  
Peripheral cutaneous HAE attacks are the most prevalent and 25 studies have been found to 
report on how many patients suffer them. Table 5.3.2.2.1 illustrates that on over 2,000 
patients, about four out five patients have suffered this type of attack.  
 
# of sources 25 
Sources (Aabom, 2017), (Agostoni, 1992), (Agostoni, 2004), 
(Andrejevic, 2017), (Bernstein, 2014), (Bonner, 2015), 
(Bork, 2006), (Bork, 2009), (Bork, 2010), (Bork, 2015),  
(Bygum, 2015), (Deroux, 2016), (Farkas, 2002), (Farkas, 
2010), (Huang, 2014), (Karkasharif, 2015), (Lei, 2011), 
(Nanda, 2015), (Narissara, 2018), (Nygren, 2016), 
(Psarros, 2014), (Riedl, 2015), (Steiner 2016), (Wilson, 
2010), (Xu, 2013) 
Total # of patients 2,034 
Weighted average 82% of HAE patients suffered from peripheral cutaneous 
attacks 
Range 41%-100%  
Table 5.4.7 - Percentage of patients suffering from peripheral cutaneous HAE attacks 
When searching for the share of total attacks, 25 sources could be identified which in the 
aggregate report that almost half of the attacks are peripheral and cutaneous, as illustrated 






# of sources 15 
Sources (Banerji, 2017), (Bork, 2006), (Bork, 2009), (Bouillet, 
2013), (Caballero, 2014), (Caminoa, 2013), (Federici, 
2018), (Jolles, 2014), (Levi, 2006), (Perego, 2017), 
(Steiner 2016), (Tourangeou, 2012), (Zanichelli, 2010), 
(Zanichelli, 2015) 
Total # of patients 2,434 
Weighted average 45% of HAE attacks were peripheral cutaneous attacks 
Range 24%-62%  
Table 5.4.8 - Peripheral cutaneous attacks as a percentage of all HAE attacks 
5.4.2.3 Laryngeal HAE attacks  
Laryngeal attacks were of particular interest as they can be lethal if not treated properly, and 
therefore are also the main source for the comorbidities anxiety and depression (see section 
3.8). 
 
# of sources 36 
Sources (Aabom, 2017), (Agostoni, 1992), (Agostoni, 2004), 
(Andrejevic, 2017), (Bernstein, 2013), (Bernstein, 2014), 
(Bonner, 2015), (Bork, 2001), (Bork, 2003), (Bork, 2006), 
(Bork, 2009), (Bork, 2010), (Bork, 2015),  (Bouillet, 
2013), (Bygum, 2015), (Farkas, 2002), (Farkas, 2010), 
(Gower, 2011), (Huang, 2014), (Jolles, 2014), 
(Karkasharif, 2015), (Lei, 2011), (Longhurst, 2012), 
(Lumry, 2010), (Nanda, 2015), (Narissara, 2018), (Nygren, 
2016), (Nzeako, 2001), (Ohsawa, 2015), (Psarros, 2014), 
(Riedl, 2015), (Steiner 2016), (Wilson, 2010), 
(Winnewisser, 1997), (Xu, 2013) 
Total # of patients 4,011 
Weighted average 36% of HAE patients have suffered from laryngeal attacks 
Range 7%-90%  
Table 5.4.9 - Percentage of HAE patients suffering of laryngeal attacks 
A search through the databases identified 36 studies which reported data on more than 4,000 
HAE patients and resulting in an average that more than a third of patients have experienced 
this type of attacks before, as presented in Table 5.3.9. 
The frequency of laryngeal attacks was of particular interest and the thesis determined that 
less than half (16) studies reported such data, extracted from more than 2,000 patient 






# of sources 16 
Sources (Bork, 2006), (Bork, 2009), (Bouillet, 2013), (Caballero, 
2014), (Caminoa, 2013), (Federici, 2018), (Jolles, 2014), 
(Karkasharif, 2015), (Levi, 2006), (Longhurst, 2012), 
(Perego, 2017), (Steiner 2016), (Tourangeou, 2012), 
(Zanichelli, 2010), (Zanichelli, 2015) 
Total # of patients 2,040 
Weighted average 4% of HAE attacks were laryngeal attacks 
Range 1%-8%  
Table 5.4.10 - Laryngeal attacks as a percentage of all HAE attacks 
With a variance between 1% and 8%, on average 4% of HAE attacks appear to be laryngeal.  
5.4.3 Severity of attacks (with treatment) 
Measuring the severity of an attack is challenging as there is no universally accepted 
definition of severity, and the assessment of the severity of an attack can be subjective and 
different patient to patient. With HAE there is the additional complication of two 
dimensions: pain during an attack and frequency of attacks, which do not always correlate. 
Prior (2012) proposed a set of criteria to describe the severity of HAE attacks. For instance, 
‘Asymptomatic’, when the patient reports no angioedema episodes and is not taking any 
treatment. The term ‘Mild’ is preferred when the patient has non-life-threatening HAE 
episodes. less than six attacks per year and is not taking long term prophylactic treatment. 
Similarly, ‘Moderate’ is used when the patient has less than 12 not life-threatening attacks 
per year, without taking into account long term prophylactic treatment, or more than six 
attacks per year with long term prophylactic treatment. “Severe” if the patient suffers life-
threatening HAE attacks and/or more than 12 attacks per year with long term prophylactic 
treatment. Using different terminologies, Zanichelli (2012) suggested that 55% of patients 
fell into the mild category, 25% in to moderate and 20% into the severe category. From a 
patient’s perspective, the severity of each attack is also measured from uncomfortable skin 
swelling to life-threatening laryngeal edema (Lei, 2011). In the following meta-analysis, the 






Between eight and ten studies could be found that report the distribution of the severity of 
the HAE attacks as illustrated in Tables 5.3.11, 5.3.12 and 5.3.13. 
 
# of sources 8 
Sources (Blasco, 2013), (Caballero, 2014), (Federici, 2018), 
(Lumry, 2010), (Perego, 2017), (Riedl, 2015), (Wilson, 
2010), (Zanichelli, 2015) 
Total # of patients 2,432 
Weighted average 28% of HAE attacks are mild 
Range 16%-37%  
Table 5.4.11 - Mild attacks as a percentage of all HAE attacks 
 
# of sources 8 
Sources (Blasco, 2013), (Caballero, 2014), (Federici, 2018), 
(Lumry, 2010), (Perego, 2017), (Riedl, 2015), (Wilson, 
2010), (Zanichelli, 2015) 
Total # of patients 2,432 
Weighted average 48% of HAE attacks are moderate 
Range 45%-56%  
Table 5.4.12 - Moderate attacks as a percentage of all HAE attacks 
 
# of sources 10 
Sources (Blasco, 2013), (Bouillet, 2013), (Caballero, 2014), 
(Caminoa, 2013), (Federici, 2018), (Lumry, 2010), 
(Perego, 2017), (Riedl, 2015), (Wilson, 2010), (Zanichelli, 
2015) 
Total # of patients 2,818 
Weighted average 25% of HAE attacks are severe 
Range 17%-32%  
Table 5.4.13 - Severe attacks as a percentage of all HAE attacks 
Taking the average across all published research, it appears that about half the attacks are 





5.4.4 Frequency of HAE attacks per year  
The thesis identified 27 publication reporting the number of attacks HAE patients can have 
in one year, measured over 3,700 patients as illustrated in Table 5.3.14. 
 
# of sources 27 
Sources (Aabom, 2017), (Banerji, 2015), (Banerji, 2017), (Bork, 
2006), (Bork, 2008), (Bork, 2009), (Bork, 2015), (Bouillet, 
2011), (Bouillet, 2013), (Bygum, 2009), (Bygum, 2014), 
(Caminoa, 2013), (Deroux, 2016), (Federici, 2018), (Levi, 
2006), (Lumry, 2010), (Perego, 2017), (Riedl, 2015), 
(Riedl, 2017), (Steiner 2016), (Tourangeau, 2012), 
(Wilson, 2010), (Zanichelli, 2010), (Zanichelli, 2015), 
(Zuraw, 2010) 
Total # of patients 3,747 
Weighted average 19 HAE attacks per year 
Range 4-94 attacks  
Table 5.4.14 - Total frequency of HAE attacks per year 
The frequency of attacks appeared to be highly variable among different patients, with 
reports ranging between four and 94 attacks per year, and a total average of 19 attacks per 
year. Aabom (2017) reported that 7% of patients had zero attacks within a year and Inhaber 
(2019) reported that attack rates and severity of attacks appear not to depend on body weight. 
The literature mentions in addition, that a patient’s experience of attack frequency can also 
vary over time depending on a number of factors such as the attack triggers, which occurred 
in a wide range for annual frequency.  
The thesis was able to extract more details, for example, that about 40% of HAE patients 
suffer less than one attack every two weeks (illustrated in Table 5.3.15), and 31% of patients 
suffer less than one attack per month (Table 5.3.16). 
 
# of sources 4 
Sources (Agostoni, 2004), (Banerji, 2015), (Banerji, 2017), 
(Federici, 2018) 
Total # of patients 844 
Weighted average 40% of HAE patients have less than one attack every two 
weeks 
Range 18%-54%  






# of sources 10 
Sources (Aabom, 2017), (Agostoni, 2004), (Andrejevic, 2017), 
(Banerji, 2015), (Banerji, 2017), (Caballero, 2014), 
(Federici, 2018), (Nordenfelt, 2014), (Steiner 2016), 
(Zilberberg, 2011) 
Total # of patients 1,299 
Weighted average 31% of HAE patients have less than one attack every 
month 
Range 18%-82%  
Table 5.4.16 - Percentage of HAE patients with less than one attack per month 
On the other side of the spectrum, four studies have reported in average that about one-fifth 
of patients suffer more than one attack per week, as illustrated in Table 5.3.17. 
 
# of sources 4 
Sources (Andrejevic, 2017), (Banerji, 2015), (Caballero, 2014), 
(Steiner 2016) 
Total # of patients 110 
Weighted average 21% of HAE patients have more than one attack per week 
Range 10%-28%  
Table 5.4.17 - Percentage of patients with more than one attack per week 
5.4.5 Duration of HAE attacks 
The duration of HAE attacks is a key indicator for the severity and length in time HAE 
patients have to suffer, which directly affects the productivity and the QoL of a patient. The 
longer the attack, the longer the probable absence from work, education or social life. The 
thesis found six studies with a combined total of 409 patients. 
 
# of sources 6 
Sources (Bork, 2005), (Bork, 2008), (Bygum, 2009), (Zanichelli, 
2010), (Zanichelli, 2013), (Zuraw, 2010) 
Total # of patients 409 
Weighted average Duration of attacks 2.3 days for HAE patients not treated 
Range 1.7-3.8 days  
Table 5.4.18 - Duration of untreated HAE attacks 







# of sources 2 
Sources (Zanichelli, 2010), (Zanichelli, 2013) 
Total # of patients 256 
Weighted average Duration of attacks 1.5 days for patients treated with 
androgens 
Range 1.5 days  
Table 5.4.19 - Duration of HAE attacks with androgen therapy 
 
# of sources 2 
Sources (Zanichelli, 2010), (Zuraw, 2010) 
Total # of patients 125 
Weighted average Duration of attacks 1.3 days for patients treated with C1-
inh 
Range 1.1-2.1 days  
Table 5.4.20 - Duration of HAE attacks with C1-inhibitor therapy 
Patients treated with androgens or with C1-inhibitor benefit from significantly shorter 
durations of attacks, 1.5 days and 1.3 days as illustrated in tables 5.3.19 and 5.3.20 
respectively.  
5.4.6 Triggers of HAE attacks 
HAE attacks are variable in location and severity, as well as unpredictable, which 
contributes to the burden of the condition. While it has been recognized that the deficiency 
of functional C1-inhibitor is the cause of most forms of HAE, the specific mechanism that 
triggers attacks has not been definitively described. Agostoni (2004) reported that in some 
patients the absence of spontaneous attacks despite strong deficits of C1-inhibitor, indicating 
the possibility that multiple biological events have to take place for HAE attacks to happen. 
Patients are naturally keen to be able to predict when attacks occur, to be able to identify 
what triggers them, in order to possibly avoid such behaviors and events and thus the attack 
themselves. This part of the search aimed to consolidate from the available studies which 






Trauma as a trigger had been studied in 14 articles of research, as illustrated in Table 5.3.21, 
which collected the data of 778 HAE patients who recognized trauma as a trigger for an 
attack. 
 
# of sources 14 
Sources (Bonner, 2015), (Bork, 2009), (Farkas, 2010), (Howlett, 
2019), (Javaud, 2015), (Karkasharif, 2015), (Lei, 2011), 
(Nanda, 2015), (Narissara, 2018), (Psarros, 2014), (Read, 
2014), (Riedl, 2015), (Steiner, 2016), (Winnewisser, 
1997) 
Total # of patients 778 
Weighted average 52% of HAE patients reported trauma to trigger attacks 
Range 10%-75%  
Table 5.4.21- Percentage of HAE patients who reported trauma as an at attack trigger 
The variability across studies is relatively high, possibly suggesting that this variable could 
be dependent on the cohort of patients. 
5.4.6.2 None/not sure 
The nine studies illustrated in Table 5.3.22, which measured the percentage of HAE patients 
not able to trace their attacks to specific triggers reported on average that about half the 
patients are unable to do so.  
 
# of sources 9 
Sources (Bonner, 2015), (Karkasharif, 2015), (Lei, 2011), 
(Nygren, 2016), (Nzeako, 2001), (Psarros, 2014), (Riedl, 
2015), (Steiner, 2016), (Winnewisser, 1997) 
Total # of patients 454 
Weighted average 49% of HAE patients are not sure or cannot trace their 
HAE attacks back to specific triggers 
Range 16%-95%  
Table 5.4.22- Percentage of HAE patients who report no attack trigger or are not sure 






Stress as a psychological trigger for an HAE attack was studied in 13 publications which 
combined included 674 HAE patients as illustrated in Table 5.3.23. 
 
# of sources 13 
Sources (Bonner, 2015), (Bork, 2009), (Farkas, 2010), (Javaud, 
2015), (Karkasharif, 2015), (Lei, 2011), (Nanda, 2015), 
(Narissara, 2018), (Psarros, 2014), (Read, 2014), (Riedl, 
2015), (Steiner, 2016), (Winnewisser, 1997) 
Total # of patients 674 
Weighted average 47% of patients reported stress to trigger attacks 
Range 14%-79%  
Table 5.4.23- Percentage of HAE patients who reported stress as an at attack trigger 
On average about half the patients reported stress to be a factor that could trigger an attack. 
5.4.6.4 Pregnancy, menstruation, hormonal factors 
Approximately the same number of articles than in sections 5.4.6.1 and 5.4.6.3 reported 
female HAE patients suffering from attacks when triggered by pregnancies, menstruations, 
or other hormonal factors.  
 
# of sources 11 
Sources (Bonner, 2015), (Bork, 2009), (Bork, 2010), (Deroux, 
2016), (Farkas, 2010), (Howlett, 2019), (Javaud, 2015), 
(Karkasharif, 2015), (Lei, 2011), (Psarros, 2014), 
(Steiner, 2016) 
Total # of patients 745 
Weighted average 47% of female HAE patients reported pregnancies, 
menstruations or other hormonal factors to trigger attacks 
Range 18%-95%  
Table 5.4.24 - Percentage of female HAE patients who reported pregnancy, menstruation,  
hormonal factors as an attack trigger 
On average about half the female HAE population is affected by attacks triggered by such 






Emotions are also psychological factors, however, only two studies, illustrated in Table 
5.3.25, appear to have measured how frequently they could trigger HAE attacks.  
 
# of sources 2 
Sources (Bonner, 2015), (Nanda, 2015) 
Total # of patients 64 
Weighted average 32% of HAE patients reported emotions to be possible 
trigger factors for HAE attacks 
Range 13%-42%  
Table 5.4.25 - Percentage of HAE patients who reported emotions or being upset as an attack trigger 
The two studies reported in aggregate that about one-third of patients, when subject by 
negative emotions such as being upset, could be facing an impending HAE attack. 
5.4.6.6 Infections 
Infections have been studies in ten articles over 549 patients as illustrated in Table 5.3.26. 
 
# of sources 10 
Sources (Bonner, 2015), (Farkas, 2010, (Javaud, 2015), 
(Karkasharif, 2015), (Lei, 2011), (Nanda, 2015), 
(Narissara, 2018), (Psarros, 2014), (Read, 2014), 
(Steiner, 2016) 
Total # of patients 549 
Weighted average 28% of HAE patients reported infections to be possible 
trigger factors for HAE attacks 
Range 13%-50%  
Table 5.4.26 - Percentage of HAE patients who reported infections as an attack trigger 
Combined across the studies in about 28% of HAE patients’ infections could trigger attacks. 
5.4.6.7 Specific foods 
Undiagnosed patients having their first attacks often seek help from the family physician or 
general practitioners, whom when observing the swelling, incorrectly assume it was caused 
by allergies. If the attack is abdominal (see section 5.4.2.1), then the hypothesis of food 
poisoning or allergy would appear plausible. The nature of the disease is not an allergic 
reaction (see section 3.8), nevertheless some foods could trigger HAE attacks in patients, as 






# of sources 5 
Sources (Bonner, 2015), (Bork, 2009), (Karkasharif, 2015), 
(Narissara, 2018), (Psarros, 2014) 
Total # of patients 194 
Weighted average 24% of HAE patients reported that specific foods could 
trigger HAE attacks 
Range 9%-40%  
Table 5.4.27 - Percentage of HAE patients who reported certain foods as an attack trigger 
Over close to 200 patients, the studies reported that on average one-quarter of the patients 
could suffer from HAE attacks triggered by specific types of food. 
5.4.6.8 Dental procedures 
Trauma as a trigger has been studied as described in section 5.4.6.1, where about half the 
patients reported it to be a trigger of attacks. Anecdotal evidence seemed to indicate that 
dental procedures could trigger the laryngeal attacks which are particularly feared as they 
could become lethal. The thesis identified five studies over 250 patients, illustrated in Table 
5.3.6.8, which specifically analyzed these factors.  
 
# of sources 5 
Sources (Bonner, 2015), (Bork, 2009), (Karkasharif, 2015), 
(Narissara, 2018), (Psarros, 2014) 
Total # of patients 251 
Weighted average 22% of patients reported that dental procedures could 
trigger HAE attacks 
Range 5%-33%  
Table 5.4.28 - Percentage of HAE patients who reported dental procedures as an attack trigger 






5.4.6.9 Lack of sleep 
During the research, two articles reported lack of sleep as a trigger factor for a share of the 
HAE population studied, illustrated in Table 5.3.29. 
 
# of sources 2 
Sources (Bonner, 2015), (Nanda, 2015) 
Total # of patients 64 
Weighted average 17% of patients reported that lack of sleep could trigger 
HAE attacks 
Range 13%-19%  
Table 5.4.29 - Percentage of HAE patients who reported lack of sleep as an at attack trigger 
These studies reported in aggregate that about 17% of HAE patients can suffer from attacks 
due to lack of sleep. 
5.4.6.10 Prodromal symptoms 
Prodromal symptoms are sensitive non-specific manifestations that patients feel hours or 
days before HAE attacks. They can include localized tingling, itching, tightness, pain, and 
rashes (like erythema marginatum), urticaria, fatigue, malaise, flu-like symptoms, 
irritability, mood changes, hyperactivity, thirst, or nausea. Prodrome can last from an hour 
to several hours and can also include mental states like unexplainable sudden anxiety, 
feelings of impending doom. Depression, mental confusion, suicidal thoughts or just 
difficulties in managing basic daily tasks, like struggles to unlock a door. Prevalence is 
variable, Dagen (2010) reported that nine out of ten patients had a prodrome before attacks 
and that therefore they could be used as an indicator to predict an attack. Kemp (2008) 
suggested that as the reproducibility of prodromes varies, they may not be sufficient 
indicators to initiate therapy. Magerl (2014) reported that over 90% of the patients reported 
being able to predict the onset of an attack with a higher than 50% certainty, although it is 
still unclear how many truly lead to an attack.  
5.4.7 Comorbidities of HAE patients 
Comorbidities are other medical conditions that a share of HAE patients suffer from possibly 
as a direct or indirect result of the condition itself. They can arise through the condition itself 
overall, by the treatment, the lack thereof, or indirectly. Agostoni (2004) reported that they 
need to be understood and considered as they might be avoidable. In some cases, they require 
diagnosis and treatment by other medical specialties beyond immunology (e.g. for 
depression). Co-morbidities not only exacerbate the negative impact of the primary 
condition on the QoL, but they can also add significant additional financial burden to the 





Of the published literature on HAE, nine studies reported the prevalence of depression in 
patients living with HAE, as presented in Table 5.3.30. 
 
# of sources 9 
Sources (Banerji, 2017), (Bernstein, 2013), (Devercelli, 2018), 
(Fouche, 2013), (Gower, 2011), (Lumry, 2010), (Steiner, 
2016), (Tachdjian, 2017), (Zilberberg, 2011) 
Total # of patients 3,365 
Weighted average 34% of HAE patients suffered from depression 
Range 19%-44%  
Table 5.4.30 - Percentage of HAE patients with depression as a comorbidity 
With 3,365 HAE patients studied, about a third also suffered under depression. Lumry 
(2010) applied the Hamilton Depression Inventory–Short Form to HAE patients and 
reported that 43% of them had scores indicating a clinically significant depressive 
symptomatology, which is more than twice the 16% of an unaffected population. Fouche 
(2014) reported patients showing a sense of helplessness and emotional distress and 
disappointment even before they got an accurate diagnosis of HAE. Kargasharif (2015) 
reported that many patients develop feelings of guilt passing the disease to their children as 
HAE is hereditary. Fouche (2014) also mentioned that a further exacerbation of the 
condition is that patients not only can feel depression and anxiety as a result of attacks, but 
that vice versa feelings of depression and anxiety can and do play a causative role in the 
initiation of the attacks themselves. It follows that substantial shares of patients receive 
treatment for depression or anxiety, reflecting the additional disease burden beyond HAE 
attacks (Tachdjian, 2017). Lumry (2010) finally reported that close to one-fifth of patients 
with HAE take psychotropic or antidepressant medication, which is nearly double the 
national average.  
5.4.7.2 Anxiety 
Anxiety as a comorbidity was measured in four studies and over 1,032 patients as illustrated 
in Table 5.3.31. 
 
# of sources 4 
Sources (Banerji, 2017), (Devercelli, 2018), (Fouche, 2013), 
(Psarros, 2014) 
Total # of patients 1,032 
Weighted average 43% of HAE patients suffered from anxiety 
Range 15%-53%  




Anxiety affected about 43% of patients and Winnewisser (1997) reported that at least one-
third of patients live in continuous apprehension of an attack. When Quincke (1882) first 
described HAE, he originally labeled the condition as “angioneurotic” edema, based on the 
suspicion that the condition was in part “neurotic”, due to the high prevalence of depression 
and anxiety coming with it. Only in recent decades, thanks to a better understanding of the 
pathogenesis, has this label fallen out of usage (Henao, 2016). While it is biochemically not 
resulting from the genetic mutation causing HAE, it comes as a result of the condition and 
can vary over time and across individuals. The unpredictability of attacks and their 
potentially life-threatening nature is still the greatest source of worry for both patients and 
physicians (Jain, 2018). Bygum (2014) reported that 85% of patients are concerned about 
the inherent risk of sudden suffocation through a laryngeal attack. This can be explained 
with 12% of patients experiencing the death of a family member due to airway closure as 
reported by Huang (2004) from a survey.  
5.4.7.3 Autoimmune disorders 
Table 5.3.32 illustrates that autoimmune disorders as a comorbidity of HAE were reported 
only in two publications with 77 patients in total.  
 
# of sources 2 
Sources (Agostoni, 2004), (Nygren, 2016) 
Total # of patients 77 
Weighted average 12% of HAE patients suffered from autoimmune 
disorders 
Range 12%-12%  
Table 5.4.32 - Percentage of HAE patients with autoimmune disorders as a comorbidity 
Relatively few studies have reported this comorbidity describing the propensity of HAE 
patients to develop autoimmune disease, which can manifest as inflammatory bowel disease, 
systemic lupus erythematosus or thyroiditis. Levy (2019) reported that the frequency of 
autoimmune diseases appears to be almost triple (>12% vs. 4.5%) in patients with HAE 
compared to the general population. Frank (2018) recommended that although these diseases 
are usually mild, they should be considered by the treating physician. They can add further 
burden and costs to the condition.  
5.4.7.4 Other comorbidities 
Nanda (2015) reported in a study of over 21 patients that 15% of HAE patients could also 
be subject to atopy.  
Bernstein (2013) in another study over 457 HAE patients reported that 71% suffered also of 
weight gain due to their condition. Anecdotal discussion with specialist treating the patients 
indicated obesity to be a co-morbidity, resulting probably from a lower propensity of 
patients to engage in high impact physical activities and sometimes even sport in general, 




impact of physical activity on the psychological well-being, a lack of the first might not only 
contribute to weight gain, but also to depression and possibly self-loathing mentioned above. 
In the same study Bernstein (2013) also reported that 60% of the HAE patients were exposed 
to mood changes, possibly driven by the disruptive nature of HAE attacks on daily life and 
long-term prospects. Lastly, Bernstein (2013) reported that 46% of HAE patients were also 
subject to sleep disturbances, which might be linked to anxiety and depression as illustrated 
in sections 5.4.7.1 and 5.4.7.2. 
Additional co-morbidities have been mentioned in the literature, however, it appears not yet 
exhaustively and quantitatively been studied. Sexton (2019) reported in one of the analyses 
as part of the HELP study for lanadelumab on the cardiovascular risk of the treatment. He 
reported that up to 24.4% of the enrolled HAE patients had a history of hypertension. Nielsen 
(1996) reported that women with HAE were showing increased symptoms of urinary tract 
infections in conjunction with the attacks. The same study mentioned also women with HAE 
experiencing more spontaneous abortions or premature labors than healthy ones.  
Savarese (2018) reported that children with HAE were showing an impaired ability to 
recognize and describe their feelings (alexithymia), which is common when they suffer from 
chronic diseases. This comorbidity is exacerbating the HAE condition as children with 
alexithymia have reduced abilities to cope with stress, which can result in increased 
perceived stress and therefore more trigger factors for additional attacks. Abdominal attacks 
cause pain ranging at the top of the scale and often require the use of narcotic analgesics. 
Zuraw (2008) reported that frequent abdominal attacks may have led to addiction and some 
patients have been inappropriately considered to be “drug seeking” having developed 
narcotic dependence as described by Hemperly (2013). Lastly, Nielsen (1996) mentioned 
that patients with HAE have also been more frequently reported showing symptoms of 
heartburn or peptic ulcers, rheumatic complaints, while Steiner (2016) reported 
dyslipidemia, deep vein thrombosis, coronary heart disease, and diabetes. 
5.4.8 Patient engagement of health care services  
Patients with HAE display a relatively high utilization of health care resources including 
hospitalizations and ER visits. Tachdijan (2018) reported in a US study on a cohort of 
commercially insured HAE patients, that on a per year-basis 18% had claims for HAE-
related ER visits, and 11.5% had claims for HAE-related inpatient stays. 
5.4.8.1 Hospitals visited  
 
# of sources 3 
Sources (Bygum, 2009), (Petraroli, 2015), (Zhi,2018) 
Total # of patients 204 
Weighted average 7.5 hospital visits per HAE patient over lifetime 
Range 5.5 – 16.8 




Studies which included more than 200 HAE patients indicated that on overage they had over 
7.5 hospital visits over their lifetime, as illustrated in Table 5.3.33.  
5.4.8.2 Doctor visits 
One study over 159 HAE patients reported that on average untreated HAE patients sought 
the help through more than 11 doctor visits when having attacks, but not having been 
diagnosed yet, as illustrated in Table 5.3.34. 
 
# of sources 1 
Sources (Zhi,2018) 
Total # of patients 159 
Weighted average 11.4 doctor visits by untreated HAE patients seeking 
treatment 
Range - 
Table 5.4.34 - Average number of doctors visited seeking treatment per HAE patient 
 
Two studies reported the same variable (doctor visits) when HAE patients were diagnosed 
and under treatment as illustrated in table 5.3.35. 
 
# of sources 2 
Sources (Banerji, 2015), (Zhi,2018) 
Total # of patients 345 
Weighted average 4.6 doctor visits per year when under treatment 
Range 4.0 – 5.2 
Table 5.4.35 - Number of doctor visits per year per HAE patient 
The frequency of doctor visits for such patients was on average 4.6 per year for example to 
monitor the evolution of the condition or renew or change the prescription of the medication 
to take. 
5.4.8.3 ER visits 
The more severe the pain of a medical condition, the higher the utilization of medical 
resources. Studies have confirmed that the higher the intensity of the pain during an attack, 
the lower the productivity, the greater the absenteeism and the higher the likelihood of 
visiting an ER for treatment. Ayggören-Pürsün (2014) reported that 19% of attacks with 
severe pain led to ER visits, while 16% did so with moderate pain and only 2% with mild or 







# of sources 7 
Sources (Bouillet, 2011), (Bouillet, 2013), (Federici, 2018) 
(Javaud, 2015), (Tourangeau, 2012), (Wilson, 2010) 
Total # of patients 1,191 
Weighted average 10% of HAE patients visit ERs 
Range 2% - 16% 
Table 5.4.36 - Percentage of HAE patients visiting ERs 
As illustrated in Table 5.3.36, on average around 10% of patients with HAE have visited 
ERs. The thesis found another group of studies which measured ER visits by HAE patients 
that were yet undiagnosed vs. patients that were already diagnosed. Two publications 
reported on average that the former visit ERs 3.2 times per year, as illustrated in Table 
5.3.37. 
 
# of sources 2 
Sources (Huang, 2014), (Zhi, 2018) 
Total # of patients 222 
Weighted average 3.2 ER visits by undiagnosed HAE patients per year 
Range 2.6 – 4.7 
Table 5.4.37 - Number of ER visits per year per undiagnosed HAE patient 
Another seven publication reported the average number to be 2.9 visits per year for 
diagnosed patients as illustrated in Table 5.3.38.  
 
# of sources 7 
Sources (Banerji, 2015), (Bernstein, 2013), (Blasco, 2013), 
(Bygum, 2014), (Javaud, 2015), (Nanda, 2015), 
(Petraroli, 2015) 
Total # of patients 1,567 
Weighted average 2.9 ER visits of diagnosed patients per year 
Range 1.0 – 4.7 





5.4.8.4 Assistance by caregiver 
Both on-demand and prophylactic treatments of HAE are administered intravenously or 
subcutaneously. This can become a challenge for pediatric, elderly or otherwise impaired 
patients, especially during an attack. 
 
# of sources 1 
Sources (Aygören-Pürsun, 2014) 
Total # of patients 164 
Weighted average 52% of HAE patients use assistance by a caregiver 
Range - 
Table 5.4.39 - Percentage of HAE patients using assistance by a caregiver 
Aygören-Pürsün (2014) quantified (see Table 5.3.39) that about half the patients were using 
the assistance of caregivers which could be family members.  
5.4.8.5 Tracheotomies 
Laryngeal attacks and their resulting risk of causing death were discussed in section 5.4.2. 
The tracheotomy is an intervention of last resort to keep patients suffering a laryngeal attack 
alive. 
 
# of sources 6 
Sources (Bouillet, 2013), (Bygum, 2009), (Javaud, 2015), 
(Psarros, 2014), (Roche, 2005), (Wilson, 2010) 
Total # of patients 1,321 
Weighted average 4% of patients 
Range 2% - 10% 
Table 5.4.40 - Percentage of HAE patients who had a tracheotomy performed on them 
Six publications covering 1,321 HAE patients established that about one patient in 25 had 
undergone such intervention, as illustrated in Table 5.3.40.  
5.4.8.6 Fatalities 
The discussion in section 5.4.2 on laryngeal attacks possibly affecting HAE patients also 
highlighted the possibility of fatal outcomes. An HAE attack causing the death of a patient 
is the ultimate burden of the disease afflicting the family and society socially and 
economically. One group of studies illustrated in Table 5.3.41 reported such outcomes 






# of sources 3 
Sources (Agostoni, 2004), (Bork, 2012), (Winnewisser, 1997) 
Total # of patients 833 
Weighted average 10% of undiagnosed patients 
Range 7% - 28% 
Table 5.4.41 - Percentage of undiagnosed HAE patients who died due to asphyxiation 
The second group of studies, illustrated in Table 5.3.42 reported that diagnosed HAE 
patients had a probability of a fatal outcome of 3%, suggesting that on average the risk of 
death could be reduced to less than a third by diagnosis and proper treatment. 
 
# of sources 8 
Sources (Blasco, 2013), (Bork, 2015), (Bygum, 2014), 
(Karkasharif, 2015), (Kim, 2014), (Lei, 2011), 
(Zanichelli, 2015), (Zilberberg, 2011) 
Total # of patients 1,960 
Weighted average 3% of diagnosed patients 
Range 0% - 6% 
Table 5.4.42 - Percentage of diagnosed HAE patients who died due to asphyxiation 
Some research indicated that zero diagnosed patients were succumbing because of an attack, 
possibly proving the great progress of modern therapy in improving QoL and preserving life 
itself.  
5.4.9 Treatment in general 
Section 3.8 mentioned that HAE can be treated on demand, when an attack occurs, or 
prophylactically with the aim to prevent attacks from occurring. 
5.4.10 On-demand treatment of HAE 
On-demand treatment is taken when an attack is occurring or about to occur. Effective on-
demand treatment can make the difference between severe pain and loss of productivity, 
absenteeism or not. It may make the difference between death by asphyxiation or not in the 





5.4.10.1 Total percentage of HAE patients treating attacks 
The thesis identified six studies which covered 1,073 HAE patients and reporting the 
treatment of attacks with on-demand drugs. 
 
# of sources 6 
Sources (Banerji, 2015), (Bygum, 2014), (Caballero, 2014), 
(Howlett, 2019), (Nanda, 2015), (Wang, 2015) 
Total # of patients 1,073 
Weighted average 67% of HAE patients treated their attacks 
Range 40% - 88% 
Table 5.4.43- Percentage of HAE patients treating attacks 
As illustrated in Table 5.3.43, on average 67% of patients treat their HAE attacks with on-
demand treatment, confirming the medical need and the positive outcome.  
Jain (2018) reported on surveys that have shown that patients sometimes are unwilling to 
administer rescue medications, preferring to use them only if an attack was “bad enough”. 
For example, a US survey reported by Castaldo (2019) and conducted exclusively with 
patient members of the HAEi organization, reported that the 37.3 patients using only on-
demand therapy leave 31% of their attacks untreated. Such behavior can be linked to the 
relatively high price of the medication. While the guidelines state that every attack should 
be treated, Federici (2018) reported in Italy that 21% of the attacks on average were not 
treated (Federici, 2018). 
5.4.10.2 C1-inhibitors 
The first category of on-demand treatment for HAE patients researched for this thesis is the 
C1-inhibitors.  
 
# of sources 8 
Sources (Aabom, 2017), (Bygum, 2014), (Howlett, 2019), (Jolles, 
2014), (Ohsawa, 2015), (Riedl, 2017), (Steiner, 2016), 
(Wilson, 2010) 
Total # of patients 1,364 
Weighted average 37% of HAE patients used C1-inhibitors to treat acute 
attacks 
Range 6% - 75% 
Table 5.4.44 - Percentage of HAE patients treating attacks with C1-inhibitors 
Eight studies spanning different healthcare systems (illustrated in Table 5.3.44) were found 
measuring the use of C1-inhibitors for on-demand treatment of HAE attacks as illustrated in 
Table 5.3.44. The weighted average of over 1,364 patients suggests that 37% take C1-




The treatment with plasma-derived C1-inhibitors is also called “replacement therapy” as it 
replaces the protein in the body, which is causing the attacks. Nzeako (202) reported strong 
efficacy of this therapy, as 69% of the attacks responded with relief after 30 minutes and 
95% after two hours, compared to only 12% after four hours by taking only a placebo. 
Studies also reported that 99% of laryngeal attacks improved within 30 to 60 minutes 
(Agostoni, 2004), and that the duration of an upper airway obstruction can be substantially 
reduced (Bork, 2001). Bork (2001) also reported that none of the patients who took C1-
inhibitors on demand, required additional emergency procedures such as tracheotomies or 
cricothyrotomies. Overall, Craig (2013) also reported that early treatment with C1-inhibitors 
within six hours after the start of the attack leads to better treatment responses. These results 
confirmed the lifesaving impact these drugs can have. For example, in a later study, Bork 
(2008) showed that that treatment of non-life-threatening skin swellings with C1-inhibitors 
can substantially reduce the time to relief from 50h to 1h and the duration of attacks from 
3.2 days to 1.7 days. 
On the other hand, Prior (2012) reported that treatment with plasma-derived C1-inhibitors 
could also lead to adverse events and contraindications, such as from the potential 
transmission of infectious and/or pathogenic viruses, infections at injection sites or 
thrombosis associated with indwelling catheters. To minimize risks, and to ensure safety, 
Hemperly (2013) listed that for example in the US only licensed sources can collect plasma 
whereas each blood donor is tested for antibodies against human immunodeficiency virus 
(types 1 and 2), hepatitis C virus, and hepatitis B surface antigen. Additionally, specific 
nucleic acid tests and polymerase chain reaction assay for hepatitis A virus, hepatitis B virus, 
and hepatitis C virus, human immunodeficiency virus type 1, and human parvovirus are 
performed. to test all serologically negative plasma. This is then followed by pasteurization 
and nanofiltration. 
5.4.10.3 Icatibant 
Icatibant is synthetic decapeptide, structurally similar to bradykinin, which acts as a potent 
selective competitive antagonist of the bradykinin B 2 receptor and has been brought to the 
market (trademark Firazyr®) in 2008. Since then both patients and physicians had the 
opportunity to gain more than ten years of experience benefiting from this drug. Several 
studies and the Icatibant Outcome Survey (IOS) have analyzed the efficacy, the safety and 
its use since its launch (Andresen, 2019) 
Table 5.3.45 illustrates the result of five studies over 714 patients indicating that about 23% 
of them use Icatibant to treat the HAE attacks on demand. The high variability of its usage 
is driven by the selection of the eligibility criteria and the primary objective of the different 






# of sources 5 
Sources (Bygum, 2014), (Howlett, 2019), (Jolles, 2014), (Riedl, 
2017), (Steiner, 2016) 
Total # of patients 714 
Weighted average 23% of HAE patients used Icatibant to treat acute attacks 
Range 6% - 100% 
Table 5.4.45 - Percentage of HAE patients treating attacks with icatibant 
Lumry (2011) reported that Icatibant improved within two hours by 50% the symptoms of 
HAE such as debilitating pain and swelling in cutaneous and abdominal attacks. Cicardi 
(2010), on the other hand, reported with the FAST study that within 8-10 hours symptoms 
of HAE in cutaneous and abdominal attacks were completely relieved as reported by. 
Icatibant is administered by subcutaneous injection, which is preferred to intravenous 
therapy. Administration can more easily be taught to patients for home use, and Degan 
(2010) observed that adverse events associated with poor technique are minimal. A noted 
minor side effect persists in the form or injection site reactions (Banerji, 2013) which can 
be self-limited erythema, pruritus or pain in the injection area (Prior, 2012).  
5.4.10.4 Tranexamic acid 
Tranexamic acid is one of the older drugs which originally was used to treat HAE for 
prophylaxis, but with less efficacy and a less compelling safety profile (Prior, 2012). The 
average share of patients using this drug for on-demand use across six studies is 6%, as 
illustrated in Table 5.3.46. 
 
# of sources 5 
Sources (Aabom, 2017), (Bygum, 2014), (Howlett, 2019), 
(Wilson, 2010), (Zanichelli, 2015) 
Total # of patients 890 
Weighted average 6% of HAE patients used tranexamic acid to treat acute 
attacks 
Range 0% - 23% 
Table 5.4.46 - Percentage of HAE patients treating attacks with tranexamic acid 
5.4.10.5 Fresh frozen plasma 
Fresh frozen plasma (FFP) has been used historically as the only therapy with the potential 
to arrest an acute attack and is still administered for acute treatment in healthcare institutions 
where modern treatments such as icatibant or C1-inhibitors are not available. Christiansen 
(2015) mentioned in her study, that because FFP is not virally inactivated, there is still a 
relatively high risk of transmitting infectious agents and blood-borne pathogens, exposing 
the patient to the risk of a blood-borne illness. C1-inhibitors, which are also plasma-derived, 




reported that FFP requires a larger dosing volume and therefore a longer infusion time, 
which can become an issue in emergency situations such as when there is imminent risk of 
asphyxiation during a laryngeal attack. Additionally, Hemperly (2013) associated FFP with 
several adverse effects, including urticaria, anaphylactic shock, and hemolysis. FFP is also 
known to potentially aggravate the severity of HAE attacks through an increase of 
bradykinin, alloimmunization, anaphylactic or allergic reactions, excessive intravascular 
volume with the risk of hypervolemia and heart failure.  
 
# of sources 2 
Sources (Tachdjian, 2017), (Wilson, 2010) 
Total # of patients 1,186 
Weighted average 6% of HAE patients used FFP to treat acute attacks 
Range 4% - 7% 
Table 5.4.47- Percentage of HAE patients treating attacks with FFP 
Kalaria (2014) additionally reported that 12% of patients being treated with FFP experienced 
a worsening of the attack, with 68% of these deemed related to the administration of the 
drug itself. Such a mixed profile explains why the two studies mentioned in Table 5.3.47 
have reported relatively and significantly lower use of FFP by on average 6% of the HAE 
patients. 
5.4.10.6 Other treatments 
Ecallantide is an acute treatment available only in the US, with associated adverse events 
such as headache, diarrhea, pyrexia, nasal congestion, and an infrequent but serious risk of 
anaphylaxis (which made a commercial use in Europe not viable (Banerji, 2013). Due to the 
severe pain, pain relievers and narcotics are used as an alternative as well. Banerji (2013) 
reported the use of psychotropic medication to treat anxiety and depression. Hemperly 
(2013) also reported the historic acute treatment of HAE attacks being restricted to 
supportive measures such as intravenous fluids administration and pain management. Use 
of corticosteroids, epinephrine, and antihistamines, all not having efficacy for this ailment, 





5.4.11 Prophylaxis treatment 
While on-demand treatment aims to treat an immediately impending or already ongoing 
HAE attack, prophylaxis treatment aims to prevent the attacks from happening altogether. 
Longhurst (2010) reported that that patients’ access to prophylactic treatment can reduce the 
severity and duration of attacks, improve QoL, reduces time off work, education or other 
social activities, while being safe. On the other hand, with prophylaxis treatment come 
additional burdens such as significantly increased frequency of drug intake by infusion or 
injection resulting in higher costs. Cicardi (2012) raised in his article that for these reasons, 
before deciding if to start a patient on prophylaxis, physicians, patients and payers should 
assess if the benefits outweigh the downsides, including also potential side effects. Riedel 
(2017) added as a factor the need for assistance at home in preparing and administering 
infusions, finding usable veins or getting the infusions to work properly. Reasons to switch 
to prophylaxis stem mainly from the overall burden of disease measured through attack 
frequency and the history of severe debilitating or life-threatening attacks. Daniel (2019) 
measured a reduction of attacks per year from 49 with no prophylaxis to four when taking 
C1-inhibitors following 19.7 months of therapy. Other factors driving a switch to 
prophylaxis can include the limited access to urgent care or the lack of efficient access to 
acute treatment – in these cases, prophylactic therapy could potentially be lifesaving.  
5.4.11.1 Total percentage of patients using prophylactic drugs to prevent attacks 
The thesis identified 15 studies over 2,719 patients and which measured to use of 
prophylaxis drugs. Virtually all studies were conducted in advanced healthcare systems 
where the diagnosis of the rare condition is established, and treatment is available. 
 
# of sources 15 
Sources (Andrejevic, 2017), (Banerji, 2015), (Banerji, 2017), 
(Bouillet, 2011), (Bygum, 2014), (Federici, 2018), 
(Karkasharif, 2015), (Nanda, 2015), (Nygren, 2016), 
(Read, 2014), (Riedl, 2017), (Roche, 2005), (Wilson, 
2010), (Zanichelli, 2010), (Zanichelli, 2015) 
Total # of patients 2,719 
Weighted average 56% of HAE patients take prophylactic HAE drugs 
Range 16% - 94% 
Table 5.4.48 - Percentage of HAE patients using prophylactic drugs to prevent attacks 
The weighted average illustrated in Table 5.3.48 suggest that 56% of HAE patients follow 
a prophylactic HAE treatment. A US survey conducted exclusively with patient members of 






C1-inhibitors (for example Cinryze®) are called “replacement therapy” as they replace the 
protein that is missing in the human body due to the genetic condition that defines HAE. 
Plasma-derived C1-inhibitors are very effective for acute and prophylactic treatment of 
HAE, while at the same time displaying a better safety profile than androgens. The most 
common side effects reported with C1-inhibitors include pruritus, rash, headache, 
lightheadedness, fever (Banerji, 2013), chills, faintness, vertigo, and paresthesia 
(Krassilnikova, 2008). A survey covering over 856 patients (taking the intravenous 
formulation of C1-inhibitors) through their treating physicians reported that only 0.6% 
experienced a thromboembolic episode (Kalaria, 2013). 
 
# of sources 8 
Sources (Banerji, 2017), (Howlett, 2019), (Javaud, 2015), (Jolles, 
2014), (Read, 2014), (Riedl, 2017), (Steiner, 2016), 
(Wilson, 2010) 
Total # of patients 1,676 
Weighted average 24% of patients 
Range 0% - 94% 
Table 5.4.49 - Percentage of HAE patients using C1-inhibitors to prevent attacks 
Eight studies researching prophylaxis treatment have been identified as illustrated in Table 
5.3.49. Combined over 1,676 patients on average they report a quarter (24%) of the HAE 
patients were using C1-inhibitors to prevent attacks.  
5.4.11.3 Androgens 
A relatively large number of studies (21) that included 5,415 patients was identified 
measuring the use of androgens for prophylaxis therapy, as shown in table 5.3.50. The 
average use of androgens was reported to be by 38% of HAE patients for prophylaxis. The 
variability is once larger and depending on the same factors as identified for C1-inhibitors. 
 
# of sources 21 
Sources (Aabon, 2017), (Agostoni, 1992), (Andrejevic, 2017), 
(Aygören-Pürsun, 2014), (Banerji, 2017), (Bernstein, 
2013), (Howlett, 2019), (Javaud, 2015), (Jolles, 2014), 
(Karkasharif, 2015), (Lei, 2011), (Levi, 2006), (Lumry, 
2010), (Perego, 2017), (Psarros, 2014), (Steiner, 2016), 
(Tachdjian, 2017), (Wilson, 2010), (Zanichelli, 2010), 
(Zanichelli, 2015) 
Total # of patients 5,415 
Weighted average 38% of patients 
Range 0% - 77% 




5.4.11.4 Tranexamic acid 
Tranexamic acid, an antifibrinolytic agent, that can be utilized as prophylactic treatment of 
HAE, despite its lower efficacy compared to androgens and the increased risk of 
thromboembolic events as reported by Bork (2001). Eight publications quantified their 
usage by HAE patients and reported it at around 8%, as illustrated in Table 5.3.51. 
 
# of sources 8 
Sources (Aygören-Pürsun, 2014), (Javaud, 2015), (Levi, 2006), 
(Ohsawa, 2015), (Psarros, 2014), (Steiner, 2016), 
(Zanichelli, 2010), (Zanichelli, 2015) 
Total # of patients 926 
Weighted average 18% of patients 
Range 1% - 50% 
Table 5.4.51 - Percentage of HAE patients using tranexamic acid to prevent attacks 
5.4.11.5 Lanadelumab 
Lanadelumab (Trademark Takhzyro®) is a monoclonal antibody launched in the Summer 
of 2018 in the US and in early 2019 in Europe. Compared to the other described therapies, 
RWE is still limited, however, the clinical data from the HELP study has shown significant 
reductions in HAE attack rates compared to placebo (Banerji, 2019). Busse (2019) reported 
a reduction of the mean monthly attack rate of 62.5% vs. placebo as a result of the HELP 
study over 28 weeks. In the same study, a rollover over 132 weeks was performed as an 
open-label extension leading to a reduction of the mean attack rate by 94.9% vs. baseline. 
An important share of patients is achieving an attack-free state, 57% of patients after three 
months as reported by a survey (Castaldo, 2019). The HELP study also reported around 97% 
attack-free days as a result of the treatment (Inhaber, 2019). Patients who were not 
responders in the HELP study continued in an open-label extension (OLE) and reported 
improvements driving them to choose to remain enrolled (Jacobs, 2019). Riedl (2019) 
reported that patients who had used C1-inhibitors for prophylaxis previously, reduced on 
average attack rates by up to 98.9% thanks to the treatment with lanadelumab. In the third 
phase of the HELP study, it was also demonstrated that patients can achieve a “biological 
steady state” where the inhibition of plasma kallikrein suppresses the production of 
bradykinin, which prevents the triggering of HAE attacks (Wang, 2019).  
5.4.11.6 Oral drugs 
Oral kallikrein inhibitors (for example BCX7353) have been under development during the 
execution of the thesis. An oral mode of administration (for example one capsule daily) was 
a new proposition as it would provide more convenience and have been preferred by patients 
compared to an infusion or an injection. The ZENITH-1 Phase 2 study had shown significant 
improvements in reduction of attack severity and reduced need for on-demand treatment 




5.4.12 Other types of treatment 
Historically and in healthcare systems with low disease awareness, the capability to diagnose 
and low access to modern medicine, corticosteroids and antihistamines had been and were 
still being prescribed. Agostoni (2005) reported these treatments to be usually ineffective, 
leading them to be part of the section on misdiagnosis and wrong treatments 5.1.2.2). A 
number of physicians have been reported in studies to prescribe pain relievers and narcotics 
mainly to mitigate the pain of HAE. 
 
# of sources 2 
Sources (Bernstein, 2013), (Wilson, 2010) 
Total # of patients 914 
Weighted average 39% of patients 
Range 32% - 46% 
Table 5.4.52 - Percentage of HAE patients using pain relievers and narcotics 
The two studies illustrated in Table 5.3.52 reported that close to 40% of patients were being 
prescribed pain relievers and narcotics, with the inherent risk of addiction (see the section 
on co-morbidities 5.4.7). The studies on comorbidities have highlighted the high prevalence 
of depression among patients suffering under HAE. 
 
# of sources 3 
Sources (Bernstein, 2013), (Tachdjian, 2017), (Wilson, 2010) 
Total # of patients 914 
Weighted average 41% of patients 
Range 20% - 55% 
Table 5.4.53 - Percentage of HAE patients using psychotropics and antidepressants and narcotics 
Three studies over 914 patients have reported about 41% of them were using antidepressants 
and narcotics, as illustrated in Table 5.3.53. These drugs possibly lead to additional burden 





5.4.13 Treatment costs 
5.4.13.1 Cost overview 
Although the per-patient treatment costs for rare diseases are often high, the perception that 
orphan treatments as a whole have an inordinate impact on total pharmaceutical 
expenditures and health care costs is inaccurate. As discussed in section 3.7.1, rare diseases 
affect about 8–10% of the population. EvaluatePharma (2015) analyzed the overall market 
and reported that orphan indications represented less than 10% of the pharmaceutical 
expenditures and only 1% of the total healthcare expenditures. Despite this, Lumry (2018) 
noted that it appeared that payers in the US and around the world, healthcare authorities put 
an inordinate number of barriers to limit the use of specific therapies for new diseases. 
Federici (2018) analyzed the composition of total treatment costs and reported that drug type 
was the most relevant cost driver. However, the share of the different cost drivers could vary 
significantly, as Wilson (2010) explained that more efficacious treatments result in fewer 
inpatient and outpatient costs, leading the drug costs to contribute proportionally higher to 
the overall cost. Wilson also reported that ER visits and hospitalizations were major 
contributing factors to the cost of treating and managing HAE. One study also included the 
drug costs and severity of attacks as main drivers of cost and resource use (Bhasin, 2014). 
Rasmussen (2016) reported the cost of emergency department visits and hospital admissions 
to account for 68% of the costs when treating a patient with severe HAE. 
5.4.13.2 Direct vs. indirect costs 
There are two types of costs: (A) Direct costs such as treatment costs (drugs, interventions, 
e.g. tracheotomies), hospital ER visits, primary care visits, specialist visits, hospital 
admissions, ICU admissions or also some nonmedical costs such as transportation to the 
hospital/ER that can be directly linked. (B) Indirect costs are defined as those incurred from 
labor productivity losses (e.g. patients’ or caregivers’ working hours), costs of missed 
workdays or cost of missed school days. In case of death, indirect costs also include the 
labor costs of lost labor, estimated by multiplying the years the patient could no longer work 
and contribute to the national wealth. Indirect costs are difficult to generalize and quantify 
as they can be individual and depending on life choices that have also an impact on QoL. 
For example, even between attacks, patients and caregivers might change their behaviors, 
might incur in additional costs to be close to acute treatment infrastructure, or might miss 
out on income-generating opportunities due to the burden of HAE.  
5.4.13.3 Cost factors in HAE 
With increasing severity of the condition, the costs of treatment increase dramatically. 
Banerji (2013) reported annual treatment costs in Europe increased from mild to moderate 
to severe from USD 14,400, to USD 26,900 to USD 96,500 respectively. Wilson (2010) 
reported similarly for the US the figures USD 3,700, USD 9,800 and USD 76,400 
respectively. Castaldo (2019) conducted a survey exclusively with patient members of the 
US HAE patient organization and reported that patients on acute treatment only incurred 




(missed work, reduced wages, under-employment) of USD 52,600 for a total of USD 
417,100 per year. The major drivers that exponentially drove the costs with increasing 
severity were caused by additional needs for ER and hospitalizations.  
The attacks that concerned HAE patients the most were the potential fatal laryngeal attacks. 
Zilberberg (2010) estimated that in the US every hospitalization cost on average USD 4,000. 
Manson (2013) attempted to quantify in more detail the costs and reported that, in addition 
to the cost of an ER visit, there could be costs resulting from intubation of USD 146 and 
artificial respiration of USD 14,809 for less than 96 hours, which could leap to USD 32,709 
if more than 96 hours were needed.  
5.4.13.4 Lifetime costs of HAE 
ICER (2018) calculated the average total lifetime direct costs for a patient with no 
prophylaxis to be around USD 9.95 million (mainly driven on-demand drug costs, but also 
USD 750,000 for ER visits, hospitalizations, and emergency procedures for those with 
laryngeal attacks). Patients who received prophylaxis treatment incurred lifetime costs 
between USD 10.3 million and USD 14.4 million depending on the treatment chosen. 
Depending on the prophylaxis drug, patients needed more or less on-demand treatment. 
Over a lifetime, patients taking C1-inhibitors consumed USD 4.6 million on additional on-
demand treatment and USD 1.2 million if on Takhzyro®.  
Using QALYs, the same analysis reported lifetime QALYs of 17.5 without prophylaxis and 
between 18.2 and 18.7 for patients taking prophylaxis treatment. Such differences combined 
with the cost differences between treatments could lead to incremental cost-effectiveness 
ratios ranging from USD 0.33 million to USD 5.95 million per QALY. Over a lifetime, 
patients had been estimated to experience 1,703 acute attacks without long-term 
prophylaxis, and between 223 attacks for patients receiving Takhzyro® and 843 for patients 
receiving a C1-inhibitor. Combining with the lifetime costs of the different therapies, this 
would lead to incremental costs per attack avoided between USD 273 and USD 5,168 
depending on the therapy selected (ICER, 2018). 
The thesis identified five publications which quantified the yearly treatment costs for HAE 
patients based on the type of therapy that they follow, as illustrated in table 5.3.54. 
 
 On-demand Prophylaxis 
 Not defined C1-inhibitors Androgens 




(Lumry W. R., 
2018) 
(Rasmussen, 2016) 
Average (USD) 38,790 334,915 494 
Range (USD) 16,108-93,194 182,829-487,000 494 
Table 5.4.54 - Yearly HAE treatment costs by type of therapy 
HAE patients that treated attacks only when they occurred, generated average yearly 




reduce or eliminate attacks from occurring, generated average yearly treatment costs of USD 
335,000. 
In addition, HAE patients that had access to modern treatment options were still at risk of 
requiring hospital treatments, as described in section 5.4.8.1), for example in case of severe 
attacks. Bouillet (2011) reported an average annual cost for hospital treatments at about USD 
5,000 in selected European countries, while Lumry (2018) reported USD 8,134. 
In section 5.4.3 different degrees of severity of HAE attacks have been analyzed. Two 
studies that quantified the dependence of the yearly treatment costs on the severity of the 
condition have been identified and the results illustrated in Table 5.3.55.  
 
 Severity of condition 
 Severe Moderate Mild 
Sources (Banerji, 2013), (Lumry, 2018) 
Average (USD) 92,600 21,600 9,900 
Range (USD) 76,400-104,900 9,800-28,800 3,700-14,400 
Table 5.4.55- Yearly treatment costs by the severity of the HAE condition 
These studies indicate that treatment of patients with a severe form of the condition could 
cost up to tenfold compared to the mild form. 
Zilberberg (2010) attempted to quantify the average hospital and ER cost per attack 
depending on the severity and reported USD 65,500 for severe attacks, USD 5,000 for 
moderate and USD 600 for mild ones. These publications measured the direct healthcare 
system costs. Lumry (2018) additionally attempted to measure indirect costs, quantifying 
the reduced productivity to cost the patient USD 5,200 p.a., the reduced income USD 6,400 
p.a., and the impact of missed work USD 4,300 p.a.  
5.4.13.5 Payers perspective and their concept of value 
In the section 3.1.16 on EBM, the shared decision-making between physician and patient 
was discussed against the background of agency theory described in section 3.6 with the role 
of the payer described with the double agency theory detailed in section 3.6.4. The 
disconnect between the three parties became obvious when on one side physicians and 
patients selected therapies that provided clinical outcomes and convenience, but on the other 
hand, payers were not concerned about ease of use or convenience. As long as treatments 
cost the same, mode of administration and convenience (for example through less frequent 
dosing or less painful administration) were perceived as added values freely available. 
However, when pharmaceutical companies began to demand a higher price for more 
innovative modes of administration (for example oral administration instead of 
subcutaneous, or biweekly instead of daily dosing), misalignment arose. Payers were 
interested in and were ready to fund solutions that limited costs and ideally kept the patients 
out of the costly ER. Therefore, payers could also question the value of expensive 





5.4.13.6 Challenges from novel treatments 
Over the past few years, there has been a rapid increase in drug development and launches 
which brought many benefits to the patients and all stakeholders, as described in sections 
5.4.10 and 5.4.11. These novel treatments could reduce the burden of the condition while at 
the same time decrease the need for emergency treatments and hospitalizations. However, 
Lumry (2018) pointed out that these modern life-changing and potentially life-saving 
therapies were much more expensive and raised concerns with payers leading to access and 
reimbursement limitations. The orphan status described in section 3.7.3 may not always have 
been considered in economic analyses, resulting in orphan treatments not being deemed 
cost-effective and the treatment not reimbursed. Pharmaceutical companies needed to 
consistently emphasize the orphan status of their innovative drugs when submitting to the 
payers the value dossiers with the intention of obtaining reimbursement for their patients. 
Kanavos (2018) reported that the consideration of orphan status may have contributed to US 
long-term prophylactic therapies for HAE to cost more than USD 30,000 per month, adding 
up to annual costs of more than USD 400,000. Such costs were well above the threshold of 
USD 150,000 which had usually been used as an upper bound for the cost-effectiveness of 
treatments. It has been estimated that 70% of the 6,500 HAE patients in the US were being 
treated with long-term prophylaxis, suggesting total yearly costs of close to USD 2 billion 
for drugs alone.  
5.4.13.7 Implications on costs, reimbursement and prices 
ICER (2018) analyzed the reimbursement procedures of US private payers and reported that 
all require a confirmed diagnosis of HAE. Most additionally require that patients suffer a 
minimum number of attacks per month, before they can be prescribed and reimbursed 
prophylaxis treatment (for example Aetna specifies that the patient must at least one attack 
per month, Cigna at least two attacks per month, Health Net more than one severe event per 
month or be disabled for more than five days per month).  
EvaluatePharma (2015) estimated that in the US the total expenditures on orphan drugs 
represents less than 10% of pharmaceutical expenditures and only 1% of the total healthcare 
expenditures. Schey (2011) quantified the share of orphan drugs to be 3.5% of the total 
pharmaceutical market, suggesting that their impact on the budget is limited and that fears 
that their expenditures will be unsustainable in the long run are not justified. Despite these 
facts, Lumry (2018) analyzed the HAE situation and determined that payers and healthcare 
authorities sometimes perceive orphan drugs to cause an excessive economic burden on their 
payment systems and put barriers in place to limit the use of new disease-specific therapies.  
Over the past years, there has been a wave of high-cost orphan drugs which augmented the 
payer’s sensitivity to cost, resulting in increased formulary restrictions (Hyde, 2010). Cohen 
(2014) found that orphan drugs appear to have more reimbursement restrictions than non-
orphan drugs. These restrictions could be in the form of requiring additional diagnostic tests 
before the drugs can be prescribed, to ensure the patient positively has the condition 
justifying the expensive medicine, or additional clinical data, authorizations or approvals 




cases healthcare authorities asked pharmaceutical companies to voluntarily reduce prices to 
‘acceptable’ price levels.  
5.4.13.8 Challenges during the review of new HAE treatments 
A dilemma arises when physicians and patients are keen to get access to a new promising 
drug, but long-term data does not yet exist. Agboola (2019) reported that for example when 
reviewing Takhzyro®, the CTAF panel decided that the evidence at the time of the meeting 
was not yet sufficient to prove that the drug’s net health benefit is superior to on-demand 
therapy only, when used as indicated for the long term. This was justified by the fact that 
the trials, which lasted 4-26 weeks, were not sufficiently long to prove the treatment’s long-
term effectiveness and safety (ICER, 2018). The comparison of HAE drugs led to the 
following results for acute treatments. Reimbursement decisions for HAE treatments 
became difficult when modern treatments were introduced into the market. These modern 
treatments were the results of significant research and development, producing significantly 
improved results, but not having any meaningful comparator to demonstrate cost-
effectiveness. For example, fresh frozen plasma used to be the only treatment for acute 
attacks of HAE (it was still being used in countries where modern drugs were not yet 
available). As discussed in section 5.4.10, FFP had questionable efficacy, imposed risks, 
had to advantage of being low cost, but did not even have the explicit indication for the 
treatment of HAE attacks. The guidelines at the time recommended physicians prescribing 
licensed treatments rather than FFP and a comparison of cost-effectiveness with modern 
treatments was impossible. Additional challenges for HAE treatments occurred when dosing 
of one drug was weight-dependent (for example Berinert®), while the other one was not (for 
example Firazyr®). Sabharwal (2013) assessed that depending on the weight of the patient 
one drug could become cost-effective while the other did not and vice versa. While some 
computation suggested Berinert® to be more cost-effective, it did not take into account that 
in real life, once a vial had been opened, all medication that had not been administered had 
to be discarded, as it could not be kept in sterile conditions until the next attack. This wastage 
did not occur with weight-independent dosing of Firazyr®. Therefore, for the cost-
effectiveness comparison, the full cost of every opened vial needed to be factored in, and 
not just the amount infused. 
5.4.13.9 Additional challenges with prophylaxis HAE treatments 
For prophylaxis treatment, the situation was different, requiring the inclusion of more 
considerations. The cost-effectiveness of prophylactic treatments needed to be compared 
between themselves and with the costs of on-demand treatment that could be avoided by 
reducing acute attacks. Prophylactic treatments for HAE must be administered regularly 
resulting in substantial treatment costs. Attacks, hospitalizations and ER visits may be 
partially or even completely offset, but even combined, these were unlikely to outweigh the 
costs of treatment which can exceed several hundreds of thousands of dollars per year. ICER 
(2018) compared the three most prescribed prophylaxis drugs in the US (Cinryze®, 
Haegarda® and Takhzyro®) and benchmarked them against the commonly accepted 




would have cost USD 5.95 million per QALY, Haegarda® USD 0.33 million per QALY, 
and Takhzyro® USD 1.11 million per QALY. Clinical trials and current pricing provided 
the following comparison: 
 
 % reduction % attack USD per Source 
 # attacks free dose 
Cinryze®  -50.5% 18.2% $2,012 (Zuraw, 2010) 
Haegarda® -84.0% 40.0% $2,090 (Longhurst, 2017) 
Takhzyro® -86.9% 44.0% $16,520 (Banerji, 2017) 
 
Takhzyro®, a monoclonal antibody and the latest prophylaxis drug for HAE, had a label for 
an initial biweekly administration which resulted in more than USD 1 million per QALY. 
However, clinical data and the FDA label also indicated that once patients reach a steady 
state of prophylaxis, measured in having been six months attack free, they could move to 
every four-week dosing. Such a switch may have been considered for about 87% of patients 
and the halved consumption would make consumption of Takhzyro® more cost-effective 
than existing treatments (ICER, 2018). An ICER analysis confirmed that long-term 
prophylaxis with these modern drugs resulted in fewer acute attacks and improved QoL, yet 
all three were estimated to be well above the threshold, and therefore should not be 
prescribed or reimbursed.  
5.4.13.10 Impact of disease variability  
HAE is highly variable and if a patient had a more significant QoL reduction due to the 
number of attacks and the clinical outcome of the treatments was the same, then cost-
effectiveness may have been achieved. ICER (2018) also reported that decision-makers 
needed to be aware that even minor adjustments in the key assumptions (e.g., frequency of 
attacks) could have resulted in substantially different cost-effectiveness results. For 
example, when changing the base assumptions of the number of attacks per month from 3.52 
to 3.32, the cost-effectiveness of prophylactic treatment with Haegarda® would have 
increased from $50,000 per QALY to $500,000 per QALY. Another assumption that played 
an important role was dosing. Takhzyro® can be dosed every two weeks or every four weeks 
depending on the patient’s profile. Assuming 75% of eligible patients could switch to the 
less-frequent dosing would make the drug meet the cost-effectiveness thresholds. 
Concretely for these drugs, Agboola (2019) used the above cost-effectiveness threshold to 
determine that Haegarda® would have become cost-effective at a monthly baseline attack 
rate of 3.43, compared to Takhzyro® at 3.78, and Cinryze® at 5.85. From a payer 
perspective, this meant that only patients that had more than 3.43 attacks should have been 
prescribed modern prophylaxis with Haegarda® and accordingly for the other treatments. 
Zuraw (2019) reported that in real life and with the reported frequencies of attacks reported 
in section 5.4.4, for the majority of HAE patients, approved prophylactic medications would 
not be cost-effective. Agboola (2019) also reported that when a panel assessed the clinical 
benefits of the three drugs, it determined that all significantly reduced the number and 




current pricing, all three were judged to represent low or intermediate long-term value for 
money. In other words, the treatments would have needed to be priced substantially lower 
than the then-current net price to reach cost-effectiveness thresholds. ICER (2018) reported 
that for Cinryze® to achieve a QALY threshold cost of USD 150,000, a price discount of 
approximately 60% from the list price would have been necessary. The same analysis 
showed there was no difference in survival among the different prophylaxis treatments, since 
death had become a rare outcome with appropriate treatment and the correct use of on-
demand drugs. 
5.4.13.11 Patient perspective 
Patients are not only affected by their conditions causing a burden on life. Depending on the 
healthcare system the burden extends into a financial burden due for example to deductibles 
and co-payments. The meta-analysis on the payers’ perspective in section 5.4.13.5 and the 
review of the HAE treatments from a cost perspective in section 5.4.13.8 explained the 
possibility that patients may have been denied access to certain orphan drugs, if the payer 
decided not to reimburse them or if they have not yet been reviewed. In some cases, 
depending on the healthcare and reimbursement system, treatment might have been 
technically approved and reimbursed. However, patients needed to navigate their insurance 
systems to obtain coverage, which could cause delays. In some cases, insurers demanded 
evidence (such as the patients having been reportedly symptomatic or providing laboratory 
data) before funding the required treatment. To help bridge the time until the drug is given 
and funded, some pharmaceutical companies supported the patients with access programs 
which could include free of charge drugs (ICER, 2018). Despite such programs, Sanger-
Katz (2018) reported that more than a third of seriously ill patients had spent all or most of 
their savings due to their conditions, even with health insurance. The same research also 
suggested that over half of the patients had faced financial difficulties due to the 
compounding burden of medical bills and due to work interrupted by illness. Calculations 
estimated going to the hospital could mean an average income reduction of 20% that 
persisted for six years or more. Section 5.1.3 showed data in line with the concept that 
debilitating chronic conditions affect also family members and caregivers. Such indirect 
impact may result in those taking care of ill relatives also facing financial challenges. 
Sanger-Katz (2018) reported in this context from the US that, as a result of caring for an ill 
person, 23% of friends or family members ran into financial strain, and 15% had to quit or 





5.4.14 Quality of life 
Since treatments had become available during the last decade, QoL has substantially 
improved. Anderson (2019) reported that highly effective HAE therapies have influenced 
the guidelines to increasingly emphasize QoL as a key aspect of HAE management. 
Christiansen (2015) reported that despite the rapid and significant treatment advancements, 
a substantial burden of illness still remained. 
5.4.14.1 Measures of QoL 
Numerous studies analyzed in the sections from 5.4.1 to 5.4.5 have described the significant 
clinical burden that HAE patients carry, despite the considerable progress of treatment 
options. Banerji (2015) conducted a QoL analysis on HAE patients to prove that 
improvement in the care was still needed. The psychological burden was significant due to 
the immediate impact of attacks and the psychological impact of living with a chronic 
unpredictable disease. This burden could be deducted from the high prevalence of 
comorbidities such as anxiety and depression discussed in section 5.4.7, largely stemming 
from the constant fear of the next attack. It could be supposed that HAE patients have a 
lower QoL than the general population, and possibly so inversely proportional to the 
increasing severity and frequency of the attacks. Banerji (2015) reported from Europe that 
QoL worsened when patients were exposed to more than five attacks per year. Devercelli 
(2018) reported from a survey that 86% of patients perceived that more than three-quarters 
of their attacks were severe enough to negatively impact their QoL. These publications 
suggested that QoL scores were generally lower with patients with a higher number of 
attacks and with patients whose most recent attack was laryngeal. Lumry (2018) advanced 
a hypothesis from his data that QoL is not only a relevant measure in its primary purpose, 
quality of life, but should also be seen as the single most meaningful way to measure how 
well a prophylactic treatment for HAE worked.  
5.4.14.2 Differences and inconsistencies across QoL measures 
Agboola (2019) compared QoL measures across trials and reported that they were used 
infrequently and inconsistently, and none of the trials used a QoL measuring instrument 
specific to HAE. This could explain why Gomide (2013) could not measure any difference 
in relation to gender, age, education level, or disease severity when using the SF-36 
instrument. In sections 3.4.5 and 3.4.6 the thesis determined that to measure the QoL impact 
of the symptoms and the treatment of a disease, tailored instruments are required. 
Historically such instruments had not been in existence for HAE, therefore some scholars 
used other questionnaires to measure the impact of treatments, such as DLQI (a validated 
dermatology QOL questionnaire) or more general QOL assessment tools such as the SF-36 
(Bygum, 2009). In his work on HAE, Lumry (2019) utilized yet other instruments such as 
the HADS (Hospital Anxiety and Depression Scale), the WPAI (Work Productivity and 
Activity Impairment) or the TSQM (Treatment Satisfaction Questionnaire for Medication). 
Nordenfelt (2017) utilized a combination of different QoL instruments such as HR-QoL: 
EQ-5D-5L, RAND-36, AE-QoL to gain comprehensive information. This approach raised 




for the patients and the treating physicians. A next step in order to develop appropriate QoL 
measurement tools  took place when researchers leveraged surveys which had measured 
different aspects such as anxiety, depression, stress, and other concerns regarding the HAE 
attacks, the methods of administration, or the ability of patients to infuse or inject themselves 
the medication (Wang, 2015). They grouped the impacts by physical manifestations, ability 
to perform daily roles, emotions, social life, appearance and morbidity to better understand 
how HAE patients are affected in their QoL. Anderson (2019) conducted qualitative 
interviews to identify concepts that characterized the QoL of patients with HAE, and which 
were used to compare different treatments from the patient’s perspective.  
5.4.14.3 AE-QoL, a QoL measure specific for angioedema 
Weller (2016) described the development of a questionnaire specific to angioedema called 
AE-QoL (Weller, 2016). AE-QoL was developed to cover 17 items and to be self-
administered by HAE patients, with each item measured over a five-point response scale 
ranging from 1 (never) to 5 (very often). This questionnaire, when completed, provided an 
overall score plus four domain scores that were regarded as relevant: (A) Functioning, 
measuring the impairment of work, physical activity and social relations, (B) Fatigue and 
mood, measuring the difficulties in falling asleep, waking up during the night, feeling tired 
during the day, challenges in concentrating or feeling down; (C) Fear and shame from having 
swellings and the shame of visiting public places, measuring the embarrassment by the 
appearance during attacks and the fear of possible long-term negative drug effects, (D) 
Nutrition, measuring the limitations in the selection of food and beverages that can be 
consumed. Weller (2016) also reported the total AE-QoL score to be proportional with the 
disease activities and, while being sufficiently sensitive to changes within patients over time, 
making it a valuable tool to assess changes of QoL impairment over time or due to treatment.  
5.4.14.4 Burden during HAE attacks 
For this section, the thesis researched data on day-to-day life implication resulting from the 
suffering of HAE. The HAE patient organization HAEi (2015) reported that more than 80 
per cent of the patients who experience severe attacks reported dysfunctions and pain which 
impacted the time they would utilize for daily activities. Seven studies on cumulatively more 
than 1,500 patients measured that on average patients miss almost seven weeks of working- 
or school days per year due to HAE attacks, as illustrated in Table 5.3.56. 
 
# of sources 7 
Sources (Aygören-Pürsun, 2014), (Bernstein, 2013), (Jolles, 2014), 
(Lumry, 2010), (Petraroli, 2015), (Tourangeau, 2012) 
Total # of patients 1,529 
Weighted average 32.8 working or school days lost per year 
Range 7.1 – 128.5 




Included in the number of working and school days lost reported in Table 5.3.56 was at least 
half a day per attack necessary to travel to a medical facility for acute treatment. Lumry 
(2010) reported in his research over 457 patients that on average they missed 3.3 days per 
attack. When asked about their most recent HAE attack, 51% of all patients who were 
employed missed at least one day of work, 44% of students missed at least one day of school, 
and 59% of respondents reported that they did. 
 
# of sources 4 
Sources (Aygören-Pürsun, 2014), (Bernstein, 2013), (Nordenfelt, 
2014), (Ohsawa, 2015) 
Total # of patients 895 
Weighted average 38% of patients of HAE patients missing work or school 
days due to attacks in a year 
Range 29% – 56% 
Table 5.4.57 - Percentage of HAE patients missing working- and school days due to attacks 
Four studies over combined close to 900 patients reported that 38% of patients on average 
missed working- or school days due to their HAE attacks as reported in table 5.3.57. 
However, the picture appeared more differentiated: Bonner (2015) reported that some 
patients learned to cope with milder attacks in order not to let them affect their life too much. 
Caballero (2014) reported that the impact of HAE on daily activities did not vary 
significantly by which part of the body was affected. In section 5.4.10 data was analyzed 
highlighting that a number of attacks were left untreated. While they there less visible to the 
health‐care system (no drugs consumed, no health care services used), they can still be 
disabling and disrupt work, education and family life (Manson, 2013), as when patients 
suffer an attack, often they are unable to perform and are forced to take time off from their 
activities (Bygum, 2015). Longhurst reported that in ERs, patients with HAE attacks may 
not have been prioritized over competing emergencies (e.g. heart attacks, stroke or severe 
injury) which led to further delays and absenteeism.  
5.4.14.5 QoL impact of treatment 
Lumry (2014) measured QoL using the SF-36 instrument during a clinical trial with patients 
taking C1-inhibitors or placebo. Patients who took C1-inhibitors scored the best. Nordenfelt 
(2017) however relativized these results and reported that QoL was not significantly affected 
by prophylaxis. QoL was mapped against disease activity and increased disease activity was 
associated with a deterioration of the QoL, independent of which the patients were on 
prophylactic treatment or not. This more differentiated results suggested that it was not so 
much the treatment per se which reduced QoL, but rather the effect of reduced disease 
activity when taking the treatment. Kavalec (2013) compared the QALY increase of two 
C1-inhibitors, Ruconest® and Berinert® and reported for both virtually identical QALYs 
gains vs. placebo.  
On the other hand, treatments do not lead only to improvements. Current modern therapies 




infusions (the first oral medication is expected towards the end of 2020). Riedl (2016) 
reported in a study on a C1-inhibitor that the most common adverse events were injection 
site reactions (reported by 84% of patients), fatigue (9%) and headache (5%). 
All mentioned studies implicitly presumed or did not raise the question if patients could be 
treated differently. Jain (2018) reviewed dialogues between patients and doctors during the 
assessment phase in order to determine and decide the treatment. Communication gaps 
between physicians and patients when discussing the burden of the disease where identified, 
remained. As discussed in the context of the agency theory in section 3.6.7, they pose a 
hurdle to achieve the optimal clinical outcome and a better QoL. 
5.4.14.6 HAE Burden on health and productivity 
In section 5.4.1 the thesis analyzed the significant delay between onset of disease and 
diagnosis. This delay leads to high anxiety and uncertainty in addition to the unmet medical 
need of patients suffering under the attacks. During the period where patients have HAE 
attacks but no diagnosis, they don’t know what condition they have, and are likely getting 
the wrong treatment that either does not work or possibly creates an additional burden. Even 
after diagnosis and with correct treatment (described in sections 5.4.10 and 5.4.11) patients 
continued to experience attacks, maybe with lesser frequency and lower severity. Banerji 
(2017) reported that a substantial burden affecting the HAE patient persisted. In his work, 
Lumry (2010) had already confirmed that the QoL of HAE patients was significantly 
impacted by the episodic and chronic nature of the disease, their overall mental and physical 
health scores were significantly lower than for the normative populations. In his study, 
Bernstein (2013) concluded that patients living with HAE displayed significant decreases in 
physical and mental health, impaired work productivity, and a significantly greater amount 
of depression.  
5.4.14.7 HAE leading to lost opportunities and missed activities 
Along the same line, Bygum (2014) reported that the significant psychological impact of the 
HAE condition restricted the lives and the activities in more than half of the patient 
population. Gomide (2013) summarized, using the QoL questionnaire SF-36, that the most 
affected domains which impaired the life of the patients were related to vitality. The thesis 
identified only a few studies that quantified the amount of time lost by HAE patients. Zhi 
(2018) performed research on 159 HAE patients and determined that 96% lost, on average, 
21 days of social life per year due to their HAE condition. These patients could not 
participate in social activities due to intensive pain, fear of attacks, or to avoid the 
embarrassment resulting from the disfigurement in case of swellings of the face. Caballero 
(2014) quantified by type of HAE attack how many hours of daily activities are prevented. 
HAE attacks at the face, neck and abdomen impacted between two and four hours, attacks 
affecting the airways, genitals, or extremities could take between 4-12h, and if more than 
one site was affected, then the impact increased. The QoL factors that constrain the life of 
patients have been further analyzed and research has determined that 53% of patients 
develop a phobia of not having drugs available when they would get the next attack. 48% of 




the possibility of not being able to reach the next ER or hospital in time in the event of a 
laryngeal attack (Bygum, 2015). Patients may be well taken care of where they normally 
live. However, when traveling, they might encounter situations during an attack where a 
competent physician is not available, where they have to articulate to a foreign healthcare 
professional who is unfamiliar with the disease their condition and how it should be treated. 
Agostoni (2004) reported that such additional anxiety prevented HAE patients from 
traveling altogether. 
5.4.14.8 HAE impact of family life and future outlook 
One-third of the patients admitted having problems in the family due to anxiety, fear, 
feelings of guilt and psychological stress. The combination of fear and feelings of guilt led 
50% of the HAE patients to avoid marriage. 44% of patients avoided trips away from home 
and 47% reported problems in their social lives. Hirose (2017) reported HAE patients in 
Japan having a fear of genetic discrimination, highlights a broader challenge for all rare 
diseases. 
Psarros (2014) reported that HAE impacted children and adolescents, for example when 
20% of them selected sports and activities with a reduced risk of injury. The study also found 
that 30% were frequently absent from school, and that 22% felt marginalized because they 
could not participate in certain school activities.  
On the other hand, Lumry (2014) measured the MCS (Mental Component Score) when 
administering a QoL questionnaire, enabling the observation that a significant share of 
patients was not lacking impairment, had learned to cope, and have accepted the burden of 
having HAE as a regular part of their life. While coping was the only option before 
efficacious treatments existed, currently, a better outlook could be provided to patients living 
with HAE. Christiansen (2015) compared the negative psychological and emotional impact 
that HAE had on patients before and after having had access to prophylaxis treatment in the 
form of C1-inhibitors. The study reported that 53% of patients suffered before or without 
treatment, and 17% did so with HAE treatment. Bewtra (2012) had already reported earlier 
that having a treatment available made more than half the HAE patients feel better and gave 
more than 80% of patients a better outlook on the future, feeling more secure about the 
danger of life-threatening attacks. 
The most modern treatments recently launched, for example, Takhzyro® discussed in 
section 5.4.11.5, opened new opportunities and appeared to offer a possibility of a life with 
zero attacks for many patients. Zuraw (2019) stated that this could be the first time since the 






5.4.14.9 Burden on career and education 
In addition to the effects of the HAE attacks themselves discussed in the sections  5.4.1 to 
5.4.5, HAE patients are additionally exposed to comorbidities (see section 5.4.7) and 
intensive use of healthcare services (see 5.4.8). All of these take a direct toll on the time that 
patients can spend on work and education. HAE is a chronic, debilitating, disfiguring 
condition, and therefore can affect all aspects of a patient’s life. For example, when attacks 
affect the feet, HAE patients cannot wear shoes, when the hands are concerned, simple tasks 
such as typing on a computer can become impossible (Banerji, 2013). Bernstein (2013) 
reported that half the HAE patients missed 47 days of work on average per year. Such figures 
were significantly higher than migraine sufferers (7 days per year) or severe asthmatics (10 
days per year). Jolles (2014) reported a rage for absenteeism between zero to 43 days. The 
large variance might have depended on the cohort, the eligibility criteria, or the healthcare 
systems which display different processes and criteria for patients having access to certain 
types of treatment. With many patients experiencing HAE work and activity impairment, 
the impact was observed not only on immediate lost work, education and leisure. Education 
and long-term career perspectives were negatively impacted as well. Manson (2013) 
observed that multiple family members were also likely to be affected as HAE is hereditary, 
which further compounded the issue. Lumry (2010) conducted a survey in the US, reporting 
that 69% of HAE patients were excluded from certain jobs due to their illness, 48% reported 
that it had hindered their education, and 58% that it inhibited their career advancement. Even 
when HAE patients were attending their work or education duties, they were often less 
productive and unable to achieve the educational and career goals, compared to if they were 
healthy (Lumry, 2018). 
Three pieces of research on a combined 1,078 patients reported that on average 44% of them 
believed that they suffered from hindered education due to their condition, see Table 5.3.58. 
 
# of sources 3 
Sources (Aygören-Pürsun, 2014), (Bernstein, 2013), (Lumry, 
2010),  
Total # of patients 1,078 
Weighted average 44% of HAE patients suffered from hindered education 
Range 41% - 48% 
Table 5.4.58- Percentage of patients suffering from hindered education due to HAE 
Two of the studies over 621 patients reported that three patients out of five were not applying 
to certain positions and roles due to their conditions, suggesting reduced freedom in their 





# of sources 2 
Sources (Aygören-Pürsun, 2014), (Lumry, 2010),  
Total # of patients 621 
Weighted average 61% of HAE patients were not applying for a certain job 
due to the disease 
Range 40% - 69% 
Table 5.4.59 - Percentage of patients not applying to certain jobs due to HAE 
This limitation might have been a contributing factor to half the HAE patients reporting their 
careers were not advancing due to their condition, as illustrated in Table 5.3.60). 
 
# of sources 2 
Sources (Aygören-Pürsun, 2014), (Lumry, 2010) 
Total # of patients 621 
Weighted average 52% of patients 
Range 36% - 58% 
Table 5.4.60 - Percentage of patients prevented from advancing their career due to HAE 
Lane (2012) reported in his research examples of HAE patients being involuntarily 
discharged from the army, having had to leave a job because the working environment 
generated triggers (e.g. fumes in a refinery), having had to work for a family member as 
only they fully understand the disease and the impact of attacks, living in seclusion because 
minor events could trigger attacks, or needing to live and work within short distance of a 
hospital due to frequent attacks (Lane, 2012). In his research on 457 HAE patients, Lumry 
(2010) determined that 16% of them were unable to work full time. Two studies illustrated 
in Table 5.3.61 reported that 12% of HAE patients had lost their last position due to HAE, 
and one study by Aygören-Pürsun (2014) found that another 9% of HAE patients had to 
change their jobs due to the condition. 
 
# of sources 2 
Sources (Aygören-Pürsun, 2014), (Psarros, 2014) 
Total # of patients 280 
Weighted average 12% of HAE patients left or lost their last position due to 
HAE 
Range 10% - 14% 
Table 5.4.61 - Percentage of patients who left or lost their last position due to HAE 
Weller (2012) observed and reported that HAE patients with recurring attacks were being 
perceived to be unreliable, confirming it to be a possible contributing factor to the challenge 




between attack frequency and the likelihood of HAE patients not applying for certain jobs, 
leaving jobs, or switching jobs.  
5.4.14.10 Caregivers 
The role and the impact of caregivers on HAE patients was discussed in sections 5.4.9 and 
5.4.13.11 in the context of treatments and costs. Aygören-Pürsün (2014) reported that on 
average 52% of HAE patients receive assistance from a caregiver, with 69% of the patients 
with severe pain requiring such help. These results suggested that family and friends of HAE 
patients also need to be included when studying QoL implication of the disease. For 
example, when HAE patients have an attack with severe pain, their caregivers often miss 
time from work or activities to assist them. Longhurst (2016) reported that that absenteeism 
of caregivers was comparable to that of HAE patients.  
When the patients are children, the lives of the parents are particularly impacted. Nygren 
(2016) recorded that the parents of 73% of the children with HAE had taken parental leave 
to care for their children when they had attacks. In addition to the time that has to be given, 
for the caregivers there is also the emotional burden of needing to be ready at any time to 
take the patient for urgent treatment. Bygum (2015) recorded that being a caregiver implied 
also providing help in administering injections or infusions or taking on additional 
responsibilities and tasks at home when the HAE patient had attacks. Longhurst (2016) 
additionally noted that the help and assistance provided by caregivers takes time and was 
mostly unpaid, indicating that the full cost of the condition to society was underestimated.  
5.4.14.11 Patient associations 
Sections 5.4.14.4 to 5.4.14.10 covered the multiple ways in which HAE impacts on patients 
and their caregivers. The condition is pervasive through all aspects of life and can lead 
patients into isolation, possibly initiating vicious circles as stress, for example, is known to 
be a trigger. Agostoni (2004) reported that since HAE is a rare condition, patients were 
mostly scattered widely across the territory and the Internet had proven to be an effective 
tool to facilitate patients’ first contact with the patient association and establishing such 
links. Patient associations were found to play a prominent role for patients so that they could 
not only share their experience with treatments and how to cope in life, but also to provide 
a sense of belonging to a community. Castaldo (2004) as president of the global patient 
association HAEi published that these associations provide a sense of community, 
information, analysis, and guidance on key issues regarding HAE management, diagnosis, 





6 CHAPTER SIX - DISCUSSION OF RESULTS 
6.1 Stakeholders 
The survey with physicians described in section4.3, with results in section 5.1.1, confirmed 
the patients as the single most important stakeholder in the therapeutic decision-making 
process. However, the second most mentioned stakeholders in the survey were the payers. 
As physicians recognize, the payers play a critical role as they decide which drugs and 
treatment to reimburse (see section 3.5.5, 3.5.14), which is also in line with the theoretical 
framework (see section 2.3) and double agency theory (see section 3.6.4 with the decision-
making process described in section 3.6.5). The search on social media with the results 
presented in section 5.3 also substantiated that patients and physicians are the key 
stakeholders, surrounded by other influential stakeholders such as patient advocacy groups, 
payers (insurance companies), family members, caregivers, other healthcare professionals 
(e.g. nurses, pharmacists), pharmaceutical companies, regulatory bodies, and media, as 
suggested in section 4.2.1. Patients and their organization were the dominant source of posts 
confirming the roles within the application of agency theory extended to all stakeholders 
which are part of the healthcare system.  
The role of patient’s associations was discussed in section 5.4.14.11. They work as 
advocates and collectively have a stronger voice with payers, authorities and pharmaceutical 
companies. Patient associations lobby with governments and health authorities to increase 
awareness and recognize HAE as a serious disabling, potentially life-threatening and chronic 
condition where patients need to be diagnosed, need to get access to treatments and be 
treated in a timely manner. This is achieved through education in the form of expert groups, 
speaker engagements at conferences, and groundwork where individual patients help other 
patients. Patient associations also foster cooperation within the scientific community with 
the objective of advancing research and clinical trials, improving treatments and ultimately 






6.2.1 Profile of HAE condition 
HAE has been selected as the rare condition to be studied in depth to answer the RQs. It is 
a genetic disease, described in section 3.8 affecting about one in 40,000 people. It manifests 
through mostly unpredictable swellings of different frequency and severity, affecting 
different parts of the body and all these characteristics vary across patients and within the 
same patient over time. 
6.2.1.1 Abdominal and peripheral HAE attacks  
In section 5.4.2 the thesis aggregated different studies and the distribution of attacks was 
extracted based on self-reported diaries, surveys or medical claims. HAE attacks can be 
abdominal, laryngeal and peripheral/cutaneous.  
As illustrated in section 5.4.2.1, two-thirds of the reported patients suffered from abdominal 
attacks and they represent 47% of the total. Cicardi (2014) reported that they typically 
manifest as severe cramping pain and last typically 2–5 days. This type of attack is the most 
frequent, the most painful and the most likely to lead to misdiagnosis. Craig (2009) for 
example reported that recurrent abdominal attacks can be associated with biliary or 
pancreatic obstruction and lead to gallbladder disease or pancreatitis, leading to 
hospitalizations and unnecessary surgical procedures. 
Peripheral attacks are the second most frequent, representing 45% of all attacks and affecting 
82% of the HAE patient population, as reported in section 5.4.2.2. These swellings manifest 
in the patients’ extremities or on their face. They are disruptive because they may be 
functionally disabling, causing, for example, an inability to operate a keyboard or work with 
the hands, or making it impossible to wear shoes. Banerji (2013) reported that facial attacks 
can be disfiguring, resulting in social stigmatization, isolation, and depression as patients 
may elect to reduce or cancel social interactions, staying homebound owing to the change 
in overall appearance. 
6.2.1.2 Laryngeal attacks 
Laryngeal attacks have been studied in section 5.4.2.3 and are the most dangerous as well 
as main source for comorbidities such as anxiety and depression, described in section 5.4.7. 
Bork (2003) reported that each laryngeal attack is potentially life-threatening and its course 
unpredictable. These attacks carry a 30% risk of death due to asphyxiation if untreated, 
however, with treatment, death is rare. Episodes last, comparably as long as abdominal 
attacks, between two to five days, and are usually self-limited (ICER, 2018). For this reason, 
Longhurst (2010) reported, attacks affecting head and neck should always be treated because 
of the risk of rapid progression and asphyxiation, even if the symptoms are initially mild. 
Section 5.4.8.5 discussed the ER interventions called tracheotomy. The frequency of use of 
this last-resort intervention depends on the maturity of the healthcare system measured for 
example in terms of how many patients have access to prophylaxis medicine or have access 
and can administer acute treatment at home. Especially the latter has contributed to almost 




reported that in some severe cases the airway cannot be unobstructed with a tracheostomy 
as the laryngeal attacks extend deep into the thorax, requiring immediate ER intervention. 
Tachdjian (2017) analyzed insurance claim data and determined that about a quarter of 
treated patients with HAE had claims for asphyxiation. Although representing less than one 
attack out of 20, about a third of HAE patients have experienced at least a laryngeal attack 
in their lifetime. However, the frequency distribution is very wide. Bork (2003) reported in 
one study of 61 patients, the number of episodes ranged from one to 200 in the lifetime of 
the patients. The initial symptoms of a laryngeal attack can be a sensation of a lump in the 
throat, a feeling of tightness, voice changes such as hoarseness and roughness (Bork, 2001). 
An HAE patient feeling those symptoms should trigger rapid action. Usually, from the onset 
of symptoms, there is sufficient time to allow for appropriate emergency procedures, as 
reported by Longhurst (2012), as the symptoms might be mild and slowly progressive for 
several hours before a rapid progression leading to asphyxiation takes place. On the other 
hand, Bork (2003) reported fatalities occurring within 20 minutes of the first symptoms. 
These extreme cases, despite the relatively low frequency of laryngeal attacks and the low 
case fatality of each attack, could partially explain why the HAE disease presents itself with 
many patients suffering also from anxiety and depression. Longhurst (2010) reported a still 
significant lifetime mortality and ICER (2018) calculated an estimated monthly probability 
of death from a laryngeal attack to be 0.0022%. Bork (2012) estimated that undiagnosed 
patients have their lifespan shortened by 31 years on average due to the risk of death by 
asphyxiation. In the same study, Bork reported that despite the clear mortality data, 31% of 
patients with fatal laryngeal attacks did not receive any emergency life-saving care and that 
of the remainder, 40% received an emergency cricothyrotomy, and intubation was attempted 
for the rest. Most of this pain, risk of death and costs could have been avoided if on-demand 
treatment would have been given at the first signs of a laryngeal attack. In conclusion, any 
HAE patient can virtually expect a laryngeal attack to take place at any time and patients 
should be carefully educated to recognize the first symptoms of upper airway obstruction, 
having available and taking on-demand medicine as described in section 5.4.10. When 
children have been diagnosed before their first symptoms as part of the family screening, it 
is important to generate awareness of the possibility that the first HAE attack might be 
laryngeal and fatal. Farkas (2002) noted that the emphasis is of high priority as children have 
smaller airway diameters in comparison to adults, asphyxia may ensue more rapidly, and 





6.2.1.3 Distribution of HAE attacks by severity 
The severity of attacks depends on a combination of the location of the attack, duration of 
the attack and level of pain caused. In section 5.4.3 the thesis discussed the categorization 
of the severity into mild, moderate and severe, with about half the attacks being moderate, 
and a quarter each being mild or severe. In addition to the statistical distribution, Aabom 
(2017) for example reported that there seemed to be no correlation between the age at which 
the first HAE attack occurred, and the disease severity measured later in life. Bouillet (2011) 
reported that 87% of patients had already experienced at least one severe life-threatening 
HAE attack in their life. 
Section 5.1.3 attempted to show how especially severe HAE attacks could be detrimental to 
the patients’ ability to work and study, leading to absenteeism and impacting his or her social 
life. Xu (2013) reported how severe cases of HAE could also provoke opiate dependence. 
Beyond the clinical and QoL consequences of severe attacks, the treating physicians would 
attempt to mitigate the symptoms and the number of attacks suffered by the patients by 
prescribing prophylaxis medicine described in section 5.4.11. This type of treatment is 
linked to significantly higher costs. Additionally, patients suffering severe HAE attacks 
require more use of healthcare services, raising the HE questions discussed in section 5.4.13. 
Lastly, these patients may often be exposed to increased indirect costs which are not borne 
by the payers. 
6.2.1.4 Risk of fatality of HAE attacks 
Despite effective treatment having been available to HAE patients for more than a decade, 
a risk of fatality still persists, as described in section 5.4.8.6. Kim (2014) estimated that HAE 
caused about 50 deaths in the US each year, which was a reduction to a quarter from the 
early to late 2000s. Jolles (2014) reported 55 deaths in 33 families, ranging from one to three 
deaths per family. Ohsawa (2015) indicated that 12% of patients had experienced a death in 
the family due to an HAE attack. Zuraw (2008) reported that before the introduction of 
modern therapy about one-third of HAE patients used to die of asphyxiation. The reduction 
of the death rates could be explained also by higher awareness, faster and more accurate 
diagnosis, in addition to improved treatments. Aabom (2017) observed that death due to 
asphyxiation could occur at any age and has been reported in children as young as two weeks 
old and in patients as old as 78 years (Nzeako, 2002). The time between the onset of a 
laryngeal edema and asphyxiation suggests a mean of seven hours. However, there have 
been reported cases of up to 14 hours, and as short as 20 minutes, which was the time it took 
a 9 year-old-boy to lose his life from his first attack (Bork, 2000). Undiagnosed patients are 
the reason for the majority of deaths due to HAE attacks, as the treating physicians might 
not have the awareness to recognize the condition, provide the right therapy and possibly 
not have the right medication on hand in the first place. Longhurst (2007) reported that a 
share of HAE-induced deaths could be avoided, reinforcing the recommendations on early 
diagnosis, self-administration of acute treatment (5.4.10) and the proactive preparation of 
ER visits. Patients and their caregivers should closely monitor laryngeal attacks for a change 




closure and possibly asphyxiation, requiring urgent preparations for intubation and possible 
tracheotomy (Zuraw, 2008). 
6.2.1.5 Frequency of attacks and acceptability threshold 
In section 5.4.4 the thesis consolidated available data from multiple research studies which 
have quantified the frequency of HAE attacks that patients had to endure. The overall 
average is 19 attacks per year as illustrated in table 5.3.41. Subsequent analysis showed the 
high variability across patients.  
The survey with physicians presented in section 5.1.2.3 reported that physicians perceived 
only 21% of the patients having the most selected frequency of attacks per year. The 
dispersion of the perceptions of the frequency of the attacks was very wide, including that 
42% of patients were thought to suffer fewer than one attack every three months.  
The survey also asked the treating physicians what number of HAE attacks would be 
considered an “acceptable stable condition”. Section 5.1.2.10 reported that the majority of 
physicians considered fewer than three attacks per year to be acceptable. This figure is much 
lower than the average number of 19 attacks per year derived from the meta-analysis and 
suggests that many more patients need to be treated with effective prophylaxis medicine, in 
order to attain an “acceptable state”. A caveat for the answers to these questions is that there 
was no consensus definition of “acceptable” or “in control”. While for one patient it is 
acceptable to go through a few extremity attacks over the year, for another even a single 
attack is too much. With the advent of new treatments with the prospect of ensuring zero 
attacks (as described in section 5.4.11.5), the definition of “acceptable stable condition” 
could be likely to shift further to fewer attacks per year. 
6.2.1.6 Variability of HAE, its drivers and knowledge limitations 
All combined, this data confirms the high variability and unpredictability of HAE attacks 
which could also be linked to the high prevalence of depression and anxiety which are 
mentioned as co-morbidities and potentially as triggers for attacks. 
A limitation of most studies is that they did not specify if the patients were under treatment 
and which, if any, drugs they were taking. From the way the studies were presented, it was 
unclear how much this plays a role. On the one hand research such as that done by Zuraw 
(2010) showed that the use of prophylaxis could reduce the attack frequency by half (for 
example from 12.7 attacks to 6.3 attacks over a 12-week period. On the other hand, other 
studies such as Winnewisser (1997) showed that for certain patients and therapies (e.g. 






6.2.1.7 Dependency of attack frequency or factors, and impact on comorbidities 
Additionally, most studies reported only the aggregated attack frequency for both genders. 
Steiner (2016) reported that women were more affected by the intensity and frequency of 
HAE attacks than men. This might be explained by the fact that women have more attack 
triggers as described in section 5.4.6. Another limitation on the data collected might have 
been that studies reported the attack frequencies aggregated across all the age segments. 
Bygum (2014) noted that population selection could introduce a bias. Lastly, the studies 
identified measuring the impact of treatment on attacks did not segment the patients by how 
many attacks they had before treatment and/or did not randomly allocate treatment. Such 
omissions could have allowed the patients suffering more severely to have a different 
treatment, causing the end results to be less comparable.  
The data collected by this thesis and presented in section 5.1.2.4 could be seamlessly 
reconciled with the outcomes of clinical studies. Given that for the survey performed for this 
thesis, the term “treated” has been used in broad way, characterizing a blend of all types of 
treatments. These include modern prophylaxis which reduces the number of attacks (see 
section 5.4.11), a modern on-demand treatment which mitigates the impact of an attack but 
does not directly reduce the attack frequency in a patient (see section 5.4.10), and other 
legacy treatments with questionable or no efficacy data available. An improvement when 
comparing untreated patients with treated patients was visible in the higher attack 
frequencies in figure 5.1.2.4.2. A possible explanation could be that patients suffering a 
higher attack frequency were considered to be more severe (see section 5.4.3) and as a 
consequence were more likely to be prescribed the significantly more expensive prophylaxis 
treatment with the consequent positive clinical result. Possibly reduction of attack 
frequencies occurred in the more severe patients as a result of therapeutic treatment, with 
the results suggesting that lower attack frequencies are similar, while higher attack 
frequencies could be reduced. With all the restrictions and limitations, responses to the two 
questions on attack frequency in the survey suggested that attack frequencies are widespread 
across all patient segments both if treated or not.  
All combined, the data collected as part of this thesis confirms the high variability and 
unpredictability of HAE attacks. Such a reality combined with the findings discussed in 
section 5.4.7, could help explain the high prevalence of depression and anxiety which are 
mentioned as co-morbidities, and potentially as triggers, for attacks. 
6.2.1.8 Duration of HAE attacks 
The meta-analysis described in section 5.4.5 quantified that on average HAE attacks last 
about two and a half days. The duration can be significantly reduced by one day or more if 
HAE medication is taken, or reduced to zero (no attack) in some cases where prophylactic 
therapy is taken as described in section 5.4.11. As highlighted in section 5.4.14.10 not only 
the HAE patients, but also their caregivers are impacted. In his study, Henao (2016) provided 
a more differentiated view, reporting that HAE attacks develop gradually, worsen over the 
first 12–24 hours and slowly resolve within 2–5 days. The on-demand treatment described 





The duration of attacks is used to measure the efficacy of drugs or when drugs should be 
taken. Studies such as for example Zanichelli (2015) have reported that the time from onset 
of attack to treatment administration had a significant impact on the total attack duration. If 
treatment was administered within an hour from the onset of the HAE attack, then its 
duration could be reduced to about six hours. Attacks treated within two hours were 
significantly shorter compared with those treated after four hours which is a strong argument 
in favor of home administration of the drugs where possible. Treating attacks later and 
allowing them to develop for more than an hour resulted in reduced response and delayed 
resolution. For this reason, self-administrators are more likely to treat, and therefore suffer, 
shorter attacks than those treated by a healthcare professional, which could make the 
difference between missing a day of work/school or not.  
6.2.1.9 HAE attack triggers  
Section 5.4.6 has collected data on possible situations, behaviors or other factors that can 
trigger HAE attacks. As reported in section 5.4.4, HAE attacks are considered mainly 
unpredictable which is a considerable driver for comorbidities such as anxiety and 
depression. Exposure to certain temperatures, trauma, activities, lack of activities, 
chemicals, food, emotions, procedures, menstruation, infections, medications and stress 
have been mentioned, yet none consistently and unequivocally provoke attacks every time. 
HAE can also occur spontaneously without any clear triggers, as reported by Kargarsharif 
(2015).  
Given the risk of provoking life-threatening attacks and pain, ethical concerns prevent a 
systematic study by provoking attacks with different possible triggers. Retrospective studies 
and real-world evidence are the sources to better understand triggers. With greater clarity on 
triggering factors, patients can be counseled towards suitable modifications of their lifestyle 
in order to avoid triggers, attacks and therefore potentially unnecessary consequences such 
as surgery or worse. For example, if trauma is identified as a likely trigger, advice could be 
given to children suffering from HAE not to participate in certain types of sport. Some 
triggers on the other side may be unavoidable in life, such as emotional stress, surgery, 
hormonal changes, or certain drug treatments. In such cases prophylaxis treatment, if 
accessible, might help to alleviate the burden as described in section 5.4.11. Despite well-
documented experience with a number of trigger factors, about half the patients are still not 
able to trace back their attacks to specific triggers, as described in section 5.4.6.2. Banerji 






6.2.1.10 Mechanical trauma as a trigger for HAE attacks 
The research analyzed in section 5.4.6.1 suggests that mechanical trauma is one of the most 
common precipitating factors. Trauma in the form of pressure (rather than sharp trauma) can 
already cause an attack. Patients who stand in one spot for a long time may be exposed to 
foot swelling, or patients who use a tool or mow the lawn may precipitate an attack in their 
hands as reported by Frank (2018). To reduce the risk of HAE attacks, patients and their 
physicians or caregivers could decide on restrictions (for example refraining children and 
adolescents from participating in certain activities). Such choices might have to be well 
considered as on the one hand they reduce the probability of HAE attacks with all of their 
negative consequences, but on the other hand, they reduce the freedom of patients, their 
execution of activities, their participation in social life, fostering potential social isolation 
and stigma. 
6.2.1.11 Stress as a trigger for HAE attacks 
Section 5.4.6.3 reported that stress had been mentioned as a trigger factor across several 
studies. Nygren (2016) even reported stress as the prominent trigger factor for abdominal 
attacks. Another scholar identified the possibility of a negative self-reinforcing cycle where 
the condition causes stress, which is a risk factor for attacks and so forth (Fouche, 2014). 
Stress being recognized as a risk factor means that attacks are more likely to occur during 
intensive moments at work or during exams. A possible implication might be that patients 
and their families might, as a result, face employment and educational disadvantages. 
Avoidance of stress is not always possible. However, as Savarese (2018) reported, helping 
patients to improve their ability to recognize when such situations arise and how to deal with 
them might be beneficial to achieve attack reduction. 
6.2.1.12 Dental procedures as a trigger for HAE attacks 
Of the possible triggers of HAE attacks, dental procedures as described in section 5.4.6.8, 
needs special mention, as they have been repeatedly mentioned in the context of the feared 
and potentially fatal laryngeal attacks. This type of trigger has also been studied in terms of 
behavioral changes by the patients. Singh (2019) reported that HAE patients had less 
frequent routine dentist visits and were more likely to use anti-bacterial toothpaste. The 
findings suggested that HAE patients were less inclined to seek dentists for routine dental 
care out of concern about triggering an attack. HAE patients undergoing surgical or dental 
procedures have also the option of taking short-term prophylaxis (STP) medication (e.g. C1-
inhibitor described in section5.4.11.2) one to two hours prior. Valerieva (2019) reported that 
97% of HAE patients who administered a C1-inhibitor for STP before undergoing dental 
procedures such as dental extractions, abscess draining, root canal or dental impaction, 






Next to triggers, research has also been conducted to identify symptoms or signs that appear 
before the attacks, called prodromal symptoms. Examples such as itching or tingling 
sensations, sore joints, nausea, feeling tired, red rings or spots on the skin have been reported 
as warning signs (Bonner, 2015). A recent survey conducted in Canada reported that the 
majority of HAE patients are knowledgeable in identifying their triggers and managing their 
attacks (Howlett, 2019). However, the link between prodromes and attacks might be heavily 
reliant on patients’ recall, thus possibly biased. As a result, initiating on-demand therapy 
following prodrome might lead to over-treatment, but the benefits of having avoided the 
attacks and improved QoL might still outweigh risks and costs. 
6.2.1.14 Comorbidities of HAE 
Section 5.4.7.1 reported that a third of HAE patients additionally suffer from depression, 
which adds not only to the burden of disease, but to also to the costs, as the treatment of this 
condition might require attention by specialists from many therapeutic areas and additional 
medication. The survey conducted for this thesis reported in section 5.1.2.11 that depression 
seems to have been observed by only 8% of treating physicians. The most frequently 
appearing comorbidity (43%) appearing in HAE patients is anxiety, as quantified in section 
5.4.7.2. The survey reported that anxiety was observed by the participating physicians to 
have occurred in about 22% of the patients. Based on the literature, one would expect a 
much larger share of physicians observing these co-morbidities, especially as most 
physicians see more than just a few patients. The discrepancy could be explained by a 
communication gap between physicians and patients (described in section 3.6.7) thus not 
enabling the former to identify the conditions. When the co-morbidities were observed, the 
participating physicians referred the patients to other specialists - in 75% of the cases with 
depression and in 46% of the cases with anxiety, indicating that additional specialized 
medical help was warranted. 
6.2.1.15 Anxiety and depression 
Undiagnosed and untreated patients show additional risks of depression and anxiety, as they 
don’t know what is happening to them when they have an attack, and their physicians cannot 
help. With the first diagnosis, there might come relief from learning about what has been 
causing the swelling attacks, followed by fear of loss of independence and worry about the 
future. Savarese reported that the unpredictability of the HAE attacks can cause more 
distress than the symptoms and the pain of the attacks themselves. The unpredictability of 
the disease causes patients to feel that their career choices are limited, especially as they 
already experienced setbacks such as being able to work only part-time, being unable to 
perform certain tasks, or being unable to keep up with work due to frequently missed days 
as discussed in sections 5.4.14. Outside of work, uncertainty about the next attack could 
further complicate everyday life and make the planning of any activity more difficult, 
impacting significantly on QoL and the social functioning of the patients. Fear of dying may 
combine with a fear of lifetime dependence on the family, which can cause self-loathing and 




to suffer intolerable pain during an attack or about transmitting HAE to their children. 
Bygum (2015) reported that anxiety about having children led some to choose not to have 
children or to have fewer than desired, which might have caused further emotional distress 
and possibly contributed to marital problems. Agostoni (2004) recorded in his work that 
patients developed ongoing anxiety concerning access to treatment when they have an 
attack, which caused some to be reluctant to travel or not to travel at all, or to refrain from 
pursuing certain hobbies. Huang (2014) reported patients who avoided activities and social 
life altogether due to fear of sudden attacks causing severe psychological distress. Zanichelli 
(2015) concluded that anxiety is potentially triggering more attacks and Craig (2009) 
reported that this comorbidity is therefore both a result and a trigger of attacks, requiring the 
physician to help the patients manage it. In addition to the strict management of HAE and 
its attacks, a more holistic view might include psychiatric care. Such an approach could 
positively impact patients both in the short-term in daily life and in the long term, possibly 
allowing for higher education and better career prospects. Besides the clinical and QoL 
impact, the overall results could also be financially positive through higher and more 
sustainable incomes.  
6.2.1.16 Other comorbidities 
The survey with treating physicians conducted for this thesis found other comorbidities have 
been observed as described in section 5.1.2.11, consistent with the literature in section 5.4.7. 
Forty per cent of physicians treated the observed additional autoimmune disorders 
themselves, in line with the fact that the vast majority of physicians treating HAE are 
immunologists and allergists. For the pain indication, the share is 46% suggesting that this 
was standard practice across specialties. The above-mentioned discrepancy between the co-
morbidities observed by the participants versus what is reported in the literature appears to 
be a common theme. The literature reports weight gains affected more than 70% of patients, 
suggesting that the majority of, if not all, physicians should be cognizant of this. The survey, 
however, indicated that only 14% of the participating physicians were aware of this 
comorbidity. A possible explanation could be differing criteria to define weight gain and 
obesity. 
6.2.1.17 Use of healthcare services and hospitalizations 
Zilberberg (2011) reported for the US that hospital costs are responsible for approximately 
one-third of the health care expenditures. An understanding of their drivers in the context of 
rare diseases and the understanding of how to optimize and contain them becomes an 
important element of this thesis. Patients living with HAE have swelling attacks that can be 
disfiguring, painful and even life-threatening. In some occasions and especially if they have 
no drugs for self-administration, they may seek help in hospitals, as analyzed in section 
5.4.8.1. The range of the number of hospital visits required by HAE patients is relatively 
high and could be explained by the fact that the studies did not factor is different parameters 
such as age, time since diagnosis, changes in the availability of self-therapy and variability 
of the condition during the lifespan of individual patients. One of these factors has been 




were taught to self-administer HAE treatment were able to reduce the mean number of 
hospitalizations from 16.8 to 2.1 (Petraroli, 2015). Hakl (2015) additionally reported that 
effective HAE treatment could reduce the share of attacks requiring hospitalization from 
2.85% to 0.93%. Ohsawa (2015) reported that around one-fifth of patients had to be admitted 
to the hospital for more than a day per year. While still a significant number, it appears to 
be an improvement compared to the time before modern therapies have been made available. 
Winnewisser (1997) had reported that three-quarter of patients suffered severe attacks and 
half of them sought hospital care when that happened.  
6.2.1.18 Cost impact of hospital stays 
Besides the disruption resulting from HAE attacks that require hospital stays, there are 
additional costs involved. Zilberberg (2010) reported with data from US hospitals that stays 
caused by HAE cost around USD 2,000 per day. A similar study conducted in Europe 
(Helbert, 2013), reported the mean length of stay for an HAE event to be 2.8 days and an 
average yearly cost per patient of approximately USD 3,500. While different costs of 
hospitalization persist between healthcare systems, the total figures are significant and there 
are opportunities for improvements. Martinez-Saguer (2012), for example, reported a 
reduction of the mean annual number of hospital days from 15.9 to 0 when HAE switched 
from an androgen to a C1-inhibitor therapy. The latter is an important consideration when 
considering the impact of long term HAE prophylaxis treatments. 
6.2.1.19 Visits to physicians and Centers of Excellence 
In some cases, patients suffering attacks see doctors instead of hospitals, as quantified in 
section 5.4.8.2. Undiagnosed HAE patients sought on average 11 doctor visits and diagnosed 
ones see a doctor on average 4.6 times per year. This figure can vary significantly across 
healthcare systems. For example, anecdotal evidence indicates a frequent use of 
automatically renewing prescriptions for chronic diseases in the Netherlands, allowing 
patients in control to see their physician only once a year, while in other systems (such as 
China) prescriptions can be written for maximally one month or one acute treatment at the 
time, forcing a patient to see his or her physician 12 or more times per year. Such differences 
have subsequent repercussions on the respective healthcare costs and the burden of disease. 
Riedl (2015) reported that 97% of physicians treating HAE are allergists and immunologists, 
with the former being involved mostly because HAE symptoms present as allergic reactions. 
While this situation could change depending on the healthcare system, the insurance 
coverage or the culture, it has to be noted that patients of rare diseases face additional 
challenges which explain the relatively high number of visits. For example, Bonner reported 
of patients seeking treatment for HAE attacks but having been given inappropriate treatment 
because doctors were unfamiliar with the condition. In some cases, unnecessary surgery was 
performed or attempted to be performed, for example, to treat abdominal attacks, which 
ultimately exacerbated the attacks. Section 5.4.1 discussed misdiagnosis and unnecessary 
procedures, confirming how an improved awareness and education of the rare disease 
condition not only would improve clinical outcomes and QoL but might also decrease health 




The rarity of the conditions leads to a high concentration of HAE patients around relatively 
few physicians, mostly specialists. Riedl (2015) studied this phenomenon and reported that 
for example in the US 70.4% of physicians see less than five HAE patients per year, while 
another 19.3% see between six and ten patients per year. Such concentrations reinforce the 
establishment of centers of excellence like in Germany, where hundreds of patients are 
treated by highly trained and specialized physicians. 
6.2.1.20 Visits to Emergency Rooms 
When HAE patients are suffering potentially life-threatening laryngeal attacks or the pain 
becomes unbearable, they might visit Emergency Rooms (ER). In section 5.4.8.3 the thesis 
found that 10% of HAE patients had already had the need to do so. Craig (2009) reported in 
the US 15,000 to 30,000 ER visits annually associated with HAE attacks. While the 
condition is rare, the number of visits to ERs, the number of hospital stays and the costs are 
relatively high (Zilberberg, 2011). It would be expected that patients undergoing a 
prophylaxis treatment would visit ERs less frequently. However, grouping the data by 
undiagnosed and diagnosed (and more likely treated) patients, Perego (2017) and others 
suggested the difference to be merely marginal. Javaud (2015) attempted to explain the 
result through different factors such as the patients running out of acute drugs. Manson 
(2013) noted that despite prophylaxis treatment, HAE patients could still suffer so-called 
breakthrough attacks requiring urgent ER care. Although the use of medications might 
prevent emergencies and hospitalizations, laryngeal (potentially fatal) and complex attacks 
may still require emergency care and visits to the ER. As discussed in sections 5.4.2.3 and 
6.2.1.1, the evolution of laryngeal attacks can be especially unpredictable and can lead to 
death. Cicardi (2012) recommended, based on clinical experience, that if the symptoms 
persisted despite the initial treatment, the patients should immediately report to the hospital 
in such cases.  
A discussion on ER treatments of HAE patients requiring urgent help needs to include the 
fact medical staff may be unfamiliar with their rare condition. Manson (2013) reported this 
unfamiliarity with the condition to have led to long waiting times. HAE (and other rare 
conditions) require unique treatments. Banerji (2015) advised treating physicians and 
patients to proactively communicate with local hospitals and ERs to share their medical 
record and discuss action plans in anticipation of an urgent situation that is likely to happen. 
Such preparation would both improve the patient’s control over the condition, as well as 
ensure that a robust mechanism for emergency treatment is in place to provide appropriate 
and timely treatment while eliminating or minimizing side effects. For a patient to have to 
visit the ER is not ideal not only for the burden and the costs, but also because of the time 
between attack onset to ED arrival and treatment. Javaud (2015) reported that the median 
time between attack onset and arrival to the ER was 5.6 hours. This compared unfavorably 






6.2.2.1 First steps and initial challenges to achieve an HAE diagnosis 
The studies discussed in section 5.4.1.1 spanned over 15 years and over 2,900 patients, found 
that HAE manifested itself for the first time through an attack. The large data range for this 
variable could be explained by the fundamental challenge of rare diseases. Sample 
populations for any type of study are rarely representative and the cohorts of study subjects 
are not always comparable. This and several of the other variables were determined based 
on the memory of the subject, trying to remember events that took place many years, or even 
decades, earlier. Recollection bias and possibly different interpretations of “onset” (first real 
attack vs. symptoms) added further noise to the data. Despite the limitations, the weighted 
average of age of onset in the early teens was not conflicting with the assessments of most 
authors identified and used as a reference for the thesis. While HAE was already described 
by Osler in 1888, its diagnosis continued to be challenging as well as its main appearance.  
6.2.2.2 Lack of HAE disease awareness 
One of the challenges of rare conditions such as HAE is the lack of awareness of the 
condition and its treatment within the general population and within the medical community. 
This has been researched (see discussion in section 3.7.7) and shared through real-life 
examples, for example when patients share their experiences on social media platforms as 
described in section 5.3.1.2. The search on Twitter postings discussed in section 5.3.2.1 
Twitter reported that 51% of the postings made by and into HAE accounts were invitations 
to HAE events and activities. As noted for Facebook and when discussed with the patient 
organizations (for example see section 5.3.1.1) these events served to both generate disease 
awareness (a major challenge discussed in sections 3.7.7 and 5.4.1) and to foster a sense of 
community which is particularly important for patients suffering from rare diseases, who are 
often isolated and sometimes misunderstood in their suffering. These events contributed to 
improving their QoL while also generating attention in the media which influenced the 
medical and the payer community, thus enhancing and expanding funding and treatments 
for better clinical and RWE outcomes. The consequences of the lack of awareness of a 
condition could be delayed diagnosis or misdiagnosis (described in section 5.4.1) and in 





6.2.2.3 Patients contributing to spreading disease awareness 
The research on social media identified and described in section 5.3.1.3 found that numerous 
patients, directly or through the patients’ association, attempted to improve awareness of the 
condition. This is achieved by means of publications and activities. For example, the thesis 
found that the most frequent postings on Facebook were by patients and social media users 
inviting the readers to attend HAE events and activities as described in Section 5.3.1.1. 
Section 5.3.1.4, described the posts inviting the readers to HAE education events, which 
could be an example of patients and other stakeholders aiming to overcome hurdles specific 
to rare conditions and to close information asymmetries (described in section 3.6.7) which 
are the basis of the challenges described in the double agency theory (see 3.6.4). Section 
5.3.1.5 described postings offering information about HAE treatments to prepare the patients 
for discussions with their physicians, covering specific drugs, treatment regimens and 
diagnostic tools. Lack of knowledge on diagnostic tools is a characteristic of some rare 
diseases as they are difficult to diagnose with doctors sometimes not knowing or not having 
access to the latest tests (see sections  3.7.7 and 3.7.11). In some cases, patients advised each 
other on which medications to switch to in case of a specific disease profile (see high 
variability of the symptoms across patients and within the same patients over time 5.4.2, 
5.4.3, 5.4.5, 5.4.6 and 5.4.7).  
6.2.2.4 Need for funding 
Such activities require funding, and the research on social media also measured (for example 
on Facebook), that about 15% of the postings had as objective to raise funds, mainly in the 
form of donations. This could be constructed as another instance where the agency theory 
underlying this thesis (see section 3.6.4) or the healthcare systems in our society (described 
in section  3.5.5) are not entirely efficient or sufficient. Due to the funding or drug access 
constraints and tradeoffs discussed in section 3.5.6, patients are forced to take a higher share 
of responsibility to improve outcomes. On Twitter, as reported in section 5.3.2.7 only about 
3% of postings aimed to raise funds and only generic invitations to donate, shared with the 
whole platform community, were visible. It was therefore not possible to assess the impact, 
for example in relation to personal invitations being sent to individual members of the 
organization, or to pharmaceutical companies active in the specific field. 
6.2.2.5 Disease education 
On Twitter, the research on social media found that about 9% of posts were about disease 
education. Twitter is a platform for the general public and most of the content is 
communicated in a language suitable for the layman. However, rare diseases differ from 
most primary care diseases in that the general level of knowledge is much smaller, less 
widespread, and less established. Given the highly debilitating nature of the condition, its 
potentially lethal consequence, and the fact that it cannot be cured, only mitigated by 
treatments. Possibly for these reasons, patients appeared quite committed to learning about 
the most recent scientific advances, in the hope to gain early access to new medicines, either 




educational posts linked directly to scientific literature and presentations given at scientific 
events. These posts were made by both patient organizations and by individual users. 
6.2.2.6 Additional burdens due to clinical manifestations of HAE 
Kim (2014) reported that the swellings that HAE patients have, do initially not point toward 
a specific etiology. HAE is diagnosed based on the physician’s assessment of a patient’s 
signs and symptoms, family history and results of laboratory testing. However, in many 
cases, HAE could easily be confused with angioedema (AE), for which prevention and 
treatment are different (Zilberberg, 2010). The clinical presentations can range from an 
occasional skin edema to one or more attacks of swelling every month, from attacks with 
debilitating abdominal pain, to whole extremity swellings, and to potentially fatal laryngeal 
edemas that obstruct the airways (Krassilnikova, 2008). HAE could impair the patients’ 
ability to perform their daily activities increasingly with the level of severity of the attacks 
as described in sections 5.4.3 and 5.4.14.4. Such experiences cause significant psychological 
burden such as anxiety or depression and impairment that continues also between swelling 
episodes as covered in the sections on comorbidities 5.4.7 and 6.2.1.14. During attacks, 
patients are often absent from their jobs or education which could result in lower 
productivity and missed opportunities for advancement. Pagnier (2015) reported that with 
pediatric patients’ diagnosis of HAE is made more challenging as numerous differential 
diagnoses need to be considered. Kavalec (2013) reported that many people suffering under 
HAE had such infrequent attacks and of such moderate strength, that the symptoms were 
not recognized by physicians, especially when they were not aware of the disease of if they 
had never seen HAE patients before. The theoretical framework utilized for this thesis, 
agency theory, discussed in section 3.6.7, discussed the risk of communication gaps between 
physicians and patients. Consistent with theory, Jain (2018) reported the misalignment on 
symptom assessment and difficult communications and interactions between HAE patients 





6.2.2.7 Time from onset of disease to diagnosis 
The World Allergy Organization (WAO) issued guidelines for the diagnosis of HAE, which 
included the identification of recurrent episodes of angioedema without urticaria, recurrent 
episodes of abdominal pain and vomiting, a family history, and the performance of 
laboratory tests to measure serum C4, C1-inhibitor protein and functional C1-inhibitor to 
differentiate HAE from other types of angioedema, reported by Maurer (2018). Despite 
well-documented descriptions of different symptoms, and existing procedures for testing 
and issued guidelines, the time between the onset of symptoms and the diagnosis of the HAE 
condition is significant and can span several decades (Bygum, 2014). Data collected for a 
population close to 4,300 patients and 33 research studies discussed in section 5.4.1.2, 
indicates an average time to diagnosis of over 23 years. The survey with HAE physicians 
conducted as part of this thesis and described in section 5.1.2.2, concluded that about a third 
of physicians estimated that less than 10% of patients had been diagnosed with HAE. This 
result falls in line with the meta-analysis outcome that the median age of onset of the 
condition is at about 13.3 years, however, the median age of diagnosis is at 23.4 years (see 
Section 5.4.1).  
6.2.2.8 Differences across healthcare systems 
Factoring in that most of the studies have been performed in Europe and North America, the 
data is skewed towards earlier and more widespread diagnosis rates. The range of the 
diagnostic delay was significant as well. Zanichelli (2013) reported that Germany and Italy 
showed ranges of diagnostic delay of two years and fifteen years respectively. The survey 
noted that more advanced healthcare systems in Europe and North America had a higher 
likelihood for patients born there to be diagnosed. Possible explanations could be the 
differences in maturity of the healthcare systems, their ability to identify and diagnose rare 
diseases, the proximity of patients to state of the art clinical facilities and labs, patient 
demographics, differences in HAE awareness among health care professionals, and patient 
selection bias. While the substantial burden of the condition is acknowledged in most 
countries, recognition of HAE as a burdensome condition may still be lower in somewhere 
other much more prevalent and life-threatening conditions are still not properly managed. 
Kargarsharif (2015) raised the hypothesis that children may benefit from shorter diagnostic 
delays when whole families are tested for the condition, or when the clinical manifestations 
of HAE are better known among clinicians. Jolles (2014) suggested that in some cases 
children with HAE can even be identified and diagnosed before their first attack strikes. On 
the other hand, Jolles (2011) reported that 25% of patients without a family history or with 






6.2.2.9 Role of family history 
HAE is a hereditary condition that is mostly transmitted across generations. According to 
scholars including Andrejevic (2015), Bonner (2015) and Lei (2011) reported that 77%, 33% 
and 100% of their observed patients had a family history of HAE. Riedl (2025) reported that 
a third of the enrolled relatives of HAE patients in his research had lab results indicative of 
HAE, reinforcing the importance of testing family members. Other research by Bernstein 
(2013) indicated that HAE patients had an average of two immediate and two extended 
family members also diagnosed with HAE. The same scholar reported that about half (48%) 
of their immediate family members and a quarter (26%) of extended family members had 
never been tested before. Despite the real risk and the guideline that early diagnosis and 
treatment are highly recommended, the data suggests that many family members of 
diagnosed HAE patients often do not seek evaluation diagnosis or treatment. Further 
communication of the guidelines and potentially systematic screening of family members 
could possibly alleviate delays in and incorrect diagnoses (Lunn, 2010). Once family 
members have been identified and diagnosed, the follow-up should be made with all family 
members including caregivers to include treatment, methods of emergency help, advice on 
the most suitable means of lifestyle modification, addressing risks and prevention of social 
stigmatization, engagement with self-help groups and patient organizations (Agostoni, 
2004). The full range of activities can lead to improved clinical outcomes and improved 
QoL.  
6.2.2.10 Misdiagnosis of HAE 
Banerji (2015) reported in her research over 186 patients that 65% had been misdiagnosed 
prior (see section 5.4.1.3). Read (2014) reported that half of the centers treating children 
with HAE in the UK reported initial misdiagnosis. The number of studies on this variable is 
small and, given the high variability of the numbers, it is difficult to make more precise 
statements. Three studies quantified HAE attacks affecting patients before they were 
diagnosed with HAE: for instance, Aabom (2017) and Psarros (2014) reported that out of a 
total of 138 patients, 51% suffered abdominal attacks. Similarly, Aabom (2017) and 
Zanichelli (2010) reported that out of a total of 125 patients, an average of 48% experienced 
peripheral attacks. In this context, it has been described that HAE, often obscures its 
diagnosis due to its tendency to mimic other dissimilar conditions (Agostoni, 2004). Patients 
with HAE frequently require hospitalizations and there is a high rate of ER (Emergency 
room) visits as described in section 5.4.8. Rizk (2013) reported that when patients show up 
at the ER with large, painful and potentially life-threatening attacks, staff may not recognize 
the symptoms and proceed with the appropriate triage. This can be partially explained by 
the fact that ER staff rotates relatively frequently, with a resulting lower probability that a 





6.2.2.11 Unnecessary procedures due to misdiagnosis 
The consequence of misdiagnosis could be that abdominal symptoms, which mimic acute 
appendicitis or other forms of acute abdomen, can lead to unnecessary abdominal surgery 
(Gower, 2011). Other likely differential diagnostic factors for misdiagnosis of abdominal 
attacks include acute appendicitis, intussusception, mesenteric lymphadenitis, strangulation 
ileus. With young children, it becomes even more difficult as 'belly ache' is a common 
symptom with a multitude of possible causes (Farkas, 2002). Patients with an angioedema 
attack are easily mislabeled as having an allergic reaction or anaphylaxis. When the right 
diagnostic test is unknown, not available, or beyond the reach of the patient, the right 
diagnosis becomes impossible. Zilberberg (2011) reported that such challenges in 
recognizing the disease likely leads to an overall underestimation of the full burden and costs 
of hospitalizations. Banerji (2013) reported that some patients had also been misdiagnosed 
as having psychosomatic symptoms and were subsequently referred for psychiatric 
evaluation. Bernstein (2013) also noted erroneous diagnoses of HAE patients suggesting 
they were suffering from a psychosomatic illness instead. In addition to leading to 
inappropriate pharmacologic therapies, a misdiagnosis could lead to unnecessary surgical 
procedures and to an increased risk of death. Bork (2000) calculated that undiagnosed and 
untreated patients have a permanent risk of dying of asphyxiation that is 2.7 higher than 
diagnosed ones.  
Section 5.4.1.3 found that about 22% of patients had undergone unnecessary surgery due to 
misdiagnosis. Kargarsharif (2015) had reported that acute abdominal pain resulted in an 
urgent surgery in 34% of the patients and Henao (2016) reported that as many as one-third 
of the patients had undergone abdominal operations before being diagnosed with HAE. 
When patients presented with severe cramps, nausea, and vomiting, it could easily have been 
mistaken for an acute abdomen, especially if unaccompanied by cutaneous symptoms. ER 
physicians might have decided to perform unnecessary surgical abdominal explorations and 
the excision of otherwise normal gallbladders and appendixes. Nzeako (2002) reported that 
patients with abdominal HAE attacks had been left undiagnosed for decades despite 
presenting themselves repeatedly to the emergency department with the same complaints. 
Huang (2004) reported in his work of 27% of HAE patients who had gone to the ER during 
an attack to have been treated for anaphylaxis or other disorders, with one half being given 
epinephrine injections resulting in less than a third showing a positive response. Roche 
(2005) listed other cases where patients were given antihistamine or corticoid treatments 
which were completely ineffective for resolving HAE attacks. Such low outcomes led to 
40% of surveyed HAE patients reporting that they had no trust in ER physicians, as reported 
by Banerji (2013). Repeated misdiagnosis and erroneous intervention not only failed to treat 
the condition and may have added additional risk for the patients but may also have added 





6.2.2.12 Patients sharing personal experience to mitigate issues 
The search on social media conducted for this thesis illustrated the results in section 5.3.1.2 
where the second most frequent type of postings was experience sharing (about 20% of the 
HAE-related posts on Facebook). Besides sharing their experience with the symptoms and 
how to cope in daily-life, HAE patients also shared their experience with the physicians, for 
example when there are communication barriers or disagreements on the treatment to 
pursue. These postings seemed to provide concrete examples of the challenges of the agency 
theory describing the relationship between patients and doctors (see sections 3.6.1,  3.6.5 
and 3.6.7), which could lead to wrong treatment decisions. 
Jaiganesh (2012) raised that beyond the ability to diagnose, ERs need to have access to the 
correct treatment and be trained to administer them. In his study, he found that 94% of ERs 
in the UK had a supply of C1-inhibitors (discussed in section 5.4.10 to be highly effective 
for treating HAE attacks, but only 49% had any guidance with regard to their use. Patients 
could be facing the challenge of getting the correct treatment even when the drug is 
available. 
6.2.2.13 Learning from disease attributes and diagnosis 
Section 6.2.2.10 suggests that focusing on early and effective diagnosis would allow patients 
to have early access to effective treatments and help ensure that HAE attacks are shorter and 
less severe, as discussed in section 6.2.1.3. In addition, early and correct diagnosis is also 
both cost-effective and lifesaving. Beyond the duration and the severity of the attack, 
undiagnosed patients are at a much greater risk of mortality from a laryngeal attack than 
those who are diagnosed (Riedl, 2015). The rare incidence of the HAE condition could be a 
force for both clinicians and researchers to pool their experiences and data, with the aim of 
attaining statistically significant insights that subsequently allow for more effective 
diagnosis and treatment. Medical education and the raising of disease awareness among 
physicians could lead to more timely and accurate diagnosis, resulting in earlier treatment 
and improved clinical outcomes and resulting in positive QoL impact, as suggested by 
Zanichelli (2013). Zanichelli (2015) also reported that HAE patients have a shorter life 
expectancy compared to the general population. Earlier diagnosis and effective use of 






6.3.1 Treatments in general  
6.3.1.1 Drivers for the use of guidelines 
The survey conducted as part of this thesis reported in section 5.1.2.13 that two-thirds of 
physicians believe a reduction in frequency and severity of HAE attacks is critical. This 
perspective was in line with the historic focus of EBM discussed in section 3.1 on clinical 
outcomes. Improving QoL and enabling patients to conduct a normal life were assessed to 
be critical for about a third of the physicians in about equal proportion. These are factors 
that are critical or highly important for over 90% of participants suggesting that modern 
medicine has moved beyond the narrow scope of clinical outcomes to encompass the holistic 
view of patients’ QoL and roles in society. Treatment of HAE has increased over the past 
decade thanks to more widespread awareness and diagnoses, but also thanks to launches of 
drugs that have proven to be effective, as discussed in sections 5.4.10 and 5.4.11. Currently, 
guidelines described in sections 3.1.10, 3.1.12, 3.1.13, assist physicians and patients in 
making decisions about appropriate treatment of HAE in specific clinical circumstances. 
Principles that lead to practical and credible guidelines have been applied by WAO (World 
Allergy Organization) when devising HAE guidelines through their cycles and updates 
following a multidisciplinary process and scheduled reviews: Validity (strong evidence, 
ideally through RCTs), reliability, reproducibility, clinical applicability and flexibility and 
clarity.  
6.3.1.2 HAE-specific challenges for the preparation of guidelines 
Compared to other more widespread, historically better researched and well-known 
conditions, rare diseases and especially HAE faced a few challenges. Modern HAE 
treatment became available after 2008. Cicardi (2012) noted that prior to that, there were 
also few controlled studies and consensus guidelines were mainly based on limited case 
series, observational studies, and expert opinions leading to treatments which were based 
mostly on empiric evidence. It is still difficult to directly compare drugs as part of the 
preparation of the guidelines. The ethical concerns of possibly giving less effective drugs to 
patients with high severity of disease and induce significant health risks and possibly 
mortality, inhibit the willingness to execute head to head studies. Another reason for the lack 
of head-to-head comparisons is the difficulty to recruit sufficient patients due to the rarity 
of the condition. An alternative option is to conduct indirect treatment comparisons, which 
once more due to small patient numbers, are exposed to considerable uncertainty around the 
outcomes and their interpretation. A multi-disciplinary steering group of clinicians, nurses 
and a patient representative has been assembled in 2012 to develop a consensus with 48 
recommendations, which were distributed to relevant clinicians and a representative group 




6.3.1.3 HAE guidelines agreed during the writing of the thesis 
Consistently with the profile of the disease and the high variability of the manifestations, 
some statements had been agreed upon early on (Cicardi, 2012). (1) The reduction of 
morbidity and mortality in HAE must begin with early and accurate diagnosis, (2) HAE 
patients should have a specialist familiar with the disease involved in their care, (3) 
Treatment for HAE must be individualized to the patient’s needs and request to provide 
optimal care and restore a normal quality of life. A UK consensus on HAE reinforces 
patients’ rights and possibilities which take into account different aspects discussed above 
(Longhurst, 2015). “Each C1 inhibitor-deficient patient should be able to manage his or her 
symptoms proactively in such a way that they maintain personal safety and minimal 
disruption in living a healthy and productive life” emphasizes the importance of QoL. “All 
disabling attacks irrespective of location are eligible for treatment as soon as they are clearly 
recognized” addresses QoL and enables the patient to take medication at the earliest signs 
for better clinical outcomes. “Patient self-treatment is the ideal service model in line with 
government policy” acknowledges both the importance of early treatment to shorten the 
attack and the fact that self-administration is more cost-effective than visits to the ER or 
hospital stays. “Every patient should hold a safe quantity (minimum of one) of acute 
treatment doses at home dependent on individual needs” addresses the permanent risk that 
the next attack could be laryngeal and potentially fatal if not treated in time. The last update 
and revision of the global WAO guideline for HAE was published in 2017 and provides up-
to-date consensus recommendations for the management of HAE (Maurer, 2018). The goal 
of the guideline update and revision was to provide clinicians and their patients with 
guidance on making rational treatment decisions for HAE. The guidelines issued 
recommendations on how to define and classify HAE, how to diagnose HAE, which 
treatment option (prophylactic and/or on-demand treatment to prescribe), should HAE 
management be different for special patient groups such as pregnant/lactating women or 
children and lastly should HAE be self-administered.  
6.3.1.4 Specific situations not covered by the HAE guidelines 
Bygum (2014) reported that despite the guidelines, different patients choose different 
approaches to treatment, in terms of which drug they take and when they take it: some 
patients opt to take their drugs at the earliest signs of a forthcoming attack, while others first 
want to ensure the impending attack would be very painful or significantly interfere with 
their daily life before administering treatment. The former might be the result of high anxiety 
and could lead to overtreatment (and unnecessary costs) in case of false prodromes, the latter 
might lead to longer attacks and unnecessary burden of disease (see also impact of taking 
on-demand medication earlier vs. later (5.4.10). Riedl (2017) noted the flexibility in the way 
treating physicians prescribe therapies, when reporting that 74% of patients had an 
individual treatment plan. The same study reported that 78% of patients were satisfied with 
the care prescribed by their doctor. A possible alternative and partial explanation for the 
high satisfaction could also be that newly prescribed treatments had higher efficacy and 




6.3.1.5 The role of social media in informing patients on treatments 
The search on social media found for example on Twitter, that a significant share of postings 
was about informing the public on HAE treatments, as described in section 5.3.2.5. For 
example, for many patients updates of the guidelines could open up new treatment 
opportunities as when in 2018 C1-inhibitors had been lifted to the status of first-line 
treatment. Having demonstrated better efficacy and improved safety profile compared to 
androgens, and being listed as first line, C1-inhibitors could be prescribed by the physicians 
and reimbursed by their insurance. On-demand treatment with this product in case of one 
HAE attack could cost between several hundred and several thousand USD depending on 
the healthcare system, as discussed in section 5.4.13. If the potentially life-saving products 
were not reimbursed but accessible as self-pay only, it would have posed an unsurmountable 
affordability barrier and put most patients at risk. The news that the pharmaceutical company 
and the healthcare authorities, respectively the payers, were able to negotiate and agree on 
a reimbursement price, could be significant news and even live-altering for all affected 
patients. Social media could become an excellent and rapid communication channel for all 
stakeholders involved.  
6.3.1.6 The role of the patients’ organization 
The patient advocacy group HAEi has also issued principles for the treatment of HAE which 
could be adapted and generalized to all rare diseases within the scope of this research (HAEi, 
2015). They include the ambition for every patient to live as normal a life as possible via an 
optimal individualized treatment plan. They acknowledge that HAE can successfully be 
managed with modern therapies which should be made accessible, and demand that the 
treatment choice should be taken together by patient and physician. Given the hereditary 
nature of the condition, they recommend that family members of patients with HAE should 
be screened so that appropriate therapy can be available for treatment. While the guidelines, 
the consensus and the principles issued by HAEi are general, they provide flexibility in their 





6.3.1.7 Criteria for therapy selection  
The survey conducted for this thesis reported in section 5.1.2.5 that the most important 
criteria for physicians when selecting the therapy for their HAE patients is the previous 
history of laryngeal attacks. This criterion was followed by efficacy and safety profile of the 
drugs, and subsequently by the costs of the treatment. These results confirmed the focus on 
treating and possibly preventing laryngeal attacks which occur in only about 4% of all 
attacks (see section 5.4.2), affecting approximately 36% of patients, but with a significant 
probability of becoming lethal if not treated properly. With the high variability of the HAE 
disease symptoms combined with the different levels of patient experience in terms of QoL 
(see section 5.4.14), it followed that different drugs are prescribed for different situations. 
Self-administration at home offers benefits, but intravenous administration is more difficult, 
requires more training and might not be suitable for everybody, when compared for example 
with oral administration. Dosing frequency played an increasingly important role as newer 
prophylactic drugs required only biweekly (and in some cases monthly) dosing, compared 
to twice weekly with the older C1-inhibitors. 
The survey reported also that the age of patients was critical or highly important for 63% of 
the physicians. This figure could possibly be driven by the physicians and the caregivers’ 
objective to minimize disruption through attacks for young patients in their education and 
professional development phase, which could be achieved by prescribing a higher share of 
prophylaxis drugs. Another influencing factor could have been that older drugs like 
androgens are significantly more likely to cause side effects in young patients in their growth 
phase (see section 5.4.11). The distance of the patient’s domicile from the next hospital was 
reported as being highly important or critical for 60% of the treating physicians, confirming 
the high urgency for treatment in case of attacks, especially in case of laryngeal attacks 
described in sections 5.4.1 and 5.4.8. Timeliness for last resort ER treatment needed to be 
factored in to reduce and possibly eliminate otherwise likely fatal situations. Patients who 
could not reach an ER within a short time period during a laryngeal attack are at imminent 
death risk, unless they have effective on-demand medication at hand, or even better, are on 
prophylaxis therapy aiming to avoid a priori such situations. 
For the physician and patient to make the right informed therapeutic decision, which might 





6.3.2 On-demand treatment 
6.3.2.1 Share of treatments and results 
In section 5.4.10 the thesis focused on on-demand treatments of HAE and in section 5.4.10.1 
it illustrated that two-thirds of HAE patients treated their attacks. The remaining patients 
who did not treat their attacks could be partially explained by their attacks having been 
predominantly mild or moderate overall, or that these patients have gotten used to coping 
with these symptoms or that simply they did not have access to the needed medicine. A US 
survey conducted exclusively with patient members of the HAEi patient organization 
reported 37% of patients using only on-demand therapy and treating on average 69% of their 
attacks (Castaldo, 2019). Several studies, amongst which Maurer (2013) have demonstrated 
that on-demand treatment, if taken early enough after first symptoms of an attack, can 
significantly reduce the duration from 16.8 hours to 6.1 hours. Zanichelli (2015) reported a 
reduction of angioedema-related morbidity from 26 to five days per year for patients being 
administered modern treatment.  
6.3.2.2 Differences and gaps in treatment and results 
Despite the strong evidence of a positive clinical outcome if on-demand treatment is taken 
early, research has shown that not all attacks have the same likelihood of getting treated. 
More severe attacks are more debilitating on daily activities and/or can have more dramatic 
consequences (for example the laryngeal attacks described in section 5.4.2.3). Caballero 
(2014) reported that face-, neck- and laryngeal attacks were treated 100% of the time, while 
cutaneous attacks involving the genitals or buttocks were treated only 58% of the time. 
Modern on-demand treatment effectively reduces the HAE-related disability. Zanichelli 
(2010) reported that if success was incomplete, it appeared not to depend on the limited 
efficacy of the drugs, but rather on them not having been used to their full potential. Such 
observations reinforce the need for improved awareness of the condition and especially of 
the available treatment options.  
There are differences in the way patients with HAE are treated by various physicians, and 
analysis has demonstrated there are gaps between the availability of treatments and their 
actual use (Agostoni, 2004).  
6.3.2.3 Possible solutions to close gaps 
To close these gaps, the establishment and training on the guidelines could be a necessary 
initial step, followed by individual therapy plans for patients that should include training in 
recognizing prodromal symptoms, recognize (and avoid as much as possible) trigger factors, 
and ultimately self-administering on-demand therapy during acute episodes. Steiner (2016) 
suggested that beyond improved clinical outcomes, such an approach would enhance the 
patient’s independence, self-responsibility and QoL. The value of self-administration has 
been recognized in several healthcare systems, and in Italy for example, Zanichelli (2015) 
reported that more rigorous adherence to the guidelines has led to an increase of the use of 
on-demand treatment to 50% of HAE attacks. A more detailed analysis showed that the real 




5.4.10.2 to 5.4.10.6 analyzed usage and profiles of the different on-demand treatments. C1-
inhibitors have, for example, been reported to effectively reduce the days of absenteeism 
and the inability to engage in social life by half. Icatibant on the other hand, with its 
subcutaneous mode of administration, could contribute to reducing the need for medical 
administration and emergency room visits, offering opportunities to reduce healthcare costs 
(Blasco, 2013) while at the same time improving QoL.  
6.3.2.4 Conclusion on demand treatment 
The survey executed as part of this thesis determined that icatibant and C1-inhibitors were 
the most prescribed on-demand therapies and that 40% of physicians prescribed on-demand 
therapy to less than a third of their patients. The use of icatibant and C1-inhibitors illustrated 
in figure 5.1.2.6.2 as the most prescribed on-demand therapies was in line with the 
guidelines and the efficacy data described in section 5.4.10. 
However, the guidelines discussed in section 6.3.1 were more stringent as they suggest that 
every patient with HAE should always have on-demand therapy in case of an attack. From 
the survey, it appeared that only one-quarter of the participating physicians followed the 
guideline, spread between prescribing icatibant or C1-inhibitors. Possibly alarming is that 
40% of the physicians prescribed on-demand therapy to less than a third of their patients. 
The possible reasons for this could be that their patients were asymptomatic or that they had 
full confidence in their prophylaxis treatments - although it has been reported that such 
treatments do not offer complete freedom from attacks as described in section 5.4.11. 
6.3.3 Prophylaxis treatment 
6.3.3.1 Progress in treatment options 
In section 5.4.11.1 the thesis reported that, based on the available studies, 56% of HAE 
patients take prophylactic drugs with the aim of preventing attacks from happening. The 
older and cheaper androgens, which are taken orally but have a long list of side-effects which 
limited their use, were taken by 37% of the HAE patient population (see section 5.4.11.3). 
The more modern C1-inhibitors which have better efficacy and safety profiles, but have to 
be taken either intravenously or subcutaneously and are significantly more expensive, were 
taken by 25% of the HAE patients (see section 5.4.11.3). The latest generation prophylactic 
drug (Takhzyro®, see section 5.4.11.5) was taken by a small percentage of HAE patients as 
it had just been launched during the time of this research. There is long-term prophylaxis 
(LTP) and short-term prophylaxis (STP). With LTP the patient takes the medication 






6.3.3.2 QoL, the rationale behind prophylaxis treatment 
From a QoL perspective, prophylactic treatment can help mitigate the anxiety about future 
attacks caused by the significant uncertainty regarding the onset and pattern of acute attacks, 
and improve the ability to attend work or school, to plan future life events and travel, and to 
conduct activities of daily living. Prophylaxis may reduce the restrictions on participating in 
sports, hobbies, or social activities, and improve productivity at work and in school, which 
subsequently improves the perspectives on career advancement and educational attainment. 
Lastly, caregivers may also be less burdened timewise, financially or emotionally. From a 
clinical viewpoint, the switch should take place if there is insufficient benefit from on-
demand therapy, measured for example in number of days per year impacted. Longhurst 
(2010) for example reported of a program in Denmark, which considered moving patients 
from on-demand to prophylaxis treatment if they had more than one moderate or severe 
attack every month. However, Nzeako (2002) reported that 84% of patients who had 
succumbed due to a laryngeal attack, had previously experienced no more than three attacks 
per year. The available data could suggest that prophylaxis treatment might have prevented 
the tragic results. Patients who have experienced laryngeal attacks, which can result in death, 
may have been extremely frightened and may, therefore, want prophylactic therapy to 
reduce their chances of another future event of this kind. As Riedl (2015) noted, from a 
patient perspective cost and insurance coverage are also important factors for decision 
making, followed by convenience.  
6.3.3.3 Adaptations of prophylaxis treatments to specific patient situations 
Riedl (2017) reported that of patients who took STP, 65% did so before they needed to do 
dental work (see also section 6.2.1.9 on HAE attack triggers), 59% before undergoing 
surgery, 30% before they embarked on travel, 11% in anticipation of stressful events, 11% 
before physical exercise, and 8% before other unspecified special events. LTP may or may 
not need to be lifelong: the condition can change its clinical course over the patient’s 
lifetime, requiring that the patient's clinical need for prophylaxis can and should be 
periodically reviewed (ICER, 2018). Similarly to the discussion in section 6.3.2 on on-
demand treatment, the patient association HAEi has issued principles (HAEi, 2015), which 
with slight adaptations could be generalized to all rare conditions which have similar 
treatment methods. In particular, the following are relevant in this context: modern HAE 
medications should be prioritized over older outdated medications such as androgens and 
oral antifibrinolytics (e.g. tranexamic acid) should not be used as on-demand treatment. The 
suggested approach with prophylactic treatment should rest on the assessment if on-demand 
acute treatment is inadequate to minimize the suffering, the impact the attacks have on the 
patient’s QoL, other health problems and patient preferences. STP should be considered 
especially before surgeries where the airways are manipulated, such as dental ones or 






The studies on C1-inhibitors identified and reported in section 5.4.11.2 showed that 24% of 
HAE patients were administering C1-inhibitors. The large variations could be explained by 
the different eligibility criteria, the different geographic locations for the studies, the 
different healthcare systems, or simply the availability of different drugs, respectively how 
established and funded they were during the time of the research. The survey conducted with 
HAE physicians as part of this thesis reported in section 5.1.2.7 that 36% of patients were 
administering C1-inhibitors. The difference to the 24% in section 5.4.11.2 might be 
explained by the fact that the meta-analysis contained studies that were conducted when C1-
inhibitors were not yet launched, reimbursed and prescribed in the same way as during the 
writing of this thesis. In the past years, the industry also faced supply issues with 
significantly reduced access to these drugs by patients, that have now mostly been addressed. 
Historically there have been concerns with plasma-derived products and the transmission of 
diseases (e.g. HIV in the 1980s). Reassuringly, Bork (2013) reported that, irrespective of the 
treatment duration with C1-inhibitors, there has been no transmission of viruses and no 
development of antibodies. Replacement therapy with C1-inhibitors has been shown to be 
effective for patients receiving home therapy and STP and LTP (Bork, 2013). Bork (2005) 
has shown that treatment with C1-inhibitors reduced the mean duration of abdominal attacks 
from 92 hours when untreated, to 40 hours when treated. In the same study, patients reported 
a mean maximal pain score reduction from 8.6 (range 1-10) for untreated attacks compared 
to 4.5 when treated. These results were consistent with the study by Rasmussen (2016), who 
reported that when using C1-inhibitors for LTP, the mean duration of an attack could be 
reduced by 52%. Prophylactically treating HAE attacks with C1-inhibitors was reported to 
reduce the overall attack rate by 63%, life-threatening attacks in the head and neck area 
could be reduced by 80%, also confirmed by another study (Kreuz, 2011). Zuraw (2010) 
measured the attack frequency comparing the prophylactic treatment with a C1-inhibitor vs. 
placebo, the former significantly reducing the frequency of HAE attacks from 4.2 to 2.1 
attacks per month. The study also reported a reduction of the severity, the duration of attacks 
and the need to use on-demand treatment in case of breakthrough attacks. More recently, 
Agboola (2019) reported a reduction of the mean attack rate by 71%-85% when comparing 
a C1-inhibitor with placebo.  
6.3.3.5 Difficulty in comparing C1-inhibitors to other HAE treatments 
The thesis could not find any published direct head-to-head studies between treatments. A 
comparison between prophylactic C1-inhibitor therapies and attenuated androgens was also 
problematic since the published data was accumulated using vastly different study designs 
separated by decades. Additional complexity stemmed from the fact that some patients 
required dose escalations of their treatments to achieve the desired efficacy. As Bernstein 
(2014) reported, HAE patients could increase their dosing of C1-inhibitors to reduce attack 
frequency while still well-tolerating the additional drugs taken. Lastly, when patients had 
access to home treatment and self-administration, sometimes this involved a significant 
increase in the dosing frequency, as reported by Kreuz (2011), which makes comparison 




of this thesis, IV-administered C1-inhibitors were the only approved therapy for LTP against 
HAE attacks in children aged 6–11 years in the EU and the US, as reported by Soteres 
(2019). Such broad use was made possible as this class of drugs had proven itself to be 
effective, safe, and well-tolerated.  
6.3.3.6 Recent developments on C1-inhibitors 
Since 2017 C1-inhibitors have also been made available through the subcutaneous mode of 
administration offering improved clinical outcomes and convenience leading to better QoL 
(Lumry, 2019). The most common adverse events (Measured over 18,699 injections) are 
injection-site reactions that were 99% mild and resolved, as reported by Li (2019). The same 
study reported that no thromboembolic events occurred with the subcutaneous formulation, 
while Tachdjian (2019) reported from a survey in the US a reduced likelihood of attacks in 
the real world as well. Another study reported that some patients preferred subcutaneous 
administrations because they were not comfortable with IV and they became able to self-
administer (Wayner, 2019). All combined, the data discussed strongly suggest that C1-
inhibitors in combination with home therapy improve the QoL of patients and are a patient-
friendly treatment option which allows patients greater control over their lives. 
6.3.3.7 Androgens and their limitations 
Androgens (see section 5.4.11.3) have historically been used for other indications than HAE. 
They have proven to be effective for both LTP (long-term prophylaxis) and STP (short-term 
prophylaxis), although the mechanisms causing the beneficial effects in patients with HAE 
are unknown (Agostoni, 2004). Androgens are also convenient to take (administered orally) 
and inexpensive. On the other hand, as Banerji (2013) reported, androgens show significant 
side-effects and may be contraindicated for different types of patients incl. children and 
pregnant women. The list of side effects reported in several studies such as Bork (2001), 
Cicardi (2012), Dagen (2010) and Prior (2012). Bernstein (2013) reported weight gain for 
more than 70% of patients, mood changes for 60% of patients and sleep disturbances or 
agitation for 46% of patients. Dagen (2010) reported virilization in women (hirsutism, 
deepening of the voice, and decreased breast size), menstrual irregularities or absence, 
headache, depression and hypertension with subsequent increased risk of cardiac and 
vascular disease. Bork (2001) observed the induction of liver cell adenoma or carcinoma in 
patients who took androgens for more than ten years. Lastly, Lumry (2010) reported 
decreased attention span, acne, muscle cramps, myalgia, fatigue, hemorrhagic cystitis, 
hepatic necrosis or cholestasis, sexual dysfunction, reduced libido, increased cholesterol, 
blood clots, stunted growth and anxiety. In the same study, he reported that only 6.2% of 
patients taking androgens did not suffer any side effects. Bork (2001) concluded that despite 
the attenuated androgens had shown efficacy in preventing HAE attacks, because of the side 
effects, they could not be recommended routinely to all patients. Later Bork (2008) reported 
that adverse effects occurred in 79% of patients and 25% of patients had to discontinue the 
therapy with androgens because of them. Specifically, for the following patient groups a 
treatment with androgens was contraindicated: pregnant or lactating women, children and 




nephrotic syndrome or significant alteration of hepatic function (Prior, 2012). In addition, 
Gower (2011) published data showing that androgens lost their effect in some patients after 
four to six years of treatment. The patient association also recommends that androgens 
should be avoided when contraindicated, for example when patients are at for adverse 
events, and when prescribed, patients should be routinely monitored for adverse events 
(HAEi, 2015). A survey conducted by Riedl (2015) showed results indicating that the share 
of physicians who preferred androgens as LTP had declined from 56% to 23% in the years 
prior to 2015. At the same time, C1-inhibitors increased as preferred treatment from 20% to 
57%.  
6.3.3.8 Modern use of androgens 
The survey with HAE-treating physicians described in section 5.1.2.7 found a relatively high 
usage of androgens. The reason why androgens appeared to be prescribed closely as often 
as C1-inhibitors (weighted average of 34% vs. 37% of patients) might be explained by their 
much lower treatment costs, their improved convenience from being administered orally 
instead of through infusion or subcutaneously, the ability of physicians to titrate the dosing 
in such a way to minimize side effects, and lastly by the possibility to still be able to control 
the condition with on-demand treatment always available as per the guideline. 
6.3.3.9 Tranexamic acid 
Data on tranexamic acid was shown in section 5.4.11.4 with 18% of patients taking this 
medication for HAE prophylaxis. Prior (2012) reported that for patients suffering nausea, 
vomit, headache, diarrhea, orthostatic regulation disturbances, myositis, muscle necrosis, or 
with increased in the risk of thrombosis, treatment with tranexamic acid is contraindicated. 
With new and more effective prophylaxis drugs available, the use of tranexamic acid could 
be expected to decline. 
6.3.3.10 Lanadelumab 
Lanadelumab (Takhzyro®), discussed in section 5.4.11.5 has shown strong efficacy data 
which could lead to a paradigm change in the treatment for HAE. Treatment with this novel 
class of drugs could allow HAE patients for the first time realistically to aim for zero attacks, 
and virtually forget to have the condition. As the treatment had just been launched during 
the writing of this thesis, there was not a lot of patient usage data available. 
6.3.3.11 Clinical trials challenges and trends 
Section 3.7.15 discussed RCT (randomized clinical trials for the development of new drugs, 
section 3.7.17 the challenges when performing them for rare conditions, and section 3.7.18 
the transition to RWE (real-world evidence). The research on social media conducted for 
this thesis reported in section 5.3.1.7 that about 2% of the posts on Facebook were invitations 
to patients, and sometimes caregivers, to participate in clinical trials, survey or registries, 
that had as an objective to gain new knowledge on the condition, possible treatments and 
other ways to improve the situation. Pharmaceutical companies, contract research 




attempting to overcome the difficulties in recruiting a sufficient number of patients affected 
by rare conditions to fulfil the requirements for their studies. All activity with patients after 
the invitation was received and followed up upon, is confidential and protected by privacy 
laws, hence it was impossible to assess the success rate of such approaches. On Twitter, only 
about 1% of postings were of this type as reported in section 5.3.2.9. The relatively few 
mentions on Twitter of clinical trials were mainly for sharing results and not for recruitment 
purposes. This is also in line with the setup of clinical trials discussed in section 3.2.1, which 
requires strict adherence to a protocol and the fulfilment of eligibility criteria. Normally the 
recruitment for RCTs is performed through selected physicians – investigators. With the 
rarity of the discussed genetic condition combined with the broad implications (QoL, 
financial impact) on patients, caregivers (reported in sections 5.4.13 and 5.4.14) more data 
from patients and caregivers could enable better treatment and funding decisions. Survey 
and registries could provide broader and more comprehensive data for treatment decisions 
leading to better outcomes, as well as for health economic decisions (by integrating all cost 
factors), leading to more efficient use of healthcare and financial resources.  
6.3.3.12 Home treatment vs. hospital treatment 
Home therapy has been available for hemophilia patients since the 1980s and since then has 
been considered to be a routine approach, as reported by Longhurst (2007). HAE patients 
had to wait longer. HAE attacks are unpredictable, can happen anywhere, anytime, be highly 
debilitating, extremely painful and potentially fatal. They make HAE very stressful for 
patients and their families. Normal life during an attack is not possible, a visit to an ER 
and/or a hospitalization are a normal reaction for a suffering patient. The on-demand 
treatment options discussed above have opened the opportunity for home treatment and its 
strong impact in multiple ways. Gregory (2014) reported in his study conducted in the US 
that the share of patients who self-administered more than doubled from 20% to 44% in the 
years before it was conducted, confirming that this approach to treatment was viable, 
feasible and well accepted by stakeholders. Craig (2013) reported that an increasing number 
of healthcare providers adopted the approach and are offering more patients the option of 
self-therapy. A few years later Riedl (2017) reported that 82% of patients where self-
administering, of which 61% with no help, indicating that 39% would and could get 
assistance by a relative or caregiver when required. An analysis based on a cohort of patients 
aged between two and 18 years old part of the IOS registry reported that for 92% of attacks 
icatibant was administered by a family member or caregiver (Andresen, 2019).  
6.3.3.13 Hurdles, requirements and steps to establish home treatment 
Similarly, Petraroli (2015) reported that self-administration of an intravenous infusion of 
C1-inhibitors can be taught to patients and/or caregivers within one day. How the training 
and support are provided can differ from one healthcare system to another. In the US home 
care agencies train patients and follow-up with them in their homes, while in Canada 2-3h 
were seen to be sufficient for training (Symons, 2013). Caballero (2013) identified three 
main requirements for a patient to qualify for self-administration, patient motivation, patient 




considered for self-administration as the process does not have to be either long or 
complicated. During such training patients are also advised to keep a log of their condition, 
noting the attack types, the severity, the medication taken, the time to resolution, and more, 
which help to reduce recall bias and the physician to adapt the treatment as necessary. Part 
of the training includes a sterile technique and the use of equipment for home administration, 
including how to manage emergencies and when to present to an ER (Rizk, 2013). Riedl 
(2017) reported that once taught, few patients refused self-administration. However, when 
patients refused it, they indicated as reasons the fear of injections, concerns about possible 
infections, lack of skills (specifically dexterity, interference with daily activities, and 
financial restraints. Tuong (2014) reported that some of the nurses involved in the training 
mentioned worries about safety, the risk that patients might not retain their acquired skills, 
and/or that might make inappropriate use of the drug. When discussing intravenous 
treatment such as with C1-inhibitors, a challenge arises in obtaining venous access, yet Rizk 
(2013) showed that less than 2% of self-administration through venipuncture resulted in 
technical failure. With the proper training and practice, home therapy has not caused a 
significant increase in the dosing, however a significant increase in dosing frequency.  
6.3.3.14 Results and benefits from home treatment 
All types of attacks can be treated, and in his research, Kreuz (2011) could not observe 
additional side effects or injection site complications. Normally nurses conduct the training 
and guide the patients, offering to continue ongoing support as needed, as reported by 
Gregory (2014). Levi (2006) assessed that all patients can be capable of self-administering, 
with technical failure rates of self-injection being less than 2%. Graig (2013) had already 
suggested that patients appear to learn the skills of self-administration quicker than expected 
and in fewer sessions than the guidelines recommend. Researching the results of the 
approach, Abdel-Karim (2014) reported that pediatric patients aged 13 had rapidly learned 
self‐administration and subsequently benefitted from reduced frequency and severity of 
attacks. Despite these considerations, proper training to suitable patients should be pursued, 
as there is an inherent risk of long term intravenous access, corroborated by reported 
fatalities due to pulmonary arterial embolization due to inappropriate infusions (Tilles, 
2013). Combining all factors, it appears that home treatment offers a further range of 
advantages. 
6.3.3.15 Benefit of early intervention and shorter time to relief 
Self-administration of medication contributes to early intervention, it can help to 
significantly reduce the time between the onset of the attack and taking the medication, 
which above has shown to contribute to a lower severity and shorter time to resolution – 
with the critical threshold being at about one hour. Petraroli (2015) reported that patients 
taking icatibant within one hour from onset can reduce the attack duration from an average 
of 16.8 hours to 6.1 hours. Craig (2013) reported in his study with C1-inhibitors for 
prophylactic use that treatment taken within 6 hours after the onset of the attack resulted in 
considerably shorter times to onset of symptom relief compared to placebo. If treatment was 




C1-inhibitors for on-demand treatment and reported that home treatment prevented more 
severe attacks and additionally allowed for a lesser consumption of drugs, while Tourangeau 
(2012) measured the attack frequency to remain approximately similar. Lastly, Longhurst 
(2007) reported that 58% of patients administering prophylaxis drugs themselves, enjoyed 
complete freedom from attacks. 
6.3.3.16 Benefit of more rapid resolution of HAE attacks 
Looking at dosing, Gregory (2014) measured that the treatment doses per week increased 
from 1.40 in infusion centers and physicians' offices to 1.85 at home, indicating a higher 
propensity to take medication which by itself may also have led to better clinical outcomes. 
Banerji (2013) suggested that home administration may have decreased dosing needs, while 
Rizk (2013) reported that patients who self-administer on average took treatment 1.4 hours 
after onset, compared to 3.4 hours for those who relied on medical professionals. Combined 
with the superior clinical results from treating as early as possible (see also sections on 
icatibant 5.4.10.3 and 6.3.2), this leads to complete resolution of symptoms 5.9 hours after 
self-administration, vs. the 13.8 hours with conventional treatment (Rizk, 2013). Research 
with a different cohort of patients has shown a reduction of the time between the onset of 
the attack and the initiation of relief or complete resolution of symptoms from 7.9 hours to 
2.2 hours thanks to self-administration (Levi, 2006).  
6.3.3.17 Benefit of reduced mortality 
Ghazi (2013) suggested that the more rapid dosing of the drug in the case of laryngeal attacks 
led to a potentially reduced mortality, while Longhurst (2007) reported improved life 
expectancy with self-administration. 
6.3.3.18 Benefit of healthier and more productive life 
Longhurst (2010) also reported that the improved control over the symptoms enabled 
patients to live healthier and more productive lives, possibly allowing them to resume a 
normal life without restrictions caused by HAE (Bygum, 2009). These patients have been 
observed having a reduced need for health centers or ER visits (Blasco, 2013), less 
hospitalization time and less absenteeism from school or work (Rusicke, 2006) and possibly 
a decreased mortality (Wang, 2015). Bygum (2014) measured a reduction of acute hospital 
visits by 84% thanks to home therapy, Javaud (2015) measured an 11-fold lower risk of 
needing admission to an ER following self-injections of icatibant, and Kreuz (2011) reported 
a reduction of the mean annual number of days hospitalized from 3.8 during physician-based 





6.3.3.19 Benefit of increased independence  
Patients who have learned to self-administer the medication (by infusion or subcutaneous 
injection) during an emergency, acquired a strong sense of independence and felt much 
safer. Bygum (2009) reported patients having been no longer afraid of life-threatening 
laryngeal attacks or painful abdominal attacks, which was discussed in section 6.2.1.14 to 
be a main source of the comorbidities anxiety and depression. The acquired autonomy may 
boost self-confidence and QoL, as HAE patients are subject to less disruption in their daily 
activities (work or leisure). Patients reported less pain, less vomiting, fewer circulation 
breakdowns, no more waiting for emergency medical personnel, no more use of drugs that 
would not work, because the treating physician was not trained in HAE. Rauch (2004) 
observed that in case of laryngeal attacks, HAE patients on self-administration of on-demand 
treatment had no longer a need to run to the hospital breathless and in a panic and potentially 
facing the risk of their orphan drug not being in stock at the hospital pharmacies (Banerji, 
2013). The same results could be achieved or even reinforced when in addition to the patient, 
also the caregivers are taught to administer the infusion or injection to the patient (Bygum, 
2015). Longhurst (2016) reported in addition that the shift from depending on health care 
professionals to being able to self-administer triggers a transformation from being a disabled 
HAE patient to being able to perform a controlled treatment and be in charge of one’s QoL. 
6.3.3.20 Benefit of reduced costs 
Long before HAE therapy for home treatment had been developed, home therapies for 
hemophilia and antibody therapy were studied and reported to reduce costs by up to 20% 
compared with in-hospital treatment. Rodriguez (1991) reported that they were shown to 
improve the patients’ independence, with less feeling of illness and less absenteeism. Home 
therapy requires a significantly lesser deployment of healthcare resources, as studies have 
reported a decrease in the mean annual number of hospitalizations from 17 to two and a 
reduction of missed work/school days from 20 to seven compared to conventional treatment. 
For example, Petraroli (2015) measured for HAE patients within the Italian National 
Healthcare System savings of 11.3% (from around USD 30,000 p.a. for hospital treatment 
to USD 26,600 for home treatment). The same study reported that within the Spanish 
National Health System, home treatment was shown to reduce the cost per attack by 7.1% 
from USD 1,180 to USD 1,090, mainly driven by fewer visits to the ER and from diminished 
use of other medical facilities. The reduction in costs could be split into 74% from savings 
of direct costs, and 26% from lower indirect costs. Blasco (2013) reported the combined 
savings from home therapy to add up to a few million dollars per year. 
A limitation of these studies was that they could not measure over or underdosing of drugs. 
Additional inaccuracy might result from early treatment, as potentially severe attacks may 
have turned into mild attacks, in which case the clinical benefits and the cost savings might 
have been even more important than estimated. Wang (2015) summarized that for different 
reasons, switching to self-administration therapy was looked upon favorably from a patient’s 
perspective and Caballero (2013) concluded the same from a clinician’s perspective. Lumry 
(2018) identified in his research that in many countries (for example Japan, Greece and most 




example Brazil or Mexico) it was available but not reimbursed. If on-demand therapy can 
only be obtained, if at all, in a hospital or in specialty clinics, then HAE patients may be 
exposed to additional risks (due to the untimely resolution of attacks as described in section 
6.3.2), additional costs, and lower QoL. 
6.3.3.21 Conclusion on home treatment 
In conclusion, self-administration suggests significant health benefits, possible cost savings 
and improved QoL. Riedl (2017) reported from a survey that 71% of patients who treated 
themselves reported high rates of satisfaction, and 78% believed that their approach might 
have lowered their levels of anxiety and depression. Such encouraging results supported the 
recommendation by Symons (2013) that all patients who are willing and able to self-
administer should be offered this treatment option, as it can also be lifesaving. Along the 
line of these arguments, the patient association HAEi issued principles (HAEi, 2015), which 
with slight adaptations could be used for all rare conditions which have similar treatment 
methods. The recommendation to patients was to self-treat attacks as early as possible, as 
all attacks could become debilitating, and airway attacks could become life-threatening. 
Further, all patients should always have modern therapy available to treat an acute attack, 
and they should be trained in self-administration. While attacks can occur in any location, 
all could be treated at home and all should be considered eligible for treatment. In the case 
of laryngeal attacks, HAE patients should seek the ER for expert medical advice, even if 
normally they self-treat at home. A survey conducted in the US in the years where these 
observations were made, reported that the percentage of attacks self-treated at home 
increased from 8% to 27%, which by itself led to a decrease in ER visits from 61% to 54% 
and a decrease in hospitalizations from 13% to 3%. In the same survey physicians perceived 
an increase of patients satisfied with their HAE treatment from 13% to 40% (Riedl, 2015). 
6.3.3.22 HAE switching treatments 
The survey conducted for this thesis asked physicians treating HAE how often patients 
switched their treatment and reported the results in section 5.1.2.8. 54% of patients never 
change their medication and the vast majority not more than once during their lifetimes. This 
result could be seen as unexpected for a few reasons. First, the condition manifests 
differently over time and patients could be in control with an acceptable QoL with on-
demand treatment only, until the number and severity of attacks increased in such a way that 
prophylaxis could become the preferred solution. Second, over the past decade, there has 
been enormous progress with the development of innovative therapies which should have 
replaced old treatments which have less efficacy and more side effects, as described in 
sections 5.4.11.5, 6.3.3.4 and 6.3.3.9. A possible reason for this relative “stickiness” could 
have been the hesitation of physicians and patients to change a therapeutic approach that 
delivered acceptable results, and to experiment with a new drug, even if the clinical data 
suggested much better outcomes are possible. With the current introduction of Takhzyro® 
more switches were expected, as the drug has already shown transformational outcomes and 




conducted in a few years’ time, the results might show an important shift to at least two 
therapeutic changes. 
6.3.3.23 Reasons for switching HAE treatments 
The survey also asked the physicians to provide the reasons why they and the patients agreed 
to switch medication, with presented in section 5.1.2.9. The most mentioned reasons were 
the side effects (for 17% of patients), the lack of efficacy (for 15% of patients), and costs 
(for 12% of patients). Possibly, this explains switches from androgens to C1-inhibitors as 
the former have a long list of side effects described in section 6.3.3.7. In comparison, modern 
therapies showed relatively fewer and milder side effects such as injection site reactions on 
the skin. Clinical studies investigating the efficacy and safety profiles of HAE drugs already 
showed improvements. These reasons are followed in equal percentage by the strive towards 
improved convenience (which can be explained by a preferred mode of administration, a 
dosing frequency, or adverse events) and by supply issues (Different C1-inhibitors were 
exposed to supply issues over the past years de facto forcing patients to switch medication). 
The change of frequency of attacks as a reason to switch treatment was mentioned to be 
relevant for less than around 10% of the patients. This could be either because an increase 
in the number of attacks justified moving to prophylaxis therapy, or because a decrease in 
the number did not warrant it any longer. 
The switches due to costs could have been driven by the insurance companies not funding 
the treatment due to HE aspects, based on the process described in sections 3.7.25 and 
3.7.26. Alternatively, it could also have been because patients could not afford or didn’t 
want to pay the copayments, which, given the costs of the drugs, could be significant 






6.4.1 Six types of cost analysis 
Referring to section 5.4.13.1 on the costs of rare conditions and HAE specifically, a 
structured approach to discussing costs of drugs as part of pharmaco-economic evaluations 
could be divided into six types with different levels of complexity.  
(1) Budget impact analysis, which considers only the direct costs of a treatment (e.g. drugs) 
and which is relatively simple. (2) Cost-minimization analysis, which assumes all treatments 
to have equivalent efficacy, and suggest the least expensive one to be the most cost-effective. 
(3) Cost-consequence analysis presents and compares all costs and outcomes associated with 
a treatment. (4) Cost-effectiveness analysis uses a measure of health benefit (e.g. HAE 
attacks avoided, life years saved) to first estimate the benefits of treatment and then calculate 
an incremental cost-effectiveness ratio (ICER), i.e. the incremental difference in costs and 
benefit between treatments. (5) Cost-utility analysis follows the same approach but using 
the QALY (Quality-adjusted live years, combining survival and quality of life) as a standard 
cost-effectiveness estimate of the intervention. QALY can also be used to compare 
interventions in different disease areas. (6) Cost-benefit analysis measures costs and benefits 
in money terms, comparing the financial value of the costs with the benefits.  
6.4.1.1 Challenges in assessing true costs of rare diseases 
It is difficult to quantify the total costs of a rare disease treatment when the medical 
management of the patients is shared across different providers such as specialist centers 
(tertiary care), ER providers (secondary care) and general practitioners (primary care). As 
discussed in sections 5.4.7 and 6.2.1.14, HAE patients were also likely to have comorbidities 
with some of them having to be treated by yet other specialists. A global and general 
discussion on costs was also made challenging as the selection of treatments, the type and 
quantity of funding of the therapies could differ between countries according to tradition, 
financial resources and health care systems, as reported by Bygum (2014). A further 
limitation identified by this thesis was that the cost of labor and the prices of the drugs could 
significantly differ across countries. For this reason, strategies and policies that help patients 
prevent ER- and hospital visits were meaningful both from a QoL and from an economic 
perspective. Newer drugs with improved effectiveness and lower risk profile were costlier 
but might have been justified in selected patients when incorporating all factors. Manson 
(2013) analyzed several healthcare systems and found that some payers were using the 
concept of Integrated Care Pathways (ICP) to map how patient interacted with different 
health professionals and types of care over time. ICP as recorded as documents part of the 
clinical record of the patients and can be utilized as a tool to ensure standard practices, 
following of guidelines and systematic controls that the treatments with the best combination 





6.4.1.2 Direct vs. indirect costs 
Section 5.4.13.2 identified from the data that the costs of health conditions can be divided 
into direct vs. indirect costs. Kavalec (2013) reported that direct costs were difficult to 
quantify due to lack of data, lack of comparability between treatment options, differences in 
prices and costs of procedures. To estimate indirect costs of a condition, like when a patient 
suffers HAE attacks, the human capital approach could be used. When patients or caregivers 
are experiencing lost productivity because of the attacks, the treatment, or the 
hospitalization, then the productivity loss can be estimated by multiplying the time required 
with the average hourly wage based on the Bureau of Statistics of the respective healthcare 
system. The gap in using all types of costs for reimbursement and treatment funding 
considerations occurs when payers, (such as for example the Spanish National Health 
System) consider in their decision making only direct costs (Blasco, 2013). This chose 
approach could be partially explained by the rapidly escalating healthcare costs which create 
tension with the need to provide adequate patient care. Rare diseases and HAE could be 
examples to showcase how prevention could reduce the need for expensive ER treatments 
and hospitalizations. Value and cost analysis need to be holistic with the aim to reduce 
patients’ exposure to the healthcare systems, for example through visits to ERs and 
hospitalizations, discussed in sections 5.4.8.3 and 5.4.13.3.  
6.4.1.3 Death and the differences across healthcare systems 
Section 5.4.8 reported on patients succumbing due to HAE, which could be seen as the 
ultimate burden of the condition resulting in significant hardship both socially and 
economically to the patient’s family and society. A review of all US death certificates from 
1999 to 2010 conducted by Kim (2014), reported HAE having been a contributing factor or 
cause of death in 600 people. These figures need to be taken within the context of the specific 
healthcare system, as there are large differences between countries in terms of healthcare 
infrastructure, reimbursement schemes, treatment modalities, income, affordability and 
willingness to treat certain conditions. For example, in some emerging countries treatment 
of rare diseases might be de-prioritized if more urgent unmet medical like child mortality or 
communicable diseases needs need to be addressed. Longhurst (2016) reported that not all 
patients could benefit from medical progress and treatment improvements enjoyed by the 
most fortunate.  
6.4.1.4 Specific cost challenges for HAE 
The clinical impact of HAE is highly variable as discussed in sections 5.4.1, 5.4.2, 5.4.3 and 
5.4.4. Federici (2018) reported that facial attacks generated 22%, laryngeal attacks 16%, and 
abdominal attacks 11% higher costs than cutaneous attacks. The same study also reported 
that severe attacks generated 30% more costs than mild attacks, with moderate one in 
between. Patients had theoretically a wide selection of treatments at their disposal, and their 
consumption of medication could depend, besides on the clinical impact, on their propensity 
to treat, or which drug they get refunded. In addition, patients may have needed supportive 
care in the form of ER, hospitalizations or nursing care for at home. Longhurst (2016) 




sections 5.1.2.11 and 5.4.7 the thesis studied the co-morbidities to which HAE patients were 
frequently subject to. They demanded separate consultations and treatments that vary across 
patients and over time for the same patients depending on numerous factors.  
HAE treatments could be taken through different modes of administration. Prophylaxis 
treatment could be administered orally, subcutaneously and intravenously (see section 
5.4.11). Wilson (2010) reported that intravenous administrations were at higher risk of 
generating complications causing a higher share of hospitalizations compared to 
subcutaneous medications (20.2% versus 5.9%), which led to higher resource utilization and 
costs. While modern treatments such as C1-inhibitors contributed to a reduction of the health 
and societal burden HAE, their increased cost compared to traditional medicine with lesser 
efficacy had impacted payers and raised concerns, as reported by Federici (2018). 
6.4.1.5 Challenges in obtaining comprehensive cost data 
Longhurst (2016) noted that few healthcare systems had the process and the infrastructure 
to be able to collect and consolidate all costs by the patient’s primary condition. Obtaining 
this type of data was as of the time to research very difficult and assumptions had to be 
made. As for other rare conditions, the costs for HAE therapies were high. The condition is 
severely debilitating during attacks and additional direct costs from providing medical care 
plus the indirect costs of the disease on patients, their families, and on society had to be 
added. When HAE patients had attacks, they and their caregivers may have missed a 
significant amount of time from work and school. Also, between attacks, they could be less 
productive at work or in their education. Studies have reported that many are unable to 
achieve their educational and career goals, or even maintain employment as a result of their 
disease. This comes in addition to a higher utilization for health care resources, which in for 
example Helbert (2013) estimated for the UK to be 160% higher for primary care and 447% 
higher for secondary care (even when excluding specialist care and medications. The cost 
considerations studied in section 5.4.13 were caused or impacted by activities or events. In 
the case of HAE costs could also arise from lack of action, for example by not treating an 
attack. Longhurst (2007) reported that untreated attacks can be costly in social, 
pharmacoeconomic and QoL terms as well. The discussion on attack triggers in section 5.4.6 
had highlighted emotional stress, minor infections or estrogens amongst others as possible 
precipitating factors. Consequently, adolescents and young adults in their education or early 
career stage may live with an increased risk in the stage of their life with the longest potential 
impact. The lifetime economic costs of a disrupted education or employment can be 
considerable. For this patient population, this adds up to the impact on the families of the 
young adults resulting from absenteeism from work or from lost opportunities. Looking 
beyond, the wider society also carries additional costs as a consequence of HAE through the 
employers and more in general as a result of the productivity loss, the burden of care and 
the economic costs of expensive orphan drugs and additional treatments that are necessary 




6.4.1.6 Impact from advent of modern HAE treatments on costs 
Before modern treatment was introduced and home and self-administration became 
available, most if not all HAE attacks had to be treated by physicians, and ER visits and 
hospitalizations were the norm. When self-administration for treatment, on-demand or for 
prophylaxis, became and was perceived as safe and effective, patients could treat and resolve 
symptoms earlier, reducing significantly ER visits and hospitalizations, improving QoL and 
reducing direct and indirect healthcare expenses for the payers and for society (Lumry, 
2018). Since 2008 new modern treatments have been discovered, developed and made 
available to HAE patients. Clinical trials and RWE suggested unprecedented levels of 
efficacy, safety, and convenience as described in sections 5.4.11.2, 5.4.11.5 and 6.3.3. 
Combined they appeared to have the potential to further transform the patient experience. 
Modern drugs may change and innovate treatment paradigms and therefore lower the costs 
and the burden of disease. Petraroli (2015) reported self-administering patients to have 
lowered their mean annual number of hospitalizations from 16.8 to 2.1, their time to 
administration of treatment from 3.2 hours to 1.9 hours, their time to beginning of symptom 
improvement from 84 minutes to 54 minutes, and their time to completely resolve their 
symptoms from 12.8 hours to 10.8 hours, while decreasing the number of missed days of 
work or school from 23.3 to 7.1 days compared to hospital administered therapy. However, 
Longhurst (2016) noted that new and improved products are normally commercialized at 
higher prices which subsequently implies additional pharmaco-economic challenges.  
6.4.1.7 Impact from increased drug development costs 
Over the last years, time-consuming and expensive drug research and development activities 
have significantly appreciated, reaching for a new prescription drug an average cost up to 
winning market approval of about USD 2.6 billion (Di Masi, 2016). This was valid also for 
orphan drugs which are no exception as they have far fewer patients to treat, and therefore 
the cost per patient must be higher to recover the initial expensed. The publication 
EvaluatePharma (2015) quantified for the top 100 drugs, that orphan drugs cost USD 
140,443 per US patient per year, compared to USD 27,756 for non-orphan ones. Lumry 
(2016) reported that HAE patients and payers were counting on market forces and 
competitive pricing to push the costs of therapies down.  
6.4.1.8 Challenges in estimating costs of co-morbidities 
HAE is often accompanied by co-morbidities (see sections 5.4.7, 6.2.1.14, 6.2.1.15 and 
6.2.1.16) and a survey conducted by the patient association HAEi in 2018 indicated 
significant medication use for these conditions as well. For example, around 90% of HAE 
patients who reported asthma as a comorbidity were taking medication to treat it. For heart 
disease, the percentage was 84%, for hypertension 71%, stroke 60%. Anxiety, the most 
frequently mentioned co-morbidity, appeared to be treated with drugs by only 26% of the 
HAE patients, depression by 17% of the patients and high cholesterol by 13% of the patients. 
A comprehensive review of available studies for the purpose of this thesis has highlighted 
the difficulty or impossibility in performing comparisons or calculating averages. Different 




occurrences, duration, frequency), did not incorporate or report the cost drivers in the same 
way, or had cost factors in different relations to each other (e.g. labor costs vs. drug costs). 
With these limitations, the thesis aimed to provide an overview of the costs to develop 
answers to the RQs. 
6.4.1.9 HAE treatment costs dependence on severity of the disease  
The large differences in costs reported in section 5.4.13.3 across healthcare systems may be 
explained by the difference in healthcare costs per capita, rather than patients in the US 
requiring multiple times more hospitalizations. The shift from healthcare professional 
administration of drugs to home and self-administration of drugs could have driven, in 
addition to improved clinical outcomes and QoL, lower overall costs. Table 5.3.13.4.2. 
appears to illustrate a link between yearly HAE therapy costs and the severity of the 
condition, but one must consider the caveat that the distribution might be skewed due to the 
diversity of patients. Their choice of medication, the consumption, the propensity to treat 
and which drug is getting reimbursed, and therefore was accessible, might have depended 
on the severity of the condition and not have been equal across all grades.  
The figures presented in section 5.4.13.2 might have to be interpreted only directionally, due 
to the paucity of other studies and the lack of standards in defining severity. Additionally, 
they described purely the direct costs of clinical treatment and intervention. In section 
6.4.1.9 it was discussed that the HAE condition, in the same way as for other rare or chronic 
diseases, also triggers indirect costs. The figures on indirect costs were only directional as 
they not only aggregated all degrees of severity, but also, they did not differentiate across 
personal job situations, or the family and wealth conditions of the HAE patients incurring 
them. 
6.4.1.10 HAE life-time costs and key drivers 
As reported in section 5.4.13.3, the lifetime costs of an HAE patient averaged at between 
USD 8-10 million per patient, if they took modern prophylaxis treatment. Riedl (2015) 
conducted and reported on a US survey that described therapeutic decision making 
depending on a number of factors in line with the concepts of EBM (presented in sections 
3.1.6, 3.1.15, 3.6.5, and 3.6.7). In reality, the study found cost and/or insurance coverage 
was to be the most important factor, in line with the survey conducted as part of this thesis 





6.4.1.11 Payers perspectives on costs 
The discussion in section 6.4.1.9 and the magnitude of the costs of treating HAE strongly 
suggest that payers pay a crucial role in funding treatments, in line with section 3.5.5 and 
5.4.13.5. Few patients and their families can shoulder yearly treatment costs that can become 
hundreds of thousands of dollars. Research has forecasted an average of new five orphan 
drug approvals per year with annual per-patient costs between a few thousand dollars to 
more than half a million dollars (Schey, 2011). Payers need also to factor in that most rare 
conditions are genetic, chronic and patients need treatment for life. In the case of orphan 
drugs costing several hundreds of thousands of dollars per year, copayments for patients can 
become tens of thousands of dollars per year. Most payers define a maximum copayment 
amount for patients, which means the payer is left to pay virtually the whole bill. For this 
reason, some payers require that the prescribing physician obtains approval from the payer 
before prescribing the treatment (Cohen, 2014), or is ready to justify in detail later why the 
drug was prescribed. For example, in the UK the National Institute for Health and Clinical 
Excellence (NICE) plays a key role in reviewing the clinical impact and the relative prices 
of expensive drugs, with the objective to force manufacturers to agree to price reductions 
when drugs do not perform as claimed (Hughes-Wilson, 2012). Although these drugs tend 
to have a high per-unit price, from a strictly economic perspective, this should not imply a 
special kind of evaluation by payers. Payers are using criteria that are being traded off 
against one another to decide on reimbursement such disease severity, availability of 
alternative treatments, level of unmet medical need and cost-effectiveness. The same criteria 
could be used across all types of drugs, including the orphan ones.  
6.4.1.12 Experts and processes to establish criteria for reimbursement decisions 
The challenge becomes that payers are struggling to develop appropriate criteria for 
evaluating which medications should best be prescribed to which patients. To help with the 
decision-making independent entities such as the Institute for Clinical and Economic 
Review (ICER) assemble experts, attempt to define the best criteria using a rigorous 
pharmacoeconomic approach to calculate the cost-effectiveness, and the issue a report with 
recommendations, which payers, physicians and patients can choose to follow (Zuraw, 
2019). In addition to a fundamental de novo analysis and recommendation, before payers 
reimburse drugs, published list prices are negotiated with pharmaceutical companies as 
described in section 3.5.14. While at a later stage confidential discounts are possible the 
effectively paid price - net price - for the drugs can be much lower, list prices are already 
subject to scrutiny. In order to get a proposed price approved, companies have to 
demonstrate that their drugs provide value, especially relative to competitors or standards of 





6.4.1.13 Additional pricing and reimbursement challenges for orphan drugs 
Orphan drug price reviews are more complicated as there might be only very few on no 
alternatives available to patients, and the prices cannot always be linked to market forces, 
respectively need to factor in the very small number of patients suffering under the rare 
condition, described in sections 3.7.22 and 3.7.25. Rosenberg-Yunger (2011) reported that 
with few alternatives available, payers have less negotiating power, and as a result, some 
orphan drugs can cost payers hundreds of thousands of dollars annually per patient. For this 
reason, payers pursue pharmacoeconomic evaluations and price referencing. Authorities and 
payers reference the prices internationally in the quest to optimize their spending as 
described in section 3.5.18. Price referencing takes place by sharing information and 
pharmaceutical companies attempt to maintain consistent prices globally. If in one country 
the price agreement is lower, this will trigger reactions from the others and with rare diseases 
the impact is multiplied considering that patients tend to stay on treatment for life. On the 
other side, in some healthcare systems lifesaving or life-extending treatments are labelled as 
essential and therefore are more likely to obtain reimbursement. An additional challenge for 
payers when making reimbursement decisions is the perceived risk of over-medication and 
economic inefficiency when a self-administered drug costing several thousand dollars per 
dose is given to patients to decide when and how often to take. When payers analyze the 
clinical benefits and the cost-effectiveness of drugs to be reimbursed, RWE is used to 
understand the value of a drug in a real-world setting. Additionally, payers have to consider 
the long term in all relevant dimensions such as efficacy, safety and costs. As discussed in 
sections 3.5.14, 3.7.22, 3.7.25 and 3.7.28, the assessment for orphan drugs is more difficult 
and often less rigorous than for non-orphan drugs. Demonstrating cost-effectiveness is 
difficult in rare diseases using traditional methods.  
6.4.1.14 Patient perspectives on payers’ decisions 
The reviews by the payers and results achieved could be disappointing for patients who are 
seeking improved treatments. A number of limitations and opportunities for improvement 
could be identified. For example, when reviewing the pharmacoeconomic considerations, a 
possible disagreement could already arise from a different understanding of the underlying 
clinical assumptions, the estimates on the impact on QoL, the inclusion or exclusion of 
indirect costs, or the consistency or not with the ethical principles of medical decision 
making. Zuraw (2109) raised that the (Incremental Cost Effectiveness Ratio (ICER) studies 
likely underestimated the percentage of attacks that would be treated with costly on-demand 
medications, did not fully include the need for retreatment, or assumed no difference in 
survival between the different treatment approaches. As indicated in section 6.4.1.4, these 
considerations only factor in the direct costs of treatment, and do not factor in the alternative 
costs of no treatment, which manifest as hospitalizations, ER visits, indirect costs and death. 
Additional benefits for the patients, the healthcare structures and society could be included 
for truly holistic review and decision making on which treatments should be paid for by 
payers or society. Questions to be considered are for example if the treatment would 
significantly reduce the patients’ caregiver or family burden, if it would provide positive 




thanks to a novel mechanism of action or approach), if it would positively impact the 
patients’ world outside their families, or if it would impact the healthcare system 
infrastructure. Beyond benefits, contextual considerations should also be made such as if the 
treatment prolongs life or improves QoL in patients with a particularly debilitating condition 
which also causes a high lifetime burden of illness, if the treatment is novel or offers 
significant improvements (such as long-term benefits). ICER considerations for HAE and 
rare conditions are made difficult and are subject to limitations for the same reasons 
discussed in 3.7.15. Scientific data is based on relatively small sample sizes, few clinical 
trials are available, and they are of short duration. Specifically, for HAE there is also a lack 
of data on the natural history of attack rates over patients’ lifetimes (ICER, 2018). 
Section 5.2.1.4 illustrated the perception treating physicians have on how much payers pay 
to reimburse treatment for HAE patients, as collected through the survey. The results suggest 
that patients bear a higher share of costs in the lower ranges and the situation becomes 
inverse for higher ranges. Payers were observed as funding more than USD 100,000 per year 
to about 20% of the HAE patients, while less than 4% of patients incur costs of more than 
USD 50,000 per year. 
6.4.1.15 HAE patients’ perspectives on costs 
The survey with physicians treating HAE patients found in section 5.2.1.1 that one-quarter 
of physicians treating HAE patients didn’t know if their patients carried part of their 
treatment costs, if they suffered from missed income or if they incurred indirect costs. It 
found that 38% of physicians believed that less than 10% of the patients were paying any 
part of the treatment costs. For a condition that has such profound impact on life through 
debilitating and potentially fatal attacks which affect every aspect of day-to-day activities, 
and of which treatment costs are known to be in the tens of thousands if not hundreds of 
thousands of dollars per year (see section 5.4.13), these answers might be surprising. A 
possible explanation could be that these physicians operate in countries where all healthcare 
costs are unconditionally reimbursed as described in section 0. An alternative explanation 
could be that these doctors focus exclusively on the clinical situations and potential 
outcomes of their patients, leaving completely alone considerations of QoL, income- and 
indirect costs. The survey also reported that 38% of physicians believe that less than 10% 
of the patients are paying any part of the treatment costs. Such realities would be ideal from 
a patient perspective and correspond to full universal reimbursement of all costs as described 
in section 0. The answer that one-third of patients incurred zero costs seemed incongruent 
with the other answers to questions in the survey and indicated that more could be done to 
generate awareness and transparency on all direct and indirect costs. With knowledge of the 
true financial impact, physicians and payers could possibly make more efficient treatment 
decisions from both an individual and aggregate viewpoint. Having insights on all cost 
drivers could induce different therapeutic decisions and allow for a different perspective on 




6.4.1.16 HAE patients’ contributions to the treatment costs 
Section 5.2.1.2 additionally illustrated from the survey that only 19% of patients are reported 
to have to contribute to a copayment. This figure may seem unexpected as most healthcare 
systems demand some form of copayment to reduce drug wastage, improve compliance and 
to reduce costs. Lastly, a percentage of physicians answered that some of the patients had to 
carry all treatment costs out of pocket, which could be a significant outlay when looking at 
the figures discussed in sections 5.4.13 and 6.4.1.9. A cross-reference with the countries of 
origin of these specific answers indicated these physicians working in emerging countries 
such as India and Brazil, where healthcare coverage, ability to reimburse and pathways to 
access to orphan drugs were not yet fully in place. 
The search on social media discussed in section 5.3.1.2, the sharing of experience among 
patients on how to address the challenge of covering the high costs of orphan drugs described 
in sections 3.7.22 and 5.4.13). In their postings on social media patients also shared how to 
navigate through the insurance and reimbursement process, which has become more 
cumbersome for reasons described in sections 3.7.25 and 3.7.26. The postings showcased 
from real-life cases on a public online platform the implications of the double agency theory 
discussed in section 3.6.4. 
6.4.1.17 Cost-effectiveness considerations and additional complications  
It is established that using cost-effectiveness as a key parameter for medical decision making 
is necessary and valid for a healthcare system with constrained resources. In the specific 
case of prophylaxis treatments for HAE, the high variability of the disease across patients 
and within patients over time, combined with the high sensitivity of the cost-effectiveness 
dependence on highly variable assumptions, make a general cost-effectiveness analysis for 
payer’s decision making impossible. Any of the prophylactic drugs can fall on either side of 
the cost-effectiveness thresholds depending on the patients or even depending on different 
moments in the life of the patients. Additional considerations complicate the situation. 
Healthcare per se and medical decision-making by a physician, on the other hand, is 
intrinsically linked to ethical principles of fairness, reducing pain and beneficence. As 
Zuraw (2019) stated, treating physicians have to follow these principles. Patients and society 
expect these principles to be followed by all stakeholders, hence once more the necessity to 
combine the three perspectives of EBM, HE and QoL into one framework. The above 
discussed indirect costs resulting from missed work, reduced productivity at work, missed 
education, missed career and income opportunities, will be covered in the next section. They 
are poorly defined and quantified, also due to the high variability and the small patient 
population to analyze, and further not considered by payers when making pricing and 
reimbursement decisions. A study states that because of these reasons, it is likely that the 
true indirect burden of HAE is significantly higher than reported in the literature (Wilson, 
2010). Research and publications sometimes refer to the role played by caregivers, who 
provide assistance to patients either during attacks or during the administration of 
intravenous medication at home. Such support may result in caregiver absenteeism and 
generated further indirect costs that are not captured, not considered for reimbursement and 




methods, it appears that the economically most efficient one is self-administered therapy, 
especially ‘‘on-demand’’ for HAE attacks. At least one study (Bhasin, 2014) reached a 
similar recommendation leading to the suggestion to physicians to encourage self-
administration as a mean to maximize cost-effectiveness while enabling patients to become 
more independent. 
6.4.1.18 Conclusion on cost considerations 
The study by means of a survey to HAE physicians described in section 5.1, the study on 
social media described in section 5.3 and the first part of the meta-analysis described in 
sections 5.4.1 to 5.4.13 have covered the dimensions in which HAE impacts patients, 
caregivers, the healthcare system, the payers and society as a whole. The dimensions could 
be grouped as follows:  
(1) The clinical course of the disease with its early onset, the delayed diagnosis, the cases of 
misdiagnosis and wrong treatments, the chronic nature and the variability of the symptoms 
as described in section 5.4.1.  
(2) The symptoms which manifest as attacks that are unpredictable, can be prolonged, can 
vary in frequency, can be disfiguring, painful, debilitating and even life-threatening; Next 
to direct symptoms are a range of comorbidities discussed in section 5.4.7. 
(3) The treatments which are currently not available to all patients globally, are expensive 
and can cause side effects.  
(4) The costs which go beyond the treatments and include direct costs by physicians, 
hospitalizations and ERs, but also the indirect costs arising from lost work and school 






6.5.1 Measures of QoL 
Section 5.4.14.1 identified different variables and instruments that have been used to 
measure QoL of HAE patients. The thesis concluded from the research that overall data was 
limited due to a small number of patients’ studies and the lack of well-defined disease-
specific QoL instruments. Different studies used many QoL instruments making it difficult 
to compare findings on the humanistic burden between them. While HAE symptoms were 
the starting point for all QoL considerations due to the attacks, the triggers and the 
comorbidities, partners and families of the patients were also affected. The relationships 
between HAE patients and their immediate social environment were impacted - for example 
by the ability to perform joint activities, or by the need of the family and caregivers to help 
administer the medicines. Day-to-day activities are affected by the ability, or not, to perform 
physical and cognitive tasks, for example when the mind is fixated on depression, anxiety, 
worry, embarrassment. Social life takes a toll when the patients are or feel constrained from 
traveling and engaging socially. Work-life and education are impacted by absenteeism, 
reduced productivity because of diminished physical and mental capacity. Vitality and 
energy levels are impacted by fatigue, sleeping disorders due to anxiety, or directly sleeping 
time lost to attacks with their pain, or impossibility and fear to perform sporting activities. 
Medical care is impacted as patients need to see physicians, sometimes be hospitalized or 
treated in ER. Measuring all the factors in a consistent and simple manner across a 
representative sample of patients over time seems not to have been attempted so far. 
6.5.2 QoL impact from HAE attacks  
In section 5.4.14.4 different studies that collected QoL data on patients during HAE attacks 
have been analyzed. These studies were performed on patients that were diagnosed and on 
treatment. The variance of the days per year missed was relatively high, which could be 
explained by the studies’ different eligibility criteria and the different ways of treating the 
condition in different healthcare systems. Additionally, HAE attacks and the condition itself 
presents in different degrees of severity as discussed in 5.4.3 and patients suffer greater QoL 
impact when having more severe attacks as they are more debilitating. More severe attacks 
cause HAE patients to stay at home and miss work and other activities, while milder attacks 
can be less disruptive. The studies identified in section 5.4.14.4 seemed to show that despite 
following the standards of care, HAE patients still have frequent and painful attacks, 
continuing to experience significant impairment physically and emotionally both during and 
between the attacks. 
As the data presented in section 5.4.10 suggested, the QoL outcome for HAE patients could 
be even worse when there are treatment delays. The delays not only prolong unproductive 
time, but increase the risk of treatment failure, the amount of time in pain and the time until 




6.5.3 QoL impact from HAE treatment 
Section 5.4.14.5 illustrated the relatively minor impact of the HAE treatment themselves on 
the patients, when compared to the attacks. However, section 6.3.3.12 illustrated the 
multiple benefits of enabling self-administration (or home treatment) of HAE medication. 
These included better clinical outcomes such as significant decreases in attack duration, 
reduced need for pain medication and lower attack severity, with no increase of serious 
adverse effects or tolerability issues. In addition, home treatment was shown to lead to lower 
costs and improved QoL, as these patients scored better psychologically and physically, 
including on the depression and anxiety scales. One possible identified explanation was that 
self-treating patients had and perceive to have had greater control over their condition and 
their lives. The thesis confirms the statement by Devercelli (2018) that despite the strong 
progress on modern treatments and home therapy, the burden of HAE on patients’ daily lives 
still remains high and could be reduced. 
6.5.4 HAE burden on education and work 
Section 5.4.14.6 illustrated from a number of data sources the different dimensions of burden 
that HAE can cause to its patients. Such a widespread array of impacts begins already during 
childhood and reinforces the need for early awareness and diagnosis, as well as a meticulous 
medical follow-up with the youngest patients. Section 5.4.14.9 reported the impact that HAE 
could have on the patients’ educations, which could have long term repercussions.  
The survey conducted with physicians treating HAE reported in section 5.1.3.2 reported a 
wide range of days of school, work or other commitments missed by HAE patients due to 
their condition. The figures differ across physicians and across studies reported in the 
literature. A possible explanation could be that several published studies were based on data 
collected before modern treatment was widespread and that during the time of this thesis, 
patients were treated more effectively. This could have led to a significant reduction of the 
number of days lost in such a way that it is not so much of an issue any longer. An alternative 
explanation could be the possible disconnect between patients and physicians described in 
section 3.6.7 as one of the challenges of the agency theory, and/or a combination of the two 
explanations. If a disconnect between physicians and patients was the cause, then it would 
suggest a missed opportunity for better clinical outcomes and QoL, as physicians might 
change treatment towards drugs with higher efficacy, if they knew of the full picture (i.e. 
missed number of days) of their patients and the impact this has on their lives.  
6.5.5 HAE impact on the personal life  
The survey with HAE-treating physicians additionally reported in section 5.1.3.3 that they 
observed 50% of patients felt an impact on family planning. Such results could be explained 
by the hereditary (dominant autosomal) nature of the condition with a 50% probability that 
the offspring of an affected patient will also bear the disease, as described in section 3.8. 
This impact of the HAE condition could also help explain the depression comorbidity, when 
for example some patients decide not to have children under the fear of passing on the 
condition and its pain. The patients who decide to procreate might subsequently suffer under 




The meta-analysis of the literature produced higher results (see 5.4.14.9) with 44% of 
patients reported suffering a hindered education, and between 50% and 60% being exposed 
to career consequences. Participating physicians reported also that a weighted average of 
18% of patients carried no long-term consequence from their condition. This result could be 
explained by these patients being either asymptomatic or by having achieved a very good 
control through a successful therapy. Overall the survey showed better results than what was 
reported in the literature, which could be explained by the different cohorts and by the fact 
that some of the published studies were much older. Contemporary treatments have led to 
improved efficacy more generally (as described in sections 5.4.10.2, 5.4.10.3, 5.4.11.2 and 
5.4.11.5).  
6.5.5.1 Awareness by physicians on HAE burden for patients 
The survey reported that depending on the long-term aspects, between 12% and 82% of the 
participating physicians were unable to answer, with an average of 35%. The difficulty 
might have been driven by HAE patients showing significant differences in how the 
condition manifests (frequency, location, severity of attacks) (see 5.4.2, 5.4.3, 5.4.4, 5.4.5), 
but also in how they let the disease influence their life, some in everything they do, others 
much less or not at all. The search on social media reported the experience sharing among 
patients in section 5.3.1.2. A significant part of postings either in this segment or the one on 
inspirational content had as its objective to support fellow patients in the achievement of 
“leading normal life”, consistent with one of the key themes of HAE and debilitating rare 
conditions as described in sections 5.3.1.6 and 5.3.2.8. Forty per cent of the physicians 
participating in the survey were unaware of the working status of their patients, as reported 
in section 5.1.3.4. While these results could again reflect a certain disconnect as described 
in section 3.6.7, they might also appear as surprising when considering how impactful the 
condition is on the education and career of the patients as quantified in section 5.4.14. On 
the other hand, this result was somewhat consistent with the answers provided to the 
previous questions in the survey in regards to the criteria relevant to decide on the treatment 
to pursue: only 30% of physicians had stated that the profession and education of their 
patients was very important to decide on the treatment (see section 5.1.1).  
6.5.5.2 Conclusion on QoL impact on HAE patients 
Combining all discussed consequences, HAE can result in productivity losses and ultimately 
financial costs to the individuals and their families, as they cannot achieve their full potential 
career and earning potential. With the key dimensions education, professional career and 
social life burdened, the introduction of modern therapy offered after 2008 for the first time 
significant positive clinical outcomes. More than a decade later and during the writing of 
this thesis, the data collected in the three studies presented in the sections 5.1, 5.3 and 5.4 
suggests that despite the availability of treatments, a large number of possibilities persist on 
how the life of HAE patients can still be restricted due to the condition.  
The research on social media conducted for this thesis illustrated in section 5.3.1.6 how the 
burdens of the conditions also expressed themselves in the postings by the HAE patients on 




challenges of obtaining the right diagnosis and of getting the best (and costlier) treatment 
approved. Depression and anxiety were commonplace. Patient groups and the social media 
community served not only as platforms for the exchange of information, but also as 
instruments that provide emotional support, where patients shared with each other life advice 
and emotional support. On Twitter, this type of postings represented only about 2% of the 
total, as presented in section 5.3.2.8. It appeared that on social media offering life advice 
and support specifically on HAE concerned only a small minority of users. 
6.5.5.3 QoL impact on caregivers of HAE patients 
Caregivers of HAE patients are affected by the condition in multiple ways and section 
5.4.14.10 reported on data available in the literature. The survey of physicians conducted 
for this thesis reported in section 5.1.2.12 that a weighted average of 38% of patients was 
observed to require help from family members when having an attack or when administering 
treatment. This figure was less than the 52% reported in the meta-analysis in section 5.4.8. 
As studies have shown, support by other people is required when taking a patient suffering 
an attack to the ER or hospital (which can happen on average three times per year as per 
section 5.4.8.3, or to provide help when administering intravenous medication for 
prophylaxis. Such support is clearly necessary for children and youths, but also provided to 
adult patients and a source of indirect costs and QoL reduction that affects the family in 
addition to the patient. The survey also illustrated that on average 41% of treating physicians 
didn’t know if their patients were requiring support. This figure seems relatively high given 
the severe burden of the disease compounded by the burden of treatment. This might be 
another indicator that the communication necessary between physicians and patients 
described in section 3.6.7 is not ideal and could be deepened to achieve a better 
understanding of the patients’ needs leading to improved clinical outcomes and reduced 
risks. 
The true costs incurred by caregivers were difficult to quantify and may change considerably 
between patients and healthcare systems. In the pursuit of a holistic assessment of the cost-
effectiveness of HAE treatments for reimbursement as described in section 5.2.1.1, they 
should be factored in. For example, when prescribing prophylaxis treatments, it should be 
taken into account that such therapy would reduce not only the number of attacks and the 
burden on the HAE patients, but also decrease the caregiver’s physical and emotional 
burden. 
6.5.5.4 Other QOL aspects affecting HAE patients 
The search on social media reported in section 5.3.2.6 that about 4% of posts on Twitter 
were offering goods and services for patients with HAE. It appeared that these offerings 
were specific to HAE patients suggesting they have a value contributing to QoL 
improvements for the patients. Most of the postings were offering material to generate 
awareness, which could be seen as evidence for patients attempting to close one of the gaps 
of the agency model. However contrary to the agency model described in section 3.6.7, from 
this part of the research it appeared that the information asymmetry was in favor of the 




physicians and other stakeholders who also have a say on the therapy. Another type of 
postings in this category was offering scholarships to patients suffering from HAE. These 
acquired a particular meaning since people living with HAE are burdened by both additional 
significant financial outlays (see section 5.4.13.11) and by a negative impact on their 
education and career prospected due to absenteeism and other consequences of the condition 
(see section 5.4.14.6 and 5.4.14.7). For a youth with a debilitating chronic genetic condition 
which deeply affects not only his or her QoL but also the ability to attend educational 
programs, any form of help that could alleviate the additional burden can be 
transformational. Using social media for this type of offer may generate hope and success 
offsetting some of the depression and anxiety observed in sections 5.4.7.1 and 5.4.7.2. 
Combining the results of different studies: taking on-demand treatment as soon as possible 
after the onset of an attack is most likely possible if the HAE patient can perform home 
administration (see section 6.3.3.12). This would reduce the duration of the attack, the 
severity of the attack, and therefore mitigate also the QoL impact by reducing, and possibly 





7 CHAPTER SEVEN - CONCLUSION 
7.1 Connection between thesis results, RQs and emerging themes from 
the literature search 
The literature search identified recurring themes which in section 3.10 were connected to 
the problem statements and RQs: 
RQ 1.1: How do different stakeholders and decision-makers have an impact on 
patients with rare diseases? 
RQ 1.2  Are diagnosis and treatment decisions made with EBM, QoL, HE and RWE 
considerations in mind? 
RQ 2: How can the decision-making process and the available and potentially available 
data be combined to allow the stakeholders to make economically more efficient therapeutic 
decisions with better health and QoL outcomes?  
Pursuing the research design and methodology described in section 4, the results described 
in sections 5.1, 5.3 and 5.4 were attained and discussed in section 6. All combined they can 
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the patient’s point of view. For rare 
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pharmaceutical companies are 
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Price differences for same 
treatments across healthcare 
systems and different levels of 
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7.2 RQ 1.1 - Impact of different stakeholders and decision-makers on 
patients 
7.2.1 Importance of the question and underlying theoretical framework 
RQ 1.1: How do different stakeholders and decision-makers have an impact on 
patients with rare diseases? 
This thesis aimed to measure the impact of the different stakeholders and the roles of the 
different perspectives in the decision making and execution of alternative therapies, with the 
objective to explore the combination of all in order to attain superior outcomes in a more 
cost-effective way. Social acceptability plays a key role, as Doll (Doll, 1974) already noted, 
“there is no point providing a health service that is clinically effective and economically 
efficient, but no-one wants”. The agency model applied to healthcare and discussed in 
section 3.6.1 describes the most immediate way on how patients are impacted by physicians: 
patients are principals who depend on physicians for medical advice, and physicians are 
agents who are responsible for making optimal health-related decisions on behalf of the 
patients. When the payers, public or private insurances which ultimately fund medical 
treatment (see 3.5.5), and their constraints (see 3.5.6) are factored in, the theoretical 
framework to be used becomes the double agency model discussed in section 3.6.4 with the 
subsequent conclusions on the decision-making (see 3.6.5), eventual disconnects (see 
section 3.6.7), possible consequences and how they could be mitigated (see section 3.6.8 
and following).  
7.2.2 Answer contributions from the study and the meta-analysis 
A survey with treating physicians has confirmed the impact both physicians (see section  
5.1.1) and payers have on clinical outcomes and QoL of patients. Other stakeholders such 
as family members, caregivers, patient organizations, etc. can play a role, however the main 
and more directly affected one, and in scope of this thesis, are the patients, the physician and 
the payer, who encourage physicians to follow treatment guidelines, leading to outcomes 
with increased cost-effectiveness, utilizing the HE methodology discussed in section 3.5 and 
consistent with replies to the survey in section 5.1.1). The evaluation of health care depends 
on the criteria used by every stakeholder. Historically it has been advocated that three criteria 
should be used: clinical effectiveness, economic efficiency and social acceptability (Doll, 
1974). EBM (see section 3.1) is defined as the explicit, judicious, and conscientious use of 
current best evidence from health care research in decisions about the care of individuals 
and populations (Brian Haynes, 2002). Once a diagnosis of the condition is confirmed, 
ideally patients and physicians decide together on the course of action based on the available 
and known evidence produced by RCTs (see section 3.1.15) and ideally also by RWE (see 
section 3.3). To facilitate decision-making and reduce risks, both physicians and patients 
can follow the guidelines discussed in sections 3.1.10, 3.1.12, and 3.1.13), which are built 
on evidence and experience. Payers also attempt to enforce guidelines as their 
recommendations are proven or more likely to produce maximized clinical outcomes and 
reduce the possibility of unnecessary costs generated by misdiagnosis, or inappropriate 




clinical evidence discussed in section 3.2, but also reflect the patient’s values, preferences, 
circumstances and local context (Hoffmann, 2014). Lastly, a broader perspective developed 
in attempting not only to achieve the best clinical outcome, but to holistically maximize 
QoL, which is directly experienced by the patients on a daily basis and over the course of 
their lives (see 3.4 and responses by physicians to survey 5.1.3). 
7.2.3 Validation of agency theory as theoretical framework 
Agency theory describes the partnership between patients and clinicians (see section 3.6) 
and how it presumes that the treating physician facilitates patient involvement and is open 
to adjusting the treatment to the preference of the patient. Studies have shown that patients 
are unable to fully partner during the clinical encounters, and at the same time, physicians 
don’t like their patients to engage (or interfere) in the decision-making process (Couet, 
2013). Lack of time, skills, knowledge, mutual respect and effective communication 
processes pose barriers to effective shared decision-making (Staniszewska, 2014). A large 
portion of doctors believe they know how much the patient wants to be involved and even 
what therapy the patient would prefer, if he or she had full access to and ability to fully 
interpret the clinical data. This scenario may be more likely with rare conditions where the 
information asymmetry between physicians and patients is more significant, and where 
clinical data and experience are not yet translated into common language and made 
accessible to the layman through the normal channels. However, the survey has also 
highlighted that for some critical matters, a large share of physicians is not able to answer 
basic questions such as what the approximate financial implication or QoL impacts of the 
condition are for patients (see sections 5.1.3 and 5.2). Research on social media analyzing 
postings by HAE patients has identified instances where patients are advising one another 
on how to communicate with doctors, highlighting gaps, theoretically known through the 
agency theory, that could be closed). Nevertheless, EBM can turn into forcing evidence and 
measures onto a not fully engaged patient resulting in suboptimal adherence and clinical 
outcomes. The best working solution is best described as shared decision-making, where 
both clinician and patient jointly assess options with their benefits and harms, and together 
decide, incorporating the patient’s values, preferences, and circumstances (Hoffmann, 
2014). The survey with physicians has also confirmed that the patients are the most 
important stakeholders (besides the doctors themselves) necessary to reach a treatment 
decision (see 5.1.1). High-quality patient experience demands a few additional attributes 
from the interaction with the physician: the patient is an active participant, the physician is 
responsive with his or her services, he or she offers an individualized approach, provides a 
lived experience that includes continuous care and relationship, and lastly offers timely 
communication, information and support (Staniszewska, 2014), which takes commitment 





7.2.4 Analysis of the variables  
Section 4.2.1 suggested from the literature search that patients and physicians are the key 
stakeholders, surrounded by other stakeholders or influencers such as payers (insurance 
companies), family members, caregivers, patient advocacy groups, other healthcare 
professionals (e.g. nurses, pharmacists), pharmaceutical companies, regulatory bodies, 
media). The importance and order of priority of the variables was analyzed in section 5.1 
and is consistent with the outcomes of the survey and the research on social media described 
in section 5.3. The metanalysis performed and discussed in section 5.4 indicated especially 
physicians and patients to be the main stakeholders exposed to the condition and sources of 
data and insights on the condition and its treatment. The metanalysis also suggested the 
payers as key stakeholders, including the type of considerations they make to decide which 
treatments to fund. The criteria utilized for diagnosis, treatment decisions and for assessment 
of outcomes stated in section 4.2.2 were also substantiated by the survey with treating 
physicians in section 5.1 and found some mention in the social media as discussed in section 
5.3. Epidemiology, symptoms (frequency, location, and severity) of HAE attacks, fatalities, 
co-morbidities, QoL impact and treatment costs have been extensively studied through 
numerous studies, surveys and RWE and consolidated conclusions discussed in the meta-
analysis in the sections from 5.4.1 to 5.4.14). Analogously QoL variables measuring the 
burden of disease such as QoL scores using different types of instruments, days missed from 
work, school or social life due to the condition, hindered careers and reduced incomes, have 
been described both by the survey in 5.1, while also being measured, analyzed and discussed 
in the meta-analysis in section 5.4. Lastly, the economic costs of a condition, its treatment, 
and its impact on society comparing different alternatives, is the objective of HE and RWE 
as described in sections 3.3 and 3.5. The variables are the costs expressed in monetary terms 
as they are borne by patients, caregivers, employers, the healthcare system and society as a 
whole. The survey discussed in section 5.1 has shown costs and financial implications of the 
condition to play a role in the choice by the physician of a treatment for the patient to pursue, 
although a large share of physicians seems unaware or unable to quantify the full and true 
costs of the condition they treat. In the meta-analysis (section 5.4.13) the thesis identified a 
number of reports which quantified the different costs that are resulting from a patient 
carrying the HAE condition.  
7.2.5 Assessment of methodology used 
The thesis used a combination of a survey, a search of social media and a meta-analysis on 
a wide spectrum of publications, research reports, clinical studies, RWE, guidelines that 
were all peer-reviewed and cover the HAE conditions and aspects relevant to it. The 
different approaches provided to be consistent and complementary in their findings, while 
at the same time confirming the limitations described by applying the double agency theory 






7.3 RQ 1.2  Diagnosis and treatment decisions EBM, QoL, HE and 
RWE considerations  
7.3.1 Answer to RQ 1.2 
RQ 1.2  Are diagnosis and treatment decisions made with EBM, QoL, HE and RWE 
considerations in mind? 
The survey with physicians treating patients with HAE provided the data enabling the 
analysis of the criteria they use to make treatment decisions (see section 4.1 and results in 
section 5.1.2.5) covering all aspects with different degrees of priority. First priorities appear 
to be classical EBM parameters expressed in clinical terms such as patient history 
(symptoms and co-morbidities), the efficacy of treatment and safety. These are followed by 
health economics and lastly by QoL considerations. The survey highlighted that the 
physicians’ knowledge and ability to answer decreased significantly when considering 
aspects that are not strictly medical in nature. This finding appears in line with the fact that 
QoL and HE are areas of expertise that fall outside the strict boundaries of the classical 
medical education which shapes and forms a clinical physician. The corollary of this 
observation is that gaps arise as described in the agency theory described in section 3.6, 
further enhanced by communication barriers between the three main stakeholders 
physicians, patients and payers. The analysis of the data gathered from the survey, the 
research on social media and the meta-analysis of the relevant scientific literature, appear to 
confirm how treatment decisions are made. However the analysis also suggested that the 
role of non-medical factors is under-represented causing potential additional challenges with 
patients and suboptimal outcomes from an HE perspective.  
7.3.2 Confirmation of the model describing the current situation 
The model proposed in section 4.1 appears to be confirmed by the utilized research 
instruments which include the direct observations of physicians, through a broad survey, 
and patients, through a search of social media postings, and the payers complemented by a 
meta-analysis covered in section 5.4, which aimed to include all relevant research and 
publications on the specific object. The influence of the payers was substantiated by their 
assessed importance for treatment decisions discussed in section 5.1.1 and the importance 
of the insurance coverage as a selection criterion for the drugs to be prescribed discussed in 
section 5.1.2.5. QoL parameters were assessed as relatively less significant and physicians 
appeared overall less knowledgeable both in quantity and in quality than what is known in 
the literature, as described in section 5.4.14. 
7.3.3 Assessment of methodology used 
To answer RQ 1.2 the same methodology and the same sources of data were used, hence the 
assessment of the methodology could be confirmed. The thesis was able to include a large 
number of diverse sources including the bulk of scientific literature on the subject, direct 
contribution by a large number of physicians spread across different geographies, as well as 
a large number of social media postings by patients themselves. With all sources, the thesis 




significantly undermine the model or invalidate the theoretical framework utilized. Both 
model and theoretical framework appear to be validated and the thesis could apply them to 
the specific rare genetic conditions of HAE, allowing to reach a conclusion which can be 





7.4 RQ 2  Combination of EBM with QOL and HE for better and more 
efficient outcomes 
7.4.1 Importance of the RQ and method to develop an answer 
RQ 2: How can the decision-making process and the available and potentially available 
data be combined to allow the stakeholders to make economically more efficient therapeutic 
decisions with better health and QoL outcomes?  
The combination of the perspectives clinical outcomes (EBM), QoL and HE/RWE has to be 
pragmatic and consistent, allowing the stakeholders to speak the same language, align their 
incentives and maximize the outcome for the population. This was the core element of the 
thesis and the objective was the development of a framework which enables refinements of 
the therapeutic and funding decisions to produce better health outcomes in a more cost-
effective way, leveraging new insights from the studies 1-3, the identified dependencies 
between EBM, QoL and HE/RWE and the integration into one framework. The framework 
was expected to determine optimized solutions measured as health outcomes for the patient 
population achieved in more cost-effective ways. The thesis aimed for the framework to be 
pragmatic and ready for use in the real world. 
The first step was to consolidate outcomes by linking the variables through direct 
dependencies and co-dependencies (for example clinical decision based on EBM impacts 
QoL in a specific and measurable way. causing monetary costs and benefits). Subsequently 
the thesis estimated alternative outcomes by changing the assumptions and the decisions 
made to produce optimal results by integrating the three perspectives (which could be 
expressed in statements such as “patients with specific clinical and QoL attributes could 
benefit from increased prophylaxis treatments which would result in significant better 
clinical outcomes (reduced number and severity of attacks) which cost marginally more”). 
7.4.2 Answer to RQ 2 
7.4.2.1 Analysis of stakeholders, decision making process and methodology to 
provide answer  
The stakeholders and the decision-makers who have an impact on patients suffering under a 
rare condition have been analyzed through different independent studies and the results have 
been summarized when answering RQ 1.1 in 7.2.2. Within the theoretical framework agency 
theory, physicians follow the EBM approach described in section 3.1.6, building on 
scientific research, RCTs that prove efficacy and safety profiles of drugs as discussed in 
section 3.2.1, with the objective of improving and maximizing the clinical outcomes for the 
patients. Rare conditions however present themselves with a number of additional 
challenges (see section 3.7) which begin with the clinical aspects such as low disease 
awareness, difficulty of diagnosis, recruitment challenges for RCTs (discussed in sections 
3.7.16 and 3.7.17), continue with significant QoL impacts due to the frequently devastating 
impact of genetic conditions (see section 3.7.19) to finish with the important financial 
considerations that are observed both from a treatment perspective (see sections 3.7.20 and 




and their caregivers’ perspective (see section 5.4.14). The motivation for the thesis explained 
in section 1.3 was born from the observation that most of these concepts are not considered 
in a holistic and fully integrated way when treatment decisions are made for and with the 
patients (see sections 3.6.5 and 3.6.7). The aim of the thesis was to first understand and 
describe in a structured way the current decision-making process (see section 1.4) 
confirming the proposed model. Three studies were proposed and executed: a survey with 
treating physicians described in section 4.3 with results in section 5.1, a study on social 
media postings described in section 4.4 and results in section 5.3, and a comprehensive meta-
analysis which aimed to cover all relevant scientific literature on the chosen condition HAE 
described in section 4.5 and results in section 5.4.  
7.4.2.2 Application of answer to theoretical framework 
The three studies confirmed the agency theory model and have contributed to answer RQ 
1.1 and RQ 1.2, and additionally, they provided data to enable proposing an answer to RQ 
2. Historically already with the advent of EBM the concept of shared decision making was 
developed as described in sections 3.1.5 and 3.6.5, whereas treating physicians and patients 
jointly assess the options and decide on the best treatment to pursue. This concept helps to 
overcome the main challenge identified leveraging the agency theory to describe the 
physician-patient relationship (see section 3.6.1) with possible disconnects (see section 
3.6.7). With increasing costs of medical treatments, further exacerbated within the category 
of rare diseases and orphan drugs (see sections 3.7.2 and 3.7.3), payers play a prominent 
role as a small minority of patients can afford the treatments without support by means of 
reimbursement as described in sections 3.7.20, 3.7.22 and 3.7.25. HE considerations become 
prominent (see section 3.7.26) and the payers take the role of an additional agent and the 
double agency theory can be applied as discussed in section 3.6.4. With three main players, 
patients, physicians and payers, complexity, asymmetry of information and risk of 
misalignment increase. The data produced with this thesis through a survey described in 
section 4.3, a primary search of stakeholders content on social media described in section 
4.4, and through a meta-analysis of available scientific and published literature described in 
section 4.5, utilized the variables discussed in section 4.2 and confirmed the model 
underlying the thesis design described in section 4.1.  
7.4.2.3 Possible improvements of clinical practice based on the findings 
The findings suggest that room for improvement is possible if the three stakeholders were 
to share the actual values of the variables. Currently treating physicians focus on the clinical 
outcomes more directly linked to their fields of study, such as symptoms and clinical 
outcomes (see section 5.1.2) having also attained knowledge of and observed the positive 
impact of correct diagnosis, the positive impact of treatment (illustrated in section 5.1.2.4), 
the criteria for the selection of the treatment (see section 5.1.2.5), and the comorbidities (see 
section 5.1.2.11). However, when considering the QoL aspects, more than half of the 
physicians seems to know relatively little about the impact of the condition on the patients 
(see sections 5.1.3.1 and 5.1.3.2), while those who had the opportunity to show interest, 




A similar outcome was observed when studying the financial impact of the rare condition 
through the patient's financial exposure (see section 5.2.1.1), their reimbursement status (see 
section 5.2.1.2) or the yearly treatment costs to them and their payers (see sections 5.2.1.3 
and 5.2.1.4). Of the three dimensions EBM, QoL and HE, most physicians are only fully 
informed and considering the first one, with information and consideration gaps in the latter 
two. The search on social media raised through the postings aimed on education, experience 
sharing and support (see sections 5.3.1.2, 5.3.1.4 and 5.3.1.6) that patients are putting effort 
in closing the information asymmetry by advancing relevant information and their agenda 
with the objective to obtain better and more timely treatment resulting in a superior QoL and 
better long term prospects.  
7.4.2.4 Possible impact if improvements executed 
The physicians participating in the survey for this thesis are treating slightly short of 3’000 
patients suffering from HAE. If the half of them, who is not fully aware of QoL aspects and 
financial implication of the condition, were to close their knowledge gap and adjust their 
treatment approach correspondingly, then it could have a life-changing impact for their 
patients. Possibly more efficacious modern prophylaxis treatment with better safety profile 
would be prescribed as described in section 5.4.11, which would reduce the number of HAE 
attacks, the risk of fatalities, and the prevalence of comorbidities (with some of them being 
themselves also triggers of even more attacks, as discussed in section 5.4.7. Further, the 
estimated 1,500 patients might enjoy a better QoL and become financially better off, as the 
financial impacts of suffering from HAE would also be significantly reduced. These figures 
result from simply applying the findings to the population covered by the survey, located 
dominantly in advanced Western healthcare systems in Europe, North America and selected 
South America.  
7.4.2.5 Differences across healthcare systems 
A separate discussion needs to be made for other applied to other geographies and emerging 
markets such as in the Asia Pacific, Middle East, Eastern Europe and Africa. The same as 
above might produce more dramatic impact, as the vast majority of patients has not been 
diagnosed and still needs to close the first gap of being treated with EBM in mind, as in 
order of priority removal of pain and life-threatening health situation (for example through 
laryngeal attacks discussed in section 5.4.2) should be addressed first. On the other side, the 
economic situation and the state of the healthcare system in most emerging markets require 
other actions and progress first (discussed in section 0) such as for example first addressing 
and improve the general population’s healthcare impacted by more basic widespread 
diseases (for example infectious diseases) and living conditions. An essential condition to 
improve diagnosis and treatment rates discussed in section  5.4.1, is having sufficiently 
trained and aware specialist physicians, as most rare conditions are genetic and are treated 
by either immunologists or allergists), a basic awareness in the population of rare diseases 
and a functioning referral system where doctors can advance their patients to the right 
specialist. The meta-analysis has shown that the time between the first onset of HAE and 




advanced healthcare systems where the studies have been performed, illustrated in sections 
5.4.1.1 and 5.4.1.2. In emerging markets, these timelines can be significantly longer, and the 
vast majority of patients has never been diagnosed at all. There is wide disparity of most of 
the variables, from the frequency (see section 5.4.4), to the severity of the attacks (see 
section 5.4.3), from the number of hospital visits (see section 5.4.8) to the type of 
intervention needed, from the comorbidities to how and if they are treated by which type of 
HCP (see section 5.4.7), from the type of treatment to the drug selected (discussed in sections 
5.4.10 and 5.4.11), from the price of the treatments to the price of the healthcare services 
provided across systems (see section 5.4.13), from the level of reimbursement to other 
financial consequences impacting patients, their caregivers and society (see section 5.2). 
The differences and the variability are observable across different maturity levels of 
healthcare systems (from advanced Western countries to emerging market), across types of 
healthcare systems (from universal healthcare to fully self-pay), across social segments and 
income groups, and lastly across individual patients.  
7.4.2.6 Challenge in reconciling the differences 
The data available through publications, RCTs, observations, surveys and social media 
appear to be not sufficient in quantity and granularity to be able to quantify every sub-
segment of patients, possibly also due to the fact that the absolute number of patients 
themselves is relatively small, caused by the intrinsic nature of a rare condition. These 
factors make it difficult to develop simple quantitative models which incorporated all EBM, 
QoL and HE variables and which could be used to develop an overall optimized solution.  
7.4.3 Application of research 
7.4.3.1 Overview 
Taking all into account, the development of an algorithm that incorporates all variables and 
which could be applied to the general population appears not possible for now. Both the 
variabilities of the individual variables (see tables in section 5.4) and the fact that due to 
multiple, not controllable and not influenceable factors they could reinforce or partially 
offset one another, would widely disperse the end result in such a way that no clear 
conclusion or call for action can be drawn. However, the thesis has shown and structured 
several concrete opportunities where improvements can be achieved, which will lead to 
better clinical outcomes, better QoL and more efficient economic effectiveness. The most 
significant ones could be achieved by addressing the challenges already raised by the double 
agency theory (described in section 3.6.4).  
7.4.3.2 Prominent opportunities for application of the thesis 
Prominent first opportunity would be an attempt to close or minimize the disconnects 
between the agents. The study has shown large shares of treating physicians not being aware 
or knowledgeable about key aspects affecting the lives of their patients and which should 
play a role in the decision of which therapy to pursue. The next important gap is when payers 
do not factor in all costs (not only the direct ones) into their HE considerations leading to 




unconsciously aware that here more can be achieved and are taken matters into their own 
hand as proven by analyzing their voices on social media either directly or by way of the 
patients’ advocacy groups representing their interests. This thesis could provide further and 
broader evidence for this mission. 
7.4.3.3 Impact of the application of the thesis 
Taking the study results on the individual variables analyzed in section 5.4, all of the ones 
linked to human behavior such as diagnosis, treatment decisions, use of healthcare services, 
life decisions on education, career, social activities, family planning, show individually 
opportunity for improvement. Nature of the studied condition and other rare diseases is, that 
the variables are interlinked. A patient who is diagnosed years earlier, already in his or her 
youth, can be treated immediately, suffers fewer attacks, is exposed to fewer setbacks in his 
or her education and social life, can pursue a more normal life with less pain, improved QoL 
and less financial burden. In aggregate, beyond the patient, also the caregivers, the 
community and society will benefit. 
7.4.4 The possibility of a comprehensive treatment algorithm 
The thesis has answered the RQs and substantiated the application of the double agency 
theory as an underlying theoretical framework. The variables are interrelated and 
theoretically it would be possible to code them into an algorithm or a formula which would 
allow to optimize the outcome of the treatment and the funding decisions. However, there 
are significant variabilities due to the intrinsic properties of the studied condition, combined 
with the challenge of obtaining sufficient data points which is typical of rare diseases. These 
constraints would probably cause such an algorithm to be cumbersome and of limited use in 
real life. On the other hand, the quantification of the variables as discussed in sections 5.1, 
5.3 and 5.4, may be instrumental in prioritizing the efforts of physicians, patients and payers 
to improve the prospects of patients suffering from rare conditions, as discussed in section 
7.4.3.  
7.4.5 Assessment of methodology used 
The methodology described in section 4, using a combination of a broad survey with treating 
physicians, a search through the voices of the patients expressed through social media, and 
the meta-analysis of scientific articles and research on the condition and ancillary relevant 
aspects since it was first diagnosed, seem to have proven to be a valid approach which has 
delivered consistent insights from different perspectives. Thanks to the methodology 
chosen, the thesis can possibly become a good fundament for the stakeholders exposed to 






8 CHAPTER EIGHT - CONTRIBUTIONS, 
LIMITATIONS AND FURTHER RESEARCH 
8.1 Learnings from the thesis 
The literature review in section 3 collected and structured what is known and what has been 
researched in the field of rare diseases, HAE, EBM, QoL and HE, confirming the motivation 
to conduct this thesis and supporting the development of the RQs and the methodology. The 
review did not find any evidence of a large scale survey covering the three dimensions, any 
analysis on patients’ thoughts and messages expressed on social media, nor a broad meta-
analysis of the available scientific literature and publications and not direct application of 
the double agency theory in the area of rare diseases. The pursuit of the thesis with three 
types of study allowed to broaden the sources, obtain different perspectives, attain 
confidence when there were overlaps and the findings when they were consistent, but also 
identify potential gaps and misalignments when they were not. The results confirmed the 
chosen research design and the decision to utilize a diverse range of sources, methodologies 
and analytical methods. The thesis obtained broader and stronger results, identified new 
areas for research and provided to the affected stakeholders, patients, doctors and payers, a 
more robust instrument to enhance the impact of their actions.  
8.2 Contribution to theory 
The thesis was conceived to add a more comprehensive framework as a basis to explore the 
network of relationships between all stakeholder patients, physicians, payers, caregivers, 
and society. The framework is based on currently available and potentially available data 
which incorporates classical EBM, QoL considerations, HE and RWE. The associations that 
exist within the healthcare system factor together clinical outcomes, economic 
considerations and ethical considerations. The challenge in these associations stems from 
the complication of expressing the drivers within the healthcare system from the diverse 
disciplines that exist (medicines, economics, business, and ethics) into variables that can be 
combined, compared and benchmarked. Different stakeholders have different objectives 
which may not be aligned as described by the double agency theory. A combined framework 
might generate controversy with some stakeholders and ultimately different solutions can 
be addressed through scholarly debate or, even better, through improved real-life health 
outcomes. These outcomes and potential benefits lie at the forefront foremost for people 
living with rare diseases and often similar conditions. This thesis has contributed to the 
double agency theory by extending its application to the new field of rare diseases, 
confirming the variables, analyzing the interdependencies and attempting to pave the way 
to a comprehensive framework which could be expressed as an algorithm that produces the 
optimal therapeutic decision. The framework and approach could subsequently be 





8.3 Contribution to practice 
The scope of this thesis was to explore the combination of EBM, RWE, HE and QoL for 
rare diseases and HAE has been analyzed in detail as an example that might be generalized 
and applied to all rare conditions which combined affect around 8% of the population. The 
findings of the thesis project could have a positive impact for all stakeholders with the 
patient at the center of the attention, while offering a comprehensive approach that factors 
in not only clinical outcomes, but also socio-economic considerations. Understanding of the 
different levers will set the priorities and help define a roadmap for further improvements, 
which can be in the form of better diagnosis and treatment with a focus on effectiveness, but 
also a confirmation or refinement of the focus of scientific research driven by new insights 
on medical needs and their impact on society. The integration and consistent modeling of 
information, is expected to highlight the importance of monitoring, collecting and 
interpreting real-life data, while integrating such activities and their results into the processes 
for the standard of care definition, regulatory approvals and reimbursements. Change of 
practice and behaviors could subsequently be facilitated by refined incentive systems for 
different stakeholders which focus on overarching goals, and which are complemented by 
education and awareness programs. Each item could open up new opportunities for research, 
and ultimately clinical outcomes measured as a longer and less painful life with fewer 
disruption to work, education and social relation might be achieved. 
8.4 Contribution to the industry 
A more detailed, consistent and holistic understanding of all stakeholders, their drivers, and 
the criteria and variables for decision making covering all dimensions from clinical 
outcomes to economic and ethical considerations, will allow pharmaceutical companies to 
better position, price and promote their drugs. The prescription, frequency of use, price paid, 
and adherence to treatment depends on all researched factors, and not just on efficacy, safety 
profile and price. The pharma industry could leverage the outcome of the thesis to better and 
more profitably serve all stakeholders, engage closer with the patients, the payers and society 
as a whole. Possibly this might contribute to the effort of improving the perception that 
pharmaceutical company are dominantly focused on profits, while ultimately benefiting the 
people living with the conditions that their products treat.  
8.5 Contribution to the wider society 
This thesis and its resulting findings and insights could contribute to providing greater clarity 
and a more holistic perspective to all stakeholders, which they can use when they make 
decisions based on their respective needs. This includes better insights on outcomes, their 
costs and the compromises that need to be made, which ultimately benefits both the 
undiagnosed and untreated people living with a rare disease leading to accelerates treatment 
opportunities (Schieppati, 2008). 
Access and use of a holistic and structured transparent framework which factors in all drivers 
and limitations, offers the opportunity of a certain peace of mind that would replace wide-




as “Healthcare decisions are discretionary or mysterious in how they have been made”, 
“Some treatments are over-priced”, “Society is two-class where a majority has no access to 
needed treatment”, “Healthcare organizations are inefficient and slow”, “The 
pharmaceutical industry is solely profit-focused”, “Payors don’t care about the patients”, 
“Doctors don’t listen to patients”, or “Patients are not informed and not compliant”. More 
concretely, the thesis highlights the multiple ways that patients with a rare disease are 
affected, including all the reverberations on society as a whole. If thanks to the contribution 
of this thesis patients with rare diseases have better clinical outcomes, better QoL, can better 
fulfil their education potential, can be more productive professionally and are less hindered 
in their social life, then wider society benefits. 
8.6 Contribution to the knowledge area 
This thesis builds a bridge of connectivity between the different stakeholders. It does this by 
exploring the research questions and their relevant interdisciplinary relatedness. The 
underpinning objective of the thesis is to build and describe a comprehensive framework 
which can be utilized in real life to achieve better healthcare outcomes. This bridge of 
knowledge sharing augments the knowledge within the different disciplines as they look 
beyond what is immediate, but also adds new aggregate knowledge within the ontology of 
rare diseases and how they can be better understood (analogue to the laws of 
thermodynamics which cannot trivially be extracted from the laws governing the individual 
atoms and molecules). The different stakeholders mentioned in the thesis could build on its 
holistic approach to make their specific therapeutic-, funding-, or policy- decisions 
incorporating the broader context leading to an improved overall outcome. 
8.7 Dissemination of research outcomes 
The thesis generalizability extends to virtually all rare diseases, estimated at more than 
8,000, which taken together affect approximately between 6% and 10% of the population. 
HAE has been selected as a representative condition, which shares most of the attributes of 
rare conditions: genetic, incurable, significant symptoms that dramatically influence the 
affected patients, exacerbated by such things as low awareness, low diagnosis rates, low 
treatment rates and expensive medication. The findings of the thesis have been formulated 
within concepts and terms that can be applied across the medical field. Dissemination of the 
information is planned across three main journal channels: (1) GP (General Practitioners) 
who might have the first interaction with a patient showing “inexplicable symptoms” or who 
follow the diagnosed patient through his life-long journey; (2) Allergists, often times the 
first level specialists who see the patients as the symptoms are similar or identical to allergic 
reactions, and (3) Immunologists, the experts in genetic conditions. As such, dissemination 
can be run through medical journals, allergy journals and/or immunology journals. A 
possible fourth option is via dissemination through mainstream media, given the epidemic 





8.8 Potential issues and difficulties 
Healthcare spending accounts for one of the largest shares of GDP spending in virtually 
every advanced economy. The stakes are significant in aggregate but also at an individual 
level. The selected area, rare diseases, is chronic, and in most cases cannot be cured, limits 
longevity and quality of life, with treatment options costing up to hundreds of thousands of 
dollars per year for the rest of a patient’s life (Schieppati, 2008). Despite these significant 
stakes, there is surprisingly little research, consensus and consistency on how different 
treatment decisions are made and funded (Schieppati, 2008). The difficulties lie in lack of 
data discussed in sections 3.7.13 and 3.7.15, which is also compounded by the absence of a 
universally recognized coding system for most of the rare diseases. Fragmentation, lack of 
information exchange and education leads to suboptimal systems, processes, platforms and 
divergent value systems. Different drivers lead to very high costs of drugs and treatments in 
general, putting payers under pressure when deciding if to fund them, based on incomplete 
information vs. the expectation by patients, caregivers and physicians to have access to the 
drugs discussed in section 5.4.9. Like many others, this area is not devoid of conflicting 
incentives across stakeholders, territoriality and aversion to share in a world of competition 
and often zero-sum games, as described in the agency theory described in sections 3.6.1 and 
3.6.4. A secondary aim of this thesis is to instill a sense of goodwill and foster a spirit of 
cooperation by building on the promise that additional insights will enable better results for 
all stakeholders. 
8.9 Delimitation of scope 
The thesis will focus on a well-defined enclosed market, spanning rare diseases and orphan 
drugs. This particular category of the healthcare market is particularly suitable because it is 
relatively new, dynamic and not yet established. The treatment of rare diseases with their 
lower patient and specialized healthcare professional numbers is concentrated around a few 
centers of excellence. The existence of fewer therapeutic options, and drugs with more 
differentiations, enables more data-driven and science-based decision making. Scope and 
depth of available data can be well captured, although due to the low prevalence of the 
conditions and the differing standards of care across the healthcare system, it is more 
difficult to find sufficient and consistent data (see 3.7.9). The selected area is of interest as 
the impact of drugs on both health outcomes (5.4.10 and 5.4.11) and QoL is significant (see 
5.4.14). The chosen condition HAE has a devastating impact and can be fatal for any patient 
any time (see 5.4.1 and following). Patients’ and treating physician’s commitment to follow 
through on treatment is high, given the life-altering impact of the condition. On the other 
side the costs for research and development of new drugs are equally large, which poses 
important pricing and market access challenges (see 5.4.13). The scientific rigor of this 
thesis is further enhanced by these conditions not being mainstream and thus their treatment 






8.10 Limitations of the research 
8.10.1.1 Overview 
Research on rare conditions faces limitations which have multiple repercussions for all 
stakeholders. For example, low numbers of double-blind, placebo-controlled trials on HAE 
treatments made it difficult during the second Canadian Consensus discussion to assemble 
a sufficiently strong level of evidence to support a recommended treatment algorithm 
(Bowen, 2008). Overall, while reviewing the studies available for the meta-analysis 
performed in section 5.4, following observations could be made: study protocols are 
heterogeneous, the distributions of patients between the arms were seldom clearly described 
(possibly for the reason explained in C. below). Few efforts were made in trying to explain 
the high variability of the main outcomes through an analysis of the random variability in 
the data and the patients. In several studies there was a relatively large number of patients 
dropouts, but little or no explanations on the causes being the condition, the intervention 
selected or other factors. Similar observations could be made on the frequent lack of 
reporting of the probability values for the main outcomes, the lack of controls of the 
appropriateness of the statistical tests used to assess the main outcomes, and the lack of 
controls of the compliance following the treatments (for example, there seems to be no 
viable path to control if patients really have an attack, how they are taking the drugs 
inappropriately or even in the absence of a true HAE attack). 
8.10.1.2 Limitations due to the low number of HAE patients 
The existence of relatively few patients and the limited number of treating physicians and 
drugs make it challenging to derive statistically significant results from any quantitative 
research. Building patient databases and registries from which to collect RWE in the form 
of diagnoses, prescribed treatments, clinical outcomes and economic and social effects 
(Schieppati, 2008) is made difficult by the absence of a universally recognized coding 
system for most rare conditions (ICD – International Classification of Diseases). Studies on 
rare diseases are exposed to the fundamental limitation of being able to recruit a sufficient 
number of patients. Systematic recruitment has been attempted, but researchers have 
ultimately resorted to self-selection (Caballero, 2014). One study reported that the 
willingness of patients to participate in a research or a survey increases with disease severity 
(Aygören-Pürsün, 2014), which might lead to a bias towards more severe cases. 
8.10.1.3 Limitations due to quality aspects of the studies on HAE 
As clinical outcomes are retrospective and self-reported (e.g. location, frequency and 
severity of attacks), such recruitment method and the potential for recall bias may affect the 
representativeness of the study population and the generalizability of the results. When 
reviewing the studies available for inclusion into the meta-analysis conducted in section 5.4, 
the thesis observed that several of them have not done or were not clear on key aspects of 
high-quality RCT such as randomization, concealment of treatment allocation or ensuring 
the similarity of groups in terms pf prognostic factors. The vast majority of the studies in 




subjects were representative of the entire population, or if the staff, places, and facilities 
where the patients were treated, were representative of the treatment the majority of patients 
receive. One research reported that randomization of subjects was also not feasible due to 
specific aspects of HAE (Tourangeau, 2012). For example, some patients are not 
comfortable with self-injections or other patients live too far from healthcare centers to 
ensure timely travel for treatment in case of life-threatening HAE attacks. 
8.10.1.4 Limitations due to lack of head-to-head comparison studies on HAE 
Treatment for HAE can vary over time, and so the clinical outcomes even when taking the 
same drug at the same doses (for example if the body develops antibodies or if it moves into 
a steady state). However, none of the available trials and cohort studies analyzed or reported 
if there were different lengths of treatment or periods between the interventions and the 
clinical outcomes. This omission might have been due to prevent further reduction in subject 
numbers, which were already difficult to recruit due to the rarity of the condition. To 
determine the clinical efficacy of one treatment vs. another, head-to-head studies are 
normally conducted. When the treatments are absolutely comparable and close to each other 
in their efficacy, larger study populations would be required to achieve sufficient statistical 
significance of reported results. As investigators are already struggling to recruit patients for 
placebo-controlled studies, it is not surprising that until now no head-to-head trials 
comparing treatments could be identified. The lack of head-to-head comparisons between 
drugs was reported as the cause for the difficulty by payers to assess which prophylactic 
treatments for HAE are superior in efficacy and effectiveness (ICER, 2018). 
8.10.1.5 Limitations due to heterogeneity of the studies on HAE 
Further different trials showed significant heterogeneity (e.g. different eligibility criteria or 
different endpoints) so that reliable indirect comparisons through common comparators 
between trials are not possible as already analyzed and reported by a study (Kavalec, 2013). 
For example, the research could not find consistent definitions of how the total time to onset 
of symptom relief is between different studies. These might be common challenges across 
studies on rare conditions. The methodology of this research in performing a meta-analysis 
was chosen to mitigate these limitations.  
8.10.1.6 Limitations due to the variability of the HAE condition 
Some rare conditions, especially HAE, also display a high variability of symptoms and 
burden of the conditions across patients and within patients across time, which make 
producing statistically significant results additionally difficult (see sections 5.4.2., 5.4.3, 
5.4.40, 5.4.5 and 5.4.65.4.6). The lack of significant clinical results poses a challenge in 
writing guidelines for treatments as described in sections 3.1.10, 3.1.12 and 3.1.13. The next 
best alternative would be for experts to reach a consensus as an interim guide for 
practitioners in the therapeutic area. Ideally, such a guide should be replaced as soon as 
feasible with guidelines based on the whole package comprised of large phase III and IV 
clinical trials, meta-analyses, patient registries, QoL and cost-benefit analyses for the 




by the variability in the way patients report attacks, QoL impact depending on severity, 
attack frequency, or cultural background or age amongst other factors. Studies on the 
efficacy of prophylactic treatment are additionally limited by the absence of an active 
control, as there is no evidence that the number of reported or prevented attacks corresponds 
to the attacks that actually occurred or might have occurred (and where they were 
prevented). 
8.10.1.7 Limitations due to the severity of the condition 
As rare conditions are often devastating for the patients, once a treatment becomes the gold 
standard, it is ethically not warranted to explore in real life the alternatives on patients, 
especially if the resulting outcomes would result in significant pain, life-altering events and 
potentially fatalities. Research built on clinical trials reported that double-blind treatment of 
randomized patients was not justifiable because of the life-threatening nature of the 
condition (Bork, 2001). 
8.10.1.8 Limitations due to costs 
Significant costs for research, development and manufacturing limit the readiness to conduct 
sensitivity experiments on alternative courses of action, unless explicitly required for 
titration purposes (adaptation of dosing based on individually required efficacy and safety 
requirements). Significant pricing and market access challenges discussed in section 
5.4.13.80 drive the affected stakeholders to become reticent to share anything in regard to 
their positions, their cost structures, and their alternative options, as these are key bargaining 
tools during the ongoing negotiations and worth major amounts of money. From another 
perspective, possibly pressure on cost was the cause for virtually none of the studies 
reporting high-quality consistent data on QoL. 
8.10.1.9 Limitations due to privacy 
In some markets increasingly stringent privacy laws make it impossible for the non-involved 
healthcare professional to gain access to patient-level data, even if anonymized. This can be 
partially overcome by gaining access to primary and syndicated reports which then flow into 
meta-analysis. 
8.10.1.10 Limitations due to bias 
Several studies utilized for this research are retrospective nature which is therefore exposed 
to potential biases. Bias can be introduced by most studies available including patients only 
from a specific country or healthcare system. Given the low prevalence of the conditions 
and the need for sufficient subject to reach statistical significance, it is not always possible 
to recruit a representative sample of the population (Bouillet, 2013) and for some studies, 
the subjects were chosen at the discretion of the investigators instead of random (Anderson, 
2019). Several studies have reported significant numbers of people suffering from HAE to 
be underdiagnosed, possibly because their attacks are mild, or because the physicians may 




Another form of bias may arise because not all patients are treated in the same way. Patients 
domiciled or having access to centers of excellence in close proximity to universities, may 
have access to the most expert physicians and most modern treatments, while other patients 
have not, with resulting large differences in clinical outcomes and QoL. Patients with a 
milder form of the disease might be underdiagnosed and or not being treated with the most 
impactful medicine, albeit still showing good QoL scores. Additionally, patients may not 
remember all the attacks they had or only report only the most severe ones, even as many 
keep a log or diary on their disease. To remove some of the bias, attempts could have been 
too blind study subjects to the intervention they were going to receive, and/or to blind those 
measuring the main outcomes of the intervention. However, such attempts are not mentioned 
in the studies.  
8.10.1.11 Limitations through types of collection and cohorts 
As indicated above, due to the rarity of the conditions, few patients are available for 
recruitment for either studies or surveys. The Icatibant Outcome Survey (IOS) is probably 
the largest and longest-running, international, prospective observational study monitoring 
long terms safety and effectiveness of icatibant in a real-world setting (Andresen, 2019). 
Since 2009 it has been collecting including baseline demographics, attack characteristics, 
and treatment outcomes. However, as this registry is observational and covering only a 
cohort of patients treated with icatibant, despite its wealth of data, all results can only be 
considered exploratory. 
Other surveys have generated results that might be exposed to other interpretations or 
refinements as critical information such as dosing was not collected, or as figures were based 
exclusively on patient’s self-reporting (see limitation from memory and recall bias above), 
e.g. (Tachdjian, 2019). 
8.10.1.12 Limitations of the survey 
The survey with HAE physicians was performed using convenience sampling for the reasons 
listed in section 4.3. While it allowed maximizing the number of respondents, it also 
introduced a bias towards more advanced healthcare systems, physicians that are involved 
academically, physicians that follow the latest guidelines, and physicians or patients that 
have access to the most modern (and expensive) treatments. Any data and insights on 
patients also carry the bias towards the more severe cases discussed in section 5.4.3 as these 
are more likely to be treated and remembered (see also recall bias). Until an established, 
validated and the global patient registry is in existence, research in this area might have to 
compromise with these limitations. 
8.10.1.13 Limitations of social media search 
The social media search was conducted to include the patients’ perspective into the findings. 
Facebook and Twitter were selected as the two sources as they have a broad diffusion in the 
population while being easily accessible and searchable as discussed in section 4.6.2. For 
ethical reasons no access to closed groups was attempted, where the conditions of admission 




presumes a number of conditions that need to be met and hence introduce bias into the 
findings. The patients need to be aware of their condition, have access to a device, internet 
and an account that enables postings. In addition, they need to be willing to share with the 
whole world about their symptoms, treatments, feelings, results etc. that are a consequence 
of their condition. Self-reports by patients are subject to a number of biases such as 
recollection bias or the tendency to share only about the most dramatic events. It cannot be 
excluded and verified that some posts are fake or made by users who aim to propagate a 
certain narrative or who have an agenda. 
8.10.1.14 Other limitations 
In the cost analysis of the different options to determine the effectiveness of treatments, 
several aspects were not included, for example, the costs of training patients to self-
administer the treatments (see section 6.3.3.13), or the vast majority of indirect costs, or 
non-medical costs (see section 6.4.1.2). The research noted a general lack of data on costs 
of living, costs of (missed or slowed) education, missed or reduced career opportunities, 
reduced productivity (Federici, 2018), transportation, infrastructure). More indirect impacts, 
such as due to the influence of HAE on other members of society than patients or social 
perspectives, are not considered in clinical studies and mostly not mentioned or quantified 
in QoL or HE studies. The same can be said for the relatively long list of co-morbidities (for 
example depression, anxiety) and all may cause further impacts on their own, as discussed 
in section 6.4.1.8. 
Studies that are based on insurance claims are limited by coding errors, incomplete claims 
information, misclassifications of patients and other possible inaccuracies (Tachdjian, 
2017). Not all are identified, and it is not reported how significant they are in affecting the 





8.11 Further research 
For this research a survey, a search on social media and a meta-analysis the publicly 
available body of research was performed. Sources searched include Medline, Embase, 
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, 
conference proceedings and presentations, regulatory documents, scientific meeting 
abstracts and publications on the topic. These sources were supplemented by information 
provided by manufacturers and other grey literature. 
Within HAE, confirmation or strengthening of results could be achieved with head-to-head 
clinical trials, access to patient registries that still have to be established, access to studies 
that use a consistent methodology of protocol and outcome/parameter definitions, and more 
in general, research that mitigates or eliminates the sources of bias mentioned in 8.10). 
To strengthen the findings and their applications to other rare conditions, similar studies 
could be conducted on other genetic conditions such as Fabry’s disease, Gaucher’s disease, 
being able to tap into a selection of the more than 7,000 existing. An approach could be to 
validate key assumptions and variables from this research and subsequently confirm the 
generalizability of this thesis to other rare conditions.  
Big data, AI and machine learning have been attracting significant attention and funding by 
both pharmaceutical and technology companies during the writing of the thesis. However, 
as the time of the research these approaches were not widespread or established in their day-
to-day application, resulting in relatively little data or academic work from which significant 
new insights could be gained. A summary search suggest that progress could be rapid, and 
further research to include them is warranted to verify or build and possible new insights 
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10.2 Survey with physicians 
















































10.4 Reflections of the researcher 
The researcher’s academic career covers both scientific and business angles. His background 
in Physics enabled him to contribute with methodology, conceptual and quantitative 
modeling tools combined with the rigor to test and validate the variables, models and the 
correlations, causalities, or independence of different parameters leading to replicable 
outcomes. After a short stint in research, the researcher moved into business, attained an 
MBA which was followed by an 20-year career in healthcare covering Pharmaceuticals, 
Medical Devices and Services, which exposed him to a large and diverse population of 
stakeholders in the healthcare space. Operating at different levels of large organizations, in 
different functions and across multiple market models, he worked with and learned to 
understand the different stakeholders, what drives them and how they influence one another 
to generate positive or negative impact on the patient, the ultimate center of all healthcare 
efforts. The healthcare sector is a complex setting with different (and sometimes 
independent and even misaligned) processes and incentive systems. Ultimately different 
levels of education, asymmetry of information and the differing stakes (level of 
commitment) may cause outcomes that are not linearly dependent and yet affect society as 
a whole. All of these are drivers to for the proposed research, having the objective to better 
grasp complexity, leverage the newly available quantity and quality of information, utilize 
innovative analytical and interpretative methods and yet deliver pragmatic 
recommendations to improve healthcare in an economically optimized way. Previous and 
current work done on the topic was performed while engaged with Novartis, Abbott and 





10.5 Publication plan 
Three articles are planned to be submitted for publication where the research gaps discussed 
in section 3.11 based on the literature review could possibly be addressed in part with the 
findings of the thesis. The draft titles, the content and the type of journals to be addressed 
for a potential publication are described as follows: 
• “Achieving economically more efficient therapeutic decisions with better health 
and QoL outcomes”. 
Built on sections from the literature review such as in section 3.3 on Real World 
Evidence (RWE) with the efficacy and effectiveness of Evidence Based Medicine 
(EBM), section 3.4 on Quality of Life (QoL), and section 3.5 on Health Economics 
(HE). These are integrated and analyzed within the Agency Theory framework 
discussed in section 3.6 and applied to rare diseases discussed in section 3.7. 
The article is planned to be submitted to a highly rated journal which takes a holistic 
view on medical treatment and where ethical considerations are prioritized, such as 
the Journal of Business Ethics (https://link.springer.com/journal/10551). 
• “The physicians’ perspective on treating patients suffering of a rare condition – 
results from a survey” 
Built on the results of a survey with physicians treating a rare condition discussed in 
section 5.1 and focused on the importance of the different stakeholders (see section 
5.1.1), the clinical aspects considered for treatment decisions (see section 5.1.2), the 
QoL aspects (see section 5.1.3) and the economic aspects (see section 5.2).  
The article is planned to be submitted to medical journals addressing physicians who 
treat patients in general but specifically with a higher likelihood of treating patients 
suffering of rare conditions. This could be immunologist (as many rare conditions are 
genetic) or for example allergists (as the symptoms of some rare conditions manifest 
in similar ways as allergic reactions).  
• “The benefits of home treatment in terms of clinical results, quality of life and 
health economics for rare diseases” 
A literature review of the scholar research found a limited number of publications 
discussing the value of self-administration or home-administration of treatments of 
rare conditions. Some research was discussed in section 5.4.14 on QoL. However the 
broader approach of the thesis supported the argumentation for physicians and payers 
to further encourage self-treatment for patients suffering of selected rare conditions. 
This approach may lead to better clinical outcomes, superior QoL and more effective 
health economics. This article will derive its content from sections 6.2, 6.3, 6.4 and 
6.5.  
This article would be submitted to journals covering rare diseases (for example the 
Orphanet Journal of Rare Diseases - https://ojrd.biomedcentral.com), journals on  
medical treatments and guidelines (for example the Medical Letter - 
https://secure.medicalletter.org/archives-tgl), or journals on immunology (as rare 
disease dominantly genetic conditions).  
 
